Synthetic endeavours involving sparsomycin : the development of an antitumor antibiotic by Broek, Ludovicus Adrianus Gijsbertus Maria van den
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/30057
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
SYNTHETIC ENDEAVOURS 
INVOLVING SPARSOMYCIN: 
THE DEVELOPMENT OF AN 
ANTITUMOR ANTIBIOTIC 
L.A.G.M. van den Broek 

SYNTHETIC ENDEAVOURS INVOLVING SPARSOMYCIN: 
THE DEVELOPMENT OF AN ANTITUMOR ANTIBIOTIC 

SYNTHETIC ENDEAVOURS INVOLVING SPARSOMYCIN: 
THE DEVELOPMENT OF AN ANTITUMOR ANTIBIOTIC 
EEN WETENSCHAPPELIJKE PROEVE OP HET GEBIED VAN 
DE WISKUNDE EN NATUURWETENSCHAPPEN 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR AAN DE KATHOLIEKE 
UNIVERSITEIT TE NIJMEGEN VOLGENS BESLUIT VAN HET COLLEGE VAN 
DECANEN IN HET OPENBAAR TE VERDEDIGEN OP DONDERDAG 8 SEPTEMBER 
1988 DES NAMIDDAGS TE 1.30 UUR PRECIES 
DOOR 
LUDOVICUS ADRIANUS GUSBERTUS MARIA VAN DEN BROEK 
GEBOREN TE TILBURG 
1988 
Dmk: Krips Repro Meppel 
Promotores: Prof. Dr. H. С. J. Ottenheijm (VU Amsterdam) 
Prof. Dr. D. J. Th. Wagener 
Prof. Dr. J. P. G. Ballesta (UA Madrid) 
The investigations of which the results are presented in this thesis were carried out in the Department of 
Organic Chemistry, University of Nijmegen, Nijmegen, The Netherlands. 
These studies were carried out under the auspices of the Netherlands Foundation for Chemical Research 
(SON, project no. 700-339-027) with financial aid from the Netherlands Organization for Scientific 
Research (NWO), the Netherlands Cancer Foundation (KWF, project no. NUKC 84-1), the North 
Atlantic Treaty Organization (NATO, grant no. RG 85/0376) and Pharmachemie B.V., Haarlem, The 
Netherlands. Pharmachemie B.V. is acknowledged for their financial support of this thesis. 
The lay-out of this thesis has been prepared with aid of ChemText Version 1.10 (Molecular Design 
Limited). 
ISBN 90-9002318-6 
Ter nagedachtenis aan Richard van den Heuvel 

EEN WOORD VAN DANK 
Graag wil ik hier iedereen die op de een of andere wijze heeft bijgedragen aan de totstandkoming van 
dit proefschrift van harte bedanken. Vooral mijn ouders, die mij een academische opleiding hebben 
laten volgen en die mij altijd hebben gestimuleerd om naar het hoogst haalbare te reiken. 
In volgorde van binnenkomst: Hans Colstee, Paul Fennis, Frank Missler, Ad Antonisse en Peter in 
't Veld voor hun belangrijke bijdrage aan de synthese van nieuwe sparsomycine verbindingen en 
Ronald Wiegers voor een gedeelte van het onderzoek dat niet beschreven is in dit proefschrift. 
Alle medewerkers, staf, promovendi, analisten, studenten, stagiaires en secretaresses van de 
vakgroep Organische Chemie en met name de mede-promovendi Rolf Feenstra, Pedro Hermkens, Bert 
Zeegers en Ralf Plate alsmede Edwin Stokkingreef, Jan van Maarseveen en Wim Lousberg voor een 
prettige en bovenal leerrijke samenwerking. Mijn collega van kamer U78 wil ik in het bijzonder 
bedanken voor het op mij overbrengen van zijn liefde voor de klassieke muziek, al moet ik toegeven dat 
een en ander het gevolg moet zijn van de mij opgelegde beperking in werkruimte en muziekkeuze. Peter 
Weijers, Pieter van der Meer, Peter van Galen, Ad Swolfs, Michel Broekman, Ruud Zwijnen en Jos 
Joordens voor de technische ondersteuning van het onderzoek en voor de analyses van vele stoffen. 
Wolter ten Hoeve voor het opnemen van verschillende CD spectra, zodat ik niet al te vaak naar 
Groningen hoefde te reizen. 
Alle leden van de Nijmeegse Sparsomycine Werkgroep, met name Zbigniew "Ben" Zylicz en Wim 
de Grip, voor de hechte samenwerking en voor de vele discussies over de verkregen 
onderzoeksresultaten en de nog uit te voeren experimenten. Ook wil ik hier Dick de Vos en zijn 
medewerkers noemen voor hun bijdrage aan de maandelijkse bijeenkomsten van de werkgroep. 
Quiero agradecer a Ana San Felix y a Ester Lázaro por su colaboración en las investigaciones sobre 
la esparsomicina, especialmente durante mis visitas al Centro de Biología Molecular en Madrid. 
También les agradezco sus esfuerzos y su amistad. Yo me sentía como si estuviera en mi propia casa. 
Gracias a vosotros mi estancia en Madrid fue un experiencia inolvidable. 
Peter Lelieveld (TNO) voor het testen van vele sparsomycine derivaten, Frans Kaspersen 
(Organon) voor de synthese van [3H] sparsomycine en Jan Kelder (Organon) voor het uitvoeren van 
QSAR berekeningen, welke ik echter niet in dit proefschrift heb kunnen opnemen. Ik wil hen vooral 
bedanken voor hun enthousiasme en belangstelling voor mijn onderzoek. 
Prof. Nivard voor zijn volsterkt belangeloze bereidwilligheid om de laatste versie van het 
manuscript te corrigeren. 
De medewerkers van de afdelingen illustratie en fotografie voor het reproduceren van de CD 
spectra. 
Ria, je hebt nu van nabij ervaren wat er komt kijken bij het vervaardigen van een proefschrift. Ik 
hoop datje over twee jaar, net zoals ik nu, met voldoening kunt terugkijken op "onze samenwerking". 

CONTENTS 
CHAPTER 
1. GENERAL INTRODUCTION 13 
2. STRUCTURE-ACnVITY RELATIONSHIP STUDIES ON ANALOGUES 
OF SPARSOMYCIN. IN VITRO PROTEIN SYNTHESIS AND (TUMOR) 
CELL GROWTH INHIBITION 
2.1 Minimum structural requirements for biological activity 31 
2.2 The effect of increasing the lipophilicity of the drug 
on the biological activity 43 
2.3 The effect of modification of the hydroxymethyl function 
on the biological activity 69 
2.4 The effect of modification of the uracil fragment 
on the biological activity 85 
3. EVALUATION OF SELECTED SPARSOMYCIN DERIVATIVES FOR 
BROAD-SPECTRUM BIOLOGICAL ACTIVITY 
3.1 In vitro antiparasitic activity 97 
3.2 In vitro antiviral activity 105 
3.3 In vitro and in vivo antitumor activity 113 
4. INTERACTION OF SPARSOMYCIN WITH PEITIDYL TRANSFERASE 
4.1 Synthesis of [3H]sparsomycin 127 
4.2 Synthesis of a phenol derivative suitable for ribosome 
affinity studies 133 
4.3 Synthesis of aryl azide analogues of sparsomycin suitable 
for ribosome photoaffinity labeling studies 143 
5. CHIRAL ECONOMY IN THE SYNTHESIS OF SPARSOMYCIN 151 
6. THE TOTAL SYNTHESIS OF γ-GLUTAMYLMARASMINE USING THE 
SYNTHETIC METHODOLOGY DEVELOPED FOR SPARSOMYCIN 157 
SAMENVATTING 165 
LIST OF PUBLICATIONS 173 
CURRICULUM VITAE 175 

CHAPTER I 
GENERAL INTRODUCTION 
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Sparsomycin (l), 1 , 2 a bacterial metabolite of Streptomyces sparsogenes, has attracted considerable 
attention because of its interesting chemical structure and biological activity. The monoxodithioacetal 
moiety RS(0)CH2SMe is one of its diverse functions. This moiety is rarely encountered in natural 
products but has attracted recently the attention of organic chemists due to its synthetic utility. 
Biological activity. Inhibition of protein biosynthesis. Sparsomycin is a strong inhibitor of protein 
biosynthesis. The antibiotic has achieved prominence in the past 25 years as a tool to study the protein 
synthesis machinery. It interferes with the formation of the peptide bond, the central step in protein 
synthesis, which is carried out at the peptidyl transferase center of the ribosome.3"6 In this active center, 
which is part of the large ribosomal subunit, the transfer of the peptidyl residue from the peptidyl-tRNA 
bound to the P-site, to the aminoacyl-tRNA bound to the Α-site, takes place. Several model systems for 
peptide bond formation have been explored with sparsomycin including the polyphenylalanine 
synthesis assay,7 the fragment reaction8 and the puromycin reaction.9 
The polyuridylic acid-directed synthesis of polyphenylalanine, using ribosomes and supernatant 
factors from E. coli от S. cerevisiae has been used frequently as an assay for protein synthesis 
inhibition. Sparsomycin inhibits this polymerization of phenylalanine with a 50% effective dose (EDJQ) 
value of around 1-10 μΜ.10 The simplest model assay for peptide bond formation is the fragment 
reaction. In this test the ribosome catalyzes the transfer reaction between the donor substrate, an 
/V-acetyl-aminoacylpentanucleotide, and puromycin in the absence of both mRNA and even the small 
ribosomal subunit. The reaction requires, however, the addition of an organic solvent, usually ethanol. 
ED50 values of around 1-10 μΜ are obtained for sparsomycin.
10
 In the puromycin reaction puromycin, 
an analogue of the 3' end of the aminoacyl-tRNA, acts as an acceptor substrate in peptidyl-puromycin 
formation. Sparsomycin inhibits this reaction with an ED^ value of around 0.1 μΜ.10 
Cytotoxicity. Sparsomycin, being an inhibitor of protein synthesis, is intrinsically toxic to cells 
permeable to the drug. 1 1 1 3 A broad spectrum of biological activity including antiparasitic,14 
antiviral,1516 antibacterial,17,18 antifungal19 and antitumor activity12·1921 has been observed. It has been 
reported that sparsomycin does not penetrate intact reticulocytes and HeLa cells, leaving these cells 
unaffected.22·23 
In vitro combination with other cytotoxic agents. Sparsomycin, as a protein synthesis inhibitor, 
potentiates the activity of other cytotoxic drugs. Preincubation of Chinese hamster ovary cells, growing 
in vitro, with moderate concentrations of sparsomycin prior to the administration of cisplatin rendered 
these cells more sensitive to cisplatin.13 Protection against cisplatin-induced cytotoxicity was observed, 
however, when low sparsomycin concentrations were used. Recently, modification of the in vitro 
cytotoxicity of several other clinically important cytotoxic agents, viz. melphalan, arabinoside-C, 
methotrexate, vincristine, doxorubicine, 5-fluorouracil and bleomycin, has been described.24 
In vivo antitumor activity. Owen, Dietz and Camiener, in 1962, were the first to point out the in 
vivo antineoplastic activity of sparsomycin; they observed activity in 11 out of 20 rodent tumor models 
tested.19 However, the panel of tumors and activity criteria that were used then do no longer meet today 
standards. Lately, sparsomycin and six selected analogues were evaluated for their in vivo activity 
against L1210 lymphoid leukemia, P388 lymphocytic leukemia, B16 melanoma. Walker 256 
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carcinosarcoma, RC renal cell carcinoma, C38 colon carcinoma, LL Lewis lung carcinoma, C22LR 
osteosarcoma and M5076 sarcoma.24 Sparsomycin itself showed only moderate activity in the P388 
system, borderline activity against L1210 and no activity in the other tumor models. 
Three lipophilic analogues of sparsomycin, viz. pentyl-sparsomycin (2), deshydroxy-sparsomycin 
(3) and ethyl-deshydroxy-sparsomycin (4), showed high activity against L1210 leukemia, P388 
leukemia and RC renal cell carcinoma. The other tumors appeared more or less resistant to these drugs. 
The in vivo antitumor activity was tested also in other -drug route of administration/tumor location-
settings than the common -intraperitoneaVintraperitoneal- model.24 
Scheme I. Sparsomycin and analogues 
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In vivo combination chemotherapy. The cytotoxicity of cisplatin in in vivo tumor models was 
modulated too by sparsomycin.25 When given prior to cisplatin, sparsomycin prolonged significantly 
the survival of mice bearing L1210 leukemia intraperitoneally; the drug combination gave up to 66% 
cures, whereas cisplatin or sparsomycin alone was not able to give any cure. Normally, weight-loss is 
observed when animals are treated with cisplatin. When sparsomycin was incorporated into the 
treatment schedule, even protection against this cisplatin-induced weight-loss was observed. Similar 
potentiation was observed for the combination of ethyl-deshydroxy-sparsomycin (4) and cisplatin 
against subcutaneously inoculated L1210 in mice; deshydroxy-sparsomycin (3) affected only 
moderately the cytotoxicity of cisplatin in this tumor model.24 The deshydroxy drugs, however, did not 
protect the animals against cisplatin-induced weight-loss. 
Pharmacokinetics and toxicology. As a preliminary to a clinical evaluation, sparsomycin (1) and 
the three most promising analogues, viz. 2, 3 and 4, were analyzed for their toxicology and 
pharmacokinetics in mice and beagle dogs.24 The toxicology of the drugs is related mainly to lowering 
of protein levels. As the most important side effect coagulation disorders were observed with the 
hydroxy-containing drugs. Sparsomycin entered a phase I clinical trial in 1964, just two years after its 
isolation.19 This study was discontinued, since a sparsomycin-induced retinopathy was observed.26 
Recently, investigations looking into the occurrence of this rctinotoxicity were performed. These 
studies indicated that this retinopathy is found only in very sick animals and that with healthy animals 
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sparsomycin does not pass the blood-retina barrier.24 
Mechanism of action. The exact molecular mechanism by which sparsomycin exerts its effects is 
not yet fully understood. Sparsomycin has been shown to inhibit the interaction of substrates with the 
peptidyl transferase Α-site, while stimulating at the same time the binding of substrates at the P-site. 
This mutual interaction was postulated to be due to an allosteric effect.10 Sparsomycin has structural 
similarities with the 3' end of the acceptor tRNA molecule.2 This resemblance was supported by an 
X-ray structure analysis of the acid fragment (5) of sparsomycin.27 The binding of sparsomycin to a site 
on the peptidyl transferase center that partially overlaps with the interaction site for the aminoacyl-
adenine moiety of aminoacyl-tRNA was proposed as the most straightforward interpretation of the 
available data.2 The drug thus will block totally the interaction of small-size substrates, such as the 3' 
terminal fragments and puromycin. It is also able to disturb the correct positioning of the 3' end of the 
large aminoacyl-tRNA molecule. 
When it was established that sparsomycin interacts with peptide bond formation, its interference 
with other cellular processes were disregarded. That other effects must have occurred was concluded 
from the finding that the inhibition of cell growth by sparsomycin was accompanied by the release of 
several free amino acids from the cells into the culture medium. The amount of amino acids released 
was dependent on the extent of growth inhibition.11·18·28 
The peptidyl transferase center of the ribosome is the target of a considerable number of antibiotics 
that, like sparsomycin, inhibit the peptide bond formation. Valuable information on their mode of 
action, as well as on the structure of the peptidyl transferase center, has been derived from studies on 
their mutual competition for binding to the ribosome.29 It was shown for example, that sparsomycin 
blocks the binding of puromycin to the ribosome completely, thus the binding sites of both compounds 
must overlap to a large extent30 The analysis of ribosomal alterations in mutant strains as a 
consequence of the action of an antibiotic, could provide also structural data on antibiotic binding sites. 
Although three sparsomycin-resistant strains have been reported, studies looking into possible 
ribosomal alterations have not been carried out.2 1·3 1·3 2 
It has been suggested that sparsomycin causes an irreversible inactivation of ribosomes.33,34 
Coutsogeorgopoulos,35 Vince36 and Flynn37 have called this permanent inactivation of ribosomes by 
sparsomycin the "preincubation effect". Flynn and co-workers suggested a peptidyl transferase-
mediated Pummerer rearrangement involving the sulfoxide group of sparsomycin to be responsible for 
this effect.37 As a result, the drug is supposed to be linked covalently to the nascent peptide chain. 
Isolation and structure elucidation. Sparsomycin (1), was detected initially in beers and was 
isolated subsequently by Owen, Dietz and Camiener in 1962 as a secondary metabolite from a 
fermentation broth of Streptomyces sparsogenes.19 The antibiotic was found to be active against KB 
human epidermoid carcinoma cells in tissue culture. A few years later, the isolation of sparsomycin was 
reported also from the culture fíltrate of Streptomyces cuspidosporus?9 
The structure of sparsomycin remained unresolved until 1970, when Wiley and MacKellar reported 
their results of synthetic, spectroscopic and degradation studies.39 They established that the molecule 
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contained a modified uracil base, a iranj-olefin bond, a cysteine fragment of which the chiral carbon 
atom was shown to have the S configuration, and a chiral sulfur atom, the chirality of which remained 
unspecified. The sulfoxide group was found to be part of a monoxodithioacetal function 
RS(0)CH2SMe, a moiety that is rarely encountered in natural products. The chirality of the sulfoxide 
sulfur atom was elucidated in 1981 by Ottenheijm, Helquist and co-workers.40 From circular dichroism 
spectroscopy and single-crystal X-ray analysis it was concluded that sparsomycin possesses the ScRs 
configuration. 
Synthesis. Sparsomycin has attracted much attention since its discovery, not only because of its 
broad-spectrum biological activity, but also for its unique structural characteristics and synthetic 
challenge. The activity arises as a result of protein synthesis inhibition, a mechanism of action unlike 
that of most cytotoxic drugs in common use in the clinic. Although the antibiotic was accessible from 
natural sources in limited amounts, a total synthesis was desirable (i) for confirming the chemical 
structure, (¿0 for allowing the preparation of structural analogues of the drug and (ιϊι) for providing 
sufficient quantities of selected compounds for extensive biochemical studies and preclinical testing. 
Scheme II. Retrosynthetic analysis of sparsomycin 
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Total syntheses of sparsomycin were investigated by the groups of Ottenheijm41-43 and 
Helquist.44·45 Sparsomycin was considered to be an amide derived from the acid 5 and the amine 6, 
derived from 6-methyluracil (7) and D-cysteine (8), respectively (Scheme Π). A synthesis of the acid 
fragment was described first by Wiley and MacKellar.39 However, since then, several groups have 
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reported better synthetic methods for the acid; the overall yield was improved considerably.42·45·46 The 
synthesis of the amine component was more challenging because of the unusual S(0)CH2SMe moiety, 
for which new methodologies had to be developed. 
Three different approaches have been used successfully in the synthesis of protected derivatives of 
the amine 6, viz. 13 (Scheme ΙΠ). The first approach developed in 1979 by Ottenheijm and co-workers, 
features the reaction of an α-chloro sulfoxide derivative of cysteine (10) with sodium methyl 
mercaptìde.41·42 Another key step in this route is the reaction of properly protected D-cysteine (9) with 
chlorine and acetic anhydride to give a sulfinyl chloride, which is subsequently treated with 
diazomethane to give the chloromethyl sulfoxide 10. 
The second approach developed by the same group in 1981, features the nucleophilic ring opening 
of a cyclic sulfinate ester or γ-sultine (l l) . 4 3 The cyclic sulfinate ester was prepared by reaction of 9 
with N-chlorosuccinimide and acetic acid. The γ-sultine has a sulfur atom activated for nucleophilic 
attack and has simultaneously a protected alcohol function which makes the route via the cyclic 
sulfinate ester particularly attractive. 
The third route described by Helquist and co-workers in 1979, involves the sulfenylation of an 
a-sulfinyl carbanion.44·45 The methyl sulfoxide 12 was prepared from L-cysteine by methylation of the 
mercapto group and subsequent oxidation of the thioether. This route involves a racemization and 
resolution sequence as a result of starting with the L-amino acid rather than using D-cysteine. 
Scheme ΙΠ. Synthetic approaches to sparsomycin 
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An elegant approach, thus avoiding the inefficient resolution step, involves a formal "inversion" of 
the configuration of L-serine by selective manipulation of the functional groups surrounding the chiral 
carbon atom. Helquist and collaborators showed that the carboxyl group of L-serine can be converted 
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into a mercaptomethylene moiety.45 This strategy permits entry into the D-cysteine system without 
actually operating upon the chiral center itself; the configuration at the carbon atom of sparsomycin 
corresponds with the chirality of D-cysteine. The principle of this approach is shown in Scheme Г . The 
use of L-amino acids is especially attractive with respect to their availability and cost (vide infra). 
The investigations in the aforementioned synthetic routes leading to sparsomycin unequivocally 
provided definite proof of the chemical structure of sparsomycin. These routes are capable of providing 
practical quantities of sparsomycin for biochemical and preclinical testing. Moreover, these routes 
allow the synthesis of structural analogues of sparsomycin. 
Scheme IV. Amino acids in the synthesis of sparsomycin and analogues 
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Synthesis of analogues. The active interest shown in the synthesis of sparsomycin analogues has 
been prompted undoubtedly by the usefulness of the antibiotic as a potent protein synthesis inhibitor 
and as a potential anticancer drug. All of the various syntheses of derivatives related to the drug 
followed the retrosynthetic Scheme II. 
Among the 64 structural analogues of sparsomycin that had been prepared by several groups of 
invesrigators up to the moment the research that is described in this thesis was started are: 
(/) derivatives in which the CT^SMe moiety has been replaced by various, mostly hydrophobic, 
substituents,18,22 
(ii) compounds in which the S(0)CH2 moiety has been removed,20'36,47·48 
(HI) analogues in which the CH2OH group has been substituted for hydrogen and/or the entire 
S(0)CH2SMe moiety has been replaced by various substituents,48,49 
(iv) derivatives that lack the double bond in the acid fragment,50 
(v) analogues that have the uracil nucleus replaced by other aromatic groups,51 and 
(vi'J a hybrid antibiotic between sparsomycin and chloramphenicol called sparsophenicol.52 
One major shortcoming of initial attempts to synthesize structural analogues of sparsomycin, however, 
is that the synthesis started with either L-cysteine or racemic cysteine. Consequently, various structural 
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parameters were varied simultaneously. This allowed only a limited interpretation of the results with 
regard to the effect of the respective functionalities of the molecule on the biological activity. 
OUTLINE OF THIS THESIS 
The following objectives were pursued by the investigations described in this thesis: 
(0 to synthesize analogues of sparsomycin in order to establish the importance of each of the 
structural characteristics of the molecule for biological activity, 
(ii) to prepare derivatives that would show high antitumor activity and low toxicity in animal 
models, with the development of a potent anticancer drug for clinical use as the ultimate goal, 
(ι//) to synthesize analogues suitable for affinity and photoaffinity labeling studies in order to study 
the interaction of sparsomycin with the ribosome in protein synthesis, 
(iv) to optimize the efficiency of the route to the most promising sparsomycin analogue in terms of 
yield and economy of chirality, and 
(v) to test the generality of the synthetic methodologies developed by a total synthesis of a 
structurally related fungal metabolite called γ-glutamylmarasiTiine. 
Structure-activity relationship studies. We set out to prepare structural analogues of sparsomycin 
and to test these derivatives for their in vitro and in vivo biological activity (Chapter 2). 
Of all analogues prepared, the inhibition of peptide bond formation as well as the tumor and 
bacterial cell growth inhibitory activity was tested first. Subsequendy, of selected derivatives from 
these in vitro assays, the acute toxicity in mice and the antitumor activity in mice bearing L1210 
leukemia was investígated. Of the most promising analogues the antitumor activity in several animal 
models as well as the pharmacokinetics and toxicology in mice and beagle dogs was studied. The in 
vivo investigations were carried out by Z. Zylicz from the Division of Medical Oncology of the 
University Hospital Nijmegen. 
To allow an unambiguous interpretation of structure-activity relationships we started with the 
preparation of 14 analogues possessing not more than two structural modifications of the sparsomycin 
molecule. In this way a general idea about the structural requirements for displaying biological activity 
was obtained (Scheme V). The results of this study are presented in Chapter 2.1. As tests for inhibition 
of protein synthesis we employed the polyphenylalanine synthesis assay7,10 and the fragment 
reaction8·10 using ribosomes from E. coli, S. cerevisiae or S. solfataricus, and the puromycin reaction9·10 
using ribosomes from E. coli. Cell growth inhibition was evaluated using a variety of bacteria,10 and the 
antineoplastic activity of the drugs was assayed in the L1210 leukemia colony formation system in soft 
agar.10·53'55 We found that an increase in the lipophilicity of the drug, by replacing the SMe group by 
larger alkylthio or aralkylthio groups, increased the biological activity of the compound. 
The effect of the lipophilicity of the drug on its activity and toxicity was studied subsequently in 
detail (Chapter 2.2). Two homologous series of compounds were prepared having the SMe group 
substituted for alkylthio {S(CH2)rtMe) or alkyl {(CF^Me) groups of increasing length (Scheme VI). 
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A similar homologous series of S-substituted compounds was synthesized that differed from the 
previous one in that the CH2OH function was replaced by a Me group. 
Scheme V. Structure-activity relationships of sparsomycin 
± ++ ++ 
11 
++· 
H 
+ important for activity 
unimportant for activity 
• OH 
Me , , 0 С 
о.. 
ι/ 
s s 
^У ^Ме 
++ ± 
Scheme VI. Lipophilic derivatives of sparsomycin 
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The use of L-amino acids in the synthesis of analogues of sparsomycin is especially attractive, 
since they offer the possibility to introduce various substituents at the chiral carbon atom of the 
molecule (see Scheme IV). The deshydroxy-sparsomycin analogues 3 and 4 have been prepared starting 
from L-alanine. So, the CO2H group of L-alanine was transformed into the CfySiCtyCI^SMe side 
chain of sparsomycin. 
That this approach is a general one is shown in Chapter 2.3, where the synthesis is reported of 
structural analogues of sparsomycin having the CH2OH moiety replaced by alkyl or aralkyl groups. We 
were able to incorporate the L-amino acids valine, isoleucine, phenylalanine and proline in the structure 
of sparsomycin (Scheme VII). The corresponding glycine sparsomycin derivative, having two 
hydrogens at the α carbon atom, was prepared via a different route starting from cysteamine 
(2-aminoethanethiol). 
The importance of the uracil nucleus for sparsomycin to display biological activity was 
investigated. The results are presented in Chapter 2.4 (Scheme ПІ). 
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Scheme VII. L-amino acid derivatives of sparsomycin 
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Scheme ПІ. Modification of the uracil fragment 
At this stage we had prepared a variety of structural analogues of sparsomycin. Some of these 
derivatives showed better protein synthesis inhibition as well as tumor and bacterial cell growth 
inhibitory activity than sparsomycin itself. Having now a number of potent analogues of the drug at 
hand, we initiated more elaborate investigations on the antiparasitic and antiviral activity of these 
derivatives. Also their antineoplastic activity against some human tumor cell lines and in mice bearing 
L1210 leukemia was studied (Chapter 3). 
We investigated the effect of sparsomycin and some analogues on the proliferation of 
promastigotes of Leishmania d. donovani in vitro (Chapter 3.1). The antiviral activity of sparsomycin 
was early recognized.17·18 However, no systematic study on the antiviral effect of analogues of 
sparsomycin has been reported. We initiated a study on the stmcture-activity relationship of selected 
derivatives of sparsomycin against a variety of viruses including the human immunodeficiency virus 
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(Ш ) (Chapter 12). 
The use of the L1210 murine leukemia clonogenic assay in soft agar is well established in drug 
antitumor activity screening.5355 However, for a better predictive value of the results of such screening 
for ultimate application of thus-selected drugs in man, other in vitro assays are required. Human tumor 
cell lines are thought to resemble tumors in man better.55·56,57 We have investigated the effect of 
sparsomycin and some analogues against several human tumors in tissue culture (Chapter 3.3). 
In vivo antitumor activity and acute toxicity tests in animals were included also in the biological 
activity screening (Chapter 3.3). The murine L1210 lymphoid leukemia tumor is used in an in vitro as 
well as in an in vivo setting.55·58,59 We have investigated the activity of some lipophilic analogues of 
sparsomycin in the in vitro L1210 clonogenic assay in soft agar and in the in vivo model of L1210 
leukemia in mice and also measured their acute toxicity in mice. Some physicochemical parameters, 
viz. lipophilicity and water solubility, of the drugs investigated were also included for analysis of 
apparent relationships between drug hydrophobicity and biological activity. 
Interaction of sparsomycin with peptidyl transferase. The true molecular mechanism by which 
sparsomycin exerts its effects is not yet fully understood. Flynn and co-workers have proposed a 
peptidyl transferase mediated Pummerer rearrangement involving the sulfoxide group of sparsomycin to 
be responsible for the observed "preincubation effect".35"37 As a result, the drug is supposed to be linked 
covalently to the nascent peptide chain. 
Scheme IX. [3H]Sparsomycin 
τ
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We set out to study whether indeed sparsomycin binds covalently to the nascent peptide chain or to 
the ribosome (Chapter 4). This problem was addressed in the following way. A route to radioactively 
labeled sparsomycin was developed. In Chapter 4.1 the synthesis of [3H]sparsomycin (14, Scheme DC) 
is described. The radiolabel, i.e. tritium, was introduced by reduction of a suitable cysteine methyl ester 
derivative with lithium borotritide. Presently, the interaction with the ribosome,60 as well as the 
pharmacokinetic behaviour in mice,61 of this radioactive analogue is being studied. 
For fast analysis of certain biochemical experiments by autoradiography, we required another 
compound that could be obtained in radioactive form in high specific activity. Introduction of a phenol 
group into the chemical structure of sparsomycin gives the opportunity to prepare a highly radioactive 
molecule by standard radioiodination techniques. In Chapter 4.2 the synthesis is described of the 
phenolic analogue 15 of sparsomycin (Scheme X). Compound 15 shows affinity for the ribosome at a 
Chapter 1 23 
level comparable to that of sparsomycin Investigations on its effect on nbosome binding and protein 
synthesis are in progress From preliminary results we conclude that 16 and probably also 15 and 
sparsomycin (1) do not interact irreversibly with the nbosome.60 
Scheme X. Phenolic sparsomycin 
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Then, for investigating the site of interaction of sparsomycin at the peptidyl transferase we 
considered the synthesis of photoreactive analogues of sparsomycin Photoaffimty labeling has proven 
to be a powerful technique for an unambiguous identification and charactenzation of the site of 
interaction of a drug with its receptor62 6 5 Photoreactive aryl azide analogues are among the most 
frequently used drug denvatives for photoaffimty labeling studies. In Chapter 4 3 the synthesis is 
descnbed of three aryl azide-containing denvatives of sparsomycin, viz 17, 18 and 19 (Scheme XI). 
We envisaged that the ethylamine moiety of cysteamine (2 aminoethanethiol) might be used to link the 
RS(0)CH2C1 fragment of sparsomycin with the photoreactive aryl azide group This approach was 
found to be viable The sparsomycin photoprobes 17, 18 and 19 thus-prepared, showed nearly the same 
affinity for the nbosome as sparsomycin Investigations attempting to identify the site of interaction of 
sparsomycin at the peptidyl transferase are in progress 6 0 
Scheme XI. Sparsomycin analogues for photoaffimty labeling studies 
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Economy of chirality. The need for larger amounts of those analogues of sparsomycin that have 
been identified as potential antitumor drugs called for an evaluation of the economy of their synthetic 
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routes. Our studies had demonstrated unequivocally the importance of the absolute configuration at the 
chiral carbon and sulfur atom for biological activity.10 
Scheme XII. Reduction-oxidation-separation tandem sequence 
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(Í) 2-phenylene phosphochloridite, (//) mCPBA 
The strategy that had been employed so far, involved a separation step of the two a-chloro 
sulfoxide diastereoisomers 20 and 21, leaving up to 50% of the chiral material unused (Scheme XII). 
We studied whether this material, viz. 21, having the "wrong" chirality at the sulfur atom, could be 
recycled. In Chapter 5 a convenient method is described for the selective epimerization at sulfur of the 
highly functionalized, optically active sulfoxides at stake. The approach involves a sulfoxide reduction -
oxidation - separation sequence of steps. 
Scheme ΧΙΠ. γ-Glutamjlmarasmine 
ScRcSs 
Generality of the synthetic strategy. The methodologies that have been developed in the 
synthesis of sparsomycin allowed the preparation of a variety of structural analogues. As mentioned 
earlier, the S(0)CH2SMe moiety of sparsomycin is rarely encountered in natural products. Beside the 
bacterial metabolite sparsomycin, there have been identified, however, four fungal metabolites, that are 
γ-glutamylmarasmine 23 б б (Scheme ХШ), SE-3 (a precursor of lenthionine),67·68 djenkolic acid 
monosulfoxide and its N-acetyl derivative69 that contain this uncommon fragment. We selected 23 in 
Chapter 1 25 
order to verify the generality of the methodologies developed. The total synthesis of this fungal 
dipeptide is described in Chapter 6. 
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CHAPTER 2 
STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON ANALOGUES OF SPARSOMYCIN. 
IN VITRO PROTEIN SYNTHESIS AND (TUMOR) CELL GROWTH ΙΝΗΙΒΙΉΟΝ 

CHAPTER 2.1 
MINIMUM STRUCTURAL REQUIREMENTS FOR BIOLOGICAL ACTIVITY 
General structure-activity relationships 
± 
++ 
++ 
Conclusions: 
-it is allowed only to modify the SMe and OH group 
-in fact, more active drugs are obtained by increasing 
the alkylthio side chain length 
-the ScRs chirality and integrity of the S(0)CH2SMe 
moiety must not be affected 
-the antitumor activity is a direct consequence of 
the inhibition of protein synthesis 

Chapter! 1 31 
Reprinlcd from Journal of Medicinal С hemislr> 1987, Wt J2:) 
Structure-Activity Relationships of Sparsomycin and Its Analogues. Inhibition of 
Peptide Bond Formation in Cell-Free Systems and of L1210 and Bacterial Cell 
Growth1 
Leon A G M van den Broek/ Rob M J Liskamp,' J Hans Colstee,' Peter Lelieveld,s Miguel Remacha, 
David Vazquez, Juan Ρ G Ballesta, and Harry С J Ottenheijm*' 
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The biological activity of 14 analogues of sparsomycin (1) was studied in cell free systems of tschenchia coll 
Saccharomyces cereuisiae, and Sulfolobus solfatancus by measuring the inhibition of protein synthesis The inhibition 
of L1210 colony formation in soft agar and bacterial cell growth in solid as well as in liquid medium was also examined 
Each analogue possesses not more than two structural modifications of the sparsomycin molecule Thib enabled 
us to determine unambiguously several structural and stereochemical features that are required for an optimal biological 
activitj in those assays Sparsomycin having the S t ß s chiralitv is the most potent of the four possible stereoisomers 
The results obtained with compounds 5-7 indicate that the presence of an oxygen atom on the S(or) atom is essential 
Substitution of the bivalent sulfur atom by a CH2 group (10) or of the SCHj moiety by a CI atom (12) affects the 
activity of the molecule partially Compound 12 is surprisingly active against intact cells Substitution of the C(6) СНз 
group by a H (14) reduces the activity of the molecule Isomenzation of the trans double bond into the cis double 
bond yields cis sparsomycin (15), which is inactive The hydrophobic derivatives β 9 and 11 are considerably more 
active than sparsomycin, thus the nbosomal binding site for sparsomycin mav have a hydrophobic character 
Sparsomycin (I) 1 is a potent inhibitor of protein syn­
thesis, and there is ample evidence that its site of inter­
action is the larger nbosomal subumt, where it prevents 
peptide transfer by interfering with the pcptidyl transf­
erase center 2 * Sparsomycin has been shown to inhibit 
the interaction of substrates with the peptidyl transferase 
A site, while stimulating at the same time the binding of 
substrates at the Ρ site This mutual interaction might 
be due to an allostenc effect.7 It was shown recently that 
the sulfoxide moiety of sparsomycin is important for its 
a c t i v i t y " It was observed, moreover, that the proper 
oxidation state of the sulfur atom of sparsomycin is im­
portant for the enhanced inhibition of peptidyl transferase 
that is observed when Escherichia coli polysomes are 
preincubated with the drug, this effect was called the 
"preincubation effect" β 1 0 It was proposed that a peptidyl 
transferase mediated Pummerer rearrangement of the 
sulfoxide moiety of sparsomycin is responsible for this 
preincubation effect 9 This mechanistic rationale of the 
mode of action of sparsomycin was corroborated recently 
by studying the four possible stereoisomers of sparsomycin 
as inhibitors of peptide bond formation in E coli poly-
' Department of Organic Chemistry 
1
 Present address. Institute of Cancer Research, Cancer Center 
of Columbia Univereity, 701W, 168 Street, New York, NY 10032 
1
 Radiobiological Institute 
1
 Centro de Biologia Molecular 
1
 Dedicated to Dr В Witkop on the occasion of his 70th 
birthday 
somes " It was found that only the Я
С
Д
Ч
 stereoisomer 
(1) places the sulfoxide moiety m the same orientation as 
the nitrogen carbon bond of the natural substrate, ι e , 
L aminoacyl-tRNA, thus inducing the Pummerer rear­
rangement This stresses the structural similarity of the 
drug and the natural substrate of peptidyl transferase 
(1) Sparsomycin is a metabolite of Streptomyces sparsogenes 
(Argoudelis, A D , Herr, R R Antimicrob Agents Chemother 
1962, 780) and of Streptomyces cuspidosporus (Higashide, Ε , 
Hasegawa, Τ, Shibata, M Mizuno, К , Akaidc, H Takeda 
Kenkyusho Nempo 1966, 25,1, Chem Abstr 1967, 66, 54238) 
(2) Pestka S Ann Rev Microbiol 1971 25, 488 
(3) Vazquez, D FEBS Lett 1974, 40, S63 
(4) Vazquez, D Mol Biol Biochem Biophys 1979, 30 
(5) Pestka S In Molecular Mechanisms of Protein Synthesis, 
Weisbach, H , Pestka, S , Eds , Academic New York, 1977 pp 
467-553 
(6) Goldberg, I H In Antibiotics, Hahn, F E, Ed , Springer-
Verlag Berlin, 1979, pp 2Ь4 271 
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Table I Sparsomycin and Its Analogues 
-OH 
О О < 
Sparsomycin (1) 
Sparsomycin manifests its action in intact prokaryotic 
cells,12 14 eukaryotic cells1215—including transformed16"19 
and/or virus-infected cells2021—and in various cell-free 
systems 12 ^ - 2 6 The behavior of sparsomycin with regard 
to its inhibitory action and its influence on hepatic poly­
somes has also been investigated in vivo " " Since 
sparsomycin has been shown to be active against trans­
formed cells and various tumors, it has been investigated 
as a potential cytostatic drug A phase I clinical trial of 
sparsomycin, however, revealed eye toxicity ж 3 1 
Recently, both we32·33 and Helquist3436 succeeded in 
developing total syntheses of sparsomycin Most of the 
structure-activity relationship studies of sparsomycin that 
appeared12 3e~42 prior to its first total synthesis were con-
(12) Ash R J , Fit«, L D , Beight, D W , Flynn, G A Andmicrob 
Agents Chemother 1984 25, 443 
(13) SlechU, S In Antibiotics, Gottlieb D , Shaw, Ρ D , Eds, 
Springer Verlag Berlin, 1967, Vol 1, pp 410-414 
(14) Bannister, E R , Hunt, D E.PlltiUo, R F Can J Microbiol 
1966, 12, 595 
(15) Goldberg, Ι H , Mitsugi, К Biochem Biophys Res Commun 
1966, 23 453 
(16) Lin, С С L, Dubois, R J J Med Chem 1977,20,337 
(17) Owen, S Ρ , Dietz, A , Camiener, G W Aniimicroò Agents 
Chemother 1962, 772 
(18) Kuwano, M Takenaka, К , Ono, M Biochim Biophys Acta 
1979,565,479 
(19) Bhuyan, В К , Scheidt, L G , Fraser, Τ J Cancer Res 1972, 
32, 398 
(20) Thiry, L J Gen Virol 1968, 2, 143 
(21) Contreras, A , Carrasco, L J Virol 1979 29,114 
(22) Bagliom С Biochim Biophys Acta 1966, 729, 642 
(23) Emmerich, В , Hoffmann, H , Erben, V , Rastetter, J Biochim 
Biophys Acta 1976. 447, 460 
(24) Pestka, S Proc Natl Acad Sci USA 1968, 61, 726 
(25) Carraeco, L, Fresno, M , Vézquez, D FEBS Lett 1975,52, 236 
(26) Flynn, G A , Beight, D W Tetrahedron Lett 1984,25, 2655 
(27) ТгакаЫІи, А С Proc Natl Acad Sci USA 1968,59,854 
(28) Sidransky, H , Verney, E J Natl Cancer Inst 1979 63, 81 
(29) Sarma, D S R , Murty, С N , Sidransky, H Biochem Phar 
macol 1974, 23, 857 
(30) Close, Η Ρ , McFarlane, J R Cancer Chemother fiep 1964, 
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(31) McFarlane, J R, YanofT, M , Scheie, H G Arch Ophthalmol 
1966 76 532 
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Boot«, H A , Tijhuis, M W J Org Chem 1981, 46, 3273 
(33) Liskamp, R M J , Zeegen, H J M , Ottenheijm, Η С J J 
Org Chem 1981, 46, 5408 
(34) Helquist, Ρ . Shekhani, M S J Am Chem Soc 1979, 101, 
1057 
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1985 50, 1264 
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cerned with analogues in which several structural param­
eters had been varied simultaneously, mixtures of stereo­
isomers were frequently studied This allowed only a 
limited interpretation of the results with regard to the role 
of the various structural fragments 
To obtain an unambiguous interpretation, we prepared 
recently eight analogues of sparsomycin (i e , 2-8 and 15) 
possessing not more than two structural modifications of 
the sparsomycin molecule 9 
The cytostatic activity of sparsomycin and these eight 
analogues against intact murine leukemia L1210 cells in 
an in vitro clonogenic assay was studied 9 We found that 
the cytostatic activity changed significantly by modifying 
some of the substituents of sparsomycin To determine 
whether the observed structure-activity relationship re­
flects the affinity of the compounds studied for the pep-
tidyl transferase center, we decided to investigate the ac­
tivity of these analogues and six additional ones (i e, 9-14) 
in cell-free protein-synthesizing systems The results are 
reported here A prokaryotic as well as an eukaryotic 
cell-free system was chosen for this study, and m both cases 
the fragment reaction47 for peptide bond formation as well 
as the polyphenylalanine synthesis assay was used. 
So far several studies have been reported that deal with 
structure-activity relationships of sparsomycin and ana­
logues in cell-free systems S 1 1 1 2 M 3 * 3 7 3 9 In all of these 
studies the puromycin assay43 was used Therefore, in 
order to correlate our results with those obtained previ­
ously, we also used the puromycin reaction Next to the 
in vitro data, the results obtained in in vivo growth in­
hibition tests using several Gram-positive and Gram-neg­
ative bacteria are reported Finally, the inhibitory activity 
(43) Goldberg, I H , Friedmann, Ρ A Pure Appi Chem 1971,28, 
499 
(44) Nirenberg.M W.Matthei.J H Proc Natl Acad Sci USA 
1961, 47, 1588 
(45) Barr, Ρ J , Jones, A S , Verhelst, G , Walker, R Τ J Chem 
Soc , Perkin Trans 1 1981. 1665 
(46) Cammarano, Ρ , Teichner A Londei Ρ , Acca, M , Nicolaus, 
Β. Sanz, J L, Amila, R EMBO J 1985, 4, 811 
(47) Monro, R E Methods ЕлгутоІ 1971, 20, 472 
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of the six newly synthesized analogues against lymphocytic 
leukemia L1210 cells in vitro was studied. 
Resulte 
Chemistry. The compounds studied are listed in Table 
I. The syntheses of analogues 2-8 and 15 as well as the 
rationale for their selection have been described before.9 
Compound 9, benzylsparsomycin, was prepared as de­
scribed earlier9 for the synthesis of octylsparsomycin (8). 
The a-chloro sulfoxide 18 was used as a key intermediate 
in the synthesis (see Scheme I). The diastereomeric 
sulfoxides 18 and 19 were separated by column chroma­
tography on silica gel. Substitution of the chlorine atom 
in 18 by SCH2Ph and subsequent removal of the amino 
protecting group yielded the amine 22. This compound 
was coupled in a mixed anhydride procedure with acid 2732 
to give analogue 9. For the preparation of compounds 10 
and 11 the S-oxidated and S-alkylated cysteinol derivatives 
24a and 24b were used. The sulfoxides 24 and 25 were 
easily obtained from the corresponding sulfide by oxidation 
with sodium metaperiodate and subsequent separation of 
the resulting diastereomers by column chromatography on 
silica gel. Removal of the N-protection group in 24a and 
24b yielded compounds 26a and 26b, respectively. The 
amino alcohols 26a and 26b were coupled with acid 27 to 
give the analogues 10 and 11. By coupling of 20 and 21 
with acid 27, the sparsomycin derivatives 12 and 13 were 
obtained. Compound 14, uracilsparsomycin, was obtained 
by the same reaction sequence used for the preparation 
of 1: now uracil acrylic acid 284 5 was used instead of 27. 
C T ^ N 
Η 
он 
27 R.CHs 
2eR=H 
26 
Biological Activity. The assays used and results ob­
tained are described briefly here. 
Inhibition of Polyphenylalanine Synthesis4 4 (See 
Table II). Sparsomycin (1) and analogues 2-15 have been 
tested in a cell-free system for phenylalanine polymeri­
zation with use of ribosomes and supernatant factors from 
three different species, i.e., Saccharomyces ceremsiae, 
Escherichia coli, and Sulfolobus solfatancus, belonging 
to the eukaryotes, eubacteria, and archaebacteria, re­
spectively. In these species, three analogues show a con­
siderably higher activity than sparsomycin, i.e., octyl­
sparsomycin (8), benzylsparsomycin (9) and S-oxo-S-
decylsparsomycin (11). Compounds 10 and 12 show some 
activity in this assay. S. solfatancus is rather insensitive 
to sparsomycin as it is to most antibiotics;46 in this species 
only the analogues 9 and 11 have E D ^ values lower than 
100 μΜ. The activity of compound 15 is commented on 
in the Discussion. Further, the polymerization assay does 
not discriminate between the activities of the various less 
active analogues in this assay (i.e., 2-7 and 12-14). 
Inhibition of the Fragment Reaction (See Table II). 
The simplest model assay for peptide bond formation is 
the fragment reaction.47 In this test the ribosome catalyzes 
the transfer reaction between the donor substrate, i.e., 
N-acetyl-Leu-ACCAC(U), and puromycin in the absence 
of both mRNA and even the small ribosomal subunit. The 
reaction requires, however, the addition of an organic 
solvent. This assay has been used extensively to study the 
mode of action of several antibiotics.3 
Our results are depicted in Table II. A comparison of 
the activity of the compounds tested in the polyphenyl­
alanine synthesis assay and in the fragment reaction 
demonstrates that in both assays sparsomycin is quite 
active. This does not hold for the analogues; compounds 
10 and 12 are very active in the fragment reaction, as well 
as in all but one of the other assays reported in Table II. 
Only in the polyphenylalanine synthesis assay these com-
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Table II. Inhibition of Peptide Bond Formation and L1210 Leukemia Colony Formation by Spareomycin and Ita Derivatives 
compd 
1 
2 
3 
4 
S 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15' 
E coli 
8 5 
2000 
2000 
2000 
2000 
2000 
2000 
1 6 
0.6 
140 
1 8 
450 
2000 
600 
22 5 
polyphenylalanme" 
S ceremsme 
5 2 
2000 
2000 
2000 
2000 
2000 
2000 
1 3 
0 6 
42 
0 2 
220 
2500 
1000 
10 
synthesis in: 
ED», 
5 solfalancus 
900 
60 
1000 
30 
5000 
5000 
μΜ 
fragment 
E coli 
3 2 
1000 
700 
1000 
550 
1000 
750 
60 
7 6 
4.5 
5000 
7 6 
5000 
30 
14 5 
reaction 0 in 
5 cerevisiae 
2 8 
1000 
65 
650 
150 
550 
350 
300 
2 6 
6 2 
700 
17 
5000 
50 
32 5 
puromycin" 
reaction in 
£ . cod 
0 1 
100 
13 
40 
7 
looo 
160 
0 25 
0 13 
0 23 
0 08 
0 65 
5000 
50 
0.4 
IDs,, μΜ L1210 
0 40' 
300» 
5 8' 
300' 
12 8 ' 
300» 
180' 
0 1 0 ' 
0 1 1 
0 75 
0 14 
0 29 
30 
12 7 
0 85» 
"The values given are the average of three experimenta and have an average error of ±20% 
and 15 (ratio 2 3) was used.9 'The data are from ref 9
 CA mixture of 1 
Table III. Effect of Different Organic Solvents on Inhibition of 
the Fragment Reaction by Spareomycin and Three Analogues6 
percent of inhibition by 
solvent 
methanol 
ethanol 
2-propanol 
butano! 
1, 10 
μΜ 
57 
91 
64 
86 
9, 10 
μΜ 
25 
29 
20 
54 
11, 100 
μΜ 
44 
35 
12 
15 
1,20 
μΜ 
64 
92 
76 
8,200 
μΜ 
42 
30 
6 
"The percent of inhibition at the given drug concentration is 
shown In eipenment A 100% activity in the absence of drug 
corresponds to 2300, 1670, 1510, and 760 cpm in case of methanol, 
ethanol, 2-propanol, and butanol, respectively. In experiment В 
100% activity in the absence of drug corresponds to 1110, 905, and 
925 cpm in case of methanol, ethanol, and 2-propanol, respectively. 
In all cases the final concentration of the organic solvent in the 
reaction mixture was 33% 
pounds are considerably less active than sparsomycin. An 
opposite effect can also be found in Table II. In the 
fragment reaction the hydrophobic analogues 8, 9, and 11 
are as active (i.e., 9) or considerably less active than 
sparsomycin. In the polyphenylalanine synthesis—and as 
a matter of fact in all the other assays mentioned in Table 
II—these analogues are more active than sparsomycin. So 
it appears that in all but one assay an increase in lipo-
philicity of a compound is accompanied by an increase of 
activity of that compound; only the fragment reaction fails 
to demonstrate this correlation. 
The effect of the organic solvent, used in the fragment 
reaction, on the inhibition of peptide bond formation was 
studied in greater detail. The results shown in Table III 
indicate that the inhibitory activity of the drugs is affected 
by the polarity of the medium in the reaction mixture. 
Inhibition of the Reaction of JV-Acetyl-Phe-tRNA 
with Puromycin (See Table II). A convenient way to 
study the ribosomal function is by the use of the antibiotic 
puromycin, an analogue of the aminoacyladenosine end of 
tRNA. Thus, in the formation of polylysylpuromycin48"60 
and acetylphenylalanylpuromycin,51 sparsomycin acts as 
a competitive inhibitor of the peptidyl transferase reaction 
with respect to puromycin. This reaction, in the presence 
of the cognate mRNA and 70S ribosomes, is another 
(48) Goldberg, Ι Η , Mitaugi, К Biochemistry 1967, 6, 372 
(49) Goldberg. Ι Η ; Mitsugi. К Biochemistry 1967. 6, 383 
(50) Goldberg. I Η Cancer Chemother Rep.. Part I 1974.58.479 
(51) Pestka, S Methods Emymol 1974.30 
standard assay for peptide bond formation and useful in 
the study of antibiotics.52 This assay is considerably more 
sensitive to the drugs studied than the two systems pre­
viously described. The large differences in activity between 
the derivatives found in the polymerization assay and to 
a lesser extent in the fragment reaction are markedly re­
duced in this assay. Compounds 8-11 show comparable 
activity to sparsomycin itself. 
L1210 Clonogenic Assay (See Table II). The inhib­
ition of colony formation of leukemia L1210 cells in soft 
agar medium (0.3%) by sparsomycin (1) and the analogues 
2-8 and 15 was used as a first evaluation of the antitumor 
activity of these drugs.9 It was observed that there is a 
good correlation between the in vitro and in vivo activity 
of drugs tested. Thus, the in vitro system is of predictive 
value for the leukemia L1210 in vivo system in the mouse, 
which is generally used in standard screening of com­
pounds of potential interest. In Table II the IDg, values 
of the analogues 9-14 and the previously reported values9 
of compounds 1-8 and 15 are presented. Only the lipo­
philic analogues (i.e., 8, 9, and 11) and, surprisingly, also 
compound 12 are more active than sparsomycin in this 
assay. 
Inhibition of Bacterial Growth (See Table IV). 
Several Gram-positive and Gram-negative species were 
assayed. The inhibitory capacity of the antibiotics on the 
growth of these cells was tested in bacterial cultures by 
using the agar plate technique. In the case of E. coli 
MRE600 the inhibition test was also carried out in liquid 
medium; the results are summarized in Table IV. As ex­
pected, the extent of inhibition depends not only on the 
organism but also on the antibiotic used. Compounds 1 
and 9-14 were also tested against Pseudomonas aeruginosa 
but were found to be inactive. 
Discussion 
Of the four stereoisomers 1-4 tested, sparsomycin (1) 
having the S cßs chirality is by far the most potent in-
hibitor of protein biosynthesis. This confirms the previ-
ously made observations about the requirement for the 
proper configuration at the two chiral centers of sparso-
mycin for its activity: the S c ß s stereoisomer is the 
strongest inhibitor of protein synthesis in a cell-free system 
as measured by the puromycin reaction on polysomes" and 
has the highest cytostatic activity against intact murine 
(52) Bemabeu, С ; Vázquez, D.; Ballesta. J. P. G. Eur. J. Bwchem. 
197«, 69, 233. 
Table 
compd 
IS 
IV. Inhibition of Bacteri 
E coli 
MRF.600 
liquid6 
1 (11) 
0 01 
0 92 
0 32 
1 8 
0 01 
0 40 
2 5 
1 
0 30 
3 6 
0 55 
0 0 1 
0 27 
0 47 
E col, 
MRE600 
1 (14) 
0 
1 
0 5 
1 5 
0 
0 6 
0 7 
12 
0 7 
1 1 
0 8 
0 
0 7 
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lal Growth by Sparsomycin and It4 Derivatives" 
E coi. 
AB301 
1 (14) 
0 
0 6 
0 2 
0 4 
0 
0 2 
0 
0 
1 
0 
1 1 
0 
0.9 
0 7 
£ coii 
N281 
1 (18) 
0 
0 8 
0 1 
0 6 
0 
0 4 
0 
0 3 
1 
0 
1 
0 
0.5 
0 8 
E coli 
W3110 
1 (14) 
0 
0 6 
0 1 
0 6 
0 
0 2 
0 
0 1 
0.7 
0 
0 7 
0 
0 7 
0 8 
Bacillus 
cereus 
1 (10) 
0 
0 3 
0 1 
Ofi 
trace 
trace 
0 1 
0 9 
1 
1 9 
2 
0 
0 3 
0 7 
Bacillus 
subtili* 
1 (7) 
0 
0 
0 
0 9 
0 
0 
oi 
0 
0 6 
2 4 
1 2 
0 
trace 
0 4 
Saremo 
lutea 
1 (10) 
0 
0 3 
0 
0 6 
0 
0 
12 
3 3 
1.2 
3 6 
1 2 
0 
0 
0 8 
Salmonella 
typhimunum 
1 (6) 
0 
0 
0 9 
0 
1 2 
0 
0 
Corine 
bacteri-
um 
serosib 
1 (20) 
0 
0 1 
0 
0 5 
0 
0 
0 1 
1 
0 4 
0 6 
0 5 
0 
0 
0 7 
35 
Staph\l-
ococcus 
aureus 
1 (7) 
0 
0 
0 
trace 
0 
0 
trace 
0 7 
0 
0 7 
0 
0 
0 4 
" The diameter of the inhibition zone on agar plates was used as a measure for the activity of each drug The numbers given express the 
ratio of the diameter measured for a drug and the diameter measured for sparsomvcin The diameter (in millimeters) of the inhibition zone 
for sparsomycin is given in parentheses ''The numbers express the ratio of the EDM, value of sparsomvcin and the ED«, \я!ис of the 
analogue, EDjo representa the dose in μΜ that inhibits growth to 50% of control growth The EDJQ value for sparsomvcin is given m 
parentheses 
leukemia L1210 cells9 (see Table II). 
Confirmation of this conclusion as far as the chiral 
carbon atom is concerned is found in the IDJQ, and bac­
terial growth inhibition values of the S-deoxo analogues 
5 and 6; compound 5 having the S configuration at the 
chiral carbon atom is substantially more active than its 
enantiomer 6. 
A comparison of the IDjo, ED^,, and bacterial growth 
inhibition data of compounds 1 vs 3 and 12 vs. 13 (see 
Tables II and IV) stresses the importance for the correct 
chirality at the sulfoxide sulfur atom. Particularly, ana­
logue 13 is totally inactive in all the assays tested. 
The low activity of the S-deoxo analogue 5 is remarka­
ble, since a racemic mixture of 5 showed a comparable 
activity to sparsomycin in the puromycin reaction.36·37 Our 
results employing the puromycin reaction as well as all 
other assays used (see Table II) indicate that compound 
5 is less active than sparsomycin. This discrepancy in 
results indicates that one has to be careful in the com­
parison and interpretation of data obtained in different 
systems. Another example that underlines this view can 
be found in Table II. Comparison of the E O
w
 values of 
1, 3, and 5 obtained in the fragment reaction in S. cere-
uisiae suggests that the presence of an oxygen atom on S(a) 
increases the activity, whereas this reaction in E. coli in­
dicates that the stereochemistry of the sulfoxide sulfur 
atom is more crucial than its oxidation state. 
The importance of the sulfoxide moiety of sparsomycin 
has been alluded to in the past 3 7 A comparison of the IDs, 
and EDJO values of 1, 3, and 7 indicates that the proper 
position of the sulfoxide moiety in the cysteinol side chain, 
S(a) vs. S(/?), is important. In addition, analogue 7 shows 
a diminished activity compared to the corresponding S-
deoxo analogue 5, suggesting an adverse effect of a sulf­
oxide function at the S(ß) position in both the S. cerevisiae 
cell-free system employing the fragment reaction and in 
the puromycin reaction. 
The results obtained with IS suggest that this compound 
is inactive. Starting from this assumption, the experi-
mental data for 15 are in accordance with calculated IDM 
and EDJO values based on pure 1 and on the observed ratio 
1/15 = 2:3. Previously, we had estimated that 15 has still 
considerable activity.' This conclusion had to be corrected 
as it is the result of an error in calculation. Future ex-
periments will be necessary to clarify the activity of pure 
cis-sparsomycin (15). Analogue 14 lacking the C(6)-methyl 
group shows low activity in all tests, indicating that this 
methyl group is important for an optimal activity. 
The results on analogues 8, 9, and 11 indicate that the 
addition of a large hydrophobic group at the sulfur-con-
taining end of the sparsomycin molecule increases the 
activity of the drug considerably. These analogues are 
considerably more active than the unmodified drug in both 
the polymerization and in the L1210 colony formation 
assays Comparison of the activity of compounds 1,8, 10, 
and 11 suggests that the presence of the bivalent sulfur 
atom is not required for activity when the added hydro-
phobic side chain is sufficiently large. The activity of 
compound 10, in which the bivalent sulfur atom has been 
substituted by a CHj group, is partially affected (see Table 
II). Substitution of the SCH·) moiety by a CI atom (12) 
also reduces the activity of the molecule. 
Remarkably, the hydrophobic drugs 8, 9, and 11, al-
though quite active in the polymerization assay, are almost 
inactive in the fragment reaction A possible explanation 
for these observations can be found in the reaction con-
ditions used for this reaction. The reaction is carried out 
in the presence of 33% of aqueous ethanol. Organic sol-
vents altering the polarity of the medium are known61,62 
(53) (a) For hydrophobic effects in the peptidyl transferase center, 
see: Rychlik, I., Cerna, J ; Chlâdek. S , Pulkrábek, Ρ , Zemlrôka, 
J Eur.J.Biochem. 1970,16. 136 (b) Chlâdek, S In Biological 
Implications of Protein-Nucleic Acid Interactions, Augus-
tyniak, J., Ed., Elaevier-North Holland Biomedical: Amster-
dam, 1980; pp 149-173. 
(54) Pörez-Gonzalez, J Α.; Vara, J.; Jiménez, A. J Gen. Microbiol. 
1985, 131, 2877 
(55) Slechta, L Antimicrob. Agents Chemother. 1965, 326 
(56) Fernández-Muñoz, R.; Vázquez, D. Mot Biol Rep 11973, Λ 
27 
(57) Staehelm, T.; Magio«, D. R. Methods Enzymol 1971,20,449. 
(58) Sánchez-Madrid, F.; Reyes, R., Conde, Ρ , Balleeta, J P G . 
Eur. J Biochem 1979, 98. 409 
(59) Brownlee, P. J Ε.; Cox, M. E., Handford, В. О ; Marsden, J. 
С, Young, G Τ J. Chem. Soc 1964, 3832 
(60) Ottenheijm, H. С. J., v. Niepen, S P. J. M., Sinnige, M. J. 
Tetrahedron Lett 1976, 1899. 
(61) Fernández-Muñoz, R ; Monro, R Е., Torres-Pinedo, R , 
Vázquez, D. Eur J. Biochem 1971, 23, 185. 
(62) Bernabeu, С , Vázquez, D ; Ballesta, J P G FEBS Lett. 1979, 
99, 251. 
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to affect the affinity of substrates for the nbosome In 
particular, lipophilic substrates are expected to be most 
sensitive to this effect If so, changing the polarity of the 
solvent would change the affinity of one particular drug 
for the nbosome Moreover, this change would be de­
pendent upon the lipophihcity of the analogue The data 
from Table III clearly show that the inhibitory activity of 
the drug is indeed dependent upon the polarity of the 
organic solvent For compounds 8 and 11a correlation was 
found in that an increase in lipophihcity of the alcohol used 
resulted in a decrease in activity of the drug Care is 
necessary when using the fragment reaction to compare 
analogues with different physicochemical properties 
In spite of the high activity in the polyphenylalanme 
synthesis assay, the hydrophobic derivatives 8, 9, and 11 
are roughly equivalent to sparsomycin when tested in the 
puromycin reaction Sparsomycin is known63-65 to com­
pete with the acceptor substrate for binding to the peptidyl 
transferase A site These results can be rationalized as 
follows " Sparsomycin has structural similarities with the 
3' end of the acceptor tRNA molecule The binding of 
sparsomycin to a site on the peptidyl transferase center 
that partially overlaps with the interaction site for the 
aminoacylademne moiety of the aminoacyl-tRNA is the 
most straightforward mechanism of action The bound 
drug will totally block the interaction of small-size sub­
strates, such as the З'-terminal fragments and puromycin 
It is also able to disturb the correct positioning of the 3' 
end of the large aminoacyl-tRNA molecule In both cases, 
the formation of the peptide bond will be inhibited It 
should be pointed out here that the polyphenylalanme 
synthesis assay may reflect inhibition of several particular 
reactions whereas the puromycin reaction is a model of 
formation of a single peptide bond 
This hypothesis of overlapping binding sites agrees with 
the competitive nature of the puromycin reaction inhib­
ition by sparsomycin It is compatible with a high sen­
sitivity of this reaction to sparsomycin (ED^, ~ 0 1 μΜ), 
considering the low affinity of puromycin for the nbosome 
(K, ~ 100 μΜ) M In the case of the amino acid polym­
erization assay, the higher affinity of aminoacyl-tRNA for 
nbosomes (if, ~ 1 μΜ) explains the lower sensitivity of 
this reaction toward sparsomycin ( E D M ~ 1 μΜ) 
The results obtained using the more hydrophobic de­
rivatives of sparsomycin support the view that the binding 
sites of the aminoacyl moiety of aminoacyl-tRNA and 
sparsomycin overlap at the peptidyl transferase 3 The high 
sensitivity of the phenylalanine polymerization assay to 
sparsomycin analogues carrying a hydrophobic group at 
the sulfur-containing end of the molecule suggests that 
these compounds interact with a region on the peptidyl 
transferase that probably functions as the recognition site 
for the lateral chains of the hydrophobic amino acids 
during protein synthesis The existence of such a region 
at the peptidyl transferase is supported by data obtained 
by using different aminoacyl-A-C fragments as acceptor 
substrates "* It has been reported531' that Phe-A-C, 
probably the most hydrophobic of these substrates, shows 
the lowest K
m
(app) in the peptide bond forming reaction, 
suggesting that it has the highest affinity for the nbosome 
Recent data indicate that demethylation of the tyrosine 
residue in puromycin abolishes the activity of this anti­
biotic м So, apparently, puromycin displays like sparso-
(63) Hishizawa Τ Lessard, J . Peatka, S Proc Ναίί Acad Sci 
USA 1970 66 523 
(64) Hishizawa Τ Pestka, S Arch Bwchim Biophvs 1971 147, 
624 
(65) Peslka S Proc Natl Acad Sci USA 1969 64,709 
mycin a hydrophobic interaction with the nbosome On 
the basis of our results, we anticipate that increasing the 
hydrophobicity at the tyrosine end of puromycin will in­
crease the inhibitory activity of the molecule We are 
presently synthesizing such puromycin derivatives 
The data from the peptide bond formation assays cor­
relate well (except for compound 12) with those on in­
hibition of L1210 colony formation (see Table II) This 
correlation—not found with prokaryotic cells (vide in­
fra)—confirms that in eukaryotic cells inhibition of protein 
synthesis is the mam effect of sparsomycin and derivatives 
Support for this is found by the isolation of a mouse 
mammary carcinoma cell line resistant to the antibiotic 
blasticidin S 1β This mutant cell line--altered m the 60S 
nbosomal subunit—shows some cross-resistance to spar­
somycin 
The effect of sparsomycin and analogues on the growth 
of several bacteria in the solid phase, as well as in liquid 
medium, was studied The results of this study, which are 
summarized in Table IV, allow the following conclusions 
(1) Only a partial correlation exists between the observed 
structure-activity relationship in whole-cell systems and 
that observed in the cell-free peptide bond formation as­
says The relationship between the chiralities at the carbon 
and the sulfur atom and the antibacterial activity corre­
lates, for all species tested so far, to that observed in the 
peptide bond formation assays, compare the activities of 
compounds 1-6, 12, and 13, shown in Tables II and IV 
(2) In most of the bacteria tested there is no correlation 
between the activity of a given drug in peptide bond for­
mation assays and the antibacterial activity The hydro­
phobic analogues 9 and 11 show high activity in the po­
lymerization and puromycin reaction but are inactive 
against £ coil AB301, E coli W3110, S aureus, and S 
typhimurium in the bacterial growth inhibition assay 
This inactivity might be the result of permeability barriers 
(3) Conversely, compounds 3, 5, 7, and 12, which show 
a low activity in the peptide bond formation assays, are 
surprisingly active against E cok MRE600 and N281 
Besides, compound 12 showed in the L1210 test a re­
markable high activity and is very active against practically 
all species tested One might interpretate this result on 
the basis of changes in the permeability properties of these 
derivatives, facilitating their penetration through the cell 
membrane However, this explanation is unlikely, since 
the growth inhibition observed would then have required 
a too high concentration of the analogue inside the cell to 
be realistic. 
It is worthwhile to note that in initial studies on the 
mode of action of sparsomycin on bacteria, the release of 
amino acids to the growth medium was reported я On the 
basis of this and of the above-mentioned results, it is 
questionable whether alterations in cell membrane 
permeability are associated with cell growth inhibition 
Therefore, a direct action of the drug on the membrane 
permeability cannot be excluded 
(4) The antibacterial activity of analogues 5, 8, and 11 
depends on the species as well as on the strain used The 
stram dependency is illustrated by the fact that, of the four 
E coli strains tested, only the growth of strain MRE600 
is inhibited by compounds 8 and 11 Compound 5 is only 
against this strain more active than sparsomycin Pres­
ently, ignorance of the permeability mechanisms for 
sparsomycin as well as that of the detailed cell wall 
structures of the different bacterial species and strains 
precludes an interpretation of these data 
So far, we have not been able to assess unambiguously 
the role of the hydroxy function of sparsomycin In order 
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to achieve this, the O-methylated derivative of 1, as well 
as analogues in which the hydroxyl group has been re­
placed by hydrogen, has been prepared The activities of 
these compounds will be the subject of a future report 
Experimental Sect ion 
Biological Activity. The peptidyl transferase activity was 
measured by the polyphenylalanme synthesis assay, the fragment 
reaction, and the puromycin reaction In all the in vitro tests, 
ι e , polyphenylalanine synthesis, fragment reaction, and puro­
mycin reaction, nbosomes from E coli MRE600 and 5 cereuisiae 
Y166 were used 
The reaction mixture for polyphenylalanine synthesis was 
slightly different for E coli, S cereuisiae, and S solfataricus 
E. coli. The reaction mixture (50 ML) contained 50 mM 
Tris-HCl, pH 7 6, 15 mM MgCl2, 90 mM KCl, 15 mM 0-mer-
captoethanol, 1 mM GTP, 10 mM ATP, 0 2 mg/mL polyundylic 
acid, 1 5 mg/mL tRNA, 0 3 mM nbosomes, 2 5 mg/mL phos-
phoenol pyruvate, 20 Mg/mL pyruvate kinase, the required con 
centration of spaisomycm or its analogue, and 5 ßh of supernatant 
fraction S-100 Subsequently, 30 μΜ ('Hlphenylalamne (about 
60 cpm/pmol) was added to start the reaction Incubation was 
at 37 °C for 30 mm The reaction was stopped by the addition 
of 1 mL of 10% TCA, and the samples were filtered through glass 
fiber filters The filters were washed with 10 mL of cold 10% 
TCA, dried, and counted for radioactivity 
S. сеге івіае. The test was carried out as indicated above 
for E coli The phophoenol pyruvate and pyruvate kinase were, 
however, replaced by creatine phosphate (20 mM) and creatine 
Phosphokinase (50 Mg/mL) The incubation was performed at 
30 °C for 30 min, and the samples were processed as described 
above 
Under these conditions the control samples polymerized 5-14 
and 3-8 molecules of phenylalanine per nbosome derived from 
E coli and S cereuisiae, respectively Riboeomes and supernatant 
factors from E coli and S cereuisiae were prepared according 
to standard procedures 5 7 '5 e 
S. solfataricus. The reaction mixture (63 μΐ,) contained 15 
mM Tris-HCl, pH 7 3,6 mM NH,C1,18 mM magnesium acetate, 
1 mM dithiothreitol, 3 mM spermine, 2 4 mM ATP, 1 6 mM GTP, 
0 16 mg/mL poly(U), 20 μΜ [3H]phenylalanine, 0 3 μΜ nbosomes, 
and 5 ML of supernatant fraction S-100 The incubation was 
carried out at 75 e C for 40 mm, and the samples were processed 
as described above for E coli 
Riboeomes and supernatant factors from S solfataricus were 
prepared as has been described earlier M 
The fragment reaction was carried out in 150 μί, of 33 mM 
Tris-HCl pH 7 4, 270 mM KCl, 13 mM magnesium acetate 
containing 1 mg/mL nbosomes, 2 mM puromycin, 1 pmol of 
N-acetyl-[3H]Leu-ACCAC(U), the required concentration of 
sparsomycin or its analogue, and 33% methanol The reaction 
was initiated by the addition of the alcohol and allowed to proceed 
at 0 0C for 30 min and was then stopped by the addition of 100 
ML of 0 3 M sodium acetate, pH 5 5, saturated with MgSO« The 
samples were extracted with 1 5 mL of ethyl acetate, and 1 mL 
of the organic phase was checked for radioactivity The 3'-terminal 
pentanucleotide N-acetyl-[3H]Leu-ACCAC(U) was prepared from 
N-acetyl-[3H|Leu-tRNA by ribonuclease Tl as described by 
Monro47 
The puromycin reaction was earned out in 25 ßL of 30 mM 
KCl, 50 mM ΝΗ,α, 30 mM Tns-HCl, pH 7 8, 20 mM MgCl2,10 
pmol of nbosomes, 100 Mg/mL poly(U), and 15 pmol of JV-
acetyl-[3H]Phe-tRNA The reaction mixture was incubated for 
30 min at 37 °C, and then 1 ML of 20 mM puromycin was added 
and incubation was followed for an additional 5 mm To the 
samples were added 250 ML of 0 1 M sodium carbonate and 0 7 
mL of ethyl acetate, the samples were shaken for 1 mm centnfuged 
to separate the phases, and 0 5 mL of the upper organic phase 
was taken for estimating the radioactivity 
Inhibition of bacterial growth was tested in solid as well 
as in liquid medium For the test on agar plates, petn dishes 
containing 15 mL of LB medium (10 g/L bactotryptone, 5 g/L 
yeast extract, and 5 g/L NaCl) were covered with 5 mL of the 
same medium (kept melted at 40 °C) containing 40 ML of a culture 
of the required bacterium at approximately an A^o of 2 After 
solidification, 3-mm filter disks containing 4 ML of a 10 mM 
solution of the antibiotic in 50% EtOH/Me^SO were placed on 
the surface of the agar, and the plates were incubated at 37 0C 
for 24 h 
For the test in liquid medium, E coli MRE600 was grown in 
LB medium supplemented with 0 2% of glucose to exponential 
phase (Адо = 0 1) and distributed in 1-mL aliquots in tubes 
containing the required amount of antibiotic The tubes were 
incubated at 37 °C for 4 h and subsequently diluted with 3 mL 
of 0 1 % of sodium azide to stop growth, and the absorption at 
550 nm was measured The absorption of the medium without 
addition of antibiotic was considered as 100% growth 
Synthesis. 'H NMR spectra were measured on a Bruker 
WH-90 spectrometer with Me4Si or Me3SiCD2CD2C02Na as an 
internal standard For determination of the specific rotation, a 
Perkm-Elmer 241 Polarimeter was used Thin-layer chroma­
tography (TLC) was carried out by using Merck precoated F-254 
plates (thickness 0 25 mm) Spots were visualized with a UV lamp, 
ninhydrm, and CI2 TDM № For column chromatography, Merck 
silica gel H (type 60) was used Mass spectra were recorded on 
a double-focusing VG 7070E mass spectrometer 
(Sc«s)-2 iß («-Methyl-5-uracilyl)acrylamido]-3-[[(ben-
zylthio)methyl]eulfinyl]propanol (9, Benzylsparsomycin). 
This compound was obtained in 60% yield by coupling 22 (2 78 
mmol with 27 in a mixed anhydride procedure following the 
procedure described earlier9 for the synthesis of octylsparsomycin 
(8) The compound was homogeneous on TLC (Rf 0 53 
МеОН/СНСІз, 1 4), lH NMR (D20) δ 2 42 (s, 3 H, С(б)-СНз), 
2 77-3 22 (m, 2 H, CHCHjSfO)), 3 64-3 77 (m, 2 H, CH2OH), 3 88 (s, 2 H, SCH2Ph), 3 89 and 4 02 (AB q, </Ав = 14 0 Hz, 2 H, 
S(0)CH2S), 4 55-4 78 (m, 1 H, CHCH2OH), 7 03 and 7 47 (AB 
q, J A B = 16 0 Hz, 2 H, CH=CH), 7 33 (br s, 5 H, Ph), FAB MS, 
m/e 438 ( M + + 1), [α]^+121» (с 0 135, H20) Anal Caled for 
СиДа^ОА-гНгО С, 48 19, Η, 5,74, Ν, 8 87 Found С, 48 88, 
Η, 5 30, Ν, 8 81 
(S
c
«
s
)-2-[£-(6-Methyl-5-uracilyl)acrylamido]-3 [ η -
propylsulfinyljpropanol (10, S-Oxo-S-propylsparsomycin). 
Compound 10 was prepared in 52% yield by coupling 26a (0 65 
mmol) with 27 in a mixed anhydride procedure as has been 
described earlier9 for the preparation of 8 TLC R/ 0 27 (eluent 
МеОН/СНСІз, 1 4), Ή NMR (D20) 6 1 06 (t, J = 7 6 Hz, 3 H, 
СН2СНэ), 1 80 (hextet, J = 8 0 Hz, 2 H, СН2СЯ2СНз), 2 40 (s, 
3 H, С(б)-СНз), 2 93 (t, J = 7 5 Hz, СН2СН2СНз), 3 10 (d, J = 
3 0 Hz, 2 H, CHCHjSfO)), 3 70 and 3 77 (AB part of ABX 
spectrum, 7 lines, J ^ = 3 6 Hz, J B X = 6 3 Hz, J ^ = 11 4 Hz, 2 
H, CH2OH), 4 36-4 64 (m, 1 H, CHCH20H), 7 04 and 7 40 (AB 
q, J A B = 15 6 Hz, 2 H, CH=CH), FAB MS, m/e 344 (M+ + 1), 
[apt, +98 9° (c 0 185, H20) Anal Caled for CnH^NjOsS^HjO 
C, 44 31, H, 6 64, N, 1107 Found C, 44 31, H, 6 43, N, 11 04 
(S
c
A
s
)-2-[/J-(6-Methyl-5-urBcilyl)acrylamido]-3-[n-
decyUulfinyl]propanol (11, 5-oxo-S-decylspareomycin). 
This compound was obtained in 13% yield by coupling 26b (1 19 
mmol) with 27 in a mixed anhydride procedure following the 
procedure described earlier9 for the preparation of 8 The com­
pound was homogeneous on TLC (Я, 0 47, МеОН/СНСІз, 1 4), 
FAB MS, m/e 441 (M+), [ a p o +57° (с 0 175, MeOH), Ή NMR 
(D20 + NajCOj) { 0 71-0 93 (m, 3 H, СНгСНз), 1 04-1 48 (m, 16 
H, (СЯ2)вСНз), 2 38 (s, 3 H, С(б)-СНэ), 2 82-3 24 (m, 4 H, 
CHCH£(0), S(0)CH2CH2), 3 64-3 84 (m, 3 H, CHCH2OH), 6 97 
and 7 61 (AB q, J « = 15 0 Hz, 2 H, CH=CH) Anal Caled for 
C2iH38N305S2-2H20 C, 52 81, H, 8 22, N, 8 79 Found С, 51 38, 
H, 7 33, Ν, 8 67 
(SCÄS)- and (ScSs)-2-[/î-(6-Methyl-5-uracilyl)acryl-
amído]-3-[(chloromethyl)eulfinyl]propanol (12 and 13, 
Chloroeparsomycin). These compounds were prepared from 
the corresponding a-chloro sulfoxides 18 (0 34 mmol) and 19 (1 
mmol), respectively The Boc group was removed with tn-
fluoroacetic acid according to the procedure that has been de-
scribed earlier 32 Treatment with 1 equiv of tnethylamine gave 
20 and 21, respectively, which were coupled with 27 in a mixed 
anhydride procedure following the procedure described earlier9 
for the preparation of 8 The yields were 31% and 20% for 
compounds 12 and 13, respectively Both compounds were ho-
mogeneous on TLC (12, R/O 15, 13, fyO 19, МеОН/СНСІз, 1 4) 
(66) Arx, E von, Faupel, M J Chromatogr 1976, 120, 224 
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For 12 Ή NMR (DjO) ί 2 40 (β, 3 Η, C(6) CHj) 3 10 and 3 33 
(AB part of ABX spectrum, 7 lines, J^ = 3 6 Hz, J B X = 11 7 Hz, 
J A B - 14 4 Hz, 2 H, CHCH2S(0)), 3 75 (d, J = 3 0 Hz 2 Η 
CHjOH), 3 98-4 53 (m, 1 H, CHCH2OH) 4 81 and 4 96 (AB q, 
.¡m = 12 0 Hz, 2 H, S(0)CH2C1), 7 05 and 7 41 (AB q, ^  = 162 
Hz, 2 H, CH=CH), FAB MS, m/e 350 (M* + 1) [ α ] 2 5 0 +102° (cOU.HjO) Anal Caled for CSHUNJOSSCI-VJHJO C, 40 17, 
H, 4 77, N,1171 Found C, 39 94, H, 4 46, N, 11 43 
For 13 Ή NMR (D20) i 2 40 (s, 3 H, C(6) CHn), 3 22 and 3 38 (AB part of ABX spectrum, 8 lines, JAX = 5 4 Hz, J B X = 9 0 Hz, 
JAB = 13 5 Hz, 2 H, CHCH2S(0)), 3 76 (d, J = 2 5 Hz, 2 H, 
CHjOH), 3 98-4 53 (m, 1 H, CHCH2OH), 4 90 and 5 04 (part of 
AB q, 2 H, S(0)CH2C1), 7 04 and 7 40 (AB q, J A B = 16 2 Hz, 2 
H, CH=CH), FAB MS, m/e 350 (M+ + 1), | o ] B D +14° (с 0 2, 
H20) Anal Caled for С,2Н,6^0,8СІ-72Н20 с, 40 18, H, 4 77, 
Ν, 1171 Found С, 40 20, Η, 4 45, Ν, И 67 
(So-Rs) 2-[0-(5 UracilyDacrylamido] 3 [[(methylthio)-
methyl]sulfinyl]propanol (14, Uracilsparsomycm). Com 
pound 14 was obtained in 30% yield by coupling 20 (0 5 mmol) 
with 28 in a mixed anhydride procedure following the procedure' 
described for the synthesis of 8 TLC Д, 0 20 (eluent MeOH/ 
CHCI3, 1 4), Ή NMR (D20) i 2 26 (s, 3 H, SCH3), 3 14 and 3 22 (AB part of ABX spectrum, 5 lines, JAX = 9 9 HZ ί/
Β
χ = 45 Hz, 
JAB = 13 5 Hz, 2 H, CHCH2S(0)), 3 60-3 82 (m, 2 H, СЯ2ОН), 
3 95 and 4 10 (AB q, J ^ = 14 1 Hz, 2 H, S(0)CH2S), 4 36 4 62 (m, 1 H, CWCH2OH), 6 98 and 7 22 (AB q, JAB = 1« 0 Hz, 2 H, 
CH=CH), 7 88 (s, 1 H, C(6) H), FAB MS, m/e 348 (M* + 1), 
[ o ] 2 5 D +88'' (c 0 171, MeOH/H20, 11) Anal Caled for 
CzHpNaOsSj-HjO C, 39 44, H, 5 24, N, 11 49 Found С 40 27, 
Η, 5 05, Ν, 10 85 
S-Oxo-S-[(benzylthio)methyl]-D-cyBteinol (22). This 
compound was prepared m 98% yield by removal of the Boc group 
from the corresponding N-protected compound (2 84 mmol) by 
treatment with tnfluoroacetic acid following the procedure that 
has been described earlier32 The reaction product was used 
without further purification for the synthesis of 9 
N-(tert-Butyloxycarbonyl)-S-oxo-S-[(benzylthio)methyl)-D-
cysteinol was prepared from 18 (10 9 mmol) by treatment with 
sodium (10 9 mmol) and freshly distilled benzyl mercaptan in 60 
mL of dry ethanol The reaction mixture was worked up following 
the procedure that has been described earlier9 for compound 8 
to give the desired compound m 96% yield TLC fy 0 29, (eluent 
MeOH/CHCl·,, 7 93), Ή NMR (CDCI3) ί 1 44 (s, 9 H, t-Bu) 2 97 
and 3 22 (AB part of ABX spectrum, 8 lines, JAX = 6 6 Hz, JBx 
- 6 0 Hz, JAB = 13 2 Hz, 2 H, СНСЯ23(0)), 3 60 and 3 64 (part 
of AB q, 2 H, S(0)CH2S), 3 73 (m, 2 H, CH2OH), 3 88 (s, 2 H, 
SCH2Ph), 4 06 (m, 2 H, СНСЯ2ОН), 5 51 (d, J = 9 0 Hz, 1 H, 
NH),7 28(brs,5H,Ph) Anal Caled for С 1 6 Н ^ 0 4 8 2 С, 53 46, 
H, 7 01, Ν, 3 90 Found С, 53 46, Η, 6 99, Ν, 3 92 
JV-(tert-Butyloxycarbonyl) S-propyl-D-cysteine Methyl 
Ester (23a). This compound was prepared in 92% yield from 
the hydrochloride of S-propyl-D-cysteine methyl ester (10 mmol) 
by treatment with di-iert-butyl pyrocarbonate following the 
procedure that has been desenbed earlier32 TLC Я/ 0 80 (eluent 
MeOH/CHCl3, 3 97), Ή NMR (CDC13) S 0 97 (t, J = 7 0 Hz, 3 
H, СН2СНз), 1 45 (s, 9 H, í-Bu), 1 48-1 80 (m, 2 H, CHjC/^CHj), 
2 51 (t, J = 7 0 Hz, 2 H, SCH2CH2), 2 95 (d, J = 5 0 Hz, 2 H, 
CHCH2S), 3 77 (s, 3 H, С02СНз), 4 37-4 67 (m, 1 H, CHCH2S), 
5 33 (br d, 1 H, NH) Anal Caled for С 1 2 Н ^ 0 4 8 С, 51 96, H, 
8 36, N, 5 03 Found С, 51 76, H, 8 33, N, 4 97 
The hydrochloride of S-propyl-D-cysteine methyl ester was 
prepared from S-propyl-D-cysteine (20 mmol) by treatment with 
thionyl chloride m methanol following the procedure that has been 
described earlier32 to yield the desired compound in 95% TLC 
R, 0 75 (eluent sec-BuOH/NH4OH, 55 22), Ή NMR (CD3OD) 
6 1 02 (t, J « 7 0 Hz, 3 H, СН2СЯэ), 1 64 (sextet, J = 7 0 Hz, 2 
H, СЯ2СНз), 2 60 (t, J = 7 0 Hz, 2 H, ЗСЯ2СН2), 3 10 and 3 13 (AB part of ABX spectrum, 8 lines, JAX = 4 8 Hz, J B X = 6 9 Hz, 
JAB = 13 5 Hz, 2 H, CHCtfjS), 3 86 (s, 3 H, СОгСНз), 4 31 (X part 
of ABX spectrum, 4 lines, JAX + J B X = 119 Hz, 1 H, СЯСНгЗ) 
S Propyl D-cysteine was prepared from D-cysteine (20 8 mmol) 
and 1 bromopropane with sodium in liquid ammonia according 
to procedures described earlier32·37 38·59·«1 in 98% yield TLC Rf 
0 26 (eluent sec-BuOH/NH4OH, 55 22), Ή NMR (D20) Í 0 93 (t, J = 6 5 Hz, 3 H, СН2СЯз), 1 62 (sextet, J = 7 0 Hz, 2 H, 
СН2СЯ2СНэ), 2 57 (t, J = 7 0 Hz, 2 H, ЗСЯ2СН2), 3 01 and 3 07 
(AB part of ABX spectrum, 8 lines, J « = 4 5 Hz. J B X = 7 5 Hz 
JAB = 14 9 Hz, 2 H, СНСНгЗ), 3 91 (X part of ABX spectrum 
4 lines J A X + J B X = 11 5 Hz 1 H, СЯСН25) Anal Caled for 
CeHnNOjS C, 44 15, H, 8 02, N,8 58 Found C, 44 08, H, 7 96, 
N 8 60 
N (tert Butyloxycarbonyl) S decyl D cysteine Methyl 
Ester (23b) This compound was prepared in 92% yield from 
the hydrochloride of 5-decyl D cysteine methyl ester (15 mmol) 
by treatment with di-terf butyl pyrocarbonate following the 
procedure that has been described earlier32 TLC fy 0 47 (eluent 
MeOH/CHClj, 1 99), Ή NMR (CDCl,) 6 0 88 (br t J = 7 2 Hz, 
3 H, СН2СЯз), 1 15-1 71 (br s, 16 H, (СЯ2)ёСНп), 1 46 (s, 9 H. 
í Bu), 2 53 (t, J = 7 8 Hz, 2 H, SCH2CH2), 2 95 (d, J = 2 5 Hz, 
2 H, СНСЯ28), 3 75 (s, 3 H, СОгСНз), 4 36-4 64 (m, 1 H. 
СЯСН28), 5 33 (br d, I H, NH) Anal Caled for C . ^ N O . S 
C, 60 76, H, 9 93, N, 3 73 Found С, 60 63, H, 9 93, N, .1 68 
The hydrochloride of 5 decyl D cysteine methyl ester was 
prepared in 90% yield from 5 decyl D cysteine (18 mmol) by 
treatment with thionyl chloride in methanol following the pro­
cedure that has been described earlier 3 2 TLC Rf 0 68 (eluent 
sec BuOH/NH4OH, 55 22), Ή NMR (CD3OD) δ 0 84 (br t, J = 
7 9 Hz, 3 H, СН2СЯз), 1 15-1 73 (br s 16 H (СЯ2)вСНз) 2 55 (br 
t, J = 7 2 Hz, 2 H, ЗСЯ2СН2), 3 00 and 3 11 (AB part of ABX 
spectrum, 8 lines, JAX = 4 8 Hz, J B X = 6 6 Hz, JAB = 14 4 Hz, 2 
H, CHCHjS), 3 82 (s, 3 H, С02СНз), 4 24 (X part of ABX spec 
trum, 4 lines, JAX + J B X = 11 7 Hz, 1 H, CHCHjS) Anal Caled 
for С14НзоШ2ЗС1 С, 53 91, H, 9 69, N 4 49 Found С, 52 65, 
H, 9 54, N, 4 39 
S Decyl D-cysteine was prepared m 98% yield from D-cysteine 
(20 8 mmol) and l-bromodecane with sodium in liquid ammonia 
according to procedures described earlier '""з85'™ TLC Л/0 36 
(eluent sec BuOH/NH4OH, 55 22) The reaction product was 
used for estenñcation as described above without purification 
N (tert Butyloxycarbonyl)-S-oxo-S-propyl-D-cyeteiiiol 
(24a and 25a). These compounds were prepared by reduction 
of N-(tert butyloxycarbonyl)-5 oxo-S propyl D-cysteine methyl 
ester (4 mmol) with lithium borohydnde following the procedure 
that has been desenbed earlier 32 Separation of the diastereomers 
by column chromatography on silica gel (eluent MeOH/CH2Cl2, 
3 97) afforded 24a and 25a in 37% and 357» yield, respectively 
Both compounds were homogeneous on TLC (24a, R/ 0 19, 25a, 
R/ 0 22, МеОН/СНСЦ, 7 93) 
For 24a Ή NMR (CDCI3) S 1 08 (t, J = 7 0 Hz, 3 H, СНгСЯз), 
1 42 (s, 9 H, ί Bu), 1 84 (sextet, J = 7 0 Hz, 2 H, СЯ2СНз), 2 47 (br s, 1 H, СН2ОЯ), 2 60-3 15 (m, 4 H, CHCHjStO), SiO)CH2CHJ, 
3 68-3 98 (AB part of ABX spectrum, 2 H, СНСЯ2ОН), 3 98-4 24 (m, 1 H, СЯСН2ОН), 5 46 (br d, 1 H, NH) Anal Caled for 
CuHaNOjS C, 49 79, H, 8 74, N, 5 28 Found С, 49 82, H, 8 64, 
N,5 16 
For 25a 'H NMR (CDCI3) ί 110 (t, J - 7 2 Hz, 3 H, СН2СЯз), 
1 44 (s, 9 H, i-Bu), 1 63-2 16 (8 lines, 2 H, CHjCHj), 2 79 (d of 
t, J = 7 5 Hz, 2 H, S(0)CH2CH2), 3 00 and 3 14 (AB part of ABX 
spectrum, 8 linee, JAX = 6 0 Hz, J B X = 3 1 Hz, JAB = 13 5 Hz, 2 
H, СНСЯ28(0)), 3 56-3 91 (AB part of ABX spectrum, 2 H, 
СНСЯ2ОН), 3 98-4 38 (m, 1 H, СЯСН2ОН), 5 52 (br d, J = 7 Hz, 
1 H, NH) Anal Cakd for CnHaNOiS C, 49 79, H, 8 74, N, 
5 28 Found С, 49 48, H, 8 70, N, 5 16 
N-(tert-Butyloxycarbonyl)-S-oxo-S-propyl-D-cysteine methyl 
ester was prepared by oxidation of the corresponding sulfide 23a 
(5 2 mmol) with sodium metapenodate according to the procedure 
that has been described earlier32 to give the desired product as 
a mixture of diastereomers in 93% yield TLC R/ 0 15 (eluent 
MeOH/CHClj, 5 95), Ή NMR (CD3OD) ί 1 08 (t. J = 7 0 Hz. 
3 H, СН2СЯз), 1 44 (θ, 9 H, t-Bu), 1 77 (sextet, J = 7 0 Hz, 2 H, 
СЯ2СНз), 2 48-2 88 (m, 2 H, 8(0)СЯ2СН2), 2 98-3 36 (m, 2 H, 
СНСЯ28(0)), 3 80 (β, 3 H, С02СНз), 4 51-4 87 (m, 1 H, 
СЯСНгЗЮ)), 5 51-5 91 (br d, 1 H, NH) Anal Caled for 
CijHaNOjS C, 49 13, H, 7 90; N, 4 77 Found С, 49 11, H, 7 85, 
N,4 71 
JV-( tert -Butyloxycarbonyl)-S-oxo-S-decyl-i>-cyet«mol (24b 
and 25b). These compounds were prepared by reduction of 
N (tert butyloiycarbonyl)-S-oxo-S-decyl D-cysteme methyl ester 
(4 mmol) with lithium borohydnde following the procedure that 
has been described earlier31 Separation of the diastereomers by 
column chromatography on silica gel (eluent MeOH/CHjC^, 4 96) 
afforded 24b and 25b in 37% and 35% yield, respectively Both 
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compounds were homogeneous on TLC (24b, R/ 0 24,25b, fy 0 27, 
MeOH/CHCl·,, 5 95) 
For 24b Ή NMR (COCÍ,) Í 0 88 (br t, J = 6 0 Hz, 3 H, 
CH2CH,), 1 27 (br s, 14 H, (CH2)-CH3), 1 42 (s, 9 H, t-Bu), 
1 59-1 97 (m, 2 H, SfOlCHjCH;), 2 77 (d of t, J = 8 0 Hz, 2 H, 
S(0)CW2CH2), 2 89-3 21 (AB part of ABX spectrum, 7 lines, 2 
H, CHCKiSfO)), 3 47 (br t, J = 6 0 Hz, 1 H, CHjOH), 3 64-3 99 
(AB part of ABX spectrum, 8 lines, 2 H, CHCH2OH), 3 89-4 26 
(m, 1 H, СЯСН2ОН), 5 50 (br d, 1 H, NH) Anal Caled for 
σ,β^,ΝΟ,Β С, 59 47, Η, 10 26, Ν, 3 85 Found С, 59 46, Η, 
10 34, N,3 89 
For 25b Ή NMR (CDClj) ä 0 88 (br t, J = 6 Hz, 3 H, СН
г
СНз), 
1 27 (s, 14 H, (CH2),CH3), 1 43 (s, 9 H, Í-Bu), 1 56-2 10 (m, 2 H, 
S(0)CH2CH2), 2 82 (d of t, J = 8 Hz, 2 H, S(0)CH2CH2), 3 02 
and 3 16 (AB part of ABX spectrum, 8 lines, JAX = 60 Hz, </
Β
χ 
= 3 7 Hz, JAB = 13 5 Hz, 2 H, CHCHjS«))) 3 59-3 92 (AB part 
of ABX spectrum, 7 lines, 2 H, CHCH2OH), 3 98-4 44 (m, 1 H, 
CHCHjOH), 5 59 (br d, J = 7 Hz, 1 H, NH) Anal Caled for 
С 1 8 Н,^0 4 8-7 2 Н 2 О С, 58 03, H, 10 01, N,3 76 Found С, 57 72, 
H, 10 08, Ν, 3 73 
N-(tert Butyloiycarbonyl)-S-oio-S-decyl-D-cysteine methyl 
ester was prepared by oxidation of the corresponding sulfide 23b 
(5 mmol) with sodium metapenodate according to the procedure 
that has been described earlier32 to give the desired product as 
a mixture of diastereomers in 99% yield TLC R/ 0 31 (eluent 
MeOH/CHClj, 3 97), Ή NMR (CDCl·,) 6 0 86 (br t, J = 6 0 Hz, 
3 H, СН2СНз), 1 26 (br s, 14 H, (CH2)7CH3), 1 44 (s, 9 H, i-Bu), 
1 53-1 73 (m, 2 H, S(0)CH2CH2), 2 73 (d of t, J = 7 0 Hz, 2 H, 
8(0)СН2СН2), 3 06-3 31 (m, 2 H, CHCtfjSfO)), 3 77 (s, 3 H, 
COjCHj), 4 53-4 82 (m, 1 H, CHCnßiC»), 5 51-5 86 (m, 1 H, NH) 
Anal Caled for C A N N O S S C, 58 28, H, 9 52, N, 3 58 Found 
С, 58 56, H, 9 54, Ν, 3 50 
5-Oxo-S propyl D-cyeteinol (26a). This compound was 
prepared from 24a by treatment with tnfluoroacetic and according 
to the procedure that has been described before 3 2 TLC Rj 0 46 
(eluent sec-BuOH/ΝΗ,ΟΗ, 55 22), Ή NMR (D20) J 1 08 (t, J 
= 7 5 Hz, 3 H, CH2CH3), 1 80 (sextet, J = 8 0 Hz, 2 H, CH2CH3), 
2 93 (t, J = 8 0 Hz, 2 H, S(0)CH2CHj), 2 83 and 3 00 (AB part 
of ABX spectrum, 8 lines, «/дх = 5 4 Hz, JBX = 117 Hz, </AB = 
13 2 Hz, 2 H, CHCHßiO)). 3 20-3 47 (m, 1 H, CHCH2OH), 3 60 
and 3 66 (AB part of ABX spectrum, 8 linee, JUÍ = 90 Hz, </
Β
χ 
= 2 7 Hz, JM = 11 4 Hz, 2 H. CHCW2OH) 
S Oxo-S decyl-D-cyeteinol (26b). This compound was 
prepared from 24b by treatment with tnfluoroacetic acid according 
to the procedure that has been described earlier3 2 TLC R/ 0 62 
(eluent sec-BuOH/ΝΗ,ΟΗ, 55 22), Ή NMR (CD2C12) S 0 73-0 95 
(m, 3 H, СН2СЯз), 1 29 (br s, 8 H, (СЯ2)4СН3), 1 70 (br s, 8 H, 
S(0)CH2(CH2)4), 2 58-2 93 (m, 4 H, CHCHsStO), 3(0)СЯ2СН2), 
3 48-3 68 (m, 1 H, СЯСН 2 0Н), 3 75 (s, 2 H, CHCH2OH) 
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CHAPTER 2.2 
THE EFFECT OF INCREASING THE LIPOPHILICITY OF THE DRUG 
ON THE BIOLOGICAL ACTIVITY 
Lipophilic derivatives 
Conclusions: 
-substitution of CH2OH for Me and of SMe for (CH^Me 
or S(CH2)„Me results in an increase of the activity 
-an optimum in the relationship between lipophilicity 
and activity was observed 
-the alkyl(thio) side chain interacts with a hydrophobic 
region on the peptidyl transferase 
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SUMMARY 
Fourteen derivatives of sparsomycin (1) were synthesized and their biological activity was tested in 
cell-free protein synthesis inhibition systems, and in bacterial and murine leukemia L1210 cell growth 
inhibition assays. Ribosomes from both an eukaryotic and a prokaryotic organism were used in the 
protein synthesizing systems. Six of these analogues were prepared following novel synthetic routes 
starting from the L-amino acid alanine. We found that an increase in hydrophobicity of the drug as a 
result of replacing the SMe group of 1 with larger alkylthio groups causes an increase in the antitumor 
activity of the drug. However, not only the hydrophobicity but also shape and size of the substituent are 
important; in the homologous series 1-9-10-11-12, 21-22-23-24 and 30-31-32-33, highest protein 
synthesis inhibitory and cytostatic activity is found with compounds 11, 23 and 32, respectively, and in 
comparison with the highly active η-butyl compound 10, the isomeric ferr-butyl compound 13 is rather 
inactive. Polar substituents replacing the SMe group, i.e. CI in 17 and 35, also render the molecule 
inactive. Substituting the bivalent sulfur atom with a methylene group decreases the drug's activity. 
This effect can be compensated for by increasing the length of the alkylsulfinyl side chain. The 
agreement between the results derived from cell-free and "in vivo" tests is good. The assays using 
ribosomes of bacterial and eukaryotic organisms give similar results although the latter seem to be more 
sensitive to changes in hydrophobicity of the drug. Our results confirm the presence of a hydrophobic 
region at the peptidyl transferase center of the ribosome; the interaction of sparsomycin with this region 
is more pronounced in the eukaryotic particles. 
INTRODUCTION 
Sparsomycin I 1 is a broad spectrum antibiotic active against parasites,2 viruses,3,4 fungi,5 and 
bacteria.6,7 The antibiotic has achieved prominence in the past 25 years as a tool to study the protein 
biosynthesis machinery. Since the isolation of sparsomycin from Streptomyces sparsogenes in 1962, 
much attention was focused on its early observed antitumor activity.5 
Recently, both we8,9 and Helquist10 succeeded in developing total syntheses of sparsomycin. In 
1984, our synthetic route to sparsomycin allowed the preparation of the first analogue, i.e. 
octyl-sparsomycin (12), which proved to be three times more active against L1210 leukemia in vitro 
than the natural product itself.11 Three years later, a structure-activity relationship study was 
published12 in which the biological activity of 14 analogues of sparsomycin was studied in both 
cell-free and whole-cell systems. Each derivative possessed not more than two structural modifications 
of the sparsomycin molecule. Increase of the lipophilicity of the molecule was found to have a marked 
effect on the biological activity of the antibiotic. A correlation was found between protein synthesis 
inhibition and antitumor activity. 
Sparsomycin blocks the peptidyl transferase center in the large ribosomal subunit by interfering 
with the binding of substrates.13,14 Sparsomycin has been shown to inhibit the interaction of substrates 
with the peptidyl transferase A site, while stimulating at the same time the binding of substrates at the Ρ 
site.15,16 This mutual interaction was proposed to be due to an allosteric effect.1 The high activity of 
hydrophobic derivatives of sparsomycin in protein synthesis inhibition assays12 indicates the existence 
44 Chapter 2.2 
of an hydrophobic region in the peptidyl transferase center. It was proposed that this site may also be 
involved in the binding of hydrophobic amino acyl residues of the amino acyl-tRNA molecules at the 
ribosomal A site. 
Scheme I. Retrosynthetic Analysis of Sparsomycin 
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The dependance of the biological activity of analogues of sparsomycin on their lipophilicity was 
the point of departure for the present study. The synthesis of 14 derivatives of sparsomycin is described 
in this report, i.e. compounds 9-11, 13, 14, 18, 22, 23, 30-33, 35 and 37. Six of these analogues, i.e. 
30-33, 35 and 37, were prepared via a novel synthetic route starting from L-alanine. The inhibition of 
protein biosynthesis in five different cell-free systems, cell growth inhibition of Escherichia coli and 
clonogenicity of murine leukemia cells was investigated for the newly prepared analogues of 
sparsomycin. Both prokaryotic as well as eukaryotic cell-free systems were chosen for this study. The 
results are reported here. 
RESULTS AND DISCUSSION 
Chemistry. According to the retrosynthetic scheme of sparsomycin (1, Scheme I), the molecule 
can be built up starting from either the amino acid D-cysteine (4) or L-serine (5). Both amino acids have 
been employed successfully for total syntheses of the natural product.8·10 The approach starting from 
the L-amino acid is particularly intriguing as it opens the way to analogues of sparsomycin having alkyl 
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or aralkyl substituents at the chiral carbon atom. We have employed this approach for the synthesis of 
compounds 30-33, 35 and 37 (Table II). The homologous series 1-9-10-11-12 (Table I), 21-22-23-24 
(Table I) and 30-31-32-33 (Table II) each contain at the sulfoxide moiety side chains of increasing 
length allowing the detailed study of the effect of increasing lipophilicity of this pharmacophore on the 
biological activity. 
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All of the variations introduced into the molecule concern modifications of the amine fragment 3 
(Scheme I). The first series of analogues of sparsomycin retaining the hydroxymethyl function is listed 
in Table I. The synthesis of compounds 9-11,13 and 14 was accomplished starting from D-cysteine (4, 
Scheme I) as depicted in Scheme II. These derivatives are characterized by substitution of the methyl 
group on the bivalent sulfur atom by other - more lipophilic - alkyl chains. The synthesis of the 
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chloromethyl sulfoxide 6 has been described earlier.8 Substitution of the chlorine atom by the 
corresponding mercaptide (90% yield), deprotection of the amine (quantitative yield) by treatment with 
TFA and coupling of the resulting amine with the acid 2 (25-35% yield) according to the isobutyl 
chloroformate mixed anhydride methode, furnished the desired sparsomycin derivatives 9-11, 13 and 
14. 
In the synthesis of pentyl-sparsomycin (11) on a preparative scale (20 mmol of 6) it was possible to 
isolate a by-product, characterized as the disulfide sparsomycin analogue 16 (Scheme ΠΙ). The 
rearrangement of the monoxodithioacetal moiety into the disulfide functionality must have occurred 
during removal of the Boc protecting group of 7c with TFA to give compound IS (Scheme III). This 
reaction is known for the preparation of mixed disulfides,17·18 and proceeds via a sulfenate ester 
intermediate with loss of formaldehyde. 
Table I. Sparsomycin Derivatives 
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Compound 18 (Table I) was obtained in the following way. After removal of the Boc group of 6 by 
treatment with TFA and coupling of the resulting amine with the acid 2 using isobutyl chloroformate, 
compound 17 was prepared.12 This compound was allowed to react in liquid ammonia with the sodium 
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salt of N-acetyl cysteamine, prepared in situ by reduction of Ν,Ν-di-acetyl cystamine with sodium in 
liquid ammonia, to give the desired analogue 18 in 23% yield.19 
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The structure of compounds 22 and 23 is characterized by replacement of the thiomethyl fragment 
by alkyl chains of increasing length. Their straightforward synthesis is described in Scheme IV. Starting 
48 Chapter 2.2 
from N-Boc-S-alkyl-cysteine methyl ester 19 the N-protected cysteinol sulfoxide 20 was easily obtained 
in three steps in 44-49% overall yield according to procedures published earlier.12 Again, deprotection 
of the amine (quantitative yield) by treatment with TFA and coupling of the resulting amine with the 
acid 2 (24-33% yield) using isobutyl chloroformate, the derivatives 22 and 23 were obtained. 
Scheme VI 
26 
The series of deshydroxy analogues comprises compounds 30-33, 35 and 37 (Table II). Their 
synthesis was achieved as follows. The amino acid L-alanine was transformed into the corresponding 
tosylate 26 (4 steps, 72% overall yield), following known procedures8 (Scheme V). The tosylate is 
unstable and should not be stored. Recrystallization of 26 yielded the cyclic urethane 34 (Scheme VI). 
Scheme П 
26 — l- • Boe N 
H 35 
^ С Н г ) ; Me 
1", il' 
37 
ÍV 
Me о .. 
B o c N * ' ^ S , v ^ ' "-^(CH^Me 
v + 2 H 
36 
(0 NaSíCHi^Me; (ti) mCPBA; (ш) separation 
(/ν) TFA; (v) EtjN, Pfp, DCC 
The next step in the reaction sequence is the introduction of the sulfur atom. Recently, a method 
using cesium thiocarboxylates was published20 for the conversion of alcohols into thiols via 
subsequently the corresponding mesylate and thioacetate. This method was found to be successful for 
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our purposes. Upon treatment of 26 with CsSAc in DMF the thioacetate 27 was formed in 80% yield. 
The thioacetate was converted into a 1:1 mixture of sulfoxide diastereomers by treatment with chlorine 
and acetic anhydride and subsequently with diazomethane.21 This reaction proceeds in yields ranging 
from 40-50%.22 From this mixture the α-chloro sulfoxide 28 was isolated by fractionated crystallization 
from ethyl acetate. After substitution of the chlorine atom in 28 by the corresponding mercaptide 
(88-98% yield), deprotection of the amine function (quantitative yield) by treatment with TFA and 
coupling of the resulting amine with the acid 2 employing isobutyl chloroformate, the desired analogues 
30-33 were obtained in yields ranging between 37% and 71%. 
Compound 35 was prepared starting from compound 28 (Scheme V). After removal of the Boc 
protecting group by treatment with TFA (quantitative yield) and coupling with the acid 2 using isobutyl 
chloroformate, compound 35 was obtained in 26% yield. 
The straightforward synthesis of compound 37 is presented in Scheme VII. This compound has the 
bivalent sulfur atom in 30 substituted by a methylene group as is the case with compound 21 versus 1. 
Reaction of the tosylate 26 with sodium 1-propanethiolate afforded the substitution product 35 in 92% 
yield. Oxidation of 35 with mCPBA23 gave a nearly 1:1 mixture of the sulfoxides 36 and its 
corresponding S-epimer (not shown) in 91% yield. After separating 36 from this mixture of 
diastereomers, the Boc protecting group of 36 was removed by treatment with TFA. The amine was 
coupled with the acid 2 via its pentafluorophenyl ester,24 prepared in situ by reaction of 2 with 
pentafluorophenol and DCC, to give compound 37 in 72% overall yield. This pentafluorophenyl ester 
amide coupling procedure is superior in yield in comparison with the isobutyl chloroformate mixed 
anhydride procedure. 
Table Π. Sparsomycin Derivatives 
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CD Spectroscopy. The assignment of the chirality at the sulfoxide sulfur atom of the newly 
prepared compounds deserves some comment. Previously, we showed that for sparsomycin (I)8 as well 
as for several other a-functionalized sulfoxides9·19·25 circular dichroism (CD) spectroscopy can be 
employed in the assignment of the absolute configuration of the sulfoxide-sulfur atom. 
The rule of thumb used is that in the absence of strongly perturbing groups, a negative sign of the 
Cotton effect - centered at the sulfoxide absorption band at 220-240 nm - correlates with an R 
configuration whereas a positive sign correlates with an S configuration.26 
The CD spectra of the sulfoxides 20a, 28 and 36, precursors of sparsomycin, and their 5-epimers 
and of deshydroxy-sparsomycin 30 are shown in Figures Ι, Π III and Г , respectively. We employed the 
above-mentioned rule to establish the absolute configuration of the sulfoxide function of these 
compounds.27 
Comparison of Figures II and IV shows that the sign of the Cotton effect at 220-240 nm of 
compound 30 is not influenced by the other absorption bands of the molecule.8 The Cotton effect in the 
260-270 nm region in Figure IV is due to the amide chromophore. 
Figure I CD spectra 
OU 
1
 ^ ' • ' _ ' ' 
ZIO ZZO Z30 z u r - f s o 
-007 
•OU 
-ΟΖΟ 
λ| timi 
OH 
\ / BOC-N • Ч ^ 5 Ч С Н
І
> 5
/ 
\ / H 
\У 
s,-а С " S 
FigureII CD spectra 
0 65 
ScRs , 28 
Chapter 2.2 
Figure It! CD spectrum 
0 3t 
0 33 
011 
Δε 
-Oil -
-0 23 -
Me 0 
210 220 230 21.0 250 . 
\ / Xlnm) 
\ / Me .. 
\ / H*.l Ь 
Ч ^ ' B o c - N ^ ^ — ^ 
SrR« 
4Me 
Figure iv CD spectrum 
0 34 
0 23 
Oil 
Δε 
-011 
-023 
-0 31 
X|nm] 
О
 и
 Me О 
HNTV^ï^^ N Ж - ' З - ^ 5 
J^K H 
Η 
Ч і . 
S c R S l 3 0 
52 Chapter 2.2 
Biological Activity. The biological activity of the various sparsomycin analogues was tested in 
three in vitro and two "in vivo" assays. The polyuridylic acid dependent synthesis of polyphenylalanine 
and the "puromycin reaction" under two different conditions were investigated in cell-free systems 
derived from E. coli and Saccharomyces cerevisiae. As "in vivo" assays, the inhibition of E. coli cell 
growth in liquid medium and of colony formation of L1210 murine leukemia cells in soft agar were 
studied. 
In Vitro Tests. Looking at the results of the polyphenylalanine synthesis assay given in Table ΠΙ, 
it can be concluded that an increase in the length of the aliphatic side chain at the sulfur containing end 
of the molecule results in a higher inhibitory capacity. In the three homologous series investigated, i.e. 
1-9-10-11-12, 21-22-23-24 and 30-31-32-33, an optimum in activity was observed for compounds 11, 
23 and 32, respectively. 
Substitution of the bivalent sulfur atom in 1 by a methylene group to give 21 decreases the activity 
in the polyPhe assay seriously. The activity seen in the other assays tested is however much less 
affected. This loss of activity can be fully compensated for by increasing the alkyl side chain length in 
21 with four carbon atoms to give 23. Comparison of the activity data of compounds 23 and 11 shows 
that replacement of the sulfur atom in 11 by a methylene group no longer has a substantial effect on the 
biological activity. In a similar way, substitution of the bivalent sulfur atom in 30 to give compound 37 
also reduces the activity of the drug in the polyPhe assay in particular. 
The S. cerevisiae system seems to be more sensitive than the bacterial system to an increase in 
hydrophobicity of the drug. This result, as previously reported with other sparsomycin analogues,28 
indicates that these drugs can be used as probes to detect structural differences in the ribosomes derived 
from prokaryotic and eukaryotic cells, and more specifically of the hydrophobic pocket of the peptidyl 
transferase center.29,30 Our results suggest that the hydrophobic interactions during the binding of the 
aminoacyl moiety of the aa-tRNA at the A site of the peptidyl transferase are more pronounced in the 
eukaryotic particles. 
The results on compounds 13,14,17,18 and 35 indicate that in addition to hydrophobicity, also the 
shape, size and polarity of the substituents attached to the sulfoxide group influence the activity of the 
compound. In spite of the highly hydrophobic character of its fert-butyl group, 13 is rather inactive, 
especially when compared with the и-butyl derivative 10. The same is true, although to a lesser extent, 
for compound 14; compare its activity with that of analogues 11 and 12. 
The presence of polar groups in the substituent attached to the sulfoxide group affects the activity 
of the drug seriously as is exemplified clearly in the case of analogue 18. Although this analogue carries 
a linear chain of approximately the same length as pentyl-sparsomycin 11, it is rather inactive probably 
due to the presence of the amide group. The substitution of the SMe group in 1 or 30 by a chlorine 
atom, giving 17 and 35, respectively, renders these compounds very inactive. 
A similar relation between lipophilicity of the drug and its activity was observed in the puromycin 
reaction assay. However, the differences in activity among the various compounds are less pronounced 
than in the polyPhe synthesis assay. This is probably due to the fact that sparsomycin itself is a much 
better inhibitor of this reaction than of polyPhe synthesis. An increase in the affinity of the drug for the 
ribosome probably affects less the binding of puromycin to the ribosome than the binding of aa-tRNA 
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to the ribo some.12 
The third in vitro test used is the "modified fragment reaction". In the homologous series studied, 
i.e. 1-9-10-11-12, 21-22-23-24 and 30-31-32-33, no clear-cut correlation exists between the activity and 
the length of the sulfoxide substituent. In fact, the more hydrophobic compounds, e.g. 12 and 24, are 
very inactive in this assay. This result confirms our previous conclusion12 that the modified fragment 
reaction, in spite of being extensively used in studies on the mode of action of antibiotics,31,32 has 
serious short-comings for comparing antibiotics of very different hydrophobicity. 
Table ΠΙ. Inhibition of Peptide Bond Formation 
compd 
11¿ 
9 
10 
11 
1212 
13 
14 
1 712 
18 
2112 
22 
23 
2412 
30 
31 
32 
33 
35 
37 
polyPhe synthesis 
E. coli 
8.5 
3.0 
1.8 
1.0 
1.6 
31 
6.6 
450 
34 
140 
0.75 
0.48 
1.8 
14.6 
12 
3.0 
8.5 
86 
80 
S. cerevisiae 
5.2 
7.0 
1.0 
0.17 
1.3 
900(47)a 
5.1 
220 
32 
42 
0.14 
0.10 
0.20 
50 
11.1 
1.9 
1.4 
inactb 
200 
Modified fragment 
reaction 
E. coli 
EDJO, μΜ 
3.2 
5.5 
5.1 
2.6 
60 
27.5 
5.2 
7.6 
60 
4.5 
7.5 
9.0 
5000(30)a 
18 
10.3 
12.1 
46 
mactb 
NT0 
S. cerevisiae 
2.8 
7.5 
4.8 
2.7 
300 
100 
12 
17 
56 
6.2 
5.0 
5.8 
700(41)a 
39 
10.4 
15 
60 
400 
ISTP 
Puromycin 
reaction 
E. coli 
0.10 
0.08 
0.06 
0.03 
0.25 
0.31 
0.04 
0.65 
1.0 
0.23 
0.18 
0.04 
0.08 
0.25 
0.07 
0.05 
0.46 
6.6 
0.38 
"Extrapolated values; the figures in parentheses show the percentage of inhibition at 500 
μΜ; inactive at the highest concentration tested, i.e. 100 μΜ; CNT, not tested. 
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In Vivo Tests. In Table IV the activity of the sparsomycin analogues in two in vivo tests is shown. 
The correlation between the results from in vitro (Table ΙΠ) and in vivo assays is reasonably good, and 
similar conclusions can be drawn as mentioned in the discussion of the in vitro assays studied. 
The change in the hydrophobicity of the molecule must also affect the permeability properties of 
the drug and some discrepancies between the data obtained in vitro and in vivo are probably due to this 
fact. In this respect it is interesting to note that the most potent inhibitor of the L1210 clonogenic assay, 
i.e. 33, is somewhat less active than sparsomycin in E. coli cell growth inhibition. Moreover, 17 and 35 
which are very inactive in vitro are as good, or even better inhibitors than sparsomycin in vivo. These 
results suggest the possibility that in addition to altering cell permeability, some of the sparsomycin 
derivatives may act on processes other than protein synthesis in intact cells.1·12 
Table Г . Inhibition of (Tumor) Cell Growth 
compd E. coli L1210 
IDso, μΜ 
I 1 2 
9 
10 
11 
1212 
13 
14 
„12 
18 
l l 1 2 
22 
23 
241 2 
30 
31 
32 
33 
35 
37 
11.0 
5.0 
3.0 
1.0 
4.4 
15.0 
7.5 
20.0 
100 
36.0 
3.0 
1.4 
3.0 
5.6 
8.5 
2.5 
15.0 
7.5 
9.5 
0.47 
0.14 
0.10 
0.06 
0.10 
2.50 
0.60 
0.29 
1.90 
0.75 
0.14 
0.15 
0.14 
0.07 
0.15 
0.05 
0.03 
0.15 
0.45 
Considering the data all together, they confirm clearly the existence of a hydrophobic region on the 
peptidyl transferase center of prokaiyotic and eukaryotic ribosomes with which sparsomycin interacts. 
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This domain is probably involved in the binding of the hydrophobic lateral residues of the amino acyl 
moiety of aa-tRNA.29·30 It seems reasonable to think that the presence of this region will help to 
discriminate amongst the aa-tRNA molecules favouring the binding of those carrying amino acids with 
hydrophobic side chains. This might have an effect on the rate of chain elongation affecting less the 
synthesis of proteins with a low ratio of hydrophobic to polar amino acids. 
Our results show that it is possible to improve the protein synthesis inhibitory and antitumor 
activity of sparsomycin by increasing the alkyl side chain length at the sulfur substituent. These results 
and a better knowledge of the peptidyl transferase center will probably enable us to design more active 
antibiotics in the near future. In this sense it is interesting to note that the observed structure-activity 
relationship can probably hold true for other drugs acting on the same ribosomal active center 
displaying a similar mode of action such as amicetin, gougerotine, actinobolin, blasticidin S and 
anthelmycin.33 This possibility is worthwhile to explore. 
EXPERIMENTAL SECTION 
Biological Activity. All tests used have been described in detail elsewhere.11·12 The peptidyl 
transferase activity was measured by the polyphenylalanine synthesis assay, the "modified fragment 
reaction" and the puromycin reaction. The "modified fragment reaction" was performed under the same 
conditions as described for the fragment reaction31 but using intact N-acetyl-Phe-tRNA instead of its 
terminal pentanucleotidc as substrate. The ED50 values obtained for sparsomycin using either the 
N-acetyl-aa-tRNA or its terminal pentanucleotidc fragment as substrate are very similar (unpublished 
results). ED50 represents the 50% effective dose. In the in vitro tests ribosomes from E. coli MRE600 or 
S. cerevisiae Y166 were used. 
As cell growth inhibition assays the growth inhibition of E. coli MRE600 in liquid medium12 and 
the clonogenicity of LI210 murine leukemia cells11 in soft agar were measured. ID50 represents the 
50% inhibitory dose. 
The activity data on compounds 1, 12, 17, 21 and 24 are taken from reference 12. These data are 
shown here for completeness. 
Synthesis. Melting points (mp) were determined on a Reichert hot stage and are uncorrected. Ή 
NMR spectra were recorded on a Braker WH-90 spectrometer with Me4Si as an internal standard. Mass 
spectra (MS, m/z, relative intensity) were recorded on a double-focussing VG 7070E mass 
spectrometer, for FAB MS, glycerol was used. Circular dichroism (CD) spectra were recorded on an 
Auto-dichrograph Mark V apparatus (Jobin Yvon). For determination of the specific rotation ([a]20D), а 
Perkin-Elmer 241 Polarimeter was used. Analyses indicated by the symbols of the elements were within 
±0.5% of the theoretical values unless indicated. Thin-layer chromatography (TLC) was canried out on 
Merck precoated silica gel F-254 plates (thickness 0.25 mm). Spots were visualized with an UV lamp, 
ninhydrin or C12-TDM. For column chromatography, Merck silica gel H (type 60) was used. For gel 
filtration, Merck Fractogel TSK HW-40(F) was used. Ion-exchange chromatography was carried out on 
Amberlite IRA-410. 
(ScRs) W-(tert-Butyloxycarbonyl)-S-oxo-S-[(fi-propyIthio)methyl]-cysteinol (7a). This 
compound was prepared in 75% yield from the α-chloro sulfoxide б (683 mg, 2.5 mmol) by treatment 
with NaS(CH2)2Me which was prepared in situ by reaction of Na (2.5 mmol) with freshly distilled 
1-propanethiol (2.75 mmol) in 15 mL of EtOH, following the procedure that has been described 
earlier:8 TLC Rf 0.38 (eluent MeOH/CHClj, 7:93); Ή NMR (CDCI3) δ 1.01 (t, J=7.2 Hz, 3H, 
СН2СНз), 1.44 (s, 9H, í-Bu), 1.68 (sextet, J=7.4 Hz, 2H, СН2СН2СНз), 2.72 (t, J=7.3 Hz, 2H, SCH,), 
2.99 and 3.31 (AB part of ABX spectrum, 8 lines, 1^=6.6 Hz, JBX=6.0 HZ, JAB=13.3 Hz, 2H, 
CHCH2S(0)), 3.73-3.94 (m, 2H, CH2OH), 3.80 (s, 2H, S(0)CH2S), 3.8<M.31 (m, IH, CHCH2), 5.48 (br d, J=7 Hz, IH, NH). CI MS, m/z 312 (32%, M+H), 256 (22%, CgHjgNC^), 212 (30%, 
C7H18N02S2), 89 (100%, QHgS). Anal. ( C ^ H ^ N C ^ ) С, H, N. 
(ScÄs) A4terf.Butyloxycarbonyl)-S-oxo-S-[(n-butylthio)methyl]-cysteinol (7·>). This compound 
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was prepared in 74% yield from 6 (542 mg, 2.0 mmol) by treatment with NaSiCH^Me which was 
prepared in situ by reaction of Na (2 mmol) with freshly distilled l-butanethiol (2.2 mmol) in 15 mL of 
EtOH, following the procedure that has been described earlier:8 TLC Rf 0.40 (eluent МеОН/СНСІз, 
7:93); •H NMR (CDCI3) δ 0.91 (br t, J=6.7 Hz, 3H, CHjCHj), 1.23-1.80 (m, 4H, СН2СН2СЩ), 1.44 (s, 9H, f-Bu), 2.73 (t, J=7.1 Hz, 2H, SCH2CH2), 2.96 and 3.29 (AB part of ABX spectrum, 8 lines, 
JAX=6.7 Hz, JBX=6.0 Hz, 1^=13.3 Hz, 2H, CHCH2S(0)), 3.63-3.93 (m, 2H, CH2OH), 3.80 (s, 2H, 
S(0)CH2S), 3.93-4.24 (m, IH, CHCH2), 5.44 (br dj=7 Hz, IH, NH), CI MS, m/z 326 (26%, M+H), 270 (26%, C9H2oN04S2), 226 (31%, C8H20NO2S2), 103 (100%, CsHnS). Anal. ( C ^ H ^ N O ^ ^ C, H, N. 
(ScRs) A4tert-Butyloxycarbonyl)-.S-oxo-S-[(n-pentyIthio)niethyl]-cysteinol (7c). This 
compound was prepared in 78% yield from 6 (542 mg, 2.0 mmol) by treatment with NaS(CH2)4Me 
which was prepared in situ by reaction of Na (2.0 mmol) with freshly distilled 1-pentanethiol (2.2 
mmol) in 15 mL of EtOH, following the procedure that has been described earlier:8 TLC Rf 0.42 
(eluent МеОН/СНСІз, 7:93); lH NMR (CDCI3) δ 0.90 (t, J=7.0 Hz, ЗН, СН2СНз), 1.18-1.92 (m, 6Н, (СН2)зСНз), 1.44 (s, 9Н, f-Bu), 2.72 (t, J=7.0 Hz, 2H, SCH2CH2), 3.00 and 3.32 (AB part of ABX 
spectrum, 8 lines, ^ = 6 . 7 Hz, JBx=6.0 Hz, ^ = 1 3 . 3 Hz, 2H, CHCH2S(0)), 3.63-3.90 (m, 2H, 
CH2OH), 3.79 (s, 2H, S(0)CH2S), 3.93-4.24 (m, IH, CHCH2), 5.48 (br d, J=7 Hz, IH, NH). CI MS, 
m/z 340 (26%, M+H), 284 (26%, C10H22NO4S2), 240 (31%, 4 H 2 2 N 0 2 S 2 ) , 117 (100%, QH^S). Anal. (^4Η 2 9Ν0 48 2) С, Η, Ν. 
(ScRs) N-(terí-Butyloxycarbonyl)-5;-oxo-S-[(/crt-butylthio)methyl]-cysteinol (7d). This 
compound was prepared in 85% yield from 6 (393 mg, 1.4 mmol) by treatment with NaS-i-Bu which 
was prepared in situ by reaction of Na with freshly distilled 2-methyl-2-propanethiol in EtOH, 
following the procedure that has been described earlier:8 TLC Rf 0.31 (eluent MeOH/CH2Cl2,7:93); lH 
NMR (CDCI3) δ 1.37 (s, 9H, S-f-Bu), 1.44 (s, 9H, O-í-Bu), 3.09 and 3.22 (AB part of ABX spectmm, 8 
lines, JAx=7.0 Hz, JBX=6.1 Hz, JAB=13.4 Hz, 2H, CHCH2S(0)), 3.20-3.58 (m, IH, OH), 3.80 and 3.91 (ABq, JAB=13.6 Hz, 2H, S(0)CH2S), 3.58-4.36 (m. 3H, CHCH2OH), 5.20-5.62 (br d, IH, NH). CI MS, 
exact mass caled for C13H2oN04S2, m/z 326.1460 (M+H). Found: 326.1451; m/z 326 (10%), 270 (20%, 
C9H20NO4S2), 226 (15%, C8H20NO2S2), 103 (100%, C5KnS), 57 (87%, С4Щ). Anal. (^3Η 2 7Ν0 48 2) 
С, Η, Ν. 
(ScRs) /V-(/ert-Butyloxycarbonyl)-S-oxo-5-[(cyclohexylth¡o)methyl]-cysteinol (7e). This 
compound was prepared in 85% yield from 6 (399 mg, 1.5 mmol) by treatment with NaSCgHjj which 
was prepared in situ by reaction of Na with freshly distilled cyclohexyl mercaptan in EtOH, following 
the procedure that has been described earlier:8 TLC Rf 0.44 (eluent MeOH/CH2Cl2, 7:93); Ή NMR (CDCI3) δ 1.08-2.16 (m, ЮН, (CTy,), 1.46 (s, 9H, f-Bu), 2.69-3.13 (m, IH, SCH), 3.07 and 3.20 (AB 
part of ABX spectrum, 8 lines, JAX=7.0 Hz, JBx=6.1 Hz, 1^=13.5 Hz, 2H, CHCH2S(0)), 3.13-3.58 (m, 
IH, OH), 3.58-3.93 (m, 2H, CH2OH), 3.83 (S, 2H, S(0)CH2S), 3.93-4.33 (m, IH, CHCH2OH), 
6.22-6.56 (br d, IH, NH). CI MS, exact mass caled for C ^ Q N O ^ , m/z 352.1616 (M+H). Found: 
352.1612; m/z 352 (12%), 296 (20%, CHH22N04S2), 252 (14%, С 1 0 Н ^ О 2 8 2 ) , 129 (100%, С7Н1з8), 
57 (34%, QH,,). Anal. (C,5H29N04S2) C, H, N. 
(Scfls) 5-oxo-S-[(n-propylthio)methyl]-cysteinol (8a). The compound was prepared in 87% yield 
from compound 7a (553 mg, 1.78 mmol) by treatment with TFA at 0 0C and subsequent ion-exchange 
column chromatography on AmberUte following the procedure that has been described earlier:8 Ή 
NMR (CDCI3) δ 1.01 (t, J=7.1 Hz, ЗН, СН2СНз), 1.69 (sextet, J=7.5 Hz, 2H, СН2СНз), 2.06 (br s, 3H, 
NH2, OH), 3.02-3.67 (m, 4H, CHCH2S(0), S C ^ O t y , 3.33-3.65 (m, 3H, CH2OH, CHCH2), 3.79 (s, 
2H, S(0)CH2S). Anal. (C7H1 7N02S2) C, H, N. 
(ScÄs) 5-oxo-S-[(n-butylthio)methyI]-cysteinol (8b). Following the procedure that has been 
described earlier,8 the Boc amino protecting group of compound 7b (480 mg, 1.48 mmol) was removed 
by treatment with TFA at 0 0C and subsequent ion-exchange column chromatography on Amberlite to 
yield the desired compound in 89% yield: Ή NMR (CDCI3) δ 0.92 (t, J=6.8 Hz, ЗН, СН2СНз), 
1.18-1.77 (m, 4H, (СН^СНз), 2.47-3.01 (m, 7H, SCH2CH2, CHCH2S(0), NH2, OH), 3.36-3.70 (m, 
3H, CH2OH, CHCH2), 3.78 (s, 2H, S(0)CH2S). CI MS, m/z 226 (100%, M+H, C8H1 9N02S2), 136 (14%, C4H1oN02S), 103 (37%, CjHnS). 
(ScRs) S-Oxo-5-[(n-pentylthio)methyI]-cysteinol (8c). The compound was prepared in 73% yield 
from compound 7c (583 mg, 1.77 mmol) by treatment with TFA at 0 0 C and subsequent ion-exchange 
column chromatography on Amberlite following the procedure that has been described earlier:8 % 
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NMR (CDCI3) δ 0.88 (t, J=6.5 Hz, 3H, CH.CHj), 1.09-1.49 (m, 4H, (СП2)2СНг), 1.63 (quintet, J=7.4 
Hz, 2H, SCH2CH2), 1.89 (br s, 3H, NH2> OH), 2.73 (t, J=7.3 Hz, 2H, SCH2CH2), 2.82-3.18 (m, 2H, 
CHCH2S(0)), 3.34-3.71 (m, 3H, CH2OH, CHCH2), 3.77 (s, 2H, S(0)CH2S). CI MS, m/z 240 (36%, 
M+H), 136 (65%, C4H10NO2S), 117 (100%, QH^S). Anal. (C9H2 1N02S2) C, H, N. 
(ScRs) S-Oxo-S-[(ieri-butylthio)methyI]-cysteinol (8d). This compound was prepared from 7d 
(353 mg. 1.1 mmol) by treatment with TFA and ion-exchange column chromatography on Amberlite 
according to the procedure that has been described earlier8 to give the desired product in 90% yield: 
TLC Rf 0.32 (eluent MeOH/CHCl3, 1:4); 'H NMR (CDCI3) δ 1.37 (s, 9H, f-Bu), 1.82 (br s, 2H, NH2), 
2.81 and 2.93 (AB part of ABX spectrum, 8 lines, JAX=8.4 HZ, JBX=3.9 Hz, JAB=13.2 Hz, 2H, 
CHCH2S(0)), 2.82-3.27 (m, IH, OH), 3.27-3.71 (m, 3H, CHCH2OH), 3.76 and 3.91 (ABq, JAB=14.1 
Hz, 2H, S(0)CH2S). CI MS, exact mass caled for C8H20NO2S2, miz 226.0935 (M+H). Found: 
226.0935; miz 226 (100%), 136 (46%, C4H10NO2S), 103 (83%, СбНцЗ), 57 (78%, QH,,). 
(ScÄs) S-Oxo-S-[(cycIohexylthio)methyl]-cysteinoI (8e). This compound was prepared from 7e 
(353 mg, 1.0 mmol) by treatment with TFA and ion-exchange column chromatography on Amberlite 
according to the procedure that has been described earlier8 to give the desired product in 99% yield: 
TLC Rf 0.35 (eluent MeOH/CHCl·,, 1:4); Ή NMR (CDCI3) δ 1.06-2.29 (m, ЮН, (СН^), 1.97 (br s, 
2H, NH2), 2.56-3.18 (m, 4H, SCH, OH, CHCH2S(0)), 3.32-3.72 (m, 3H, CHCH2OH), 3.67 and 3.73 (ABq, J A B = 14.2 Hz, 2H, S(0)CH2S). CI MS, exact mass caled for C1 0H2 2NO2S2, miz 252.1092 (M+H). Found: 252.1093; miz 252 (9%), 136 (27%, C4H10NO2S), 129 (100%, CyH^S), 83 (84%, 
СбНц). 
(ScRs) 2-[(E)-ß-(6-Methyl-5-uracilyl)acryIainido]-3-[[(;i-propylthio)methyl]suIfinyI]-propanol 
(9). This compound was prepared in 18% yield (93 mg) from compound 8a (335 mg, 1.71 mmol) 
following the same procedure as described for the preparation of compound 12. TLC Rf 0.37 (eluent 
MeOH/CHCU, 1:4); Ή NMR (D20) δ 0.89 (d of t, J=6.9 Hz, 3H, СН2СНз), 1.53 (sextet, J=7.3 Hz, 2H, 
СН2СНз), 2.34 (s, ЗН, С(б)-СНз), 2.66 (t, J=7.5 Hz, 2H, SCH2CH2), 2.92-3.36 (m, 2H, CHCH2S(0)), 
3.40-3.89 (m, 3H, CHCH2, CH2OH), 3.91 and 4.05 (ABq, JAB=14.0 Hz, 2H, S(0)CH2S), 6.99 and 7.37 (ABq, 1^=15.5 Hz, 2H, CH=CH). FAB MS, miz 390 (15%, M+H, C ^ H ^ O ^ ) , 179 (23%, 
С8Н7№,Оз), 89 (97%, C ^ S ) ; [a]20D +80° (c 0.08, MeOH/H20,1:1). 
{ScRs) 2-[(E)-ß-(6-Methyl-5-uraciIyl)acrylamido]-3-[[(n-butylthio)methyl]suIfinyl]-propanol 
(10). This compound was prepared in 16% yield (82 mg) from compound 8b (284 mg, 1.27 mmol) 
following the same procedure as described for the preparation of compound 12:11 TLC Rf 0.37 (eluent 
МеОН/СНСІз, (1:4); »H NMR (CD3OD) δ 0.94 (br t, J=6.5 Hz, ЗН, СН2СНз), 1.18-1.83 (m, 4H, (СН2)2СНз), 2.38 (s, ЗН, С(б)-СНз), 2.80 (t, J=6.9 Hz, 2H, SCH2CH2), 2.97-3.35 (m, 2H, 
CHCH2S(0)), 3.72 (d, J=5.1 Hz, 2H, CH2OH), 3.90 and 4.04 (ABq, 1^=13.8 Hz, 2H, 8(0)0^8), 
4.33-4.71 (m, IH, СНСНг), 7.26 and 7.47 (ABq, ^ = 1 5 . 4 Hz, 2H, CH=CH). FAB MS, miz 404 (10%, 
M+H), 103 (32%, CjHnS); [a]20D +85° (c 0.22, MeOH/H20, 1:1). Anal. (C16H25N305S2.i/2H20) C, H, 
N. 
(ScRs) 2-[(E)-ß-(6-Methyl-5-uracilyl)acrylainido]-3-[[(n-pentyIthio)methyl]sulfinyl]-propanol 
(11). Following the same procedure as described for the preparation of compound 12,11 this compound 
was prepared in 40% yield (212 mg) from compound 8c (314 mg, 1.6 mmol): TLC Rf 0.45 (eluent 
MeOH/CHClj, 1:4); 1П NMR (CD3OD) δ 0.92 (br t, J=7 Hz, ЗН, СН2СНз), 1.12-1.54 (m, 4H, (СН2)2СНз), 1.54-1.88 (m, 2H, SCH2CH2), 2.40 (s, ЗН, С(б)-СНз), 2.79 (t, J=6.5 Hz, 2H, SCH^H^, 
2.95-3.35 (m, 2H, CHCH2S(0)), 3.72 (d, J=5.1 Hz, 2H, CH2OH), 3.91 and 4.05 (ABq, 1^=14.0 Hz, 
2H, S(0)CH2S), 4.28-4.69 (m, IH, CHCH2), 7.26 and 7.47 (ABq, JAB=15.3 Hz, 2H, CH=CH). FAB 
MS, m/z418 (11%, M+H), 284 (7%, С ц Н ^ О д З ) , 179 (40%, CgfyN^), 165 (12%, QH^OS^, 153 
(9%, С 7 Ш^ 2 0 2 ), 117 (57%, QiH^S); [a]20D +82° (с 0.11, MeOH/H20, 1:1). Anal. (C16H27N305S2.H20) С, H, Ν. 
(ScÄs) 2-[(E)-ß-(6-Methyl-5-uracilyl)acryIamido]-3-[[(/-butylthio)methyI]suIfinyl]-propanol 
(13). This compound was prepared in 30% yield (112 mg) from compound 8d (206 mg, 0.91 mmol) 
following the same procedure as described for the preparation of compound 12.'1 The crude reaction 
product was purified by a combination of chromatography on Fractogel (eluent MeOH/H20, 1:1) and 
counterciurent distribution (eluent CHCyCCyMeOH/buffer, 8:3:8:5; buffer: 19.3 g of NH4OAc and 
28.6 mL of HOAc in a total volume of IL of water; 240 transfers in 10 mL bank): TLC Rf 0.41 (eluent 
МеОН/СНСІз, 1:4); Ή NMR (CD3OD) δ 1.42 (s, 9Η, r-Bu), 2.39 (s, ЗН, С(б)-СНз), 3.02 and 3.35 (AB 
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part of ABX spectrum, 8 lines, JAX=9-9 HZ, J B X=3.7 HZ, 1^=13.2 Hz, 2H, CHCH2S(0)), 3.75 (d, J=5.1 
Hz, 2H, CH2OH), 4.03 (s. 2H, S(0)CH2S), 4.38-4.76 (m, IH, СНСЩ), 7.29 and 7.49 (ABq, ^ = 1 5 . 4 
Hz, 2H, CH=CH); [a]2ôD +85° (с 0.125, MeOH/H20, 1:1). FAB MS, m/z 404 (11%, M+H, 
С16Н26Ыз0552), 226 (35%, С^гоЫОгЗг), 179 (15%, С8Н7И2Оз), 103 (100%, CsHnS). 
(ScKs) 2-[(E)-ß-(6-Methyl-5-uracilyl)acrylamido]-3-[[(cyclohexyHhio)methyl]sulfinyl]-
propanol (14). Following the same procedure as described for the preparation of compound 12,11 this 
compound was prepared in 40% yield (152 mg) from compound 8e (221 mg, 0.88 mmol). The crude 
reaction product was purified by a combination of gel filtration on Fractogel and countercurrent 
distribution (420 transfers in 10 mL bank) as described for the preparation of compound 13. TLC Rf 
0.47 (eluent MeOH/CHClj, 1:4); Ή NMR (CD3OD) δ 0.77-2.26 (m, ЮН, (СН^), 2.35 (s, ЗН, 
С(б)-СНз), 2.68-3.04 (m, IH, CHS), 3.02 and 3.28 (AB part of ABX spectrum, 8 lines, 1^=10.0 Hz, 
JBX=4.2 Hz, JAB=13.3 Hz, 2H, CHCH2S(0), 3.72 (d, J=5.1 Hz, 2H, CH2OH), 3.93 and 4.03 (ABq, 
JAB=13.9 Hz, 2H, S(0)CH2S), 4.33-4.68 (m, IH, CHCH2S(0)), 7.24 and 7.45 (ABq, 1^=15.4 Hz, 2H, 
CH=CH); [a]20D +81° (c 0.130. MeOH/H20, 1:1). FAB MS, m/z 430 (10%, M+H, С^Н^^О^, 252 (33%, C1()H22N02S2), 179 (14%, С8Н7М20з), 129 (100%, €ΊΗι38). 
yV-[(E)-ß-(6-Methyl-S-uracilyl)acryloyl]-S-(pentylthio)-D-cysteinol (16). This compound was 
isolated as a byproduct (50 mg) of a large scale synthesis (2 g) of pentyl-sparsomycin (11): TLC Rf 
0.72 (eluent MeOH/H20, 1:4); lH NMR (CD3OD) δ 0.94 (br t, 1.17-1.58 (m, 4H, (CHUCHA 
1.58-1.91 (m, 2H, SCT^CH^, 2.39 (s, ЗН, С(б)-СНз), 2.76 (t, J=6.9 Hz, 2H SCHACH,), 2.80 and 3.07 
(AB part of ABX spectrum, 8 lines, JAX=6.0 HZ, J B X=4.4 Hz, 1^=13.8 Hz, 2H, CHCH2S), 3.69 (br d, 
J=4.8 Hz, 2H, CH2OH), 4.17-4.54 (m, IH, CHCH2), 7.26 and 7.45 (ABq, 3^=15.3 Hz, 2H, CH=CH); 
FAB MS, m/z 388 (38%, M+H), 284 (16%, С ц Н ^ С ^ З ) , 252 (10%, С ц Н ^ О Д 210 (26%, 
C8H20NOS2), 179 (100%, C8H7N203), 153 (16%, C-jHç^Oi), 117 (71%, С6Н1з8); [a]26D +128.5° (с 
0.135, MeOH/H20,1:1). Anal. (С16Н25Ыз0482.і/2Н20) С, H, Ν, S. 
(ScRs) 2-[(E)-ß-(6-Methyl-5-uracilyl)acrylamido]-3-[[((methylamido)ethylthio)methyI]-
sulfinyl]-propanol (18). This compound was prepared in 23% yield (15 mg) by reaction of 17 (53 mg, 
0.15 mmol) with the sodium salt of N-acetyl-cysteamine (24 mg, 0.16 mmol) in liquid NH3 for 1.5 h at 
-78 0C. The thiolate was prepared by reduction of the corresponding disulfide with 2 equiv. of Na in 
liquid NH3. The reaction vessel was kept under an argon atmosphere throughout the reaction. After 
evaporation of the ammonia, the reaction product was taken up in water and the pH was adjusted to 7 
with a 2N HCL solution. Gel filtration over Fractogel (eluent water) was carried out for purification of 
the product: TLC Rf 0.11 (eluent MeOH/CHClj, 1:4); Ή NMR (D20) δ 1.89 (s, ЗН, С(О)-СНз), 2.32 (s, ЗН, С(б)-СНз), 2.81 (t, J=6.5 Hz, 2Н, SCH2CH2), 2.98-3.18 (AB part of ABX spectrum, 4 lines, 2H, 
CHCH2S(0)), 3.33 (t, J=6.5 Hz, 2H, SO^CHj), 3.71 (d, J=5.2 Hz, 2H, CH2OH), 3.93 and 4.09 (ABq, 
1^=13.9 Hz, 2H, S(0)CH2S), 4.26-4.64 (m, IH, CHCH2), 6.99 and 7.31 (ABq, ^ = 1 5 . 3 Hz, 2H, 
CH=CH); FAB MS, m/z 433 (2%, M+H, С 1 5 Н 2 5^0 6 8 2 ), 179 (3%, CgH^Oj). 
Лу -Di-acetylcystaniine.35 This compound was prepared by a modified procedure known from the 
literature35 by reaction of cystamine dihydrochloride (1.8 g, 8 mmol) with Ac20 (4.9 g, 48 mmol) in 5 
mL of pyridine. After stirring for 1 h at room temperature a clear solution was formed. Evaporation in 
vacuo yielded the crude reaction product which was purified by column chromatography on silica gel 
(eluent MeOH/CHjCU, 3:97) to give the pure compound in 83% yield: mp 90 0C. TLC Rf 0.24 (eluent 
MeOH/CHCl·,, 1:10); Ή NMR (CDCI3) δ 2.00 (s, ЗН, С(О)СНз), 2.81 (t, J=6.0 Hz, 2H, CH2S), 3.58 (q, J=6.0 Hz, 2H, NHCH2), 6.48 (br s, IH, NH). CI MS, exact mass caled for C 8H 1 7N 20 2S 2, m/z 
237.0731 (M+H). Found: 237.0724; m/z 237 (72%), 118 (100%, C4H8NOS). Anal. (C8H1 6N202S2) C, 
Ar-(teri-Butyloxycarbonyl)-S-n-hexyl-D-cysteine Methyl Ester (19a). This compound was 
prepared in quantitative yield from the hydrochloride of 5-n-hexyl-D-cysteine methyl ester (19.6 g, 76.7 
mmol) by treatment with di-rm-butyl dicarbonate following the procedure that has been described 
earlier:8 TLC Rf 0.84 (eluent MeOH/CH2Cl2, 3:97); Ή NMR (CDCI3) δ 0.88 (br t, J=7.0 Hz, ЗН, 
СН2СНз), 1.46 (s, 9Н, f-Bu), 1.14-1.83 (m, 8Н, SCH^CH^), 2.52 (t, J=7.0 Hz, 2H, SCH2CH2), 2.95 (d, J=5.1 Hz, 2H, CHCH2S), 3.75 (s, ЗН, С02СНз), 4.31-4.66 (m, IH, CHCH2S), 5.14-5.44 (m, IH, 
NH). CI MS, exact mass caled for C^HjoNC^S, m/z 320.1896 (M+H). Found: 320.1888; m/z 320 
(17%), 264 (68%, CiiH2 2N04S), 220 (100%, Cl(fi22N02S), 203 (55%, ^οΗ 1 9 0 2 8) . 
The hydrochloride of S-n-hexyl-D-cysteine methyl ester was prepared from S-n-hexyl-D-cysteine 
(16.6 g, 81.0 mml) by treatment with SOCl2 in MeOH following the procedure that has been described 
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earlier* to yield the desired compound in 96%: TLC Rf 0.79 (eluent s-BuoH/NH4OH, 55:22). Ή NMR (CD3OD) δ 0.92 (br t, 3H, СН2СНз), 1.11-1.90 (m, 8H, S O b í O ^ ) , 2.61 (t, J=6.8 Hz, 2H, 
SCH2CH2), 3.00-3.09 (m, 2H, CHCH2S), 3.84 (s, 3H, CO2CH3), 4.13-4.46 (m, IH, CHCHjS). Anal. 
Caled for СюНггМОгЗСІ: С, 46.95; H, 8.67; Ν, 5.48. Found: С, 46.38; Η, 8.56; Ν, 5.43. 
S-n-hexyl-D-cysteine was prepared from D-cystine (10.0 e, 41.6 mmol) and l-bromohexane with 
Na in liquid NH3 according to a procedure described earlier2 in 98% yield: TLC Rf 0.60 (eluent 
л-ВиОН/НОАс/НгО, 4:1:1). CI MS, exact mass caled for Ο,Η20ΝΟ28, m/z 206.1215 (M+H). Found: 
206.1221; mJz 206 (24%), 189 (100%, (^Η19Ν08). Anal. Caled for C9H1 9N02S: C, 52.65; H, 9.33; N, 
6.82. Found: C, 51.77; H, 9.12; N, 6.86. 
yV-ftert-ButyloxycarbonyO-S-n-heptyl-D-cysteine Methyl Ester (19b). This compound was 
prepared in quantitative yield from the hydrochloride of S-n-heptyl-D-cysteine methyl ester (15.3 g, 
56.9 mmol) by treatment with di-rerr-butyl dicarbonate following the procedure that has been described 
earlier:8 TLC Rf 0.76 (eluent MeOH/CH2Cl2, 3:97); lH NMR (CDCI3) δ 0.88 (br t, J=5.4 Hz, 3H, 
СН2СНз), 1.05-1.84 (m, ЮН, SCH2(CH2)5), 1.44 (s, 9H, í-Bu), 2.51 (t, J=7.0 Hz, 2H, SCH2CH2), 2.98 (d, J= 5.1 Hz, 2H, CHCH2S), 3.71 (s, 3H, С02СНз), 4.33-4.67 (m, IH, CHCH2S), 5.51 (br d, J=7.8 Hz, 
IH, NH). CI MS, exact mass caled for С1 6Нз2К045, m/z 334.2052 (M+H). Found: 334.2045; m/z 334 (5%), 278 (44%, C12H24N04S), 234 (100%, С ц Н ^ О ^ ) , 217 (71%, СцН^О^) . 
The hydrochloride of S-n-heptyl-D-cysteine methyl ester was prepared from S-n-heptyl-D-cysteine 
(12.6 g, 57.4 mmol) by treatment with SOCI, in MeOH following the procedure that has been described 
earliei3 to yield the desired compound in 99%: TLC Rf 0.43 (eluent МеОН/СН2СІ2, 3:97); 'H NMR (CD3OD) δ 0.89 (br t, J=6.2 Hz, 3H, СН2СНз), 1.04-1.81 (m, 10H, S Œ ^ a ^ ) , 2.59 (t, J=7.1 Hz, 
2H, SCH2CH2), 3.02-3.12 (AB part of ABX spectrum, 4 lines, 2H, CHCH2S), 3.87 (s, 3H, С02СНз), 
4.20-4.33 (X part of ABX spectrum, 4 lines, J A X + J B X = 1 1 · 9 H Z . 1 H . CHCH2S). Anal. Caled for 
CHH24N02SC1: C, 48.96; H, 8.97; N, 5.19. Found: C, 48.00; H, 8.92; N, 5.09. 
S-n-heptyl-D-cysteine was prepared from D-cystine (7.6 g, 31.4 mmol) and 1-bromoheptane with 
Na in liquid NH3 according to a procedure described earlier12 in 93% yield: TLC Rf 0.47 (eluent 
n-BuOH/HOAc/HjO. 4:1:1). CI MS, exact mass caled for ^οΗ 2 2 Ν0 2 5, miz 220.1371 (M+H). Found: 
220.1368; ml ζ 220 (21%), 203 (100%, CKJH^NOS). Anal. (C10H21NO2S) C, H, N. 
(ScSs) iV-(/ert-Butyloxycarbonyl)-S-oxo-S-n-hexyl-cysteinol (20a). This compound was prepared 
by oxidation of N-ííerí-butyloxycarbony^-S-n-hexyl-D-cysteinol (18.6 g, 64.0 mmol) with ЫаІОд 
according to the procedure that has been described earlier1^ to give the desired product as a mixture of 
diastereomers in quantitative yield. The stereochemical structure of the ScRs compound is not shown in 
Scheme IV. The diastereomers were separated by repeated column chromatography on silica gel (eluent 
MeOH/CH2Cl2, gradient 3:97-5:95). The diastereomers were obtained in roughly equal amounts. Both 
compounds were homogeneous on TLC (ScSs, Rf 0.28; Sctfs, Rf 0.31; eluent MeOH/CHjClj, 7:93). 
For the ScSs compound (20a): Ή NMR (CDCI3) δ 0.90 (br t, J=5.7 Hz, ЗН, СН2СНз), 1.11-2.33 (m, 8Н, (СН^СНз), 1.44 (s, 9Н, г-Ви), 2.77 (d of t, J=7.5 Hz, 2H, S ^ C H ^ H j ) , 2.90-3.18 (m, 2H, 
CHCH2S(0)), 3.35-3.69 (m, IH, OH), 3.69-4.24 (m, 3H, CHCH2OH), 5.50 (br d, J=7.3 Hz, IH NH). 
CI MS, exact mass caled for C^HjoNC^S, miz 308.1896 (M+H). Found: 308.1891; m/ζ 308 (27%), 252 
(49%, CjoH^NC^S), 234 (35%, C10H20NO3S), 208 (100%, C9H22N02S). Anal. Caled for 
^4Η 2 9 Ν0 4 8: С, 54.69; Η, 9.51; Ν, 4.56. Found: С, 55.42; Η, 9.58; Ν, 4.51. LaJ
20D +40.2° (с 0.132, 
MeCN). CD spectrum (MeCN)·' at 217.5 nm a single positive Cotton effect was observed (де +0.28). 
For the SCÄS compound: rH NMR (CDCI3) δ 0.90 (br t, J=5.7 Hz, ЗН, СН2СНз), 1.08-2.22 (m, 8H, (СН2)4СНз), 1.44 (s, 9Н, í-Bu), 2.80 (d of t, J=7.5 Hz, 2H, S(0)CH2CH2), 3.01 and 3.15 (AB part of 
ABX spectrum, 8 lines, JAx=5.8 Hz, JBX=3.2 Hz, 1^=13.5 Hz, 2H, CHCH2S(0)), 3.52-3.96 (m, 2H, 
CH2OH), 3.96-4.47 (m, 2H, CHCH2OH), 5.52 (br d, J=6.3 Hz, IH, NH). CI MS, exact mass caled for 
C^HJQNC^S, m/z 308.1896 (M+H). Found: 308.1900; m/z 308 (11%), 252 (41%, C10H22NO4S), 234 (37%, СюНгоШзЗ), 208 (100%, <^Η22Ν028), mp 141.5-142.5 "С. [a\20D +31.2° (c 0.138, MeCN). 
CD spectrum (MeCN): at 220.5 nm a single negative Cotton effect was observed (де -0.18). 
AKterí-Butyloxycarbonyl)-S-n-hexyl-D-cysteinol. This compound was prepared by reduction of 
N-(fm-butyloxycarbonyl)-S-n-hexyl-D-cysteine methyl ester (20.6 g, 65.0 mmol) with LiBH4 
following the procedure that has been described earlier8 to give the desired product in quantitative 
yield: TLC Rf 0.64 (eluent MeOH/CH2Cl2, 7:93); Ή NMR (CDC13) δ 0.89 (br t, J=5.6 Hz, 3H, 
СН2СНз), 1.06-1.56 (m, 8H, СН^СН^), 1.44 (s, 9Н, í-Bu), 1.56-2.32 (m, IH, OH), 2.56 (t, J= 6.9 
Hz, 2H, SCH2CH2), 2.70 (d, J=6.0 Hz, 2H, CHCH2S), 3.56-3.94 (m, 3H, CHCH2OH), 4.78-5.18 (m, 
IH, NH). CI MS, exact mass caled for С14НзоЖ)з!$, m/z 292.1946 (M+H). Found: 292.1937; m/z 292 (13%), 236 (57%, QoHjjNOaS), 192 (100%, QH^NOS), 175 (86%, CçH^OS). 
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(ScSs) JV-(tert-Butyloxycarbonyl)-S-oxo-S-n-heptyl-cyste¡nol (20b).36 This compound was 
prepared by oxidation of TV-Om-butyloxycarbonyO-.S-rt-heptyl-D-CA'Steinol (15.1 g, 49.5 mmol) with 
ЫаІОд according to the procedure that has been described earlier12^ to give the desired product as a 
mixture of diastereomers in 96% yield. The structure of the ScRs compound is not shown in Scheme IV. 
The diastereomers were separated by repeated column chromatography on silica gel (eluent 
МеОН/СНгСІг, gradient 3:97-5:95). The diastereomers were obtained in roughly equal amounts. Both 
compounds were homogeneous on TLC (ScSs, Rf 0.39; ScRs, Rf 0.40; eluent MeOH/CHzClj, 7:93). 
For the ScSs compound (20b): Ή NMR (CDCI3) δ 0.88 (br t, J=5.4 Hz, 3H, CHjCHj), 1.09-2.09 
(m, ЮН, (СН2)5СНз), 1.42 (s, 9H, f-Bu), 2.49 (br s, IH, OH), 2.78 (d oft, J=7.2 Hz, 2H, S(0)CH2CH2), 
2.91-3.27 (m, 2H, CHCH2S(0)), 3.64-3.93 (m, 2H, CH2OH), 3.93-4.28 (m, IH, CHCH2), 5.50 (br d, 
J=7.0 Hz, IH, NH). CI MS, exact mass caled for C^H^NC^S, m/z 322.2052 (M+H). Found: 322.2054; 
m/z 322 (9%), 266 (34%, СцН^МС^З), 248 (29%, С
п
Н22МОз8), 222 (56%, СюН^КО^), 57 (100%, 
С ^ ) . Anal. (QsHjjNC^S) С, H, Ν. 
For the ScÄs compound: 'Η NMR (CDCI3) δ 0.89 (br t, J=5.6 Hz, 3H, СН2СНз), 1.09-2.18 (m, 
ЮН, (СН2)5СНз), 1.43 (s, 9H, r-Bu), 2.80 (d oft, J=7.3 Hz, 2H, S(0)CH2CH2), 3.00 and 3.14 (AB part 
of ABX spectrum, 8 Unes, 1^=6.0 Hz, JBX=3.4 Hz, 1^=13.5 Hz, 2H, CHCH2S(0)), 3.61-3.98 (m, 2H, 
CH2OH), 3.98-4.44 (m, 2H, CHCH2OH), 5.52 (br d, J=6.6 Hz, IH, NH). CI MS, exact mass caled for 
C15H32N04S, m/z 322.2052 (M+H). Found: 322.2048; m/z 322 (14%), 266 (31%, CnH^NC^S), 248 (43%, С ц Н ^ О з З ) , 222 (54%, ^οΗ 2 4 Ν0 2 5), 57 (100%, С ^ ) . Anal. ( Q j ^ N C ^ S ) С, Η, Ν. 
yV-(í«rf-Biityloxycarbonyl)-S-n-heptyl-D-cyste¡nol. This compound was prepared by reduction of 
N-(rm-butyloxycarbonyl)-.S-n-heptyl-D-cysteine methyl ester (18.6 g, 56.0 mmol) with LÍBH4 
following the procedure that has been described earlier to give the desired product in 92% yield: TLC 
Rf 0.62 (eluent MeOH/CH2Cl2, 7:93); 'H NMR (CDCI3) δ 0.90 (br t, J=5.7 Hz, 3H, СН2СНз), 
1.03-2.00 (m, ЮН, SCH2(CH2)5), 1.44 (s, 9H, r-Bu), 2.00-2.43 (m, IH, OH), 2.55 (t, J=6.8 Hz, 2H, 
SCH2CH2), 2.70 (d, J=6.0 Hz, 2H, CHCH2S), 3.49-4.10 (m, 3H, CHCH2OH), 4.78-5.44 (m, IH, NH). 
CI MS, exact mass caled for CuH^NOjS, m/z 306.2103 (M+H). Found: 306.2094; m/z 306 (28%), 250 
(77%, CnH^NOjS), 206 (100%, C,oH24NOS), 189 (77%, C10H21OS). 
(ScSs) 2-[(E)-B-(6-Methyl-5-urac¡lyl)acrylam¡do]-3-[n-hexylsuIfinyl]-propanol (22). This 
compound was prepared in 33% yield (380 mg) by coupling S-oxo-S-hexyl-cysteinol (619 mg, 3.0 
mmol) with 2 in a mixed anhydride procedure using isobutyl chloroformate as has been described 
earlier:11 TLC Rf 0.33 (eluent МеОН/СНСЦ, 1:4); Ή NMR (CD3OD) δ 0.91 (br t, ЗН, СН2СНз), 
1.16-1.70 (m, 6Н, (СН2)зСНз), 1.70-1.97 (m, 2Н, S(0)CH2CH2), 2.36 (s, ЗН, С(б)-СНз), 2.86 (br t, 
J=7.2 Hz, 2H, S(0)CH2CH2), 3.03 (br d, J=7.2 Hz, 2H, CHCH2S(0)), 3.68 (br d, J=5.7 Hz, 2H, 
CH2OH), 4.35-4.75 (m, IH, CHCH2), 7.20 and 7.42 (ABq, J A B=15.2 HZ, 2H, CH=CH). FAB MS, m/z 
386 (46%, M+H, C17H28N305S), 252 (19%, С ц Н ^ О Д 208 (100%, CgH^NO^), 179 (73%, 
C8H7N203), 74 (58%, C^HgNO); m/z 384 (100%, M-H, C17H26N305S); [a]4> +80.8° (c 0.104, 
MeOH/H20, 1:1). 
(ScSs) 2-[(E)-ß-(6-Methyl-5-uraciIyI)acrylainido]-3-[«-heptyIsuirinyl]-propanol (23). This 
compound was prepared in 24% yield (330 mg) by coupling S-oxo-S-heptyl-cysteinol (750 mg, 3.4 
mmol) with 2 in a mixed anhydride procedure using isobutyl chloroformate as has been described 
earlier.11 The crude reaction product was purified by a combination of gel filtration on Fractogel (eluent 
MeOH/H20, 1:1) and countercurrent distribution (eluent CHCyCCyMeOH/buffer, 7:2:8:4; buffer: 
19.3 g of NH4OAC and 28.6 mL of HOAc in a total volume of IL of water; 560 transfers in 25 mL 
bank): TLC Rf 0.35 (eluent МеОН/СНСІз, 1:4); Ή NMR (CD3OD) δ 0.90 (br t, ЗН, СН2СНз), 
1.16-1.67 (m, 8Н, (СН2)4СНз), 1.67-1.80 (m, 2Н, S(0)Cn2Cil¿, 2.33 (s, ЗН, С(6)-СНз)) 2.83 (t, J=7.5 
Hz, 2H, S(0)CH2CH2), 3.02 (br d, J=7.0 Hz, 2H, CHCH^O)), 3.67 (br d, J=5.0 Hz, 2H, CH2OH). 
4.29-4.69 (m, IH, CHCH2), 7.20 and 7.41 (ABq, 1^=15.0 Hz, 2H, CH=CH). FAB MS, m/z 400 (48%, 
M+H, C,8H29N305S], 252 (23%, С п Н , 4 ^ 0 4 ) , 222 (84%, С 1 0 Н ^ О 2 8 ) , 179 (100%, C8H7N203), 74 (60%, CjHgNO); [a]iòD +73.1° (с 0.104, MeOH/H20,1:1). 
/V-(íer/-Butyloxycarbonyl)-L-alaninol (25). This compound was prepared in 90% yield from the 
ester (2.44 g, 12 mmol) by reduction with LiBH4 in dry DME analogously to the method described 
earlier.8 The product was used for the next reaction without further purification: •H NMR (CDCI3) δ 
1.14 (d, J=6.6 Hz, 3H, CHCH3), 1.44 (s, 9H, f-Bu), 2.71 (br s, IH, CH2OH), 3.45 and 3.55 (AB part of 
ABX spectrum, 7 lines, 1^=4.7 Hz, JBx=7.4 Hz, 1^=10.1 Hz, 2H, CH2OH), 3.47-3.95 (m, IH, 
CHCH3), 4.68 (brd, IH, NH). Anal. (CgH^NOj) C, H, N. 
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/^(rerf-ButyloxycarbonyO-L-alanine methyl ester. This compound was prepared in 93% yield from 
the hydrochloride of L-alanine methyl ester (13.2 g, 94.6 mmol) by treatment with di-rm-butyl 
dicarbonate following the procedure that has been described earlier:8 TLC Rf 0.80 (eluent 
MeOH/CHCl·,, 3:97); Ή NMR (CDCI3) δ 1.36 (d, J=5 Hz, 3H, CHCHj), 1.50 (s, 9H, f-Bu), 3.76 (s, 3H, 
С02СНз), 4.03-4.65 (m, IH, CHCH3), 5.50 (br d, IH, NH). 
(S) 0-(p-Toluenesulfonyl)-A4tert-butyloxycarbonyl)-l-hydroxy-2-am¡nopropane (26). To a 
solution of the alcohol 25 (11.4 mmol) in 76 mL of dry pyridine was added tosyl chloride (12.5 mmol) 
at -10 0C. The reaction mixture was stirred at 4 0C overnight. After completion of the reaction as was 
monitored by TLC (eluent МеОН/СНСІз, 5:95), most of the pyridine was removed by evaporation in 
vacuo at room temperature. The residue was dissolved in 200 mL of CH2CI2 and subsequently washed 
two times with a 2N KHSO4 solution to remove pyridine and then with water. The organic layer was 
dried (N32804) and the solvent was evaporated in vacuo at room temperature. The crude product was 
obtained as a white solid in 87% yield. The crystalline product was not purified by recrystallization 
because of the instability of this compound. In attempts to recrystallize the product, it decomposes even 
at room temperature into the cyclic urethane 34. For 26: TLC Rf 0.79 (eluent MeOH/CHCl·,, 5:95); Ή 
NMR (CDCI3) δ 1.15 (d, J=6.5 Hz, 3H, CHCH3), 1.37 (s, 9H, f-Bu), 2.44 (s, 3H, Ph-CHj), 3.67-4.11 
(m, IH, CHCH3), 3.95 (br s, 2H, CH20), 4.53 (br d, IH, NH), 7.22 and 7.73 (ABq, 1^=8 Hz, 4H, 
Ph-H), CI MS, miz 330 (M+H, C15H24N05S). 
(S) S-Acetyl-yV-(terf-butyloxycarbonyl)-l-thio-2-aminopropane (27). To a suspension of CS2CO3 
(18.5 g, 57 mmol) in 60 mL of dry DMF was added freshly distilled thioacetic acid (9.0 g, 119 mmol). 
Previously, nitrogen had been passed through the suspension for 15 min. When the cesium carbonate 
was dissolved, the crude tosylate 26 (28.8 g, 96 mmol) dissolved in 40 mL of dry DMF was added. The 
reaction mixture was stirred in the dark for 16 hrs at room temperature and was kept under a nitrogen 
atmosphere. The reaction was monitored by TLC (eluent diisopropyl ether/hexane, 1:1). After 
completion of the reaction the solvent was evaporated in vacuo. The residue was dissolved in 300 mL 
of CH2CI2 and washed with water. The organic layer was dried (N32804) and concentrated in vacuo. 
The crude reaction product was subjected to column chromatography (silica gel, eluent diisopropyl 
ether/hexane, 1:1) to give 27 in 80% yield. The yield is based on the alcohol 25: TLC Rf 0.37 (eluent 
diisopropyl ether/hexane, 1:1); Ή NMR (CDCI3) δ 1.15 (d, J=6.5 Hz, 3H, CHCH3), 1.44 (s, 9H, f-Bu), 
2.35 (s, 3H, С(О)СНз), 3.02 (d, J=6 Hz, 2H, CHCH2), 3.59-4.03 (m, IH, CHCHj), 4.73 (br d, J=8 Hz, 
IH, NH). Anal. (C1()H19N03S) C, H, N. 
(ScRs) l-[(Chloroniethyl)sulfinyl]-2-(terf-butyloxycarbonyl)ainino-propane (28). This 
compound was prepared with some modifications of the procedure described earlier.8 Thioester 27 
(14.0 g, 60 mmol) and AC2O (6.12 g, 60 mmol) were dissolved in 150 mL of dry СН2СІ2. The solution 
was stirred and cooled to -10 0C. Subsequently, a solution of 8.9 g of dry gaseous CI2 (the theoretically 
necessary amount of chlorine was 120 mmol, 8.4 g) in 20 mL of dry CH2CI2 - cooled at -50 0 C - was 
added via a connecting tube. The temperature of the reaction mixture was kept below 0 "С. After the 
addition had been completed, the cooling was removed and the reaction mixture was allowed to warm 
up and was stìrred for 1 h at room temperature. The so-prepared sulfinyl chloride precipitated. 
Subsequently, 200 mL of dry CCI4 was added and the organic solvents were evaporated in vacuo at 
room temperature. The residue was stripped with another 200 mL of dry CCI4 to remove the AcCl. The 
resulting sulfinyl chloride was dissolved in 150 mL of dry CH2CI2 and added dropwise over a period of 
3 hrs to a stirred, cooled and dried (KOH pellets) solution of excess CH2N2 in ЕігО. During the reaction 
the temperature was kept at 0 0C. The reaction mixture was stirred overnight at room temperature. The 
solvents were evaporated in vacuo and the crude product was purified by column chromatography on 
silica gel (eluent МеОН/СНгС^, gradient from 0% to 2% of MeOH) to give the diastereomeric 
a-chloro sulfoxides in 41% overall yield. The ScSs diastereomer was formed in slight excess as 
appeared from the Ή NMR spectrum of the reaction product The structure of the ScSs compound is not 
shown in Scheme V. Separation of the diastereomeric a-chloro sulfoxides, a tedious task, was achieved 
by crystallization from EtOAc to yield the pure ScÄs compound. Subsequent column chromatography 
of the residue on silica gel (eluent i-P^O/MeOH, 93:7) yielded the pure ScSs diastereomer next to a 
considerable amount of the other diastereomer. This procedure was carried out repeatedly. 
For the SCÄS compound (28): mp 177-178 0C; TLC Rf 0.23 (eluent /-P^O/MeOH, 93:7); lH NMR 
(CDCI3) δ 1.42 (d, J=5 Hz, 3H, CHCHj), 1.44 (s, 9H, /-Bu), 3.00 and 3.17 (AB part of ABX spectrum, 
7 lines, JAX^.O HZ, JBx=5.4 Hz, JAB=13.5 HZ, 2H, CHCH2S(0)), 3.69-4.35 (m, IH, CHCH3), 4.39 and 
4.49 (ABq, 1^=11 Hz, 2H, S(0)CH2C1), 5.08 (br d, IH, NH). CI MS, m/z 256 (M+H). Anal. (C9H18N03SC1) C, H, N. CD spectrum (MeCN): at 229 nm a single negative Cotton effect was 
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observed (де -0.6). 
For the ScSs compound: mp 130 0C; TLC Rf 0.25 (eluent diisopropyl ether/methanol, 93:7); 'H 
NMR (CDCI3) δ 1.34 (d, J=6.6 Hz, 3H, CHCH3), 1.42 (s, 9H, r-Bu), 2.89 and 3.18 (AB part of ABX 
spectrum, 8 lines, 1^=9.9 Hz, JBX=5.4 Hz, JAB=13.5 Hz, 2H, CHCH2S(0)), 3.79-4.24 (m, IH, 
CHCH3), 4.57 (s, 2H, (S(0)CH2C1), 4.73 (br d, IH, NH). CI MS, mlz 256 (M+H). Anal. (CgHigNC^SCl) C, H, N. CD spectrum (MeCN): at 229 nm a single positive Cotton effect was observed 
(де +0.6). 
(ScRs) l-[[(Methylthio)methyl]sulfinyl]-2-[(/er/-butyloxycarbonyI)aniino]-propane (29a). 
Following the procedure that has been described earlier,8 28 (3.6 mmol) was allowed to react with 
NaSMe in EtOH to give the desired compound in 98% yield: TLC Rf 0.18 (eluent EtOAc/hexane, 3:1); 
Ή NMR (CDC13) δ 1.42 (d, J=6 Hz, ЗН, СНСН3), 1.44 (s, 9Н, f-Bu), 2.33 (s, 3H, SCHj), 2.85 and 3.13 (AB part of ABX spectrum, 8 lines, JAx=8.1 Hz, JBX=4.5 Hz, JAB=13.5 Hz, 2H, CHCH2S(0)), 3.69 and 
3.75 (ABq, ^ = 1 3 . 5 Hz, 2H, S(0)CH2S), 3.97-4.48 (m, IH, CHCH3), 4.97-5.40 (m, IH, NH). El MS, 
m/z 268 (M+H). Anal. Caled for Q o H ^ N C ^ : C, 44.92; H, 7.92; N, 5.24. Found: C, 45.77; H, 8.04; N, 
5.25. 
(ScÄs) l-[[(n-Butylthio)methyl]sulfinyl]-2-[(/crt-butyloxycarbonyl)ainino]-propane (29c). This 
compound was prepared in 95% yield from 28 (1.17 g, 4.6 mmol) by treatment with NaS(CH2)3Me 
which was prepared in situ by reaction of Na (4.6 mmol) with freshly distilled 1-butanethiol (5.0 mmol) 
in 20 mL of EtOH. The reaction mixture was worked up following the procedure that has been 
described earlier:8 TLC Rf 0.42 (eluent MeOH/CHClj, 3:97); Ή NMR (CDCI3) δ 0.93 (t, J=6 Hz, 3H, 
СН2СНз), 1.23-1.80 (m, 4H, СН2СН2СНз), 1.41 (d, J=6 Hz, ЗН, CHCH3), 1.44 (s, 9H, r-Bu), 2.74 (t, 
J=7 Hz, 2H, SCH2CH2), 2.82 and 3.20 (AB part of ABX spectrum, 8 lines, 1^=7.0 Hz, JBx=4.4 Hz, 
JAB=13.0 Hz, 2H, CHCH2S(0)), 3.76 (s, 2H, S(0)CH2S), 4.02-4.43 (m, IH, CHCH2), 5.06-5.41 (m, 
IH, NH). CI MS, exact mass caled for С 1зН 2^Оз5 2, m/z 310.1511 (M+H). Found: 310.1512; m/z 310 (37%), 254 (88%, C^oNOjSz), 210 (70%, C8H20NOS2), 103 (100%, CjHnS). Anal. (С13Н27Ш3$2) 
С, H, Ν. 
(ScÄs) l-[[(n-Octylthiomethyl]-sulfinyl]-2-[(tórt-butyloycarbonyl)ainino]-propane (29d). This 
compound was prepared in quantitative yield from 28 (315 mg, 1.23 mmol) by treatment with 
NaS(CH2)7Me which was prepared in situ by reaction of Na (1.35 mmol) with freshly distilled 
1-octanethiol (1.48 mmol) in 10 mL of EtOH. The reaction mixture was worked up following the 
procedure that has been described earlier:8 TLC Rf 0.57 (eluent MeOH/CHClj, 1:4); 'H NMR (CDCI3) 
δ 0.81 (br t, J=6 Hz, ЗН, СН2СНз), 1.20 (br s, ЮН, (СН2)5СНз), 1.25 (d, 3H, CHCH3), 1.37 (s, 9H, 
f-Bu), 1.40-1.78 (m, 2H, SO^CH^, 2.66 (t, J=7.2 Hz, 2H, SCH2CH2), 2.71 and 3.09 (AB part of ABX 
spectrum, 8 lines. JAX=7.2 HZ, J B X = 5 . 4 HZ, JAB=12.9 Hz, 2H, CHCH2S(0)), 3.68 (s, 2H, S(0)CH2S), 
3.91-4.31 (m, IH, CHCH3), 5.31 (br d, J=7 Hz, IH, NH). Anal. (С17Нз5Ж>з82.і/2Н20) С, Η, Ν. 
(ScRs) l-[tMethylthio)methyl]suirinyI]-2-[(E)-ß-(6-methyI-5-uracilyl)acryIainido]-propane 
(30). This compound was prepared in the following way. The Boc protecting group of 29a was removed 
by reaction with TFA at О "С.8 After concentration in vacuo, the resulting oil was used subsequently 
for coupling. To a solution of 2 (784 mg, 4.0 mmol) in 5 mL of DMF at 0 0C, was added Et3N (404 mg, 
4.0 mmol) and isobutyl chloroformate (544 mg, 4.0 mmol). After 5 min, a solution of 29a (664 mg, 4.0 
mmol) in 10 mL of DMF was added. The reaction mixture was stírred in the dark at 0 0C for 16 hrs. 
Evaporation of the solvent and gel filtration on Fractogel (eluent MeOH/H20, 85:15) afforded the 
desired compound 30 in 71% yield (based on the a-chloro sulfoxide 33a): TLC Rf 0.53 (eluent 
MeOH/CHClj, 1:4); •H NMR (D20) δ 1.37 (d, J=6.0 Hz, ЗН, СНСН3), 2.26 (s, ЗН, SCHj), 2.37 (s, ЗН, 
C(6)- CH3), 3.11 and 3.19 (AB part of ABX spectrum, 5 lines, ^ = 5 . 4 Hz, %=3.6 Hz, ^ = 1 3 . 5 Hz, 
2H, CHCH2S(0)), 3.90 and 4.06 (ABq, 1*8=13.5 Hz, 2H, S(0)CH2S), 4.31-4.62 (m, IH, CHCH3), 7.00 
and 7.30 (ABq, 1^=16.0 Hz, 2H, CH=CH). FAB MS, m/z 346 (11%, M+H), 179 (10%, CgH7N203), 
168 (5%, CsH^NOSz); m/z 344 (100%, M-H); [a]20D +80° (c 0.155, MeOH/H20, 1:1). Anal. (C13H19N304S2) С, H, N. 
(ScRs) l-[[(Ethylthio)methyl]suIfinyl]-2-[(E)-ß-(6-methyl-5-uracilyl)acrylamido]-propane 
(31). This compound was prepared in 60% overall yield starting from 28 (600 mg, 2.35 mmol) 
following the procedures which have been described for compound 30 but using NaSEt instead of 
NaSMe for the substitution reaction. Alternatively, starting from 28 (750 mg, 2.94 mmol) 930 mg (88% 
overall yield) of 31 was obtained using 1 equiv. of the pentafluorophenyl ester of 2, which was prepared 
in situ by reaction of 2 with pentafluorophenol and DCC in DMF/4 in the amide coupling reaction and 
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otherwise similar reaction conditions as used in the preparation of 30. TLC Rf 0.55 (eluent 
MeOH/CHCl3, 1:4); »H NMR (D20) δ 1.19 (t, J=7.5 Hz, 3H, СН2СНз), 1.33 (d, J=7.2 Hz, 3H, 
CHCHj), 2.33 (s, 3H, С(б)-СНз), 2.65 and 2.79 (ABq, 1^=7.3 Hz, 2H, СЩСЩ), 1.96 and 2.10 (AB 
part of ABX spectrum, 8 lines, JAX=10.1 HZ, %=3.4 Hz, JAB=13.5 Hz, 2H, CHCH2S(0)), 3.94 and 
4.08 (ABq, 1^=14.1 Hz, 2H, S(0)CH2S), 4.33-4:66 (m, IH, CHCH2), 6.96 and 7.33 (ABq, J A B=15.5 
Hz, 2H, CH=CH). FAB MS, m/z 360 (78%, M+H, С14Н22Ыз0482), 181 (10%, C6HI5NOS2), 179 (100%, С8Н7М2Оз), 75 (22%, C3H7S); [a]20D +83° (c 0.16, MeOH/H20,1:1). 
(ScÄs) l-[[(n-Butylthio)methyl]suinnyl]-2-[(E)-ß-(6-methyl-5-uracilyl)acryIamido]-propane 
(32). This compound was prepared in 37% overall yield (620 mg) (based on the chloromethyl sulfoxide 
28) from the amine (1.33 g, 4.30 mmol), following the same procedures that have been described for the 
preparation of compound 30: TLC Rf 0.66 (eluent MeOH/CHClj, 1:4); Ή NMR (CDjOD) δ 0.77 (br t, 
J=6.3 Hz, 3H, СН2СНз), 1.20 (d, J=6.9 Hz, 3H, CHCH3), 1.10-1.68 (m. 4H, СН2СН2СНз). 2.18 (s, ЗН, 
С(б)-СНз), 2.60 (t, J=7.2 Hz, 2H, SCH2CH2), 2.79 and 3.03 (AB part of ABX spectrum, 1^=9.3 Hz, 
JBX=4.4 Hz, JAB=13.0 Hz, 2H, CHCH2S(Ó)), 3.70 and 3.83 (ABq, JAB=13.6 Hz, 2H, S(0)CH2S), 
4.21-4.57 (m, IH, CHCH3), 7.02 and 7.27 (ABq, 1^=15.0 Hz, 2H, CH=CH). FAB MS, m/z 388 (17%, 
M+H), 179 (16%, C8H7N203), 103 (30%. CjHnS); [apD +80° (c 0.115, MeOH/H20, 1:1). Anal. (C16H25N304S2.H20) C, H, N. 
(ScRs) l-[[(R-Octylthio)methyl]suinnyl]-2-[(E)-ß-(6-methyI-5-uracilyl)acrylaniido]-propane 
(33). Following the same procedures which have been described for the preparation of compound 30, 
this compound was prepared in 50% overall yield (272 mg) (based on the a-chloro sulfoxide 28) from 
the amine (340 mg, 1.24 mmol): TLC Rf 0.71 (eluent МеОН/СНСЦ, 1:4); •H NMR (CD3OD) δ 0.91 
(br t, J=5.5 Hz, ЗН, СН2СНз), 1.28 (br s, ЮН, (СН2)5СНз), 1.37 (d, J=8.0 Hz, ЗН, CHCHj), 1.52-1.82 (m, 2H, SCH2CH2), 2.35 (s, ЗН, С(б)-СНз), 2.77 (t, J=7.0 Hz, 2H, SCH2CH2), 3.30 (d, J=5.0 Hz) and 
3.17 (d, J=9.0 Hz, AB part of ABX spectrum, 2H, CHCH2S(0)), 3.88 and 3.95 (ABq, 1^=13.5 Hz, 2H. 
S(0)CH2S), 4.42-4.51 (m, IH, CHCH3), 7.18 and 7.42 (ABq, ^ = 1 6 . 0 Hz, 2H, CH=CH). FAB MS, 
m/z 444 (2%, M+H), 207 (18%, C9H19OS2), 179 (3%, CgfyNjOj), 159 (4%, CoH^S); [a]20D +93° (c 
0.102, MeOH). Anal. ( C ^ H J J N J O ^ ) С, H, N. 
2-Oxo-4-methyl-oxazolidine (34). This compound was prepared in quantitative yield from 26 by 
refiuxing for 30 min in CH2C12. TLC Rf 0.28 (eluent MeOHyCHClj, 5:95); Ή NMR (CDCI3) δ 1.27 (d, 
J=5.9 Hz, 3H, CHCH3), 3.78-4.19 (m, 2H, CHCH2), 4.29-4.64 (m, IH, CH), 6.98 (br s, IH, NH). El 
MS, m/z 101 (M, C4H7N02). 
(ScRs) l-[(Chloromethyl)sulfinyl]-2-[(E)-ß-(6-methyl-5-uracilyl)acrylamido]-propane (35). 
This compound was prepared in 26% overall yield (695 mg) from compound 28 (2.04 g, 8.0 mmol) 
following the same procedures that have been described for the preparation of 30: TLC Rf 0.43 (eluent 
MeOH/CHClj, 1:4); Ή NMR (D20) δ 1.37 (d, J=6.9 Hz, ЗН, СНСН3), 2.37 (s, ЗН, С(б)-СНз), 
2.95-3.41 (AB part of ABX spectrum, 2H, CHCH2), 4.32-5.12 (m, 3H, CH, CH2C1), 7.01 and 7.39 (ABq, 1^=15.6 Hz, 2H, CH=CH). FAB MS, m/z 334 (20%, M+H, C^HnNjC^SCl), 256 (100%, 
СюНю^ОзСІ), 222 (81%, С ^ ^ з О з ) , 179 (24%, C8H7N203), 156 (22%, СлНцЖЭЗСІ). [a]20D 
+90° (с 0.115, MeOH/H20,1:1). 
l-(n-Propylthio)-2-(W-fert-butyloxycarbonyl)amino-propane (35). A solution of the tosylate 26 
(5.2 g, 15.8 mmol) in 15 mL of dry EtOH was added to a solution of NaS(CH2)2Me in 15 ml of dry 
EtOH which was prepared in situ by reaction of 1-propanethiol (1.14 g, 15 mmol) and Na (380 mg, 16.5 
mmol). The entire reaction vessel was kept carefully under an argon atmosphere. The reaction mixture 
was stirred at room temperature during the night. The solvent was removed in vacuo and the product 
was extracted between ether and water. The water layer was once extracted with ether and the 
combined organic layers were twice extracted with water and once with a saturated NaCl solution. 
After drying (MgSC^) and concentration in vacuo a yellow oil was obtained. After a quick column 
chromatographic procedure on silica gel using СН2СІ2 as eluent, 3.2 g (92% overall yield) of 35 was 
obtained as as colourless oil: TLC Rf 0.57 (eluent /-Pr20); Ή NMR (CDCI3) δ 0.98 (t, J=7.2 Hz, 3H, 
СН2СНз), 1.19 (d, J=6.5 Hz, 3H, CHCH3), 1.43 (s, 9H, r-Bu), 1.54-1.86 (m, 2H, СН2СНз), 2.52 (t, 
J=7.2 Hz, 2H, SCH2CH2), 2.54 and 2.68 (AB part of ABX spectrum, 8 lines, 1^=4.0 Hz, JBX=2.5 Hz, 
1^=11.9 Hz, 2H, CHCH2S), 3.83 (septet, J=6.5 Hz, IH, CH), 4.44-4.84 (br d, IH, NH). CI MS, exact 
mass caled for CnH^NCbS, m/z 234.1528 (M+H). Found: 234.1524; m/z 234 (14%), 178 (38%, 
C7H16N02S), 134 (31%, C6H16NS), 117 (100%, QH^S), 57 (23%, C4H9). 
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(ScSs) l-(n-Propylsulfinyl)-^-(ter/-butyloxycarbonyl)-2-amino-propane (36). This compound 
and its S-epimer were synthesized in approximately equal amounts by oxidation of 35 (1.95 g, 8.37 
mmol) in 40 mL of СН2СІ2 with mCPBA23 (2.2 g, 12.8 mmol) at 0oC for 10 min in 91% combined 
yields. The two diastereomers could be separated by a combination of column chromatography on silica 
gel (eluent THF/i-Pr20, 1:1) and crystallization from CHClj/E^O: TLC Rf 0.56 (36, ScSs) and 0.61 (Scfls) (eluent THF). 
For the ScSs compound 36: mp 139-140oC. •H NMR (CDCI3) δ 1.07 (t, J=7.2 Hz, 3H, CHjCHj), 
1.38 (d, J=5.4 Hz, 3H, CHCH3), 1.41 (s, 9H, f-Bu), 1.82 (sextet, J=7.3 Hz, 2H, СЩСЩ), 2.46-2.96 (m, 
2H, S(0)CH2CH2), 2.83 (d, J=5.7 Hz, 2 H, CHCH2), 4.17 (septet, J=6.6 Hz, IH, CH), 5.36 (br d, J=7 
Hz, IH, NH). CI MS, mlz 250 (2%, M+H), 194 (5%, С7Н 1 6Шз5), 150 (34%, C6H16NOS), 57 (100%, 
CJty, 44 (32%, C02); [aJ20D +40.8 (c 0.12, MeOH). Anal. (CnH^NOjS) С, H, N. CD spectrum (MeCN): at 216 mm a single positive Cotton effect was observed (ΔΕ +0.31). 
For the ScR% compound: mp 131-1320C. Ή NMR (CDCI3) δ 1.08 (t, J=7.2 Hz, 3H, CH2CH3), 1.37 (d, J=6.7 Hz, 3 H, CHCH3), 1.41 (s, 9H, f-Bu), 1.63-2.03 (m, 2H, СН2СНз), 2.76 (t, J=8 Hz, 2H, 
S(0)CH2CH2), 2.89 (d, J=6.6 Hz, 2H, СНСЩ, 4.88 (septet, J=6.8 Hz, IH, CH), 4.96 (br d, J=6.6 Hz, 
IH, NH). CI MS, miz 250 (1%, M+H), 194 (1%, C ^ N C b S ) , 150 (22%, C6H16NOS), 57 (100%, 
C4H9), 44 (23%, C02); [a]2ôD +20.7° (c 0.135, MeOH). Anal. (CnH^NC^S) C, H, N. CD spectrum (MeCN): at 221 nm a single negative Cotton effect was observed (де -0.21). 
(ScSs) l-(n-Propylsuirinyl)-2-[(E)-ß-(6-methyl-5-uraciIyI)acrylamido]-propane (37). The 
/V-Boc protecting group of 36 (530 mg, 2.13 mmol) was removed by stirring with 10 mL of TFA for 30 
min at 0 0C. After evaporation of the excess TFA, stripping twice with EtOH and drying in vacuo, the 
amine was dissolved in 20 mL of DMF and the solution was neutralized with Et3N. Subsequently, Et3N 
(0.3 mL, 1 equiv.) and the pentafluorophenyl ester of 2 (771 me, 2.13 mmol), which was prepared in 
situ by reaction of 2 with pentafluorophenol and DCC in DMF, were added and the reaction mixture 
was stirred in the dark for 18 h at room temperature. Concentration in vacuo and gel filtration of the 
crude reaction product on Fractogel (eluent МеОЩНгО, 1:1) afforded 502 mg (72% yield) of a white 
material after lyophilization from HOAc and drying in an exsiccator on KOH: TLC Rf 0.39 (eluent 
MeOH/CHClj, 1:4); Ή NMR (D20) δ 1.04 (t, J=7.4 Hz, ЗН, СН2СНз), 1.36 (d, J=6.7 Hz, ЗН, 
СНСНз), 1.77 (sextet, J=7.4 Hz, 2H, СН2СНз), 2.34 (s, ЗН, С(б)-СНз), 2.89 (t, J=7.4 Hz, 2H, 
S(0)CH2CH2), 3.06 (d, J=6.7 Hz, 2H, СНСНЛ 4.42 (quintet, J=6.6 Hz, IH, CH), 6.96 and 7.30 (ABq, 
JAB=15.4 Hz, 2H, CH=CH). FAB MS, miz 328 (97%, M+H, C^H^NjC^S), 179 (100%, C8H7N203), 
150 (100%, C6H16NOS); [a]20D +98.3° (c 0.115, MeOH). 
Analytical Data 
7a, C12H25N04S2: C, 46.28; H, 8.09; N, 4.50. Found: С, 46.46; H, 8.13; Ν, 4.53. 
7b, ^3Η 2 7Ν048 2 : С, 47.97; H, 8.36; Ν, 4.30. Found: С, 48.12; Η, 8.28; Ν, 4.37. 
7с, ^4Η 2 9 Ν0 4 8 2 : С, 49.53; Η, 8.61; Ν, 4.13. Found: С, 49.47; Η, 8.60; Ν, 4.15. 
7d, C13H27N04S2: С, 47.97; Η, 8.36; Ν, 4.30. Found: С, 47.96; Η, 8.35; Ν, 4.25. 
7е, ^ 5 Η 2 9 Ν 0 4 8 2 : С, 51.25; Η, 8.32; Ν, 3.98. Found: С, 51.47; Η, 8.38; Ν, 3.95. 
8а, C 7H 1 7N0 2S 2: С, 39.78; Η, 8.11; Ν, 6.63. Found: С, 39.61; Η, 7.90; Ν, 6.78. 
8с, (^Η 2 1 Ν0 2 8 2 : С, 45.15; Η, 8.84; Ν, 5.85. Found: С, 45.04; Η, 8.68; Ν, 5.86. 
10, Сі 6Н^з058 2.і/2Н 20: С, 46.58; Η, 6.11; Ν, 10.19. Found: С, 46.13; Η, 6.16; Ν, 10.03. 
11, C16H27N305S2.H20: С, 46.88; Η, 6.25; Ν, 9.65. Found: С, 47.24; Η, 6.47; Ν, 9.58. 
16, C16H25N304S2.i/2H20: С, 48.46; Η, 6.61; Ν, 10.60. Found: С, 48.53; Η, 6.49; Ν, 10.21. 
W/Z-Di-acetylcystamine, C 8H 1 6N 20 2S 2 : С, 40.66; Η, 6.82; Ν, 11.85. Found: С, 40.94; Η, 6.92; Ν, 
11.76. 
5-n-Heptyl-D-cysteine, ^οΗ 2 1 Ν0 2 8: С, 54.76; Η, 9.65; Ν, 6.39. Found: С, 54.69; Η, 9.50; N,6.52. 
20b, CUH3JN04S (ScSs): С, 56.04; Η, 9.72; Ν, 4.36. Found: С, 56.23; Η, 9.79; Ν, 4.33. [C15H31N04S 
(ScRs): С, 56.04; Η, 9.72; Ν, 4.36. Found: С, 56.12; Η, 9.71; Ν, 4.36]. 
25, C8H17N03: С, 54.84; Η, 9.78; Ν, 7.99. Found: С, 54.83; Η, 9.96; Ν, 7.96. 
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27, С10Н19Ж>з8: С, 51.48; H, 8.21; Ν, 6.00. Found: С, 51.46; Η, 8.30; Ν, 5.90. 
28, CcH^NOjSCl (ScRs): С, 42.27; Η, 7.09; Ν, 5.48. Found: С, 42.30; Η, 7.13; Ν, 5.38. 
[CgHjgNOjSCl (ScSs): С, 42.27; Η, 7.09; Ν, 5.48. Found: С, 42.04; Η, 7.10; Ν, 5.50]. 
29c, C13H27N03S2: С, 50.45; Η, 8.79; Ν, 4.53. Found: С, 50.22; Η, 8.76; Ν, 4.44. 
29d, C17H35N03S2.i/2H20: С, 54.51; Η, 9.42; Ν, 3.74. Found: С, 54.23; Η, 9.28; Ν, 3.36. 
30, C13H19N304S2: С, 45.20; Η, 5.54; Ν, 12.16. Found: С, 45.24; Η, 5.53; Ν, 11.84. 
32, C16H25N304S2.H20: С, 47.39; Η, 6.21; Ν, 10.36. Found: С, 47.47; Η, 6.47; Ν, 10.32. 
33, С 2оНзз^0 48 2 : С, 54.15; Η, 7.50; Ν, 9.47. Found: С, 53.92; Η, 7.53; Ν, 9.21. 
36, CnH^NOjS (ScSs): С, 52.98; Η, 9.30; Ν, 5.62. Found: С, 52.60; Η, 9.34; Ν, 5.55. [CnH^NOjS 
(ScRs): С, 52.98; Η, 9.30; Ν, 5.62. Found: С, 53.08; Η, 9.45; Ν, 5.61]. 
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36. Separation of the diastereomeric sulfoxides 20 can be effected by chromatography on silica gel 
using as eluent MeOH/CH^CLj, 7:93. By preparing the corresponding rm-butyldimethylsilyl ether 
of 20b, i.e. 20c, the sulfoxides could be separated more easily on silica gel using ether/hexane 7:3 
as eluent. We observed that the relative position of both diastereomers on TLC changed when 
ether/hexane was used as eluent; the configuration of the desired precursor should be checked by 
CD spectroscopy. Chromatography under pressure (0.5 atm) resulted in substantial hydrolysis of 
the silyl ether (unpublished results). 
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THE EFFECT OF MODIFICATION OF THE HYDROXYMETHYL FUNCTION 
ON THE BIOLOGICAL ACTIVITY 
Conclusions: 
-more or less equally active as sparsomycin: 
no relationship with lipophilicity 
-OH function is not essential for activity and this 
part of the molecule apparently does not interact 
with a hydrophobic region on the peptidyl transferase 
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SUMMARY 
The synthesis is described of the sparsomycin analogues 11-14 from the L-amino acids valine, 
isoleucine, phenylalanine and proline, respectively. The sparsomycin derivative 21 was not prepared in 
a similar way from glycine, but from cystamine following a different reaction route. These analogues, 
as well as the O-methylated and O-acetylated derivatives 15 and 16, respectively, were tested in vitro 
for their protein synthesis inhibitory activity and for their inhibition of colony formation of murine 
leukemia L1210 cells. The results of these assays indicate that the hydroxymethyl function of 1 is not 
essential for its biological activity, and that increase of lipophilicity in this "northern" region of 1 does 
not sizably affect the activity of the drug. 
INTRODUCTION 
Sparsomycin (I),1 a broad spectrum antibiotic, is a potent inhibitor of protein synthesis due to its 
interaction with the peptidyl transferase center located on the large ribosomal subunit. It has proven to 
be very useful in the study of various aspects of the protein biosynthesis machinery. Sparsomycin has 
also been the subject of intensive biomedical investigations due mainly to its antitumor activity. In the 
course of structure-activity relationship (SAR) studies we reported the synthesis of several analogues of 
sparsomycin that are better protein synthesis inhibitors and better antitumor drugs than the natural 
product I.1·2·3 
O H
o 
I/ 
S ^ ^ , S . 
^ X • 
O N O Sparsomycin, 1 
•Me 
Recently, we investigated the effect of the lipophilicity of these analogues on the biological 
activity.3·4 It was shown that in general substitution of the methylthio group by larger alkylthio, 
aralkylthio or alkyl groups results in a higher protein synthesis inhibitory activity as well as in a higher 
antitumor activity. However, in comparison with the highly active n-butylthio derivative, the isomeric 
rerr-butylthio analogue shows even lower biological activity than 1, demonstrating the effect of steric 
crowding in this part of the molecule on the activity. 
Replacement of the hydroxymethyl moiety at the chiral carbon center of 1 by a methyl group yields 
compound 10.4 Surprisingly, this compound shows lower activity in the protein synthesis assays, yet is 
five times more active than sparsomycin against 1Л210 leukemia cells. 
In order to study the effect of other groups replacing the hydroxymethyl moiety of sparsomycin, we 
wanted to prepare derivatives possessing branched alkyl or aralkyl groups at the chiral carbon atom of 
1. 
In all syntheses reported so far for 1 the amine fragment was derived from amino acids, either 
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D-cysteine2"5 or L-serine6 (see Scheme I). We reasoned that by analogy other L-amino acids might 
yield sparsomycin analogues having the desired branched alkyl or aralkyl chain at the chiral center. 
Following this line of reasoning we were able to prepare also deshydroxy-sparsomycin 10 from 
L-alanine4 (Scheme I). 
Scheme 1. Amino acids in the synthesis of sparsomycin and analogues 
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Here, we report that this approach is a general one. It enabled us to incorporate the L-amino acids 
valine, isoleucine, phenylalanine and proline into the corresponding sparsomycin analogues 11-14, 
respectively (Scheme Π, Table I). We chose to prepare the corresponding glycine sparsomycin 
derivative 21 via a different reaction route from cystamine, i.e. ( ^ N C ^ C T ^ S ^ (Scheme ΙΠ). 
Subsequently, the biological activity of these analogues and of the O-methylated and O-acetylated 
analogues 14 and 15, respectively, was studied. Part of these activity data have been described 
elsewhere.7 On the basis of these results we were able to draw conclusions on the structure-activity 
relationship of sparsomycin as far as the hydroxymethyl moiety is concerned. 
RESULTS AND DISCUSSION 
Chemistry. All sparsomycin analogues studied in this report are listed in Table I. The synthesis of 
10 has been described elsewhere.4 The synthetic route to the L-amino acid sparsomycin analogues 
11-14 started with the N-Boc protected amino acid methyl esters 2a-d (Scheme Π). Reduction6 of these 
methyl esters gave the corresponding alcohols 3a-d in 81-97% yield. Transformation of the hydroxy 
function into the tosylate group gave compounds 4a-d in 70-99% yield, and subsequent substitution of 
the tosylate function with cesium thioacetate in dimethyl formamide4 afforded the corresponding 
thioacetates 5a-d in yields ranging between 46% and 66%. 
These thioacetates were converted into a mixture of diastereomeric chloromethyl sulfoxides by 
reaction with chlorine, acetic anhydride and subsequently with diazomethane;4 only the ScRs 
stereoisomers 6a-d are depicted in Scheme П. Isolation of 6a-c from the diastereomeric mixtures was 
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cumbersome. It required column chromatography in combination with recrystallization; manipulations 
which were accompanied with severe loss of material. Unfortunately, we were not able to separate 6a 
and 6d completely from their diastereomeric counterparts having the ScSs chirality. 
Substitution of the chlorine substituent in 6a-d by a methylthio group employing sodium methyl 
mercaptide6 gave the corresponding monoxodithioacetals 7a-d in 76-92% yield. Removal of the Boc 
amino-protecting group by treatment with trifluoroacetic acid6 at 0 0C gave compounds 8a-d in 
73-100% yield, and coupling of the latter compounds with the 6-methyluracilacrylic acid 9 using the 
isobutyl chloroformate mixed anhydride coupling procedure6 afforded the sparsomycin analogues 11-14 
in 20-51% yield. From their 'H NMR spectra it was concluded that 11 and 14 were still contaminated 
by their diastereomeric counterparts; the ratio ScRs(ll)/ScSs was 3:1, the ratio 5cÄs(14)/ScSs was 1:1. 
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(a) R=CHMe2; (b) R=CH(Me)Et; (c) R=CH2Ph; (d) R=2-substituted-A/-
Boc-pyrrolidine; (e) R=CH2OH; (f) R=CH2ÓMe. 
Compound 15 was prepared in the following way. The hydroxy function of compound 7e was 
O-methylated by reaction with diazomethane8 to yield the methoxy derivative 7f in 45% yield (Scheme 
II). Removal of the Boc group (quantitative yield) and coupling with the acid 9 (vide supra) gave the 
desired sparsomycin derivative 15 in 30% yield. Compound 16 was synthesized by reaction of 1 with 
acetyl chloride in pyridine in 30% yield. 
Compound 21 was prepared starting from cystamine dihydrochloride (Scheme Ш). Protection of 
both amino functions of cystamine with the Boc protecting group gave compound 17 in 96% yield. 
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Reaction of 17 with chlorine and acetic anhydride and subsequently with diazomethane6 afforded 18 in 
41% yield. Compound 18 is inevitably a 1:1 mixture of both possible sulfoxide enantiomers. 
Table I. Sparsomycin Derivatives 
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Replacement of the chlorine substituent in 18 with sodium methyl mercaptide6 gave 19 in 93% 
yield. The amide coupling of the N-deprotected amine 19 with the acid 9 was effected by means of the 
pentafluorophenyl ester of 9, i.e. 20.9 This ester was prepared easily in a dicyclohexyl carbodiimide 
coupling reaction in dimethyl fomiamide from 96 and pentafluorophenol. The coupling product 21 was 
obtained in 61% yield, showing that this method is superior in reaction yield to the isobutyl 
chloroformate mixed anhydride coupling procedure. Given the reaction route followed for the 
preparation of 21, the product is a mixture of the two enantiomers. 
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Chiroptical Properties. In order to establish the absolute configuration at both chiral centers of the 
novel L-amino acid-derived sparsomycin analogues 11-13, we recorded their circular dichroism (CD) 
spectra. Earlier, we have shown that the sign of the Cotton effects in the CD spectra of sparsomycin (1) 
and its three stereoisomers is correlated with the absolute configuration at both chiral centers.6 E.g. 
Figure I showing the CD spectrum of compound 12 confirms its ScRs chirality. 
Scheme III 
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Biological Activity. The biological activity of the compounds prepared was studied in the 
following assays. Protein synthesis inhibition was measured in two cell-free systems: the 
polyphenylalanine (polyPhe) assay using ribosomes from Escherichia coli and Saccharomyces 
cerevisiae? and the puromycin reaction on ribosomes from E. coli? Cell growth inhibition was 
evaluated by studying the growth inhibition of E. coli in liquid medium.3 Antitumor activity was 
studied in the murine leukemia L1210 clonogenic assay in soft agar.2 Additional data on the biological 
activity of compounds 10-16 in other peptide bond formation assays than described here, have been 
described elsewhere.7 The results of the assays studied are presented in Table Π and the following 
conclusions can be drawn. 
Modification of the hydroxymethyl group of sparsomycin (1) or replacement by alkyl or aralkyl 
groups as in 10-13 has no significant effect on the protein synthesis inhibitory activity when tested in 
the E. coli polyPhe assay. However, the activity of these analogues in a similar assay using ribosomes 
from S. cerevisiat is considerably lower. This finding leams that structural differences in the ribosomes 
74 Chapter 2.3 
of prokaryotes, e.g. E. coli, and eukaryotes, e.g. 5. cerevisiae, can be studied well using sparsomycin 
analogues. Moreover, these derivatives are all less active than sparsomycin in the puromycin reaction. 
O-Methylation of 1 decreases the biological activity of the drug a little more than O-acetylation. 
Invariably, compound 14 shows very low activity in the cell-free protein synthesis inhibition assays 
studied. Apparently, the shape of 14 deviates too severely due to the introduction of the 
conformationally constrained pyrrolidine moiety. 
Table Π. Biological Activity 
compd 
1 
10 
11 
12 
13 
14 
15 
16 
21 
PolyPhe 
E. coli 
synthesis 
S. cerevisiae 
ΕΌ50 (μΜ) 
8.5 
14.5 
4.6 
12.0 
12.0 
220 
21 
8.0 
160 
5.2 
50 
10.0 
32 
100 
800 
43 
10.0 
170 
Puromycin 
reaction 
E. coli 
ED5o (μΜ) 
0.10 
0.25 
0.34 
0.62 
0.39 
13.1 
0.23 
0.15 
0.40 
Growth 
inhibition 
E. coli 
Εϋ5 0(μΜ) 
11 
5.6 
6.2 
9.0 
7.4 
3.8 
8.0 
12 
6.0 
Colony 
formation 
L1210 
Ιθ5ο(μΜ) 
0.40 
0.07 
0.40 
0.41 
0.48 
0.56 
1.45 
0.45 
0.75 
Removal of the hydroxymethyl group in 1 to give 21 results in a decrease of the biological activity 
of the drug. The relatively high inhibition of protein synthesis of compound 21 is surprising, however, 
given the fact that both the chirality at the carbon atom is lost and the product is a 1:1 mixture of 
enantiomers. For sparsomycin it was shown that of the possible stereoisomers only the ScRs compound 
is biologically active; the ScSs, RcSs and RcRs isomers all show an ED50 of 2000 μΜ in the polyPhe 
assay.3 
In a structure-activity relationship study where the synthesis and biological activity of analogues 
having the methylthio group substituted by larger alkylthio or alkyl groups was reported,4 we observed 
that an increase in lipophilicity of the drug resulted in an increase of biological activity. From this we 
concluded that the "eastern" region of 1 interacts with a hydrophobic region on the ribosomal binding 
site for sparsomycin; i.e. the peptidyl transferase center. From the present study, we conclude that 
increasing the lipophilicity of the drug by introduction of lipophilic groups at the chiral carbon atom of 
1 hardly affects the biological activity. Apparently, the "northern" region of the molecule does not 
Chapter 2.3 75 
interact with a hydrophobic site on the peptidyl transferase. 
The correlation in structure-activity relationships of sparsomycin observed in cell-free assays and 
in whole-cell systems is usually good.3 Surprisingly, compound 10 being less active than 1 in the 
cell-free E. coli polyPhe assay is more active than 1 against intact E. coli and L1210 leukemia cells. In 
a similar way, the activity of compounds 14 and 21 against intact cells is higher than could be expected 
on the basis of their low activity in the cell-free protein synthesis inhibition assays. This might indicate 
changes in membrane permeability properties among the various sparsomycin derivatives or point to a 
mode of action for drugs like 10,14 and 21 that differs from protein synthesis inhibition. 
Figurel.CD spectrum 
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EXPERIMENTAL SECTION 
Biological activity. All assays used have been described in detail elsewhere.2,3 The peptidyl 
transferase activity was measured in the polyphenylalanine synthesis assay using ribosomes from E. 
coli MRE600 and S. cerevisiae Y166 and in the puromycin reaction using ribosomes from E. coli 
MRE60O. These tests are used as a model for studying protein synthesis inhibition. ED50 represents the 
50% effective dose. Cell growth inhibition of E. coli MRE6(J0 was studied in liquid medium. The 
antitumor activity was evaluated in the murine leukemia L1210 clonogenic assay in soft agar medium. 
1D50 represents the 50% inhibitory dose. 
Chemical syntheses. Melting points (mp) were determined on a Reichert hot stage and are 
uncorrected. 1Н NMR spectra were recorded on a Bruker WH-90 spectrometer with Me4Si as an 
internal standard. Mass spectra (MS, m/z, relative intensity) were recorded on a double-focussing VG 
7070E mass spectrometer; for FAB MS, glycerol was used. The circular dichroism (CD) spectrum was 
recorded on an Autodichrograph Mark V apparatus (Jobin Yvon). For determination of the specific 
rotation ([a]20D), a Perkin-Elmer 241 Polarimeter was used. Analyses indicated by the symbols of the 
elements were within ± 0.5% of the theoretical values unless indicated. Thin-layer chromatography 
(TLC) was carried out by using Merck precoated silica gel F-254 plates (thickness 0.25 mm). Spots 
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were visualized with an UV lamp, ninhydrin or CI2-TDM.10 For column chromatography, Merck silica 
gel H (type 60) was used. For gel filtration, Pharmacia Sephadex LH-20 was used. Ion-exchange 
chromatography was carried out on Amberlite IRA-410 obtained from Fluka. 
A4ter/-Biityloxycarbonyl)-L-valine Methyl Ester (2a). This compound was prepared in 
quantitative yield from the hydrochloride of L-valine methyl ester (25.2 g, 0.15 mol) by treatment with 
di-rm-butyl pyrocarbonate following the procedure that has been described earlier:6 TLC Rf 0.85 
(eluent МеОН/СНСІз, 3:97); lH NMR (CDC13) δ 0.87 0.98 (dd, J=2 Hz, 6H, CH3CHCH3), 1.45 (s, 9H, 
t-Bu), 1.77-2.37 (m, IH, CH3CHCH3), 3.75 (s, 3H, C02CH3), 4.01-4.37 (m, IH, СНС02СНз), 
4.90-5.29 (m, IH, NH). 
N-(ferM$utyloxycarbonyl)-L-isoIeiicine Methyl Ester (2b). This compound was prepared in 99% 
yield from the hydrochloride of L-isoleucine methyl ester (27.3 g, 0.15 mol) by treatment with 
di-rm-butyl pyrocarbonate following the procedure that has been described earlier:6 TLC Rf 0.85 
(eluent МеОН/СНСІз, 3:97); Ή NMR (CDCI3) δ 0.73-0.99 (m, 6Η, CHCHj, СН2СНз), 1.06-1.41 (m, 
2Н, СН2СНз), 1.44 (s, 9Н, t-Bu), 3.27-3.67 (m, IH, CHCH3), 3.73 (s, ЗН, С02СНз), 4.03-4.40 (m, IH, 
СНС02СНз), 4.77-5.20 (m, IH, ΜΗ). 
N-(fer/-Butyloxycarbonyl)-I,-phenylalanine Methyl Ester (2c). This compound was prepared in 
97% yield from the hydrochloride of L-phenylalanine methyl ester (32.4 g, 0.15 mol) by treatment with 
di-rm-butyl pyrocarbonate following the procedure that has been described earlier:6 TLC Rf 0.85 
(eluent МеОН/СНСІз, 3:97); Ή NMR (CDCI3) δ 1.40 (s, 9Η, t-Bu), 3.04 and 3.11 (d, AB part of ABX 
spectrum, 2H, CHCH2), 3.70 (s, ЗН, С02СНз), 4.36-4.73 (m, IH, СНС02СНз), 4.75-5.10 (m, IH, 
NH), 7.04-7.34 (m, 5H, Ph). 
№(ferf-Butyloxycarbonyl)-L-proline Methyl Ester (2d). This compound was prepared in 
quantitative yield from the hydrochloride of L-proline methyl ester (24.9 g, 0.15 mol) by treatment with 
di-rm-butyl pyrocarbonate following the procedure that has been described earlier:6 TLC Rf 0.83 
(eluent MeOH/CHCl·,, 3:97); 'H NMR (CDCI3) δ 1.44 (s, 9H, t-Bu), 1.82-2.37 (m, 4H, CH2CH2CH), 
3.33-3.65 (m, 2H, CH2N), 3.73 (s, 3H, COjCHj), 4.04-4.45 (m, IH, СНС02СНз). 
N-(fm-Butyloxycarbonyl)-I.-valÎnol (3a). This compound was prepared in 81% yield from the 
ester 2a (9.28 g, 40 mmol) by reduction with LiBH4 in dry DME following the procedure that has been 
described earUer:6 TLC Rf 0.47 (eluent MeOH/CHCl·,, 7:93); 'H NMR (CDCI3) δ 0.92 and 0.94 (dd, 2x 
J=7 Hz, 6H, CH3CHCH3), 1.44 (s, 9H, t-Bu), 1.45-1.97 (m, IH, CH3CHCH3), 2.15 (s, IH, OH), 
3.24-3.49 (m, IH, CHCH2), 3.53-3.72 (m, 2H, CH2OH), 4.36-4.77 (m, IH, NH). CI MS, m/z 204 (31%, 
M+H, C10H22NO3), 148 (70%, QH^NOj), 104 (100%, C5H14NO), 57 (36%, QH,). 
/V-(im-ButyIoxycarbonyl)-L-isoleucinoI (3b). This compound was prepared in 97% yield from 
the ester 2b (9.84 g, 40 mmol) by reduction with LiBH4 in dry DME following the procedured that has 
been described earlier:6 TLC Rf 0.47 (eluent MeOH/CHClj, 7:93); lH NMR (CDCI3) δ 0.83-1.03 (m, 
6H, СНСНз, СН2СНз), 1.03-1.40 (m, 2Н, СН2СНз), 1.44 (s, 9Н, t-Bu), 2.21-2.61 (m, IH, СНСН3), 
3.32-3.88 (m, 4H, CHCH2OH), 4.52-4.68 (m, IH, NH). CI MS, m/z 218 (5%, M+H, СцН^Шз), 162 (49%, С7Н16Ж)з), 118 (100%, C6H16NO), 57 (44%, С^Щ). 
JV-(fm-Butyloxycarbonyl)-L-phenylalaninol (3c). This compound was prepared in 89% yield 
from the ester 2c (11.2 g, 40 mmol) by reduction with LÌBH4 in dry DME analogously to the method 
described earlier:6 TLC Rf 0.50 (eluent MeOH/CHClj, 7:93); Ή NMR (COCU) δ 1.40 (s, 9H, t-Bu), 
2.00-2.53 (m, IH, OH), 2.83 (d, J=5.4 Hz, 2H, CH2Ph), 3.33-4.08 (m, ЗН, CH2OH, CHCH^, 4.48-4.94 (br d, IH, NH), 7.22 (s, 5H, Ph). CI MS, m/z 252 (47%, M+H), 196 (66%, CIQH^NOJ), 152 (100%, 
COHHNO), 91 (5%, C7H7), 57 (21%, C4H9). Anal. C ^ ^ N O j (C, H, N). 
^-(tert-ButyloxycarbonyO-L-proIinoI (3d). This compound was prepared in 92% yield from the 
ester 2d (9.2 g, 40 mmol) by reduction with LiBH4 in dry DME following the procedure that has been 
described earlier:6 TLC Rf 0.81 (eluent МеОН/СНСЦ, 7:93); lH NMR (CDCI3) δ 1.47 (s, 9H, t-Bu), 
1.58-2.18 (m, 4H, CH2CH2CH), 3.15-3.66 (m, 4Н, CH2N, СН2ОН), 3.73-4.07 (m, IH, CHN) 4.40-4.80 (brs, IH, OH). 
(S) l-Hydroxy-O-0'-toIuenesulfonyI)-2-ainino-yV-(ter/-butyloxycarbonyI)-3-methyl-butane 
(4a). This compound was prepared in 70% yield from compound За (3.0 g, 14.8 mmol) by reaction with 
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tosyl chloride in pyridine as has been described earlier.4 TLC Rf 0.29 (eluent diisopropyl ether/hexane, 
1:1); lH NMR (CDC13) δ 0.82-0.98 (m, 6H, CHjCHCHj), 1.40 (s, 9H, t-Bu), 1.49-1.92 (m, IH, 
CH3CHCH3), 2.44 (s, Ph-СНз), 3.30-3.73 (m, IH, CHCH2) 3.86-4.22 (AB part of ABX spectrum, 2H, 
CHCH2), 4.31-4.73 (m, IH, NH), 7.34 and 7.76 (ABq, ^ = 9 Hz, 4H, Ph-H). 
(5) l-Hydroxy-0-(p-toluenesulfonyl)-2-amino-A4terf-butyloxycarbonyl)-3-methyl-pentane 
(4b). Following the same procedure that has been described earlier,4 this compound was prepared in 
85% yield from compound 3b (5.0 g, 23 mmol) by reaction with TsCl in pyridine: TLC Rf 0.27 (eluent 
diisopropyl ether/hexane, 1:1); 'H NMR (CDCI3) δ 0.70-1.00 (m, 6H, СН2СНз, CHjCH), 1.03-1.89 (m, 
ЗН, СНСН.СНз), 1.40 (s, 9Н, t-Bu), 2.44 (s, ЗН, Ph-CHj), 3.30-3.80 (m, IH, СНСН20), 4.03 and 4.07 (AB part of ABX spectrum, d, 2H, CHCH20), 4.59 (br d, J=4.5 Hz, IH, NH), 7.33 and 7.77 (ABq, 
1^=8.1 Hz, 4H, Ph-H). 
(5) l-Hydroxy-0-(p-toluenesulfonyl)-2-amino-/V-(ier/-butyloxycarbonyl)-3-phenyl-propane 
(4c). Following the same procedure that has been described earlier,4 this compound was prepared in 
89% yield from compound 3c (5.78 g, 23 mmol) by reaction with TsCl in pyridine: TLC Rf 0.23 (eluent 
diisopropyl ether/hexane, 1:1); Ή NMR (CDCI3) δ 1.37 (s, 9H, t-Bu), 2.43 (s, ЗН, Ph-СНз), 2.68-3.00 
(AB part of ABX spectrum, m, 2H, CHCH2Ph), 3.83-4.22 (m, ЗН, СНСН20), 4.56-4.86 (m, IH, NH), 
6.98-7.23 (m, 5H, CH2Ph-H), 7.32 and 7.74 (ABq, 1^=9 Hz, 4H, Ph-H). 
Tosylate of /V-(íert-Butyloxycarbonyl)-L-prolinol (4d). This compound was prepared in 99% 
yield from 3d (6.0 g, 30 mmol) by reaction with TsCl in pyrindine following the procedure that has 
been described earlier.4 TLC Rf 0.81 (eluent MeOH/CHClj, 4:96); •H NMR (CDCI3) δ 1.39 (s, 9H, 
t-Bu), 1.63-2.12 (m, 4H, CH2CH2CH), 2.44 (s, 3H, Ph-CHj), 3.11-3.54 (AB part of ABX spectrum, m, 
2H, CHCH20), 3.76-4.26 (m, 3H, CH2N, CHCH20), 7.37 and 7.79 (ABq, 1^=8 Hz, 4H, Ph-H). 
(S) l-Thio-S-acetyl-2-amino-N-(ter/-butyloxycarbonyl)-3-niethyl-biitane (5a). This compound 
was prepared in 46% yield (based on the alcohol 3a) from compound 4a (3.0 g, 8.25 mmol) by reaction 
with CsSAc in DMF as has been described earlier.4 TLC Rf 0.40 (eluent diisopropyl ether/hexane, 1:1); 
Ή NMR (CDCI3) δ 0.91 and 0.93 (dd, 2x J=6 Hz, 6H, CH3CHCH3), 1.45 (s, 9H, t-Bu), 1.52-1.98 (m, 
IH, CH3CHCH3), 2.36 (s, ЗН, С(О)СНз), 2.79-3.14 (AB part of ABX spectrum, 5 Unes, 2H, CH2S), 
3.32-3.78 (m, IH, CHCH2), 4.25-4.64 (m, IH, NH). CI MS, m/z 262 (12%, M+H), 206 (51%, 
С8Н16Ж)з5), 162 (100%, C7H16NOS), 57 (40%, QHg). Anal. С 1 2 Н ^ О з 5 (С, Η, Ν). 
(5) l-Th¡o-S-acetyl-2-ainino-/V-(ícrt-butyloxycarbonyI)-3-methyl-pentane (5b). Following the 
same procedure that has been described earlier,4 this compound was prepared in 54% yield (based on 
the alcohol 3b) from compound 4b (9.0 g, 18.9 mmol) by reaction with CsSAc in DMF: TLC Rf 0.46 
(eluent diisopropyl ether/hexane, 1:1); rH NMR (CDCI3) δ 0.78-1.02 (m, 7H, СН2СНз, СНСН3), 
1.02-1.34 (m, 2Н, СН2СНз), 1.43 (s, 9Н, t-Bu), 2.35 (s, ЗН, С(0)СН3), 2.19 and 3.09 (AB part of ABX 
spectrum, 8 lines, 1^=1.5 Hz, JBx=6.5 Hz, ^ = 1 4 Hz, 2H, CH2S), 3.36-3.84 (m, IH, CHCH2S), 
4.28-4.72 (m, IH, NH). CI MS, m/z 276 (36%, M+H), 220 (66%, С9Н18Ж)з8), 176 (100%, 
CgH18NOS), 57 (32%, C4H9). Anal. C^H^NC^S (C, H, N). 
(S) l-Thio-S-acetyl-2-amino-W-(/ert-butyloxycarbonyl)-3-phenyI-propane (5c). Following the 
same procedure that has been described earlier,4 this compound was prepared in 66% yield (based on 
the alcohol 3c) from compound 4c (8.0 g, 20 mmol) by reaction with CsSAc in DMF: TLC Rf 0.35 
(eluent diisopropyl ether/hexane, 1:1); lH NMR (CDCI3) δ 1.41 (s, 9H, t-Bu), 2.36 (s, ЗН, С(О)СНз), 
2.62-3.21 (2х AB part of ABX spectrum, 12 unes, 4H, CH2Ph, CH2S), 3.73-4.20 (m, IH, CHCH2S), 
4.37-4.76 (m, IH, NH), 7.07-7.40 (m, 5H, Ph-H). CI MS, m/z 310 (28%, M+H), 254 (50%, 
C12H16N03S), 210 (100%, CnH^NOS), 91 (5%, C7H7), 57 (28%, С4Щ). Anal. CwH^NOjS (С, H, 
Ν). 
Thioacetate of /V-(terf-biityloxycarbonyl)-L-prolinol (5d). This compound was prepared in 50% 
yield (based on the alcohol 3d) from compound 4d (10.3 g, 29 mmol) by reaction with CsSAc in DMF 
as has been described earlier.4 TLC Rf 0.56 (eluent diisopropyl ether/hexane, 1:1); 'H NMR (CDCI3) δ 
1.47 (s, 9H, t-Bu), 1.57-2.10 (m, 4H, CH2CH2CH), 2.33 (s, ЗН, С(О)СНз), 2.84-3.53 (m, 4Н, CH2S, 
CH2N), 3.73-4.09 (m, IH, CHCH2). CI MS m/z 260 (34%, M+H, С 1 2Н 2 2Шз5), 204 (67%, 
CgH^NOjS), 160 (100%, C7H14NOS), 84 (8%, CSHJQN). 
(ScRs) l-[(Chloromethyl)suinnyl]-2-[(fert-butyloxycarbonyl)amino]-3-methyl-butane (6a). 
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Following the same procedure as has been described earlier,4 this compound was prepared from 
compound 5a (2.3 g, 8.82 mmol) by reaction with chlorine, acetic anhydride and subsequently with 
diazomethane. Due to the small difference in Rf values of the a-chloro sulfoxides only 120 mg (8%) of 
pure 6a could be isolated by silica gel column chromatography (eluent МеОН/С^Ог, 3:97) and 
crystallization from EtOAc: mp 180-181 0C; TLC Rf 0.32 (eluent МеОН/СНСІз, 3:97) Ή NMR 
(CDCU) δ 0.99 (d, J=7 Hz, 6H, CH3CHCH3), 1.44 (s, 9H, t-Bu), 1.88-2.14 (m, IH, CHjCHOty, 
2.84-3.39 (AB part of ABX spectrum, m, 2H, CHCH2). 3.62-4.00 (m, IH, CHOty, 4.44 and 4.48 
(ABq, JAB=n Hz, 2H, S^CHjCl), 4.76-5.09 (m, IH, NH). CI MS, m/z 284 (7%, M+H,), 228 (38%, 
С ^ з Ш з З С І ) , 184 (100%, QH^NOSCl), 57 (34%, СдНд). Anal. СцНггМОзЗСІ (С, Η. Ν). 
(ScÄs) l-[(Chloromethyl)sulfinyl]-2-[(tert-butyloxycarbonyl)amino]-3-methyl-pentane (6b). 
This compound was prepared in 16% overall yield from compound 5b (2.8 g, 10 mmol) by reaction 
with CI2, АС2О and CH2N2 as has been described earlier.4 Due to the small difference in Rf values of 
the diastereomeric a-chloro sulfoxides only 236 mg (16%) of pure 6b could be isolated by column 
chromatography using silica gel (eluent McOHJCiijC^, 3:97) and subsequent crystallization from 
EtOAc: TLC Rf 0.28 (eluent MeOH/CHClj, 3:97); •H NMR (CDCI3) δ 0.74-1.05 (m, 6H, СН2СНз, 
СНСНз), 1.10-1.53 (m, ЗН, СН2СН3, CHOty, 1.45 (s, 9Н, t-Bu), 2.81-3.24 (AB part of ABX 
spectrum, m, 2H, CHCHjSíO)), 3.77-4.05 (m, IH, CHCHjSíO)), 4.44 and 4.52 (ABq, JAB=11 Hz, 2H, 
S(0)CH2C1), 4.80-5.14 (br d, IH, NH). 
(ScRs) l-t(ChIoromethyl)suirinyI]-2-[(tert-butyloxycarbonyl)aniino]-3-phenyl-propane (6c). 
Following the same procedure as has been described earlier,4 this compound was prepared in 15% 
overall yield from compound 5c (4.0 g, 12.9 mmol) by reaction with CI2, АС2О and CH2N2. Due to the 
small difference in Rf values of the diastereomeric a-chloro sulfoxides only 320 mg (15%) of pure 6c 
could be isolated by column chromatography using silica gel (eluent MeOH/CHjCU, 3:97) and 
subsequent crystallization from EtOAc: mp 144-146 "С. TLC Rf 0.30 (eluent MeOH/CHCli, 3:97); 'H 
NMR (CDCI3) δ 1.42 (s, 9H, t-Bu), 1.92-2.85 (m, 4H, CH2Ph, CHCH2S(0)), 4.05-4.37 (m, IH, 
CHCH2), 4.35 and 4.49 (ABq, 1^=11 Hz, 2H, S(0)CH2C1), 5.28-5.36 (m, IH, NH), 7.25 (br s, 5H, 
Ph-H). CI MS, m/z 332 (9%, M+H), 276 (25%, CnHuNC^SCl), 232 (100%, QoH^NOSCl), 91 (7%, 
C7H7), 57 (22%, C ^ ) . Anal. C^zNC^SCl (С, H, Ν). 
(ScRs) I (ScSs) l-(<er<-Butyloxycarbonyl)-2-[[(chIoromethvl)suirinyl]methyl]-pyrrolidine (6d). 
Following the same procedure that has been described earlier, this product was obtained as a 1:1 
mixture of diastereomers from compound 5d (3.3 g, 12.7 mmol) in 40% yield by reaction with CI2, 
AC2O and CH2N2. Attempts to separate the diastereomers were unsuccessful. TLC Rf 0.35 (eluent 
МеОН/СНСІз, 3:97); Ή NMR (CDCI3) δ 1.46 (s, 9Η, t-Bu), 1.71-2.33 (m, 4H, CH2CH2CH), 2.74 and 
2.84 (part of AB part of ABX spectrum, 4 lines, 1^=13 Hz, Ідх or JB X=9 Hz, IH, CHCH2S(0)), 
3.02-3.62 (m, 3H, CH2N, CHCH2S(0)), 4.02-4.38 (m, IH, CHOty, 4.38-4.87 (m, 2H, S(0)CH2C1). 
CI MS, exact mass caled for CnH^NOjSCl, m/z 282.0931 (M+H). Found: 282.0921; m/z 282 (15%), 
226 (20%, QH^NC^SCl), 182 (100%, C6H13N0SC1), 84 (29%, C5H10N). 
(ScRs) l-[[(Methylthio)methyl]suirinyl]-2-[(/ert-butyloxycarbonyl)ammo]-3-methyI-butane 
(7a). This compound was prepared in 88% yield from the α-chloro sulfoxide 6a (120 mg, 0.42 mmol) 
by treatment with NaSMe in EtOH following the same procedure that has been described earlier:6 TLC 
Rf 0.21 (eluent MeOH/diisopropyl ether, 7:93); Ή NMR (CDCL) δ 0.96 (d, J=6.4 Hz, 6H, 
СН3СНСН3), 1.41 (s, 9Н, t-Bu), 1.81-2.23 (m, IH, CH3CHCH3), 2.30 (s, ЗН, SCHj), 2.84 and 3.15 
(AB рал of ABX spectrum, 8 Unes, 1^=8.3 Hz, JBx=3.2 Hz, 1^=12.9 Hz, 2H, CHCH2S(0)), 
3.60-4.08 (m, IH, CHCH2), 3.68 and 3.74 (ABq, ^ = 1 3 . 6 Hz, 2H, S(0)CH2S), 5.08 (br d, J=9 Hz, IH, 
NH). CI MS, exact mass caled for C12H26N03S2, m/z 296.1354 (M+H); m/z 296 (16%), 240 (35%, 
C8H18N03S2), 196 (75%, C ^ g N O S ^ , 61 (100%, C ^ S ) , 57 (23%, C4H,). 
(ScKs) l-[[(Methylthio)methyl]sulfinyl]-2-[(iert-butyloxycarbonyl)amino]-3-methyl-pentane 
(7b). Following the same procedure as has been described earlier,6 the α-chloro sulfoxide 6b (236 mg, 
0.79 mmol) was allowed to react with NaSMe in EtOH to give the desired compound 7b in 92% yield: 
TLC Rf 0.65 (eluent МеОН/СНСІз, 1:4); 'H NMR (CDCL) δ 0.82-1.09 (m, 6H, CHCH3, CH2CH3), 
1.09-1.95 (m, ЗН, CHCH,, ObCH,), 1.44 (s, 9H, t-Bu), 2.32 (s, ЗН, 8СЩ), 2.74-3.38 (AB part of 
ABX spectrum, m, 2H, CHCH2S(0)), 3.74 (s, 2H, S(0)CH2C1), 3.83-4.18 (m, IH, CHCH2S(0)), 
4.94-5.27 (m, IH, NH). CI MS, exact mass caled for C U H ^ N O J S Î , m/z 310.1511 (M+H). Found: 
310.1503; m/z 310 (20%), 254 (41%, QH^NOjS^, 210 (93%, C8H2()NOS2), 61 (100%, CybS), 57 (28%, С ^ ) . 
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(ScRs) l-[[(Methylthio)methyl]suinnyl]-2-[(/er{-butyloxycarbonyl)amino]-3-plienyl-propane 
(7c). Following the same procedure as has been described earlier,6 the a-chloro sulfoxide 6c (310 mg, 
0.94 mmol) was allowed to react with NaSMe in EtOH to give the desired compound 7c in 76% yield: 
TLC Rf 0.26 (eluent ethyl acetate^exane, 3:1); lH NMR (CDC13) δ 1.42 (s, 9H, t-Bu), 2.31 (s, ЗН, 
SCHj), 2.74-3.26 (m, 4H, CHCH2S(0), CH2Ph), 3.71 (s, 2H, S(0)CH2S), 4.04-4.43 (m, IH, CHCH2), 
5.17-5.44 (m, IH, NH), 7.24 (s, 5H, Ph-H). CI MS, m/ζ 344 (18%, M+H), 288 (27%, C^HjgNOjS^, 
244 (100%, СцН^ЫОЗг), 196 (19%, Ci0H14NOS), 91 (5%, C7H7), 61 (74%, 0^Η55), 57 (23%, С ^ ) . 
Anal. C ^ H ^ N O J S Î . W H J O (С, H, Ν). 
(ScRs) I (Seis) l-(tert-Butyloxycarbonyl)-2-[[[(methylthio)methyl]sulfinyl]methyl]-pyrrolÍdine 
(7d). These compounds were obtained in 88% yield as a 1:1 mixture of diastereomers from the a-chloro 
sulfoxide 6d (590 mg, 2.1 mmol) by treatment with NaSMe in EtOH following the procedure that has 
been described earlier:6 TLC Rf 0.49 (eluent MeOH/CHClj, 3:97); Ή NMR (CDCU) δ 1.41 (s, 9H, 
t-Bu), 1.66-2.17 (m, 4H, CH2CH2CH), 2.28 (s, ЗН, 8СЩ), 2.49-3.47 (m, 4Н, CHCH2S(0), CH2N), 
3.61 and 3.72 (ABq, JAB=13.6 Hz, 2H, S(0)CH2S), 3.94-4.36 (m, IH, CHCH2). CI MS exact mass 
caled for C 1 2 H 2 4 N03^, m/z 294.1198 (M+H). Found: 294.1207; m/z 294 (55%), 238 (14%, 
C8H16N03S2), 194 (100%, C7Hi6NOS2), 84 (11%, CsHjoN), 61 (17%, C2H5S). 
(ScRs) l-[[(Methylthio)methyl]sulfinyI]-2-(/er/-butyloxycarbonyl)amino-3-methoxy-propane 
(If). To a solution of 7e (283 mg, 1 mmol) in 10 mL of CH2C12 was added 1.5 g of Merck silica gel 
60H. Subsequently, 50 mL of a diazomethane/ether solution (circa 0.25 mmol/mL) was added slowly at 
0 0C and the reaction mixture was then stirred for 2 hrs at room temperature.8 The solution was 
concentrated and the crude reaction product was purified by column chromatography (eluent 
MeOH/CH2Cl2, 5:95) on silica gel to afford the desired product in 45% yield: TLC Rf 0.56 (eluent 
MeOH/CHClj, 1:9); 'H NMR (CDCl·,) δ 1.44 (s, 9H, t-Bu), 2.31 (s, ЗН, SCHj), 2.87 and 3.10 (AB part 
of ABX spectrum, 8 lines, ^ = 5 . 4 Hz, JBX=3.6 Hz, ^ = 1 3 . 0 Hz, 2H, CHCH2S(0)), 3.33 (s, 3H, 
OCH3), 3.56 (d, J=4.8 Hz, 2H, CH20), 3.68 and 3.76 (ABq, 1^=13.5 Hz, 2H, S(0)CH2S), 4.03-4.42 (m, IH, CHCH2), 5.18-5.52 (m, IH, NH). 
(ScRs) l-[[(Methylthio)methyl]suirmyl]-2-amino-3-methyl-butane (8a). This compound was 
prepared in quantitative yield from compound 7a (110 mg, 0.37 mmol) by treatment with TFA at 0 0C 
and subsequent ion-exchange column chromatography on Amberlite following the procedure that has 
been described earlier:6 TLC Rf 0.59 (eluent MeOH/CHCl·,, 1:4); •H NMR (CDCI3) δ 0.87 and 0.89 
(dd, 2x J=6 Hz, 6H, CH3CHCH3), 1.43 (br s, 2H, NH2), 1.43-1.84 (m, IH, CH3CHCH3), 2.26 (s, 3H, 
SCH3), 2.68 and 2.74 (AB part of ABX spectrum, doublet, J=1.5 Hz and singlet, respectively, 2H, 
CHCH2S(0)), 2.93-3.28 (m, IH, CHCH2), 3.59 and 3.77 (ABq, 1^=13.5 Hz, 2H, S(0)CH2S). 
(ScRs) H[(Methylthio)methyl]sulfinyl]-2-amino-3-methyl-pentane (8b). Following the same 
procedure as has been described earlier,6 the Boc amino protecting group of compound 7b (207 mg, 
0.67 mmol) was removed by treatment with TFA at 0 0C and subsequent ion-exchange column 
chromatography on Amberlite to yield compound 8b quantitatively: 'H NMR (CDCI3) δ 0.81-1.10 (m, 
6H, CHCHj, СН2СНз), 1.10-1.72 (m, ЗН, CHCHj, СН2СНз), 1.48 (br s, 2H, NH2), 2.33 (s, ЗН, 
SCH3), 2.73 and 2.82 (AB part of ABX spectrum, 2H, CHCH2S(0)), 3.11-3.43 (m, IH, CHCH2S(0)), 
3.68 and 3.86 (ABq, 1^=13.5 Hz, 2H, S(0)CH2S). 
(ScÄs) l-[[(MethyIthio)methyl]suIfinyl]-2-amino-3-phenyl-propane (8c). This compound was 
prepared in 73% yield from compound 7c (244 mg, 0.71 mmol) by treatment with TFA at 0 0C and 
subsequent ion-exchange column chromatography on Amberlite following the procedure that has been 
described earlier:6 lH NMR (CDCI3) δ 1.38-1.82 (br s, 2H, NH,), 2.31 (s, ЗН, SCH3), 2.58-3.19 (m, 4H, 
CH2Ph, CHCH2S(0)), 3.50-3.87 (m, IH, CHOty, 3.70 (s, 2H, S(0)CH2S), 7.04-7.47 (m, 5H, Ph-H). 
(ScKs) / (ScSs) 2-[[[(Methylthio)methyl]suinnyl]methyI]-pyrroIidine (8d). This compound was 
prepared in 94% yield as a 1:1 diastereomeric mixture from compound 7d (542 mg, 1.85 mmol) by 
treatment with TFA at 0 0 C and subsequent ion-exchange column chromatography on Amberlite 
following the procedure that has been described earlier:6 ' H NMR (CDCI3) δ 1.40-2.42 (m, 4H, 
CH2CH2CH), 2.23 (s, SCH3), 2.61-3.48 (m, 4H, CHCH2S(0), CH2N), 3.48-3.92 (m, IH, CHCH2), 
3.65 and 3.93 (ABq, JAB=13.5 HZ, 2H, S(0)CH2S), 6.27 (br s, IH, NH). CI MS, exact mass caled for 
C7H,6NOS2, /π/ζ 194.0673 (M+H). Found: 194.0676; m/z 194 (100%), 146 (38%, C6H12NOS), 84 (61%, C5H10N), 61 (37%, QHjS). 
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(ScRs) l-[[(Methylthiomethyl]suinnyI]-2-[(E)-ß-(6-methyl-5-uracilyl)acrylamido]-3-methyl-
butane (11). Following the isobutyl chloroformate mixed anhydride coupling procedure with the 
6-methyluracilacrylic acid 9 as has been described earlier,6 this compound was prepared in 29% yield 
(40 mg) from compound 8a (0.37 mmol). The reaction product obtained was approximately a 3:1 
mixture of compound 11 and the corresponding ScSs compound, respectively. The ratio was determined 
by integration of the AB quartet signals for CH=CH as well as from the singlet signals for SCH3 for 
these compounds in the 'H NMR spectrum of the reaction product: TLC Rf 0.50 (eluent МеОН/СНСЦ, 
1:4); 'H NMR (CD3OD) δ 1.04 (d, J=6.6 Hz, 6H, CHjCHCHj), 1.80-2.18 (m, IH, CH3CHCH3), 2.34 
(for the ScSs compound: 2.37) (s, 3H, SOty, 2.41 (s, ЗН, C(6)-CH3), 2.39-3.22 (m, 2Н, CHCH2S(0)), 
3.89 and 4.04 (ABq, 1^=13.8 Hz, 2H, S(0)CH2S), 4.23-4.52 (m, IH, CHCH2), 7.29 and 7.49 (for the 
ScSs compound: 7.28 and 7.48) (ABq, ^ = 1 5 . 3 Hz, 2H, CH=CH). FAB MS, m/z 374 (14%, M+H, 
C ^ H ^ N j O ^ ) , 196 (5%, С7Н1 8Ж)82), 179 (9%, C8H7N203); [a)20D +92° (c 0.20, MeOH/H20,1:1). 
(ScRs) l[[(Methylthio)methyl]sulfinyl]-2-[(E)-ß-(6-methyl-5-uracilyI)acrylaniido]-3-methyl-
pentane (12). Following the isobutyl chloroformate mixed anhydride procedure that has been described 
earlier,6 this compound was prepared in 20% yield (50 mg) from compound 8b (0.67 mmol): TLC Rf 
0.52 (eluent MeOH/CHCU, 1:4); Ή NMR (CD3OD) δ 0.79-1.09 (m, 6H, CHCHj, СН2СНз), 1.09-1.91 (m, ЗН, СНСНз, СН2СНз), 2.32 (s, ЗН, SCHj), 2.39 (s, ЗН, С(б)-СНз), 2.76-3.24 (m, 2Н, 
CHCH2S(0)), 3.85 and 3.99 (ABq, JAB=14 Hz, 2H, S(0)CH2S), 4.28-4.61 (m, IH, CHCH2S(0)), 7.26 
and 7.45 (ABq, ^ = 1 5 . 5 Hz, 2H, CH=CH). FAB MS, m/z 388 (21%, M+H), 210 (8%, C8H20NOS2), 
179 (18%, C8H7N203); [α]20Ό +92° (с 0.064, MeOH/H20,1:1). Anal. Ci6H25N3O4S2.3/2H20 (С, Η, Ν). 
(ScRs) l-[[(Methylthio)methylsuirinyl]-2-[(E)-ß-(6-methyl-5-uracilyl)acrylamido]-3-phenyl-
propane (13). Following the isobutyl chloroformate mixed anhydride procedure that has been described 
earlier,6 this compound was prepared in 51% yield (112 mg) from compound 8c (126 mg, 0.52 mmol): 
TLC Rf 0.81 (eluent MeOH/CHCl·,, 1:4); lH NMR (CD3OD) δ 2.30 (s, ЗН, SCH3), 2.37 (s, ЗН, 
С(б)-СНз), 2.28-3.26 (m, 4Н, CHCH2S(0), CH2Ph), 3.83 and 3.97 (ABq, 1^=13.7 Hz, 2H, 
S(0)CH2S), 4.49-4.82 (m, IH, CHCH2), 7.19 and 7.41 (ABq, J A B=15.3 HZ, 2H, CH=CH), 7.29 (s, 5H, 
Ph-H). FAB MS, m/z 422 (66%, M+H), 344 (50%, C ^ H ^ O . S , ) , 244 (29%, CnH^NOS,), 196 
(12%, C10H14NOS), 179 (100%, C8H7N203), 91 (52%, C7H7); [ a p b +21° (c 0.06, MeOH/H20, 1:1). 
Anal. C19H23N304S2.3/4H20 (C, H, N). 
(ScÄs) / (ScSs) l-[(E)-ß-(6-Methyl-5-uracilyl)acrylamido]-2-[[[(methylthio)methyl]sulfinyl]-
methyl]-pyrrolidine (14). This compound was prepared in 36% yield (123 mg) from compound 8d 
(178 mg, 0.92 mmol), following the isobutyl chloroformate mixed anhydride procedure as has been 
described earlier:6 TLC Rf 0.58 (eluent MeOH/CHCl3, 1:4); lH NMR (CD3OD) δ 1.98-2.29 (m, 4H, 
СН2СН2СН), 2.38 (s, ЗН, SCH3), 2.41 (s, ЗН, С(б)-СНз), 2.98-3.56 (m, 2Н, CHCH2S(0)), 3.56-3.90 (m, 2Н, CH2N), 4.06 and 4.34 (ABq, JAB=13.8 Hz, 2H, S(0)CH2S), 4.47-4.77 (m, IH, CHCH2), 7.53 (s, 2H, CH=CH). FAB MS, m/z 372 (6%, M+H), 194 (12%, C7H16NOS2), 179 (16%, C8H7N203), 84 (16%, CJHJON); [a]20D -56° (c 0.13, MeOH/H20, 1:1). Anal. ClsHnN30AS2.m H 20 (C, H, N). 
(ScÄs) 2-[(E)-ß-(6-Methyl-5-uracilyl)acrylamido]-3-[[(methylthio)methyl]suirinyl]-3-methoxy-
propane (15). This compound was prepared in 30% yield (based on compound 7e) from compound 7f 
by treatment with TFA at 0 0C and subsequent coupling with acid 8, following the isobutyl 
chloroformate mixed anhydride procedure as has been described earlier:6 TLC Rf 0.45 (eluent 
MeOH/CHClj, 1:4); Ή NMR (D20) δ 2.26 (s, ЗН, SCH3), 2.40 (s, ЗН, С(б)-СНз), 3.03-3.43 (m, 2Н, 
CHCH2S(0)), 3.40 (s, ЗН, ОСНз), 3.63 (d, J=5 Hz, 2H, СН20), 3.90 and 4.06 (ABq, 1^=15 Hz, 2H, 
S(0)CH2S), 4.48-4.81 (m, IH, CHOty, 6.97 and 7.35 (ABq, JA B=15 Hz, 2H, CH=CH). FAB MS, m/z 
376 (55%, M+H, C
u
H22N305SJ, 198 (62%, C6H1 6N02S2), 179 (53%, C8H7N203); [a]20D +79° (c 
0.170, H20). Anal. C14H21N305S2.2H20 (C, H, N). 
O-acetyl-sparsomycin (16). To a solution of sparsomycin (1) (46.8 mg, 0.13 mmol) in 5 mL of 
dry pyridine was added 3 mL (0.39 mmol) of a 0.13 M solution of AcCl in СН2СІ2. The reaction was 
stirred overnight at room temperature. After completion of the reaction as was monitored by TLC 
(eluent МеОН/СНСЦ, 1:4), 2mL of dry EtOH were added. Subsequendy, the solvent was evaporated in 
vacuo and the crude product was chromatographed over silica gel (МеОН/СН2СІ2, 12:88). The product 
was obtained after final purification over Sephadex (eluent H20/MeOH, 15:85) in 30% yield. No 
attempts were made to improve the yield. Rf 0.64 (eluent MeOH/CHCU, 1:4); •H NMR (D20) δ 2.13 (s, ЗН, С(О)СНз), 2.31 (s, ЗН, SCH3), 2.43 (s, ЗН, С(б)-СНз), 3.07-3.46 (AB part of АВХ spectrum, 
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2H, CHCHjSÍO)), 3.96 and 4.18 (ABq, JAB=14 Hz, 2H, S(0)CH2S), 4.20-4.44 (m, 2H, CHCH20), 
4.44-4.70 (m, IH, CHCH20), 7.04 and 7.49 (ABq, JAB=15.5 Hz, 2H, CH=CH). Anal. 
Ci5H21N306S2.i/2H20 (C, H, N). 
WA-dKtert-ButyloxycarbonyO-cystamine (17). A solution of 6.75 g (30 mmol) of cystamine 
dihydrochloride in 40 mL of 1,4-dioxane/water (1:1) was neutralized with Ei3N. To this solution were 
added Et3N (6.06 g, 60 mmol) and di-reri-butyl dicarbonate (14.39 g, 66 mmol) and the reaction 
mixture was stirred at room temperature for 3 h. After concentration of the reaction mixture, the crude 
product was divided between CfyCb and water. The organic layer was separated and extracted once 
with a saturated NaHCOi solution. Concentration of the organic layer in vacuo and crystallization of 
the crude product from CH2C12 afforded the desired compound in 96 % yield: TLC Rf 0.82 (eluent 
MeOH/CHClj, 7:93); Ή NMR (CDCI3) δ 1.44 (s, 18H, 2x f-Bu), 2.80 (t, J=6.3 Hz, 4H, 2x CH2S), 3.45 (q, J=6.3 Hz, 4H, 2x NHCH2), 5.02 (br s, 2H, 2x NH). CI MS exact mass caled for C14H2 9N204S2, m/z 
353.1569 (M+H). Found: 353.1565; miz 353 (10%), 297 (11%, C1 0H2 1N2O4S2), 241 (36%, 
C f i H ^ N p ^ ) , 197 (100%, CsHuNzO^), 57 (70%, С4Щ). Anal. C^HjgNjC^ (C, H, N). 
yV-(/ert-Butyloxycarbonyl)-S-oxo-5-chloromethyI-cysteamine (18). This compound was 
synthesized analogously to the procedure that has been described earlier" from N^-di-Boc-cystamine 
17 (3.52 g, 10 mmol) by reaction with Ac20 (2.04 g, 20 mmol), Cl2 (2.13 g, 30 mmol) and subsequently 
CH2N2 (13 mmol) in 41% overall yield. TLC Rf 0.44 (eluent MeOH/CHClj, 5:95); Ή NMR (CDCI3) δ 
1.42 (s, 9H, f-Bu), 2.86-3.33 (m, 8 lines, 2H, CH2CH2S(0)), 3.53-3.73 (m, 4 lines, 2H, NHCH2), 4.46 
and 4.54 (ABq, J A B=11.1 HZ, 2H, S(0)CH2C1), 5.33 (br t, IH, NH). CI MS, m/ζ 242 (54%, M+H, 
C8H17N03SC1), 186 (100%, C^NOjSCl), 142 (43%, СзН^08С1), 56 (24%, QHg), 44 (63%, C02); 
EI MS, mJz 242 (3%, M+H), 57 (100%, QH,), 44 (100%, C02). 
yV-(ter/-Butyloxycarbonyl)-S-oxo-S[(methylthio)methyl]-cysteamine (19). This compound was 
prepared in 93% yield by reaction of 18 (483 mg, 2 mmol) with NaSMe in EtOH following the 
procedure that has been described earlier:* TLC Rf 0.30 (eluent МеОН/СНСІз, 4:96); lH NMR 
(CDCI3) δ 1.43 (s, 9H, f-Bu), 2.32 (s, 3H, SCHj), 2.62-3.31 (m, 2H, CH2CH2S(0)), 3.53-3.91 (m, 4H, 
CH2CH2S(0)CH2), 5.31 (br s, IH, NH) CI MS, m/ζ 254 (100%, M+H, CgH^NC^Sz), 198 (45%, 
CsH^NOjSz), 154 (13%, QH^NOS^. 
l-[(Methylthio)methyl]sulfinyl-2-[(E)-ß-(6-methyl-5-uracilyl)acrylamido]-ethane (21). This 
compound was prepared in the following way. The N-Boc protected amine 19 (235 mg, 0.93 mmol) was 
treated for 15 min at 0 0C with 15 mL of TFA.6 The excess TFA was evaporated in vacuo, the residue 
dissolved in 10 mL of DMF and the solution neutralized with Et3N. Subsequently, 1.05 equiv. (136 μι, 
0.98 mmol) of Et3N and 1.05 equiv. (353 mg, 0.98 mmol) of the pentafluorophenyl ester 20 were added 
at 0 0C. The reaction mixture was stirred overnight at room temperature in the dark. The solvent was 
evaporated in vacuo and the crude reaction product was purified by gel filtration on Fractogel (eluent 
Me0H/H2O, 1:1). The appropriate fractions were pooled and the product was obtained after 
lyophilization from HO Ac in 61% yield: TLC Rf 0.43 (eluent MeOH/CHCl·,, 1:4); lH NMR (CD3OD) 
δ 2.34 (s, 3H, SCHj), 2.38 (s, ЗН, ОД-СН,), 2.94-3.42 (m, 2Н, CH2CH2S(0)), 3.76 (t, J=6.5 Hz, 2H, 
CH2CH2S(0)), 3.86 and 4.04 (ABq, 1^=13.9 Hz, 2H, S(0)CH2S), 7.17 and 7.45 (ABq, 1^=15.2 Hz, 
2H, CH=CH). FAB MS, m/ζ 332 (62%, M+H, C12H18N304S2), 179 (53%, С8Н7К20з), 154 (27%, 
C4H12N0S2). 
Analytical data 
3c, CI4H21N03: C, 66.91; H, 8.42; N, 5.57. Found: С, 66.72; H, 8.44; Ν, 5.53. 
5a, C^H^NOjS: C, 55.14; H, 8.87; N, 5.36. Found: С, 55.41; H, 8.97; Ν, 5.36. 
Sb, CJJHJSNOJS: С, 56.69; Η, 9.15; Ν, 5.09. Found: С, 56.74; Η, 9.17; Ν, 5.20. 
5с, С^НгзМЭзЗ: С, 62.11; Η, 7.49; Ν, 4.53. Found: С, 61.93; Η, 7.51; Ν, 4.50. 
6а, СцНиШзЗСІ: С, 46.55; Η, 7.81; Ν, 4.94. Found: С, 46.52; Η, 7.75; Ν, 4.76. 
6c, CjsH^NOjSCl: С, 54.29; Η, 6.68; Ν, 4.22. Found: С, 54.39; Η, 6.69; Ν, 4.21. 
7с, C Ì . H M N O J S Z . W ^ O : С, 54.52; Η, 7.15; Ν, 3.97. Found: С, 54.61; Η, 7.33; Ν, 3.82. 
12, C16H25N3O4S2.5/2H20: С, 46.36; Η, 6.08; Ν, 10.14. Found: С, 46.29; Η, 5.94; Ν, 9.71. 
13, CJ9H23N304S2.3/4H20: С, 52.46; Η, 5.33; Ν, 9.66. Found: С, 52.75; Η, 5.50; Ν, 9.20. 
14, C15H21N304S2.i/2H20: С, 47.35; Η, 5.56; Ν, 11.04. Found: С, 47.10; Η, 5.55; Ν, 10.64. 
15, C14H21N305S2.2H20: С, 40.86; Η, 5.14; Ν, 10.21. Found: С, 40.63; Η, 5.16; Ν, 9.73. 
16, C15H21N306S2.i/2H20: С, 47.35; Η, 5.56; Ν, 11.04. Found: С, 47.10; Η, 5.55; Ν, 10.64. 
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17, C14H28N204S2: С, 47.70; H, 8.01; Ν, 7.95. Found: С, 47.58; Η, 7.98; Ν, 7.88. 
ACKNOWLEDGMENTS 
We gratefully acknowledge Prof. R. J. F. Nivard for reading and critisizing the manuscript. The 
investigations have been supported by grants from the Netherlands Foundation for Chemical Research 
(SON) with financial aid from the Netherlands Organization for Scientific Research (NWO) and by a 
grant from Fondo de Investigaciones Sanitarias de la Seguridad Social (FISSS). 
REFERENCES 
* Present address: Organon International B.V. RL 316, P.O. Box 20, 5340 BH Oss, The 
Netherlands. 
1. Ottenheijm, H. С J.; Van den Broek, L. A. G. M.; Ballesta, J. P. G.; Zylicz, Z. In Progress in 
Medicinal Chemistry; Ellis, G. P., West, G. В., Eds.; Elsevier: Amsterdam, 1986; Vol. 23, pp 
219-268. 
2. Liskamp, R. M. J.; Colstee, J. H.; Ottenheijm, H. С J.; Lelieveld, P.; Akkerman, W. J. Med. 
Chem. 1984,27,301. 
3. Van den Broek, L. A. G. M.; Liskamp, R. M. J.; Colstee, J. H.; Lelieveld, P.; Remacha, M.; 
Vázquez, D.; Ballesta, J. P. G.; Ottenheijm, H. С. J. J. Med. Chem. 1987, 30, 325. See Chapter 
2.1. 
4. Van den Broek, L. A. G. M.; Lázaro, E.; Fennis, P. J.; Missler, F. Α. Ν.; Lelieveld, P.; Ballesta, J. 
P. G.; Ottenheijm, H. С. J. See Chapter 2.2. 
5. Hwang, D. -R.; Helquist, P.; Shekhani, M. S. J. Org. Chem. 1985,50, 1264. 
6. Ottenheijm, H. С J.; Liskamp, R. M. J.; Van Nispen, S. P. J. M; Boots, Η. Α.; Tijhuis, M. W. J. 
Org. Chem. 1981,46, 3273-3283. 
7. Lázaro, E.; Van den Broek, L. A. G. M.; Ottenheijm, H. С J.; Lelieveld, P.; Ballesta, J. P. G. 
Biochimie 1987,69, 849-856. 
8. Ohno, K.; Nishiyama, H.; Nagase, H. Tetrahedron Lett. 1979,4405. 
9. Kisfaludy, L.; Schön, I. Synthesis 1983, 325. For a description for the synthesis of the 
pentafluorophenyl ester 20, see Chapter 4.2, viz. compound 6. 
10. Von Arx, E.; Faupel, M; Brugger, M. J. Chromatogr. 1976,120, 224-228. 
CHAPTER 2.4 
THE EFFECT OF MODIHCATION OF THE URACIL FRAGMENT 
ON THE BIOLOGICAL ACTIVITY 
Modification of the uracil fragment 
Conclusions: 
-no modification of the uracil fragment is allowed 
-it must play an important role in the interaction of 
sparsomycin with the peptidyl transferase 
8 4 Chapter 2.4 
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SUMMARY 
The synthesis of 14-19, analogues of the antitumor antibiotic sparsomycin (1) is described. All 
derivatives share a modified 6-methyluracilacryloyl moiety. For an evaluation of their biological 
activity, the inhibition of protein synthesis in two cell-free peptide bond formation assays, growth 
inhibition of E. coli in liquid medium and inhibition of murine leukemia L1210 colony formation in soft 
agar were studied. All variations introduced into the molecular structure of 1 render the drug 
biologically inactive; none of the compounds exhibited marked protein synthesis inhibition or cytotoxic 
activity. Apparently, the uracil ring plays an important role in the interaction of sparsomycin with the 
ribosomal peptidyl transferase and its unmodified presence is crucial for displaying antitumor activity. 
IMTRODUCTION 
Sparsomycin (I)1 is an antibiotic from Streptomyces sparsogenes showing a broad spectrum of 
activities. Its biological activity is due to inhibition of protein synthesis; peptide transfer is blocked by 
its interference with the function of the ribosomal peptidyl transferase.2^3 The molecular structure of 
sparsomycin is an unusual hybrid between a modified uracil base and a modified D-cysteine amino acid 
(see Scheme I). Structure-activity relationship studies published so far concern mainly attempts to 
improve sparsomycin's antitumor activity.1,4 
Of the structural analogues prepared so far, only a few carry modifications of the acid fragment 2 
of sparsomycin. A recent study revealed that the trans to cis isomerization of the double bond in 1 
renders the molecule biologically inactive.4 Removal of the C(6)-Me group on the uracil ring reduces 
the activity of the compound 2-3 fold.4 Dubois et aß reported the synthesis of derivatives of 1 in which 
the uracil nucleus had been replaced by other heterocyclic or aromatic residues. However, at the same 
time the chiral sulfoxide group of 1 was replaced by a bivalent sulfur atom and the analogues possessed 
the incorrect R chirality at the asymmetric carbon atom. We showed recently that the biological activity 
of sparsomycin disappears when the S chirality at this carbon atom is reversed.4 Consequently, the 
conclusion of Dubois et al that the low in vivo antitumor activity of their analogues did not warrant 
further testing, was premature. These facts called for reinvestigation. 
We wish to report the synthesis and in vitro biological activity of compounds 14-19, analogues of 
sparsomycin carrying modifications of the 6-methyluracilacryloyl fragment 2. 
RESULTS AND DISCUSSION 
Chemistry. Sparsomycin (1) can be considered to be an amide derived from the coupling of the 
acid 2 and the amine 3 (Scheme I). The former is a derivative of 6-inethyluracil (4) and the latter of 
D-cysteine (5). The synthesis of the analogues prepared for this study is based on this retrosynthetic 
scheme. Compounds 14, 15 and 19 can be prepared starting from ethyl 6-methyluracilaciylate (6)6 
(Scheme Π). 
Selective reduction of the double bond of 6 with hydrogen on Pd/C in dimethylformamide (DMF) 
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gave 7 in 93% yield. Saponification with 4N NaOH in methanol/dioxane yielded subsequently the acid 
8 in 81% yield. 
NJV-Dimethylation of 6 was carried out by reaction with methyl iodide in DMF using cesium 
carbonate as base.7,8 The di-N-methylated ethyl ester 9 was obtained in 90% yield. Base hydrolysis of 
this ester yielded 10 in 83% yield. 
Scheme I. Retrosynthetic Analysis of Sparsomycin 
The dimethoxy derivative 12 was prepared in two steps.9 Reaction of 6 with phosphorus 
oxychloride afforded the dichlorinated compound 11 in 52% yield. We observed that this reaction was 
catalyzed by the addition of 5 mol% of DMF. Treatment of 11 with sodium methoxide gave in 80% 
yield the dimethoxy compound 12.10 Saponification of 12 yielded the acid 13 in 50%. 
Each of the acids 8, 10 and 13 was brought in reaction with the amine 3 using the isobutyl 
chloroformate mixed anhydride coupling procedure,6 to give the corresponding sparsomycin derivatives 
14,15 and 19 in 20%, 24% and 31% yield, respectively. Subsequently, we found that sparsomycin itself 
could be reacted directly with cesium carbonate and methyl iodide in DMF to give the corresponding 
di-N-methylated compound 15 in 75% yield. Obviously, this route to 15 is preferable when having 
sparsomycin available in sufficient quantities. 
As we know that replacement of the methylthio group by more lipophilic alkylthio groups or of the 
hydroxymethyl by a methyl group causes an increase in the biological activity,11 we prepared the 
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analogues 16, 17 and 18. They were synthesized by direct A/,N-dimethylation ^ described for 15 from 
the corresponding sparsomycin derivatives4·11 in 75%, 86% and 76% yield, respectively. 
Scheme II 
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Biological Activity. The in vitro assays used to assess the biological activity of the newly prepared 
analogues have been described elsewhere.4,12 The inhibition of protein synthesis was measured in a 
cell-free polyphenylalanine (polyPhe) synthesis assay and in the puromycin reaction assay using 
ribosomes of E. coli MRE600 or S. cerevisiae Y166.4 These peptide bond formation reactions are 
model assays for peptidyl transferase activity. The growth inhibition of E. coli MRE600 was studied in 
liquid medium.4 ED50 represents the 50% effective dose. The antitumor activity was evaluated by 
looking at the inhibition of clonogenic growth of L1210 murine leukemia cells in soft agar medium.12 
IDso represents the 50% inhibitory dose. All results are depicted in Table I. 
We conclude that with respect to the biological activity of 1 no modification of the 6-methyluracil-
acryloyl fragment is tolerated. All derivatives tested, i.e. 14-19, are quite inactive in all assays studied 
in comparison with sparsomycin itself. In the iV//-dimethyl series 15-18 we see some variation in the 
polyPhe synthesis and puromycin reaction assays in the degree of inhibition at the highest concentration 
tested. 
These results suggest that the uracil nucleus of 1 binds to the ribosome via hydrogen bonds. 
Blocking this way of interaction between the drug and its receptor renders the molecule biologically 
inactive. Support for this conclusion is found in the work of ¿етіібка and Bhuta.13 They showed that 
both the dimethyl amide and the N-hydroxysuccinimide ester of 2 displayed, like 1, a clear competitive 
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inhibition pattern in a model assay for peptide bond formation, which stresses the importance of just the 
uracil ring of sparsomycin for binding to the ribosome. 
Sparsomycin Analogues 
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EXPERIMENTAL SECTION 
Ή NMR spectra were measured on a Bruker WH-90 spectrometer with Me4Si as an internal 
standard. For determination of the specific rotation ([a]20D), a Perkin-Elmer 241 Polarimeter was used. 
Mass spectra (MS, m/z, relative intensity), were recorded on a double-focussing VG 7070E mass 
spectrometer, for FAB MS, glycerol was used. IR spectra were taken on a Perkin-Elmer 257 grating 
spectrometer. UV spectra were measured on a Perkin-Elmer Model 555 spectrophotometer. Thin-layer 
chromatography (TLC) was carried out by using Merck precoated F-254 plates (thickness 0.25 mm). 
Spots were visualized with a UV lamp, ninhydrin or CI2-TDM.14 For column chromatography, Merck 
silica gel Η (type 60) was used. For gel filtration, Merck Fractogel TSK HW-40(F) was used. 
Ethyl ß-(l,2,3,4-Tetrahydro-2,4-dioxo-6-methylpyrimidm-5-yI)propionate (7). For reduction of 
the double bond, the ester 6° (0.4 g, 1.79 mmol) was dissolved in 25 mL of DMF, 10% palladium on 
carbon was added and the suspension was stirred in a hydrogen atmosphere for 4 h. The suspension was 
filtered through infusorial earth, and the filtrate was concentrated in vacuo. The compound was 
obtained in 93% yield after crystallization of the crude product from hot water: TLC Rf 0.75 (eluent 
MeOH/CHClj, 1:4); Ή NMR (CDCI3) δ 1.23 (t, J=7Hz, 3H, СН2СЯз), 2.22 (s, ЗН, С(б)-СНз), 
2.49-2.73 (m, 4Н, (СН2)2), 4.11 (q, J=7 Hz, 2Н, СЯ2СНз), 8.32 (br s, IH, NH), 8.82 (br s, IH, NH); CI 
MS, m/z 227.1030 (M+H); exact mass caled for С 1 0 Н 1 5 ^О4, 227.1032; m/z 227 (58%), 181 (100%, 
CgHçNjOj); IR (KBr) 1725, 1645 cm1. 
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Table I. Protein synthesis and (tumor) cell growth inhibitory activity8 
compd 
1 
14 
15 
16 
17 
18 
19 
polyPhe synthesis 
E. coli 
ED5o. μΜ 
8.5 
500(12%) 
500(23%) 
500(37%) 
500(22%) 
500(13%) 
500(42%) 
5. cerevisiae 
5.2 
inactive 
500(10%) 
500 
220 
500(7%) 
500(10%) 
Puromycin 
reaction 
E. coli 
Ε05(),μΜ 
0.1 
100(17%) 
inactive 
100(15%) 
100(30%) 
100(35%) 
100(16%) 
Growth 
inhibition 
E. coli 
EDso, μΜ 
11 
inactive 
inactive 
inactive 
inactive 
inactive 
inactive 
Clonogenic 
assay 
L1210 
ΙΌ50>μΜ 
0.47 
2.8(2.2) 
2.6(2.1) 
2.3(2.0) 
2.2(2.1) 
2.7 
2.6(2.2) 
"The numbers in parentheses indicate the percentage of inhibition at the highest 
concentration tested (polyPhe and puromycin assays) or the ID 1 0 values (L1210 assay). 
Drugs that show no inhibition at the highest concentration tested, i.e. 100 μΜ, are 
considered inactive. 
ß-(l,2,3,4-Tetrahydro-2,4-dioxo-6-methylpyrimidin-5-yl)propionic Acid (8). The ester 7 (622 
mg, 2.75 mmol) was saponified with 4N NaOH in methanol/1,4-dioxane (1:1) following the procedure 
that has been described earlier.6 After crystallization of the crude product from hot water the desired 
product was obtained in 81% yield: TLC Rf 0.73 (eluent MeOH/CHCU, 1:4); •H NMR (D20) δ 2.12 (s, 
ЗН, С(б)-СНз), 2.29-2.62 (m, 4Н, (CHj^); CI MS, m/z 199.0718 (M+H); exact mass caled for 
. . .
 1 8 1 ( 1 0 0 % i cgH9N203). IR (КВг) 1720, 1625 cm"1. UV C8HUN204, 199.0719; m/z 199 (49%). (MeOH) Хпиц, 266.5 nm, λ,^ 236 nm. 
Ethyl (E)-B-(l¿^4-Tetrahydro-l,3,6-tr¡inethyl..2,4-dioxopyr¡mid¡n-5-yl)acryIate (9). To a 
solution of 6 (1.12 g, 5 mmol) in 25 mL of dry DMF was added successively 8.15 g of cesium carbonate 
(25 mmol) and 2.1 g of methyl iodide (15 mmol).7,8 The reaction mixture was stirred overnight at room 
temperature with exclusion of light to avoid trans-cis isomerization of the double bond.4·12 The 
reaction mixture was filtered, and the eluate was concentrated in vacuo. The solid remainder was 
recrystallized from acetonitrile to yield the desired product in 90%: TLC Rf 0.76 (eluent 
MeOH/CHClj, 1:4); •H NMR (CD3OD) δ 1.19 (t, J=7 Hz, ЗН, СН2СЯз), 3.00 (s, ЗН, С(б)-СНз), 3.19 (s, ЗН, NÍD-CHj), 3.46 (s, ЗН, N(3)-CH3), 4.12 (q, J=7 Hz, 2H, CH^, 7.01 and 7.52 (ABq, 1^=16 Hz, 
2H, CH=CH). CI MS, miz 253.1189 (M+H); exact mass caled for ^ 2 Η 1 7 Ν 2 0 4 , 253.1188; miz 253 (16%), 221 (20%, C1 ( )H9N204), 157 (53%, C7H1 2N202), 91 (100%, C5H2N2). IR (KBr) 1705, 1660, 
1615 and 1575 cm"1. UV (MeOH) ^ 314.5,274.5 (sh) nm; λ,^ 235.5 nm. 
(E)-ß-(l,2r3,4-Tetrahydro-1.3.6-trimethyl-2,4-dioxopyrimidin-5-yl)acrylic Acid (10). The ester 
9 (1.0 g, 4 mmol) was hydrolyzed with 4N NaOH in methanol/l,4-dioxane (1:1) analogously to the 
procedure that has been described earlier.6 The crude product was recrystallized from 
acetonitrile-methanol and the compound was obtained in 83% yield: TLC Rf 0.40 (eluent 
МеОН/СНСІз, 1:4); Ή NMR (TFA, benzene lock) δ 2.69 (s, ЗН, С(б)-СНз), 3.68 (s, ЗН, Ш)-СНз), 
4.11 (s, ЗН, N(3)-CH3), 7.27 and 7.82 (ABq, 1^=15 Hz, 2H, СН=СН). CI MS, miz 225.0870 (M+H); 
exact mass caled for C j o H ^ N ^ , 225.0875; m/z 225 (41%), 209 (11%, Ο , Η , Ν ^ ) , 193 (100%, 
C8H5N204). IR (KBr) 1710,1645 cm 1 . UV (MeOH) λ,,,« 305.5 nm; λ,,^ 247 nm. 
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Ethyl (E)-ß-(2,4-Dichloro-6-methylpyriinidin-5-yl)acrylate (11) A suspension of 66 (1 0 g, 4 76 
mmol) in 2.6 mL of anhydrous POCI3 (28 56 mmol) and 5 mol% of DMF (18 μι, 0.23 mmol) was 
refluxed for 1 h until all solid material was solubilized 9 Evaporation of the solvents, partition of the 
remainder between diethyl ether and water, separation of the organic layer and concentration of this 
layer in vacuo yielded the desired product m 52%. The product was used without further purification for 
the next reaction. TLC Rf 0 51 (eluent MeOH/CHCl·,, 1:99), CI MS, mJz 261 (100%, M+H, 
СюНцМгОгСу, 225 (43%, ^ ο Η 1 0 Ν 2 0 2 α ) . 
Ethyl (E)-ß-(2,4-Dimethoxy-6-methylpyrimidin-5-yl)acryIate (12). A solution of 11 (64'' mg, 
2 5 mmol) m 40 mL of methanol was treated with sodium methoxide (5 25 mmol, 121 mg of Na).9 The 
reaction mixture was refluxed for 1 h. After evaporation of the solvent the residue was taken up in 
chloroform and extracted with water. The organic layer was separated and concentrated in vacuo to 
yield the product in 80% yield: TLC Rf 0 18 (eluent MeOH/CHClj, 1:4); lH NMR (CD3OD) δ 1.20 (t, 
J=7 Hz, 3H, СН2СЯз), 2.40 (s, ЗН, С(б)-СНз), 3.88 (s, ЗН, С(2)-ОСНз), 3 97 (s, ЗН, С(4)-ОСНз), 4 12 (q, J=7 Hz, 2Н, СН2), 6 47 and 7.59 (ABq, 1^=16 Hz, 2H, CH=CH). CI MS, m/z 253.1194 (M+H); 
exact mass caled for C12H,7N204, 253.1188, mJz 253 (25%), 239 (100%, С ц Н ^ О Д 207 (81%, 
СюНц^Оз). 
(E)-ß-(2,4-Dimethoxy-6-methylpyrimidin-5-yl)acrylic Acid (13). After saponification of the 
ester 12 (400 mg, 1.6 mmol) with 4N NaOH in methanol/1,4-dioxane (1.1) following the procedure that 
has been desenbed earlier, the reaction mixture was concentrated in vacuo and the resulting residue 
was recrystalhzed from acetomtnle-methanol, to give the desired product in 50% yield. TLC Rf 0 62 
(eluent MeOH/CHClj, 1 4), lH NMR (CD3OD) δ 2.46 (s, ЗН, С(б)-СНз), 3.95 (s, ЗН, С(2)-ОСНз), 
4.03 (s, ЗН, С(4)-ОСНз), 6.48 and 7.60 (ABq, 1^=15 Hz, 2Н, СН=СН). CI MS, т/г 225 (6%, M+H, 
CjoH^N.O^, 193 (6%, СсН^Оз), 181 (12%, C ç H ^ N ^ ) , 167 (21%, CgHuN^) , 153 (100%, 
С7Н<^202). UV (МеОН) λ ^ 288 5 nm; λ,,^ 235.5 nm. 
(ScRs) 2-[ß-6-Methyl-5-uracilyl)propanoylamido]-3-[[(methyUhio)methyl]sulfinyl]-propanol 
(14). This compound was obtained in 20% yield (86 mg) by coupling 8 (300 mg, 1 52 mmol) with 3 
(231 mg, 1 26 mmol) according to the isobutyl chloroformate mixed anhydnde procedure desenbed 
earlier ¿TLC Rf 0.20 (eluent MeOH/CHCl·,, 1.4), Ή NMR (CD3OD) δ 2 09 (s, ЗН, SCHj), 2 22 (s, ЗН, 
C(6)-CH3), 2.24-2.58 (m, 4H, (СН^), 1.04-1.23 (AB part of ABX spectrum, 3 lines, 2H, CHCtf2S(0)), 
3.50 (d, J=4 8 Hz, 2H, СЯ2ОН), 3.72 and 3.87 (ABq, 1^=13 6 Hz, 2H, S(0)CH2S), 4.07-4.37 (m, IH, 
СЯСН2). FAB MS, m/z 364 (21%, M+H, C ^ H ^ O s S ^ , 181 (19%, С 8 нХОз), [a]20D +48° (c 0 10, 
MeOH/H20,1:1). 
(ScRs) 2-[(E)-ß-(l,2^,4-Tetrahydro-l,3,6-trimethyl-2,4-dioxopyrimidin-5-yl)acrylamido]-
3-[[(methylthio)methyl]sulfinyl]-propanol (15). The preparation of 15 starting from 10 is not 
desenbed here. The following procedure for the synthesis of 15 is preferable (see text). To a solution of 
sparsomycin I6 (100 mg, 0 28 mmol) in 4 mL of dry DMF was added successively 225 mg of cesium 
carbonate (0.69 mmol) and 97 mg of methyl iodide (0.69 mmol).7·8 The reaction mixture was stirred 
for 3 h at room temperature in the dark in order to avoid trans-cis isomenzation of the double bond.4·11 
After evaporation of the solvent in vacuo and distnbution of the crude reaction product between 
л-BuOH and H 2 0 (31), the n-BuOH layer was separated and subsequently concentrated in vacuo The 
residue was punfied by gel permeation chromatography on Fractogel (eluent MeOH/H20, 1 1). The 
appropnate fractions were pooled and subsequendy lyophihzed from water or acetic acid to afford 80 
mg (75%) of the desired compound· TLC Rf 0.37 (eluent MeOH/CHCL, 1:9); •H NMR (D20) δ 2 27 (s, ЗН, 5СН
Э
), 2.49 (s, ЗН, С(б)-СНз), 3.18 (d, J=7.2 Hz, 2Н, СНСЯ2§(0)), 3.29 (s, ЗН, NOJ-Ol·), 
3 48 (s, ЗН, N(3)-CH3), 3.58-3.88 (m, 2H, СЯ2ОН), 3.92 and 4.11 (ABq, 1^=14.0 Hz, 2H, S(0)CH2S), 
4.28-4.62 (m, IH, CH), 7.00 and 7.46 (ABq, 1*0=15 4 Hz, 2H, СН=СН) FAB MS, miz 390 (7%, M+H, 
CisH^NjOjS^, 207 (29%, СюНц^Оз), [affi +61.7° (с 0.10, MeOH/H20,1:1) 
(ScRs) 2-[(E)-ß-(l,2^,4-Tetrahydro-l,3,6-trimethyl-2,4-dioxypyrimidiii-5-yl)acrylainido]-
3-[[(pentylthio)methyl]suirmyl]-propanol (16). This compound was prepared in 75% yield (80 mg) 
analogously to the synthesis of 15 desenbed above starting from pentyl-sparsomycin11 (100 mg, 0.24 
mmol): TLC Rf 0.40 (eluent MeOH/CHCl·,, 1.9), Ή NMR (CD3OD) δ 0.85 (br t, J=7 Hz, ЗН, 
СН2СЯз), 1.06-1 44 (m, 4Н, (СЯ2)2СНЭ), 1.44-1.75 (m, 2Н, 8СН2СЯ2), 2.41 (s, ЗН, С(б)-СНз), 2 68 (t, .1=6.9 Hz, 2Н, 8СЯ2СН2), 2 99 and 3.17 (AB part of ABX spectrum, 8 lines, 1^=8.4 Hz, ΙΒχ=1.6 
Hz, J * B = 13 Hz, 2H, CHCtf2S(0)), 3.23 (s, 3H, N(1)-CH3), 3.43 (s, 3H, N^-CHj), 3.63 (d, J=5.1 Hz, 
2H, СЯ2ОН), 3.80 and 3.95 (ABq, 1^=14.0 Hz, 2H, S(0)CH2S), 4.22-4.63 (m, IH, CH), 7.13 and 
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7.43 (ABq, JAB=15.1 Hz, 2H, СН=СН). FAB MS, m/z 446 (25%, M+H, C^Hj^OsSj), 207 (100%, 
СюНц^Оз), 117 (32%, QHjjS); [a]2ôD +68.1° (с 0.10, МеОН/Н20,1:1). 
(ScRs) 2-[(E)-ß-(l^,3,4-Tetrahydro-13,6-trimethyl-2,4-dioxopyrimidin-5-yl)acrylainido]-3-
[[(benzylthio)methyl]sulfinyl]-propanol (17). This compound was prepared in 86% yield (80 mg) 
from benzylsparsomycin4 (100 mg 0.20 mmol) following the procedure described above for the 
synthesis of 15: TLC Rf 0.41 (eluent MeOH/CHClj, 1:9); lH NMR (CD3OD) δ 2.37 (s, ЗН, С(б)-СНз), 
2.99 and 3.13 (AB part of ABX spectrum, 7 lines, JAx=7.5 Hz, JBX=0-5 HZ, JA B=13 HZ, 2H, 
СНСЯ25(0)), 3.19 (s, ЗН, N(1)-CH3), 3.39 (s, ЗН, N^-CH,), 3.63 (d, J=5 Hz, 2H, C/^CH), 3.67 and 
3.84 (ABq, JA B=13 Hz, 2H, S(0)CH2S), 3.87 (s, 2H, C//2Ph), 4.24-4.59 (m, IH, CH), 7.12 and 7.40 (ABq, J A B ^ S HZ, 2H, CH=CH). 7.21 (s, 5H, Ph) FAB MS, m/z 466 (13%, M+H, Cj^jgNjOsSj), 207 
(44%, СюНц^Оз), 137 (19%, CgHçS), 91 (65%, €
Ί
ίί
Ί
); [a]20D +138° (c 0.10, MeOH/H20,1:1). 
(ScRs) l-[[(Methylthio)methyl]sulfinyl]-2-[(E)-ß-(l,2^,4-tetrahydro-l,3,6-trimethyI-2,4-dioxo-
pyrimidin-5-yl)acrylamido]-propane (18). This compound was prepared in 76% yield (80 mg) from 
deshydroxy-sparsomycin11 (100 mg, 0.29 mmol) following the procedure described above for the 
preparation of compound 15: TLC Rf 0.43 (eluent МеОН/СНСІз, 1:9); •H NMR (CD3OD) δ 1.42 (d, 
J=6 Hz, ЗН, СНСЯз), 2.34 (s, ЗН, SCHj), 2.55 (s, ЗН, С(б)-СНз), 2.92 and 3.13 (AB part of ABX 
spectrum, 8 lines, 1^=3.0 Hz, JBX=8.0 Hz, ^ = 1 4 Hz, 2H, CHŒ2S(0)), 3.37 (s, ЗН, Ы(І)-СНз), 
3.56 (s, ЗН, N(3)-CH3), 3.92 and 197 (ABq, 1^=14.5 Hz, 2H, S(0)CH2S), 4.39-4.75 (m, IH, CH), 
7.19 and 7.54 (ABq, ^ = 1 5 Hz, 2H, CH=CH). FAB MS, m/z 374 (6%, M+H, C ^ H ^ O ^ ) . 207 
(20%, C K J H U N P J ) ; [apD +73.9° (c 0.10, МеОНУН20,1:1). 
(ScRs) 2-[(E)-ß-(2,4-Dimethoxy-6-methyIpyrimidin-5-yl)acrylamido]-3-[[(methylthio)methyl]-
sulfinylj-propanol (19). This compound was prepared in 31% yield (43 mg) by coupling 13 (80 mg, 
0.35 mmol) with 1 equiv. of 3 in an isobutyl chloroformate mixed anhydride procedure following the 
method which has been described earlier:6 TLC Rf 0.48 (eluent MeOH/H20, 15:85); lH NMR (CD3OD) δ 2.36 (s, ЗН, SCH3), 2.56 (s, ЗН, С(б)-СНз), 3.18 (s) and 3.25 (d, J=4.0 Hz, 2H, 
CHC^SiO)), 3.77 (d, J=4.9 Hz, 2H, C//2OH), 3.96-4.18 (ABq, 2H, S(0)CH2S), 4.04 (s, 3H, 
С(2)-0СНз), 4.13 (s, ЗН, С(4)-ОСНз), 4.35-4.73 (m, IH, CH), 6.88 and 7.69 (ABq, ^ = 1 5 . 7 Hz, 2H, 
CH=CH). FAB MS, m/z 390 (20%, M+H, C ^ H ^ N j O ^ ) , 207 (28%, C10H11N2O3); [a]20D +80.7° (c 
0.135, DMF/MeOH, 1:1). 
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CHAPTER 3 
EVALUATION OF SELECTED SPARSOMYCIN DERIVATIVES 
FOR BROAD-SPECTRUM BIOLOGICAL ACTIVITY 

CHAPTER 3.1 
IN VITRO ANTIPARASITIC ACTIVITY 
Conclusions: 
-the drugs show potent antiparasitic activity; 
the deshydroxy analogues are the least effective 
-the drugs interfere with protein, RNA and DNA synthesis 
-the drugs are leishmanistatic rather than leishmanicidal 
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LEON A. G. Μ. VAN DEN BROEK, HARRY С. J. OTTENHEIJM,* AND M. ROBERT-GERO: "Antiparasitic 
activity of sparsomycin analogues against Leishmania d. donovani in vitro". Manuscript in preparation. 
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INTRODUCTION 
Sparsomycin (I)1 is a potent, broad-spectrum, cytotoxic agent. Several less toxic analogues of 
sparsomycin have been synthesized in our laboratory and are currently evaluated as anticancer 
chemotherapeutic agents. These antibiotics act on protein biosynthesis by interference with the 
ribosomal peptidyl transferase. A nontoxic derivative of the antibiotic puromycin, showing a similar 
effect as sparsomycin on peptide bond formation, has been demonstrated to cure effectively 
Trypanosoma rhodesiense infections in mice.2 Recently, it was demonstrated that a nontoxic analogue 
of sparsomycin increased the survival time of Trypanosoma brucei infected mice significantly.3 
Parasitic infection remains a world health problem, and new chemotherapeutic agents for treatment 
of the disease are needed since few new drugs have been developed over the last 40 years.4 The 
protozoan parasite Leishmania d. donovani causes the disease Kala-azar or dumdum fever, which is 
common in India, the USSR, China, northern Africa, and parts of South America. The disease is 
transmitted by the bite of small sandflies; the parasite has a digenetic life cycle: as an extracellular 
promastigote in the alimentary tract of its sandfly vector and as an intracellular amastigote in lysosomes 
of cells of the reticuloendothelial system of its mammalian host. 
We detail here the effects of 11 analogues of sparsomycin on macromolecular biosynthesis and on 
the proliferation oí Leishmania d. donovani promastigotes in vitro. 
RESULTS AND DISCUSSION 
The syntheses of sparsomycin (1) and the analogues 2-12 (Table I) have been described elsewhere; 
see Chapters 2.1 and 2.2. 
The data of the effect of sparsomycin and 11 analogues on the multiplication of Leishmania d. 
donovani promastigotes in vitro are given in Table П. The inhibition of the protein synthesis in the 
polyphenylalanine synthesis assay and the inhibition of LI210 murine leukemia colony formation in a 
soft agar assay are also shown in this table. In the growth inhibition assay of Leishmania d. donovani, 
the cells were in continuous contact with the drug for 3 days. In the L1210 clonogenic assay in soft 
agar, cells were exposed to the drug for 8 consecutive days. The following conclusions can be drawn 
(see Table П). 
Of the hydroxy-containing drugs compound 4 shows, like in the polyPhe synthesis and L1210 
clonogenic assay, the highest activity in the growth inhibition assay of Leishmania d. donovani. The 
deshydroxy-sparsomycin analogues 10, 11 and 12, having the hydroxymethyl function substituted for a 
methyl group, are rather inactive, and in the deshydroxy series an increase of the lipophilicity results in 
a decrease of the activity. From this first screening for activity, compounds 1, 4 and 8 were selected for 
further testing; it was investigated whether they are leishmanistatic or leishmanicidal. 
For that purpose we exposed promastigotes of Leishmania d. donovani for 1, 2 or 3 days to a 13.8 
μΜ solution of 1, a 12 μΜ solution of 4, and a 12.5 μΜ solution of 8, giving 95, 92 and 93% growth 
inhibition of the parasites, respectively, and determined the effect of the drug on the survival of the 
promastigotes after 7 days. From the results presented in Table III, the following conclusions can be 
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drawn. Growth inhibition of Leishmania d. donovani increases as the drug exposure time increases. The 
effect is reversible to some extent, however, as the cells began to divide and growth inhibition 
decreased after the inhibitor had been withdrawn from the culture medium. The extent of inhibition falls 
from 95, 92, and 93% to 58, 58 and 75%, respectively, after 3 days of exposure and 4 days of reversion; 
see Table ΙΠ, third column. This suggests a leishmanistatic rather than a leishmanicidal effect. It is 
possible, however, that part of the cell population became resistant to the drug. Compound 8 is the most 
potent inhibitor of the three drugs. 
Table L Sparsomycin and Analogues 
R1 
C A N A ) 
0 
1 
Η 
\ R2 
compd 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
R1 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
Me 
Me 
Me 
Me 
R2 
CH2SMe 
CH2S(CH2)2Me 
СН25(СН2)зМе 
CH2S(CH2)4Me 
CH2S(CH2)7Me 
CH2SCH2Ph 
(CH2)5Me 
(CH2)6Me 
CH2SMe 
CH2SEt 
СН28(СН2)зМе 
CH2S(CH2)7Me 
It has been reported for growing cultures of E. coli that sparsomycin is mainly bacteriostatic and 
not bactericidal.5 Likewise, Chinese hamster fibroblasts incubated for 1 h with a sparsomycin 
concentration that inhibits protein synthesis for 99%, recover largely after removal of the drug.6 The 
cells do not recover their synthetic capabilities completely, however, after exposure periods exceeding 4 
h. Similar results were obtained with Chinese hamster ovary cells.7 In conclusion: sparsomycin 
compounds cause growth inhibition rather than destruction of various types of cells. 
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Subsequently, the effect of the IDJQ concentration of compounds 1, 4 and 7 on protein, RNA and 
DNA synthesis was examined by measuring the incorporation of [3HJleucine, [3H]uridine and 
[3H]thymidine, respectively, into promastigotes of Leishmania d. donovani after various times of 
contact between parasites and drug. From the results given in Table IV, the following conclusions can 
be drawn. The compounds 1 and 4 inhibit protein biosynthesis up to 48% after presence for 6 h in the 
culture medium. The drugs also interfere with cell uptake of the labeled precursor since the 
incorporation decreases upon longer incubation time. RNA synthesis is inhibited up to 94% by the 
compound 1 and 4 after presence for 3 h in the culture medium. Again, the cell uptake of uridine is 
inhibited severely by the two compounds. 
Table Π. Biological Activity Data 
compd polyPhe L1210 Leishmania 
E. coli d. donovani 
Εθ50,μΜ Η^ο,μΜ Ιθ50,μΜ 
1 
2 
3 
4 
5 
б 
7 
8 
9 
10 
11 
12 
8.5 
3.0 
1.8 
1.0 
1.6 
0.6 
0.75 
0.48 
4.6 
17 
3.0 
8.5 
0.47 
0.14 
0.10 
0.06 
0.10 
0.11 
0.14 
0.15 
0.07 
0.15 
0.05 
0.03 
2.7 
2.6 
4.9 
0.9 
2.8 
3.0 
1.8 
1.8 
2.9 
13.9(48%)а 
12.9(41%) 
11.3(10%) 
"The numbers in parentheses give the percentage of 
inhibition at the indicated highest concentration tested. 
DNA synthesis is inhibited only by compounds 1 and 4. The maximum effect (67% inhibition) is 
found for compound 1 after 6 h of incubation. In comparison with control cells (data not shown) DNA 
synthesis is even stimulated on 24 h exposure to compound 7. The uptake of thymidine is also affected 
by these drugs. Compounds 1 and 4 inhibit cell growth and DNA synthesis to the same extent; at the 
ID50 concentration the drugs affect DNA synthesis to 54 and 60% after presence for 3-6 h in the culture. 
Macromolecular biosynthesis in Leishmania d. donovani promastigotes is inhibited least by compound 
7. This compound shows even no effect at all on DNA synthesis. All drugs interfere with the uptake of 
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the labeled precursors. Surprisingly, the compounds tested inhibit predominantly the RNA synthesis. 
For E. coli,5·6 mouse livers9 and growing L cells10 it was demonstrated that sparsomycin inhibits protein 
synthesis preferentially. In E. coli various amino acids including leucine are released into the growth 
medium due to growth inhibition. 
Table III. Growth inhibition of Leishmania d. donovani 
compd 
1 
4 
8 
days of drug exposure 
1 2 3 
(% of control) 
63 41 42 
63 44 42 
60 38 25 
Although the precise mechanism of action of the compounds on Leishmania promastigotes is not 
yet elucidated, the results indicate, that differently from what has been observed in bacteria and 
mammalian cells, the primary effect in parasites is not on protein biosynthesis. 
The collective data show that analogues of sparsomycin, viz. 4 and 8, are potent inhibitors of the 
growth of promastigotes of Leishmania d, donovani. The deshydroxy derivatives 9-12 are much less 
effective than the hydroxy-containing compounds. Further study on the in vivo antiparasitic activity of 
the title compounds is required. 
EXPERIMENTAL SECTION 
Growth inhibition of Leishmania d. donovani. Promastigotes of Leishmania donovani donovani 
were seeded in 24-well microplates at 5.105 cells/well. The medium used was a 1:1 mixture of Dulbeco 
modified Eagle medium and RPMI 1640 supplemented with 10% foetal calf serum. Stock solutions of 
the drugs were prepared in DMSO, and these were diluted with phosphate buffered saline solution to 
obtain the desired drug concentration. The drug solutions were sterilized by filtration through 0.22 μ 
Millipore filters. The compounds were added to the cultures about 2 h after seeding, and the number of 
promastigotes were counted after 3 days of incubation at 26 0C. The results were compared with 
untreated controls. Each experiment was performed in duplicate, and the data presented are the mean 
values of three series of experiments. ID50 is the 50% inhibitory dose. 
In a subsequent experiment it was tested whether sparsomycin has a leishmanistatic or 
leishmanicidal effect. The parasites were incubated for 1, 2, or 3 days with a concentration of an 
antibiotic which inhibits growth almost completely: compound 1 at 13.8 μΜ giving 95% inhibition of 
cell growth, 4 at 12 μΜ giving 92% of inhibition and 8 at 12.5 μΜ giving 93% of inhibition. After the 
appropriate incubation time, the cells were centrifuged, resuspended in an inhibitor-free medium and 
incubated further for 6, 5 and 4 days, respectively. ТЪеп, after 7 days, the number of promastigotes was 
counted. 
Inhibition of protein, RNA and DNA synthesis. This was measured as has been described 
earlier.11 Briefly, promastigotes oí Leishmania d. donovani were seeded at 5.106 cells/mL (5 mL/flask 
of 25 mL). After a few hours of equilibration, cells were treated for 3, 6 or 24 h with the IDJQ 
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concentration of 1,4 or 7 , then labeled with 5 \iCi/mL of [3HJleucine, [3H]uridine or [3H]thymidine for 
2 h. Untreated controls were run in parallel. After labeling, cells were centrifuged and washed twice 
with a phosphate-buffered saline solution, and 1 mL of 5% TCA (trichloroacetic acid) was added at 4 
0C. After 20 min TCA precipitable material was filtered on GF/C Watman filters and the filters were 
hydrolyzed subsequently with 1 mL IN NaOH at 80 0C. The radioactivity was measured in the TCA 
soluble and TCA insoluble fractions in an LKB scintillation counter. The number of cpm per mg of 
proteins was calculated. Protein concentrations were determined using the Bradford method. Specific 
activities: L-[4,5-3H]leucine 130 Ci/mmol (CEA), [5-3H]uridine 30 Ci/mmol (Amersham) and 
[methyl-3H]thymidme 52 Ci/mmol (Amersham). 
Table IV. Inhibition of macromolecular biosynthesis in 
Leishmania d. donovani promastigotes by sparsomycin 
compounds 
compd drug exposure time 
3h 6h 24h 
(% inhibition) 
[3H]Leu 
[3H]Urd 
[3H]dThd 
1 
4 
7 
1 
4 
7 
1 
4 
7 
36 
33 
19 
94 
93 
50 
54 
60 
0 
47 
48 
32 
93 
79 
68 
67 
61 
0 
23 
12 
28 
9 
25 
0 
1 
2 
0 
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CHAPTER 3.2 
IN VITRO ANTIVIRAL ACTIVITY 
Conclusions: 
-selective antiviral activity in virus-infected host cells 
was observed in several cases 
-protein synthesis is affected most in Vero cells, 
while RNA, DNA and protein synthesis are inhibited 
concomitantly in PRK cells 
-toxicity to the host cells was observed in several cases 
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LEON A. G. Μ. VAN DEN BROEK, HARRY С. J. OTTENHEIJM* AND ERIK D E CLERCQ: "Antiviral activity of 
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Chapter 3.2 105 
SUMMARY 
The antiviral and antimetabolic effects of the cytotoxic agent sparsomycin (1) and three structural 
analogues, viz. 2-4, were evaluated. In general all drugs tested are rather toxic to the host cells. 
Compounds 2 and 3 showed antiviral activity against herpes simplex 1 and 2 and vaccinia virus in 
primary rabbit kidney cells and against parainfluenza and reo virus in Vero cells at concentrations that 
were about one order of magnitude lower than the concentrations at which cytotoxicity against the host 
cells was observed. In rabbit cells, antiviral activity was observed at the same concentration at which 
also protein, RNA and DNA synthesis were inhibited. In Vero cells, protein synthesis was affected to a 
greater extent than RNA or DNA synthesis. In these cells, compound 2 showed activity against 
parainfluenza virus at a concentration that was fivefold lower than that affecting host cell protein 
synthesis. 
INTRODUCTIO\ 
The broad spectrum of biological (antimetabolic, antiviral, antitumor, antibacterial, antifungal and 
antiparasitic) effects of sparsomycin has stimulated considerable interest in the synthesis and biological 
evaluation of analogues.1 Several amino acid-modified derivatives have been prepared and evaluated,1-4 
whereas parallel investigations of base-modified compounds have been less numerous.5,6 The present 
study was aimed at a comparative evaluation of some amino acid-modified analogues of sparsomycin as 
antiviral and antimetabolic agents in different cell systems. 
RESULTS AND DISCUSSION 
Chemistry. The syntheses of sparsomycin (1) and the analogues 2-4 (Table I) have been described 
in detail elsewhere.2,4,7 
Biological Activity. The methods used for measuring antiviral, cytotoxic and antimetabolic cell 
activity have been described previously.8,9 For anti-HIV activity a cell viability assay, the MTT 
reduction assay, was used.10 
Antiviral Activity. Compounds 1-4 were evaluated for their cytotoxic and antiviral activity in four 
different cell lines; the results are summarized in Tables Π and ΙΠ. The test systems consisted of (i) 
PRK (primary rabbit kidney) cells infected with herpes simplex virus type 1 (HSV-1, strain KOS), HSV 
type 2 (HSV-2, strain G), vaccinia virus (VV) or vesicular stomatitis virus (VSV), (if) HeLa (human 
carcinoma) cells infected with VSV, Coxsackie virus type B4 or polio virus type 1, (ш) Vero (African 
green monkey kidney) cells infected with parainfluenza virus type 3, reo virus type 1, Sindbis virus, 
Coxsackie virus type B4 or Semliki forest virus, and (iv) MT-4 (HTLV-I transformed human T4 
lymphocyte) cells infected with human immunodeficiency virus (НТЪ -ПІ
В
 HUT-78). 
All drugs proved quite toxic to the host cells. Sparsomycin was potent but nonspecific in its 
antiviral action. Compound 3 showed considerable antiviral activity against HSV-1, HSV-2 and W in 
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PRK cells with a ratio MCD (toxicity) over МГОзо (activity) of 50. Compound 2 showed likewise some 
selectivity against these three viruses (MCD/MID50 ratio of 14). Furthermore, compound 2 proved to be 
rather selective against parainfluenza virus in Vero cells (MCD/MID50 ratio of 25). Compound 3 had 
some selectivity (MCD/MID^ ratio of 14) against polio virus in HeLa cells and reo virus in Vero cells. 
In other instances, the drugs were devoid of antiviral activity at subtoxic doses. 
Table L Sparsomycin and Analogues 
Me о 
о 
Ν 
Η 
О 
"RS" compd R1 
CH2OH 
CH2OH 
CH2OH 
Me 
CH2SMe 
CH2S(CH2)4Me 
CH2S(CH2)7Me 
CH2SMe 
Antimetabolic Activity. The drugs were further evaluated for their inhibitory effects on protein, 
RNA and DNA synthesis in PRK and Vero cells. The results are given in Table IV. Their inhibitory 
effect on cellular DNA synthesis, RNA synthesis and protein synthesis was monitored by the reduction 
of the incorporation of [mef/iyZ-3H]dThd, [5-3H]Urd and [4,5-3H]Leu, respectively, into TCA insoluble 
material. 
PRK cellular DNA, RNA and protein synthesis were inhibited to a similar extent by sparsomycin 
and its derivatives. The sparsomycin derivatives inhibited macromolecular biosynthesis at an ID^ 
(0.3-2.5 μg/mL) that was not significantly higher than the minimum antiviral concentration (MID^ 
0.2-0.7 μg/mL) (vide supra). Thus, based upon the ratio ro^/MIDso, the compounds cannot be 
considered as truly selective antiviral agents. In PRK cells no selectivity was observed for inhibition of 
protein synthesis over RNA and DNA synthesis. 
It has been well established that sparsomycin and its analogues inhibit primarily protein synthesis, 
interfering with the function of the ribosomal peptidyl transferase.1114 In PRK cells, the sparsomycin 
analogues inhibited protein, RNA and DNA synthesis to a similar extent, but in Vero cells protein 
synthesis was affected at a 10-20 fold lower concentration than RNA or DNA synthesis. Compound 4 
was again the most inhibitory. In Vero cells antiviral activity (МШ^ 0.4-0.7 μg/mL) was observed at a 
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lower dose than that required to inhibit protein synthesis (ID50 2-2.9 μg/mL). 
It is clear that the cytotoxicity, antiviral potency and selectivity of sparsomycin can be altered 
significantly by modification of its chemical structure, i.e. by increasing the lipophilicity of the drug. In 
several instances toxicity to the host cells was observed. The potencies of compounds 2 and 3 against 
several viruses make these antibiotics attractive candidates for further studies on their efficacy against 
virus infections in animal models. 
Table II. Cytotoxic and Antiviral Activity of Sparsomycin 
Analogues in PRK, HeLa and Vero Cells 
Assay system 
Virus 
Mock-infected 
HSV-1 (KOS) 
HSV-2 (G) 
VV 
VSV 
Mock-infected 
VSV 
Coxsackie-B4 
Polio-1 
Mock-infected 
Parainfluenza-3 
Reo-1 
Sindbis 
Coxsackie-B4 
Semliki forest 
Cell 
PRK 
PRK 
PRK 
PRK 
PRK 
HeLa 
HeLa 
HeLa 
HeLa 
Vero 
Vero 
Vero 
Vero 
Vero 
Vero 
MCD' 
1 
>1 
>0.4 
>0.4 
>0.4 
>1 
4 
>4 
>4 
>1 
>4 
>1 
>1 
2 
>4 
2 
1
 or MID50,
b
 μg/mL 
2 
>10 
0.7 
0.7 
0.7 
2 
4 
>4 
0.7 
0.7 
>10 
0.4 
>1 
2 
>4 
2 
3 
>10 
0.2 
0.2 
0.2 
0.7 
10 
>4 
2 
0.7 
>10 
2 
0.7 
2 
>10 
2 
4 
>1 
>0.4 
0.2 
0.2 
0.7 
>4 
>4 
2 
>1 
>10 
1 
>1 
2 
>4 
7 
aMmimum cytotoxic dose required for a microscopically detectable 
alteration of normal cell morphology, bMinimum inhibitory dose 
required for 50% reduction of vims-induced cytopathogenicity. 
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Table ΠΙ. Anti-HIV activity οΓ Sparsomycin Analogues 
compd CD50
a
 or ЕО5 0,
ь
ц§/тЬ 
1 0.15 >0.04 
2 0.12 >0.04 
3 0.10 >0.04 
4 0.14 >0.04 
a50% cytotoxic dose, b50% effective dose. 
Table Г . Inhibition of Protein, RNA and DNA Synthesis by 
Sparsomycin Analogues 
compd ID50,
a
 μg/mL 
incorporation into TCA insoluble material of 
[4,5-3H]Leu 
PRK Vero 
1.5 2.9 
1.2 1.9 
0.5 2.5 
0.3 2.0 
[5-3H]Urd 
PRK 
1.9 
1.3 
0.6 
0.5 
Vero 
25.5 
39.8 
50.6 
69 
[Me-JHldThd 
PRK Vero 
2.5 33.3 
1.5 10.4 
1.0 23.0 
0.9 15.8 
"50% inhibitory dose 
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CHAPTER 3.3 
IN VITRO AND IN VIVO ANTITUMOR ACTIVITY 
H N ^ Y ^ ^ N ' 
N 
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Conclusions: 
-an increase of the lipophilicity of the drug resulted in an increase 
of the antitumor activity against the human tumor cell lines 
-an optimum in the relationship between lipophilicity and 
in vivo antitumor activity was observed 
-the more lipophilic, the less toxic the drug 
-the dcshydroxy derivatives are better water soluble than the 
corresponding hydroxy-containing compounds 
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This chapter is, in part, also taken up in the Ph.D. thesis of Z. Zylicz of the Division of Medical 
Oncology, University Hospital Nijmegen, as a result of the multidisciplinaiy collaboration with this 
division regarding the evaluation of analogues of sparsomycin as potential anticancer drugs. 
LEON A. G. M. VAN DEN BROEK, ZBIGNŒW ZYLICZ, MARINA GARZOTTO, D. J. THEO WAGENER, PETER 
LELIEVELD, JUAN P. G. BALLESTA, ERIK D E CLERCQ AND HARRY С J. OTTENHEUM*: "The influence of 
physicochemical parameters on the biological activity in vitro and in v ivo of sparsomycin: A structure-
activity relationship study". Submitted to the Journal of Medicinal Chemistry. 
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SUMMARY 
The Hpophilicity of 11 sparsomycin analogues was measured by determination of Rm, log k0 and 
log Ρ values. A linear correlation between these parameters was observed. Water solubility and drug 
toxicity in mice were found to be linearly correlated with hpophilicity. The deshydroxy-sparsomycin 
analogues (9-12) showed an interesting phenomenon: increase in hydrophobicity was accompanied by a 
considerable increase in water solubility. All the derivatives studied are more lipophilic than 
sparsomycin (1) itself and all show higher biological activity than 1 in the in vitro and in vivo systems 
studied. Moreover, these analogues are 5-100 times less toxic than 1. The sparsomycin analogues 4, 8 
and 9 show the highest antitumor activity against L1210 leukemia in mice, their median T/C values are 
386, 330 and 216%, respectively. Sparsomycin (1), showing a T/C value of 117%, is only marginally 
active against this tumor. 
WTRODUCTIOS 
Sparsomycin (I)1 is a broad-spectrum antibiotic active against parasites,2 viruses,3,4 fungi,5* and 
bacteria.6,7 It is a potent inhibitor of protein biosynthesis, and there is ample evidence that its site of 
interaction is the large ribosomal subunit. The drug competes with the binding of the natural substrate, 
i.e. L-amino acyl-tRNA, thereby blocking the peptidyl transferase center.1 Ever since the isolation of 
sparsomycin from Streptomyces sparsogenes in 1962, much attention was focused on its antitumor 
activity.1·5* In earlier reports8,9 on structure-activity relationships we described the synthesis of several 
analogues of sparsomycin which are more potent protein synthesis inhibitors than the natural product 1 
itself. Subsequently, the influence of lipophilicity on the biological activity in cell-free (i.e. protein 
synthesis inhibition) and whole-cell systems (i.e. growth inhibition) was investigated systematically.9 
Increase of the lipophilicity of the drug by substituting the SMe group by larger alkylthio groups (see 
structure of 1) causes an increase of the biological activity. 
Surprisingly, replacement of sparsomycin's hydroxymethyl group at the chiral carbon atom by 
more lipophilic substituents (alkyl or aralkyl groups) causes a decrease of the protein synthesis 
inhibitory capacity of these compounds.10 
The analogue having the hydroxymethyl group substituted by a methyl group (9)9 is five times 
more active than sparsomycin against L1210 leukemia in vitro, whereas the activity of the compounds 
having the hydroxymethyl moiety substituted by larger alkyl or aralkyl groups10 is equal to or even 
slightly less than that of 1. Therefore, we felt the need to study systematically the relationship between 
physicochemical properties of sparsomycin analogues, i.e. their lipophilicity and water solubility, and 
their biological activity. A number of lipophilic sparsomycin analogues was selected (see Table I).9 
In attempts to improve the prediction for clinical activity and toxicity of novel drugs, new in vitro 
screening models have been introduced lately, including human tumor cell lines.11"14 We have 
investigated the activity against five human tumors in tissue culture. 
Further, the following biological activities were studied: protein synthesis inhibition in the polyPhe 
synthesis cell-free system, antitumor activity in the LI210 clonogenic assay, acute toxicity in vivo, and 
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antitumor activity in mice bearing L1210 leukemia. The results described in this report are a firm basis 
for selection of the best drugs to be investigated in further pharmacological and toxicological studies. 
RESULTS AND DISCUSSION 
The structure of the compounds studied in this report is shown in Table I. Their physicochemical 
properties, i.e. their lipophilicity and water solubility, are given in Table II. In Tables III and IV the 
biological activity data of all drugs are presented. Regression equations describing the linear correlation 
between various physicochemical parameters studied and between lipophilicity and toxicity are shown 
in Table V. 
Table L Sparsomycin and Analogues 
R1 О .. 
I/ 
compd 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
H 
R1 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
Me 
Me 
Me 
Me 
R2 
CH2SMe 
CH2S(CH2)2Me 
СН25(СН2)зМе 
CH2S(CH2)4Me 
CH2S(CH2)7Me 
CH2SCH2Ph 
(CH2)5Me 
(CH2)6Me 
CH2SMe 
CH2SEt 
СН28(СН2)зМе 
CH2S(CH2)7Me 
On the basis of their structure the compounds studied (see Table I) can be devided into three 
classes, i.e. a series of sparsomycin analogues (1-2-3-4-5), two desthio analogues (7-8) and a group of 
deshydroxy-sparsomycin analogues (9-10-11-12). Compound 6 was included in order to study the 
me о 
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influence of the presence of an aromatic ring in the side chain on the biological activity. One 
representative of each class, i.e. compounds 4, 8 and 9 have attracted our attention because these 
compounds in relation to sparsomycin, combine a high antitumor activity with a low toxicity in vivo. 
Compounds 7 and 8 are structurally related to compounds 3 and 4, respectively. In the former two 
compounds the bivalent sulfur atom has been replaced by a methylene group. Compounds 9, 11 and 12 
carry identical side chains as compounds 1, 3 and 5, respectively. However, the hydroxymethyl group 
of the latter compounds has been replaced by a methyl group. 
Physicochemical Properties. The lipophilicity of the sparsomycin compounds can be well 
characterized by the experimentally simple deteimination of Rm values (Table II). Excellent linear 
correlations were found (entries А, В and С of Table V) between this parameter and the other 
lipophilicity parameters measured, i.e. log k0 and log Ρ (Table II). The sparsomycin analogues 1, 3 and 
5 have Rm, log k0 and log Ρ values that are lower than those of the corresponding deshydroxy-
sparsomycin derivatives 9,11 and 12, respectively (Table II). The linear correlation calculated between 
the Rm values of the series 1-5 and 9-12 versus the number of carbon atoms attached to the bivalent 
sulfur atom is given in entries D and E, respectively, of Table V. It can be seen that these linear 
regression lines have equal slopes. The difference in the Rm values of two corresponding structures in 
these series, e.g. 1 and 9, is equal to the effect of a single methylene group. 
Table Π. Physicochemical Parameters 
compd 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Rm 
-0.638 
-0.261 
-0.028 
0.160 
0.895 
-0.042 
0.235 
0.560 
-0.404 
-0.190 
0.218 
1.151 
logk0 
-0.676 
0.117 
0.777 
1.168 
3.333 
0.803 
1.111 
1.771 
-0.209 
0.079 
1.290 
3.533 
log Ρ 
-1.713 
-0.665 
0.143 
0.600 
>2.424 
0.129 
0.410 
1.021 
-0.699 
-0.301 
0.819 
>2.424 
water 
solubility 
(mg/mL) 
3.8 
1.5 
0.57 
0.28 
0.013 
0.76 
0.89 
0.22 
18.0 
8.8 
0.94 
0.015 
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Water solubility of the drugs (Table II) correlates linearly with all lipophilicity parameters used; in 
entries F and G of Table V only the correlation with log k0 is shown for the series 1-8 and 9-12, 
respectively. Surprisingly, the deshydroxy-sparsomycin derivatives 9, 11 and 12 are better water soluble 
than the corresponding sparsomycin analogues 1, 3 and 5, respectively, despite their increased 
lipophilicity. E.g. compound 9 is five times more water soluble than sparsomycin 1 itself. We do not 
have an explanation for this interesting phenomenon. 
The pKa values of sparsomycin 1 (8.97 ± 0.02) and deshydroxy-sparsomycin 9 (9.02 ± 0.02) were 
measured.5b From this we conclude that the hydroxy function of sparsomycin is poorly dissociated since 
the pKa values are virtually the same. 
Biological Activity In Vitro and In Vivo. The biological activity was studied in eight in vitro 
assays and in one in vivo system; the results are given in Tables III and IV. The following conclusions 
can be drawn. Of the hydroxy-containing sparsomycin analogues 1-8, the S-oxo-S-n-heptyl derivative 8 
possesses the highest affinity for the ribosomal peptidyl transferase (Table ΙΠ). The high activity in the 
phenylalanine polymerization (polyPhe) assay of analogues carrying a hydrophobic group attached to 
the sulfoxide function (e.g. 4 and 8) suggests that these compounds interact with a hydrophobic region 
on the peptidyl transferase. Probably this region functions as the recognition site for the lateral chains of 
hydrophobic amino acids during protein synthesis.1·8 
Comparison of the data obtained for compounds 1-5 in the polyPhe assay, in the L1210 clonogenic 
assay and in the L1210 in vivo system shows that there is an optimum in activity for pentyl-
sparsomycin 4 (Table ΙΠ). This optimum in activity is most pronounced in the in vivo L1210 system. 
Substitution of the bivalent sulfur atom by a methylene group (compare the data in Table ΙΠ of 
compound 7 vs. 3 and 8 vs. 4, respectively) has no serious effect on the in vitro and in vivo biological 
activity. The in vivo antitumor activity of compounds 7 and 8 is somewhat lower than that of 
compounds 3 and 4, respectively. In both cases a surprisingly better T/C ratio was obtained by 
extension of the side chain with a single methylene group. 
In the deshydroxy-sparsomycin series 9-12 an optimum in activity was observed for compound 11 
in the protein synthesis inhibition assay and in the growth inhibition assays of T24 and WiDr tumor 
cells (Table III). In this series compound 10 has the lowest activity in the L1210 clonogenic assay. 
Despite the lower affinity for the ribosome of compounds 9 and 10 in comparison with 
sparsomycin 1 itself, these analogues are more active than 1 in vivo against L1210 leukemia (Table III). 
Surprisingly, the antitumor activity of 11 is lower than that of 9, whereas the hydroxymethyl 
analogue of 11, i.e. 3, has a higher antitumor activity than 1 (Table Ш). 
The benzyl derivative б is quite active in the in vitro assays and although more active than 
sparsomycin in vivo, this compound is one of the less active analogues as far as antitumor activity in 
tumor-bearing mice is concerned (Table III). 
Replacement of sparsomycin's methyl group at the bivalent sulfur atom by alkyl or aralkyl groups 
(i.e. 2-6) and of its methylthio function by alkyl groups (i.e. 7 and 8), both leading to increased 
lipophilicity of the drug, results invariably in an increase of the biological activity in all assays tested 
(Tables ΠΙ and Г ). 
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The activity of the sparsomycin analogues 1-8 against the human tumor cell lines (Tables ΠΙ and 
IV) is related to the lipophilicity of the compounds. In general, an increase of the lipophilicity results in 
an increase of the activity. 
Table ΠΙ. Biological Activity 
cell-free whole-cell in vivo 
polyPhe tumor growth LD50 T/C 
synthesis inhibition 
compd E.coli 174 WiDr LÎ2Î0 L1210 
1 
2 
3 
4 
S 
6 
7 
8 
9 
10 
11 
12 
Εϋ 5 0(μΜ) 
8.5 
3.0 
1.8 
1.0 
1.6 
0.6 
0.75 
0.46 
14.5 
12.0 
3.0 
8.5 
0.91 
0.65 
0.23 
0.28 
0.06 
0.34 
0.35 
0.16 
0.44 
0.34 
0.09 
0.14 
IDso(^M) 
0.92 
0.89 
0.31 
0.40 
0.22 
0.51 
0.39 
0.28 
0.58 
0.48 
0.16 
0.28 
0.48 
0.14 
0.10 
0.06 
0.10 
0.11 
0.14 
0.15 
0.07 
0.15 
0.05 
0.03 
(mg/kg) 
0.26 
NT 
2.33 
4.7 
29.5 
5.0 
1.6 
6.1 
2.33 
8.7 
16.5 
NT 
(%) 
117 
NT 
156 
386 
151 
151 
135 
330 
216 
184 
164 
NT 
NT, not tested 
Acute Toxicity. We observed a striking linear relationship between drug toxicity in mice and 
lipophilicity; an increase of the lipophilicity results in a decrease of the toxicity. The correlations found 
for the sparsomycin compounds 1, 3-8 and for the deshydroxy-sparsomycin compounds 9-11 are 
depicted in entries Η and I, respectively, of Table V. Removal of the hydroxy group decreases the 
drug's toxicity considerably; compare the data of compounds 9 vs. 1 and 11 vs. 3, respectively (Tables 
II and Ш). Comparison of the LD^ values of compounds 7 vs. 3 and 8 vs. 4, respectively, learns that 
substitution of the bivalent sulfur atom by a methylene group has a variable effect on in vivo toxicity. 
A rationale for the decreased toxicity of the more lipophilic analogues could be the following. 
Pentyl-sparsomycin 4 has a total body clearance in Beagle dogs that is twice that of sparsomycin I. 1 5 A 
more rapid clearance permits on one hand the administration of higher doses of the drug, but on the 
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other hand produces a lower AUC (area under the curve). In other words, the body is exposed less to 
more lipophilic analogues of sparsomycin, e.g. 4, resulting in a lower toxicity. The increased volume of 
distribution and increased protein binding of these lipophilic derivatives may explain further the 
increase of the LD50 value. 
Table Г . Antitumor Activity of Sparsomycin 
ID5 0, μΜ 
Compd Murine tumor Human tumor cell lines 
cell line 
1 
4 
5 
9 
L1210/0 
2.8 
0.32 
0.21 
0.68 
Raj i/0 
5.2 
0.82 
0.51 
0.81 
Molt/4F 
4.4 
0.87 
0.59 
0.87 
MT4 
5.7 
0.67 
0.67 
0.90 
Table V. Linear regression equations1 
entry 
A 
В 
С 
D 
E 
F 
G 
H 
I 
У 
logk° 
logk° 
Rm 
Rm 
Rm 
logk° 
logk0 
logk0 
logk0 
X 
log Ρ 
Rm 
log Ρ 
Cn 
Cn 
log Sol 
log Sol 
log LDJO 
log LDso 
y = ax + b 
b 
-0.63 
-0.30 
0.07 
-0.90 
-0.64 
0.51 
1.28 
-0.06 
0.66 
a 
0.92 
0.40 
2.28 
0.22 
0.22 
-1.55 
-1.23 
0.49 
0.47 
г 
0.986 
0.989 
0.981 
0.998 
0.999 
-0.973 
-0.999 
0.937 
0.858 
η 
12 
12 
12 
5 
4 
8 
4 
7 
3 
compds 
1-12 
1-12 
1-12 
1-5 
9-12 
1-8 
9-12 
1,3-8 
9-11 
abbreviations used: a, slope; b, intercept; r, correlation coefficient; n, 
number of compounds used in linear regression analysis; Cn, number of 
carbon atoms (see text); Sol, water solubility. 
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The role of the substituent at the chiral carbon atom of sparsomycin on the biological activity in 
vitro has been investigated earlier.10 It was concluded that the affinity for the ribosome and the 
antitumor activity in vitro are hardly affected by replacement of this substituent by larger alkyl or 
aralkyl groups, or by its O-methylation or O-acylation. Some of these changes even cause a slight 
decrease in activity. Only when the hydroxymethyl group is replaced by a methyl group an increase in 
the in vitro activity in the L1210 clonogenic assay was observed. This study shows that also in vivo 
deshydroxy-sparsomycin 9 is a better antitumor drug than sparsomycin. Unfortunately, substitution of 
the methylthio group in 9 by larger alkylthio groups, as in compounds 10 and 11 does not give rise to an 
increase of the in vivo antitumor activity, as observed in the series 1-2-3-4. 
In conclusion: the therapeutic index of sparsomycin can be considerably improved by minor 
modification of the molecular structure. The drug with an n-pentyl side-chain attached to the bivalent 
sulfur atom, i.e. 4, shows the highest antitumor activity in mice. S-Oxo-S-w-heptyl-sparsomycin 8 and 
deshydroxy-sparsomycin 9 also pair high antitumor activity with low toxicity in comparison with the 
unmodified antibiotic. Compound 9 shows the unique feature of combining an increased lipophilicity 
with a considerable increase in water solubility. 
EXPERIMENTAL SECTION 
Drugs. The syntheses of sparsomycin and analogues 2-12 have been described earlier.8·9·16·17 The 
compounds used in this study are listed in Table I. 
Chromatography. Rf values were determined by high-performance thin-layer chromatography 
(hptlc) using Merck RP-8 F254
 s
 plates (eluent 60% methanol/water). Rm values were calculated from 
these Rf values by employment of the following formula: Rm = log (1/Rf - 1). 
Drug concentrations were determined using a semi-automated high-performance liquid 
chromatography (hplc) system from Kratos Analytical (Ramsey, New York, U.S.A.). This system 
consisted of two Spectroflow 400 pumps, Multiport Streamswitch with two six-way valves (Rheodyne, 
USA), a 757 UV-Vis Detector and a DS 610 Multi-range strip chart recorder. The connection of the 
sampling valves for the back flushing method has been described before.18 The whole system was 
operated by means of an hplc solvent programmer (9224, Kipp Analytical, The Netherlands) equipped 
with a digital time indicator. 
The columns used are: a concentration column (5 cm χ 3 mm id) filled with LiChrosorb RP-8 (10 
μΐη particle size) and an analytical column (10 cm χ 4.6 mm id) filled with CP"" Spher C8 (8 μτη 
particle size); both packing materials were obtained from Chrompack B.V. (Middelburg, The 
Netherlands). 
Solvent A (flow 1.3 mL/min), used for sample concentration and cleaning of the columns consisted 
of filtered tap water. Solvent В (flow 1.0 mL/min), used to flush back the sample from the 
concentration column through the analytical column consisted of 0.1 M phosphoric acid buffer (pH 6.7) 
with different amounts of methanol (Fisons, England, hplc grade) added. 
Determination of log к values by HPLC. For each drug the retention time (t,) was determined on 
hplc for at least five methanol concentrations (see above). In general, the results for each drug could be 
described by the following equation:19 logk' = log к" + bM, where k'= the capacity factor at a certain 
percentage of organic solvent in the eluent, k0 = die capacity factor obtained by extrapolation to 0% of 
organic solvent in the eluent, b = slope and M = percent of methanol in the eluent. The capacity factor 
k' is calculated from the difference between the retention time (ц) of the drug and the retention time (t0) 
of the unretained substance: log k'= log (t^t,,) - log t0. 
Octanol/water partition coefficient. The partition coefficients (P) of the drugs were measured by 
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mixing 1 mL of a solution containing 12 μ§/Γηί of a drug dissolved in demineralized water and 1 mL of 
0.1 M phosphoric acid buffer (pH 7.4) saturated with 2 mL of 1-octanol (Merck, Germany). After 
mixing for 1 min on a Vortex mixer and centrifugation at 1400 g for 10 min, 1 mL of the water phase 
was analyzed by hplc (see above). Increasing the time of mixing did not change log P. Each test was 
repeated three times and each sample was determined in duplicate. The coefficient Ρ was calculated 
from the following formula: Ρ = (С - C
w
)/C
w
, where С = total concentration of drug in both phases and 
C
w
 = concentration of drug in the water phase. 
Water solubility. An excessive amount of each drug was shaken overnight with 5 mL of 
demineralized water at room temperature (19.5 ± 0.3 0C). The drug suspension was filtered through a 
paper filter (Rundfilter, nr.595, Schleicher & Schuil, Germany). The last mL of the filtrate was 
collected and the concentration was determined by hplc (see above). Each experiment was performed 
twice. 
Dissociation constant pKa. The pKa values of 1 and 9 were determined following the method of 
Hurwitz and Liu.20 The UV absorption of several samples was measured at 328 nm (DU-7 UV-Vis 
Spectrofotometer, Beekman, USA). Samples with the same drug concentration dissolved in different 
borax and phosphate buffers (pH 3.5-12) were prepared and analyzed. The pKa value was calculated 
from the following formula: pKa = pH - log (A-AJAb-A), where pH = pH of die buffer, A = absorbance 
at a specific pH, A
a
 = absorbance in acidic solution (pH 3.5) and Ab = absorbance in basic solution (pH 
12). The pKa value is expressed as a mean of the results of each sample (n = 10) ± SD. 
Inhibition of protein synthesis in a cell-free system. The protein synthesis was measured by the 
polyphenylalanine synthesis (polyPhe) assay. This assay has been described by us in detail elsewhere.8 
Polymerization of phenylalanine using polyuridylic acid as template is generally accepted as a measure 
for the total polymerization capacity of cellular extracts. Ribosomes from Escherichia coli MRE 600 
were used. ED50 represents the 50% effective dose. The values given are the average of three 
experiments and have an average error of 20%. 
In vitro cytotoxicity/antitumor activity. The cytotoxicity against two human tumor cell lines, viz. 
T24 bladder carcinoma and WiDr colon carcinoma, was determined following a new automated 
technique for large-scale drug cytotoxicity testing, viz. the PIT method.14 The cytotoxicity against one 
murine, viz. L1210/0 leukemia, and three human, viz. Raji/0 B-lymphoblast, Molt/4F T-lymphoblast 
and MT4 T-lymphocyte, tumors in tissue culture was determined as has been described earlier.21 In 
vitro antitumor activity was determined in the L1210 murine leukemia clonogenic assay in soft agar.17 
1050 represents the 50% inhibitory dose. 
Toxicity in mice. The toxicity of each drug was determined following the NCI protocol.22 The 
tests were done on male CDFj mice and each drug, suspended or dissolved in 0.9% NaCl, was injected 
ip daily χ 9. There were 5 dose levels and 10 mice per dose level. The LD5 0 values (mg/kg/inj) were 
calculated using Weils' tables.23 The 95% confidence interval was usually within 15-20% of the value 
shown. These data were reported elsewhere.24 
Antitumor activity in mice. The antitumor activity of the drugs against L1210 leukemia was 
determined in male CDFj mice inoculated with 105 vital L1210 cells ip on day 0. Animals were treated 
with drugs dissolved or suspended in 0.9% NaCl ip on days 1-9. The median survival time of each 
treated group (T) was compared with that of the control group (C). The results are expressed as a T/C χ 
100% ratio at the optimal dose (this dose is approximately equal to the LD1 0 value). These data as well 
as the results of activity tests against other murine tumors (i.e. P388 leukemia, RC carcinoma and В16 
melanoma) were reported elsewhere.24 
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CHAPTER 4 
INTERACTION OF SPARSOMYCIN WITH PEPTID YL TRANSFERASE 

CHAPTER 4.1 
SYNTHESIS OF [3H]SPARSOMYCIN 
Radioactively labeled sparsomycin 
o^N^o 
H [3H]Sparsomycin 
Conclusions: 
-prepared by metal hydride reduction of a 
suitable precursor 
-ratio mono- /ditritiated compound is 2:1 
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SUMMARY 
The synthesis is described of tritiated sparsomycin (5), a broad-spectrum antitumor antibiotic, with 
high specific activity (31.4 Ci/mmol). The radiolabel was introduced by reduction of the cysteine 
methyl ester 1 with lithium borotritide. 3H NMR analysis of the final product showed the concomitant 
formation of the mono- and ditritiated compound in a ratio of 2:1. 
IMTRODUCTION 
Sparsomycin and several more potent analogues are broad-spectrum antibiotics.1"3 These drugs act 
on the ribosomal level and affect protein biosynthesis. Currently, sparsomycin and some selected 
derivatives are evaluated in preclinical investigations for their use as anticancer agents. For in vitro 
drug-receptor and in vivo pharmacokinetic studies we required a radiolabeled drug. We recovered from 
the literature two refences that describe biochemical studies using "tritiated" sparsomycin derivatives.4·5 
However, no information was reported on their synthesis, purity and structure identification. This report 
describes our approach to the chemical synthesis and characterization of optically active 
[3H]sparsomycin (5). 
RESULTS AND DISCUSSION 
[3H]Sparsomycin (5) was prepared in the following way. The cysteine methyl ester 1 was reduced 
with lithium borotritide, prepared in situ from NaB3H4 (s.a. 64.9 Ci/mmol) and Lil (see Scheme I).6 
Subsequently, 2 was reacted with sodium methyl mercaptide to give compound 3.6 The amino 
protecting group of 3 was removed by treatment with neat trifluoroacetic acid,6 and the resulting amine 
was coupled subsequently with the pentafluorophenyl ester 4 to yield 1.4 mCi of the desired endproduct 
5. The chemical and radiochemical purity of 5 was checked by HPTLC (silica gel, eluent 
МеОН/СНгСІг 2:8) and by HPLC (дВопгіарак C8, eluent MeOH/H20 1:9). The specific activity of 
31.4 Ci/mmol of [3H]sparsomycin was determined from a UV calibration line constructed for known 
amounts of cold sparsomycin, by HPLC analysis (U V detection at 302 nm)/liquid scintillation counting. 
The calculated specific activity is in good agreement with the isotopie abundance of about 60% of the 
sodium tritide used. 
A tritium NMR spectrum was run of the intermediate 2 and of the final product 5 for the 
determination of the position and distribution of the tritium in the labeled drug. This technique has 
proved to be a very powerful one in the analysis of tritiated drugs.7"9 Broad-band lH decoupled 3H 
NMR analysis of 2 showed that this product is a mixture of the mono- and ditritiated compound; signals 
at 3.485, 3.518, 3.537 (two overlapping signals), 3.572 and 3.581 ppm were observed (see Figure la). 
By introduction of one tritium atom in the molecule two diastereomers are formed; the singlets at 3.537 
and 3.581 represent these diastereoisomers. The signals at 3.485, 3.518, 3.537 and 3.572 form an AB 
pattern that results from the two diastereotopic tritium atoms in the ditritiated compound. That this AB 
signal is shifted upfield in comparison with the signals of the monotritiated diastereomers, is in 
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agreement with the tritium isotope effect.10·11 Integration of the NMR signals shows a ratio mono-/di-
tritiated compound of approximately 2:1. 
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[ 3 H]Sparsomycin 5 shows singlets at 3.646,3,668 and 3.684 p p m in the tritium N M R spectrum (see 
Figure lb) . The presence of two diastereomers is deduced by the presence of two singlets seen at 3.668 
and 3.684 ppm. The broadened singlet at 3.646 ppm originates from the AB pattern that is expected for 
the ditritíated compound (vide supra). This simplified AB pattern again is situated at higher field than 
the signals of both monotritiated compounds (vide supra). Integration of the NMR signals confirms the 
ratio of the mono- and ditritiated compound to be approximately 2:1 (vide supra). 
In pilot studies we had prepared tritiated sparsomycin with a specific activity of 0.3 Ci/mmol, using 
commercially available sodium borotritide. We observed that the yield of the metal hydride reduction in 
this case was far better than in case of the synthesis of tritiated sparsomycin of high specific activity. 
Tritium NMR analysis of the product with low specific activity, i.e. 0.3 Ci/mmol, revealed only the two 
singlets of the two diastereomeric monotritiated compounds of equal intensity (see Figure 1c). 
In conclusion, we have been able to synthesize tritium labeled sparsomycin in high specific activity 
by metal hydride reduction of a suitable precursor. Tritium N M R analysis of the final product pointed to 
a ratio of mono- over ditritiated compound of approximately 2 :1 . Investigations on the interaction with 
the peptidyl transferase and on the pharmacokinetic behaviour in mice of [ :}H]sparsomycin (5) are in 
progress. 
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Figure 1. Tritium NMR spectra of compounds 2 (a) and 5 (b and c) 
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EXPERIMENTAL SECTION 
The tritiation reaction was carried out at Amersham International pic, Cardiff, U.K. by their tritium 
labeling service. 3 H NMR spectra recorded with broad-band Ή decoupling, were measured on a Bruker 
AM360 spectrometer operating at 384,138 MHz.7"11 Chemical shifts (δ) are referred to "ghost" - Me4Si, 
the value of which was obtained by multiplying the 'H frequency of Me4Si by 1,06663975. For HPTLC 
an Isomess IM-3016 Radio-TLC-Analyser was used. HPLC analyses were obtained on a Waters 6000A 
system equipped with a Pye Unicam 4025 UV spectrofotometer and a Berthold LB503 liquid 
scintillation counter. 
ScRs [1-3Н]-2-[У -(^^-Ви1уІохусагЬопуІ)аіпіпо]-3-[(СЫоготеІЬу1)5и1Гіпу1]-ргорапоІ (2). To 
a solution of 1 Ci sodium borotritide (Amersham, s.a. 64.9 Ci/mmol) in 0.5 mL of dry ΊΉΡ was added 
subsequently 10 mg of Lil and 20 mg of 1 at -70 0 C. 6 The reaction mixture was stirred for 20 h at 
ambient temperature in a nitrogen atmosphere. The excess LÌBT4 was destroyed with a few drops of 
concentrated HOAc. After neutralization with ^гСОз, the reaction mixture was concentrated, the 
remainder was dissolved in МеОН/С^СЬ (95:5), the solution was filtrated and the solvents again were 
evaporated with a stream of nitrogen in order to remove any labile tritium. The crude product (263 mCi) 
was purified on silica gel (eluent CH^C^/MeOH, 95:5) giving 24.6 mCi of 2. The product co-migrated 
with unlabeled 2 on TLC. *Н NMR (2 mCi in CD3OD) δ 3.48593 (s, CT2OH), 3.518 (s, СТ2ОН), 3.537 (2х s, СТ2ОН and СНТОН), 3.572 (s, СТ2ОН), 3.581 (s, СНТОН). 
ScÄs [l-3H]-2-[^V-(terí-Butyloxycarbonyl)amino]-3-[(methyUhio)methylsuIfinyl]-propanol (3). 
Product 2 was dissolved in 1 mL of oxygen-free EtOH and 5 mg of NaSMe were added. After stirring 
for 20 h at room temperature in a nitrogen atmosphere, the solvent was evaporated with a stream of 
nitrogen and the residue was purified on silica gel (eluent СНСІз/МеОН, 93:7) to yield 20 mCi of pure 
3. The product had the same Rf value as the unlabeled material. 
ScRs [l-3H]-2-[(E)-3-(6-methyl-5-urac¡lyl)acrylamido]-3-[(methylthio)methylsuirinyl]-
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propanol (5). Product 3 was stirred in 2 mL of neat TFA for 45 min at ambient temperature.6 The 
amino deprotection reaction was followed on TLC (eluent СНСІз/МеОН, 8:2). After removal of the 
excess TFA, the residue was dissolved in 2 mL of DMF. The solution was neutralized with EtjN and 
subsequently, 25 μ ι of Eifl and 10 mg of the pentafluorophenyl ester 4 1 2 were added. The reaction 
mixture was stirred for 20 h at room temperature and the solution was then lyophilized. The product 
was First purified by chromatography on silica gel (eluent СНСІз/МеОН, 9:1) and secondly by 
chromatography on HPLC (Supelco RP8, eluent MeOH/F^O, 1:9) yielding 1.4 mCi of the pure 
compound (>96% by HPLC) next to 0.7 mCi of an impure fraction of the desired compound. 3H NMR 
(0.7 mCi in CD3OD) δ 3.646 (s, CT2OH), 3.668 and 3.684 (2x s, 2x CHTOH). 
[3H]sparsomycin (0.3 Ci/mmol): 3H NMR (2.5 mCi in DMSO-d6) δ 3.402 and 3.668 (2x s, 2x 
CHTOH). 
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CHAPTER 4.2 
SYNTHESIS OF A PHENOL DERIVATIVE SUITABLE FOR RIBOSOME AFFINITY STUDIES 
Phenolic derivative of sparsomycin 
,—R=H 
U R = 1 2 5 I 
Conclusions: 
-higher affinity for the ribosome than sparsomycin 
-radioiodination yields highly radioactive sparsomycin 
-the radioiodinated drug and probably also sparsomycin 
do not bind covalently to the ribosome 
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SUMMARY 
The synthesis of two phenolic derivatives (7 and 8) of the broad-spectrum antibiotic sparsomycin 
(1) is described. The absolute configuration of these compounds was determined by circular dichroism 
spectroscopy. The compounds were prepared starting from the amino acid L-alanine. The biological 
activity of 7 was tested in three cell-free assays for inhibition of peptide bond formation, in an E. coli 
cell growth inhibition assay and in the L1210 clonogenic assay for antitumor activity. Compound 7 
inhibits protein synthesis as effectively as sparsomycin, its antitumor activity is fourfold lower, 
however, than that of 1. 
INTRODUCTION 
Sparsomycin (I)1 is a potent inhibitor of protein synthesis. Peptide elongation is blocked by the 
interference of sparsomycin with the peptidyl transferase center located on the large ribosomal 
subunit.2,3 This mode of action causes a broad-spectrum activity of which the antitumor activity has 
attracted the most attention.4 An intriguing question is whether the interaction of sparsomycin with its 
receptor is reversible or irreversible. Flynn and Ash have proposed a mechanistic rationale for a 
covalent inhibition of peptidyl transferase.5 We have addressed this problem in the following way. A 
phenol derivative of sparsomycin, viz. 7, was selected a suitable expedient for ribosome affinity studies. 
Flynn and Beight have reported the synthesis of a phenolic sparsomycin analogue carrying the CH2OH 
function at the chiral carbon atom.6 However, their reaction route only allowed the preparation of this 
phenol compound as a mixture of all four possible stereoisomers. Compound 7 was prepared from 
L-alanine analogously to the procedure we have described elsewhere.7 
YC OH 
Η Ν Λ Υ ^ ^ Α Ν ^ ^ ^ a ^ - -.ме 
" Sparsomycin, 1 
Structure-activity relationship studies learned that simple modifications of the molecular structure 
of 1 increasing the lipophilicity of the drug, lead to compounds showing higher biological activity.7 
Thus, substitution of the SMe group in 1 for a SCQ^^Me group increases protein synthesis inhibition 
eightfold and in vitro antitumor activity sixfold.7 It is allowed also to substitute the SMe group for a 
(СН^яМе (л=4-5) group.7 Replacement of the CH2OH function by a Me group slightly decreases 
protein synthesis inhibition by a factor 1.5, but antitumor activity increases sixfold.7 Moreover, both 
analogues show a substantially higher in vivo antitumor activity and lower toxicity in mice in 
comparison with the unmodified antibiotic.8 Of all analogues studied, the deshydroxy-sparsomycin 
derivatives show the best overall results. Therefore, we chose as a sparsomycin model compound to 
134 Chapter 4.2 
prepare a phenol derivative of sparsomycin carrying a methyl group at the chiral carbon atom. 
The phenol analogue 7 can be radioiodinated under mild reaction conditions with chloramine Τ and 
Na1 2 5I to give the radioactive sparsomycin affinity label 9.9 In order to assess the biological activity, its 
precursor 7, was assayed in the polyphenylalanine polymerization (polyPhe) assay10 and the puromycin 
reaction,10 using ribosomes from E. coli or 5. cerevisiae, in a growth inhibition assay of E. coli cells in 
liquid medium and in a system for antitumor activity, viz. the murine leukemia L1210 clonogenic assay 
in soft agar.11 
RESULTS AND DISCUSSION 
Synthesis. Recendy, we described a synthetic route for sparsomycin analogues starling from the 
amino acid L-alanine.7 The key step in this scheme, the introduction of the sulfur atom, was achieved 
by substituting the tosylate group in 2 (Scheme I) with cesium thioacetate in DMF. Subsequently, the 
thioacetate group was transformed in three steps into the CH2S(0)CH2SMe side chain of sparsomycin 
(D·7 
In the present case, reaction of the tosylate 2 with 4-mercaptophenol in dry DMF using ЕізК as a 
base afforded compound 3a in 41% yield. During this reaction, despite of working carefully in an argon 
atmosphere, a considerable amount of the disulfide of 4-mercaptophenol was formed, lowering the yield 
of the reaction. We anticipated problems from the phenolic residue in the direct oxidation of 3a. 
Therefore the hydroxyl group was protected by means of a rerf-butyldimethylsilyl group12 to give 3b in 
88% yield. Subsequent oxidation of 3b with mCPBA13 afforded a mixture of the diastereomers 4b and 
5b in 71% yield. Separation on silica gel (eluent Et20) gave approximately equal amounts of the two 
compounds. 
The next step in the reaction sequence concerned the amide coupling with 6-methyluracilacrylic 
acid. Up to now we employed the isobutyl chloroformate mixed anhydride method.14 However, this 
reaction suffers a serious drawback, since the yield ranges usually between 30 and 40%. A more 
efficient coupling reaction makes use of the pentafluorophenyl (Pfp) ester 6. This mode of activation 
furnishes a higher yield in the amide coupling and allows for an easier work-up procedure in 
comparison with the mixed anhydride method. The ester 6 was easily prepared from 6-methyluracil­
acrylic acid and pentafluorophenol by reaction with DCC in DMF in quantitative yield.15 
The N-Boc protecting group in 4b and 5b was removed by reaction with TFA for 20 min at 0 0 C. 1 4 
The excess TFA was evaporated in vacuo, the residue was dissolved in DMF, and the solution was 
neutralized by the addition of Et^N. After the addition of one equivalent of Et-jN and of the Pfp ester 6, 
the reaction mixture was stirred in the dark at room temperature for 16 h. Work-up of the reaction 
mixtures gave the corresponding sparsomycin derivatives 7 and 8 in 70% and 76% overall yield, 
respectively. This coupling procedure thus increases the yields in the synthesis of sparsomycin 
analogues by a factor two in comparison with the mixed anhydride method. 
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Chiroptical Properties. We have shown earlier that the configuration of the sulfoxide group as 
depicted for sparsomycin (1) is crucial for the biological activity of the drug.10 In order to establish the 
absolute configuration of the sulfoxide group in the sparsomycin analogues 7 and 8, we recorded the 
circular dichroism (CD) spectra of the precursors of these compounds, viz. the sulfoxides 4b and 5b.16 
We have observed a correlation between the sign of the Cotton effect in the region between 210 and 
230 nm and the absolute configuration of the sulfoxide function: a negative sign correlates with the R 
configuration of the sulfoxide sulfur atom.17,18 
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The CD spectra of 4b and 5b are depicted in Figure I; from the sign of the Cotton effect in the 
210-230 nm region we assigned the absolute configurations as indicated. This assignment is supported 
by the biological activity of the end-product 7, derived from 4b, which has the "natural" ScRs 
configuration. 
The second Cotton effect in the region between 250 and 260 nm in the CD spectra of 4b and Sb 
must be due to the phenyl ether chromophore. Its sign, opposite to that in the 210-230 nm region, is 
apparently also indicative of the absolute configuration at sulfur. 
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Biological Activity. The results on the biological activity tests of compounds 7 and 8 are shown in 
Table I. The phenol derivative 7 is more or less equally active as sparsomycin in the peptide bond 
formation assays, but its antitumor activity is considerably lower than that of 1. The 5-epimer 8 is rather 
inactive in all tests. It is interesting to see that compound 7 has a high affinity for the ribosome, but is 
much less active than 1 against intact leukemia cells. This suggests poor membrane permeability 
properties for the phenol derivative. 
The low antitumor activity observed for 7 does not warrant any in vivo activity. However, its high 
affinity for the ribosome opens the possibility to study the molecular interaction of sparsomycin with 
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the peptidyl transferase by affinity labeling. The radioiodination of 7 to give 9 as well as ribosome 
binding and competition studies with other antibiotics are in progress. The first results indicate that 9 
and probably also 7 and sparsomycin (1) itself do not bind covalently neither to free 70S ribosomes nor 
to polyphenylalanine synthesizing 70S ribosomes. The drug also does not bind irreversibly to the 
growing peptide chain. These preliminary results point to a non-covalent interaction of 9 with the 
peptidyl transferase; a finding that contradicts with the Flynn hypothesis. 
Table I. Inhibition of Peptide Bond Formation and (Tumor) Cell Growth 
R1 
Me 
О H 
o^A H 
H 
о 
II 
S 
compd 
1 
7 
8 
R1 R2 
CH2OH CH2SMe 
Me C6H4-4-OH 
Me C6H4-4-OH 
polyPhe 
synthesis 
E. coli 
Εϋ5ο,μΜ 
8.5 
2.4 
500(3%)a 
S. eer 
5.2 
27 
ina«0 
Puromycin 
reaction 
E. coli 
ΕΟ^,μΜ 
0.10 
0.23 
25 
Growth 
inhibition 
E. coli 
ΕΟ50>μΜ 
11 
3.0 
100(20%)a 
Colony 
formation 
L1210 
ΙΌ50,μΜ 
0.47 
2.4(0.3)b 
142(48.5)b 
"The numbers in parentheses indicate the percentage of inhibition at the given highest 
concentration tested. bThe numbers in parentheses indicate ID 1 0 values.
 cNo inhibition at 
500 μΜ was observed. For assay conditions see reference 10 and 11. 
EXPERIMENTAL SECTION 
Synthesis. Melting points (mp) were determined on a Reichert hot stage and are uncorrected. Ή 
NMR spectra were measured on a Bruker WH-90 spectrometer with Me4Si as an internal standard. For 
determination of the specific rotation ([a]20D) a Perkin-Elmer 241 Polarimeter was used. Mass spectra 
(MS, m/z, relative intensity) were recorded on a double-focussing VG 7070E mass spectrometer, for 
FAB MS, glycerol was used. Circular dichroism (CD) spectra were recorded on an Autodichrograph 
Mark V apparatus (Jobin Yvon). Thin-layer chromatography (TLC) was carried out by using Merck 
precoated F-254 plates (thickness 0.25 mm). Spots were visualized with a UV lamp, ninhydrin or 
CI2-TDM.19 For column chromatography Merck silica gel Η (type 60) was used. For gel filtration 
Merck Fractogel TSK HW-40(F) was used. 
7V-(/ert-ButyIoxycarbonyl)-l-[(4-hydroxyphenyl)thio]-2-amino-propane (3a). This compound 
was prepared in the following way. To a solution of the tosylate 27 (3.8 g, 11.5 mmol) in 50 mL of dry 
DMF was added Et3N (1.15 g, 11 mmol) and 4-mercaptophenol (1.8 g, 14 mmol). The reaction mixture 
was kept under an argon atmosphere and was stirred at room temperature for 4 days. A considerable 
amount of the disulfide of 4-mercaptophenol was formed and consequently some of 2 remained 
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unreacted. The solvent was removed in vacuo and the residue was partitioned between CHjC^ and 
water. The organic layer was separated and subsequently extracted with an aqueous 10% Na2C03 
solution, water and a saturated aqueous NaCl solution. After separating the organic layer and drying 
(N32804), the solution was concentrated in vacuo and the crude product was purified by column 
chromatography on silica gel (eluent МеОН/СН2СІ2, 2:98) to afford 1.32 g (41%) of the desired 
compound: TLC Rf 0.47 (eluent MeOH/CHClj, 7:93); λΗ NMR (CDCI3) δ 1.16 (d, J=6 Hz, 3H, 
CHCH3), 1.36 (s, 9 H, /-Bu), 2.88 (d, J=6 Hz, 2H, CHCH2), 3.78 (septet, J=6 Hz, IH, CH), 4.73 (br d, 
J=8 Hz, IH, NH), 6.74 and 7.25 (ABq, JA B=8 Hz, 4H, Ph-H), 7.63-7.94 (br s, 1, OH). CI MS, exact 
mass caled for C ^ J N O J S , miz 284.1287 (M+H). Found: 284.1283; miz 284 (6%), 228 (24%, 
CuH^NOjS), 184 (21%, C9H14NOS), 167 (100%, СцНцОЗ), 57 (43%, QH,,); [a]20D +45° (c 0.1, 
MeOH). 
0-(/eri-ButyIdimethylsilyl)-N-[(teri-butyloxycarbonyl)-l-[(4-hydroxyphenyl)thio]-2-ainino-
propane (3b). To a solution of За (1.1 g, 3.89 mmol) in 15 mL of dry DMF was added imidazole (0.66 
g, 9.71 mmol) and »-ВиМегЗіСІ (0.7 g, 4.65 mmol).12 The reaction mixture was stirred overnight at 
room temperature. After removal of the solvent in vacuo, the residue was partitioned between CH2CI2 
and water. The organic layer was separated and subsequently extracted twice with water, dried 
(N32804) and concentrated in vacuo to yield the pure product in 88% yield: TLC Rf 0.79 (eluent 
MeOH/CHCk 7:93); •H NMR (CDCI3) δ 0.16 (s, 6 H, Si(CH3)2), 0.96 (s, 9H, Si-r-Bu), 1.18 (d, J=7 
Hz, 3 H, CHCH3), 1.40 (s, 9 H, O-f-Bu), 2.74-3.14 (AB part of ÂBX spectrum, 8 Unes, 2H, CHCH,), 
3.65-4.02 (m, 1 H, CH), 4.60 (br d, J=8 Hz, Ш, NH), 6.74 and 7.29 (ABq, JA B=8 Hz, 4H, Ph-H). CI 
MS, exact mass caled for ( ^ ^ О з 8 8 і , miz 397.2107 (M). Found: 397.2106; miz 397 (29%), 342 
(8%, C16H28N03SSi), 298 (14%, C^HjgNOSSi), 57 (100%, QH,,). 
CScÄs) and (ScSs) ^-[(terí-ButyloxycarbonyI)-0-(tert-butyldimethylsilyI)-l-[(4-hydroxy-
phenyl)suirinyl]-2-amino-propane (4b and 5b).16 These compounds were prepared in approximately 
equal amounts (71% combined yields) by oxidation of 3b (1.15 g, 2.9 mmol) in 20 mL of CH2C12 with 
mCPBA (825 mg, 4.78 mmol) at 0 0C for 10 min.13 The two diastereomers were separated by column 
chromatography on silica gel using Et20 as the eluent, The ScÄs diastereomer could be crystallized 
from и-hexane. TLC Rf 0.32 (4b, ScRs) and 0.20 (5b, ScSs) (eluent Et20). 
For the ScRs compound 4b: mp 95-97 0C. 'H NMR (CDCI3) δ 0.21 (s, 6H, 5і(СНз)2), 0.99 (s, 9Н, 
Si-í-Bu), 1.41 (d, J=6 Hz, 3H, CHCH3), 1.44 (s, 9H, O-f-Bu), 2.91 (d, J=5.4 Hz, 2H, CHCH2), 4.14 (septet, J=6.6 Hz, IH, CH), 5.22-5.64 (br s, IH, NH), 6.96 and 7.52 (ABq, JAB=8.7 Hz, 4H, Ph-H). CI 
MS exact mass caled for C20H36NO4 SSi, miz 414.213 (M+H). Found: 414.212; miz 414 (34%), 358 (100%, C16H28N04SSi), 314 (88%, С.зН^ОгЗЗі), 57 (55%, C4HÛ); [a]2()D +78.2° (c 0.11, MeOH). 
Anal. Caled for C20H35NO4SSÍ: С, 58.07; H, 8.53; Ν, 3.39. Found: С, 58.27; Η, 8.61; Ν, 3.41. CD 
spectrum (MeCN): at 215 mm a single negative (де -1.73) and at 255 nm a single positive (де +1.64) 
Cotton effect was observed. 
For the ScSs compound 5b: Ή NMR (CDCI3) δ 0.21 (s, 6H, 8і(СНз)2), 0.99 (s, 9Н, Si-t-Bu), 1.32 (d, J=6.9 Hz, 3H, CHCH3), 1.43 (s, 9H, O-t-Bu), 2.77-3.16 (AB Part of ABX spectrum, 8 lines, 2H, 
CHCHj), 3.99 (quintet, J=6.6 Hz, IH, CH), 4.81 (br d, IH, NH), 6.96 and 7.57 (ABq, 1^= 8.7 Hz, 4H, 
Ph-H). CI MS, exact mass caled for С2оНз6Ж)485і, miz 414.213 (M+H). Found: 414.212; miz 414 (62%), 358 (88%, C16H28N04SSi), 314 (92%, C15H28N02SSi), 57 (66%, QH,,); [a]20D -48.6° (c 0.105, 
MeOH). CD spectrum (MeCN): at 217 nm a single positive (де +1.68) and at 254 nm a single negative 
(де -1.76) Cotton effect was observed. 
Pentafluorophenyl (E)-ß-(6-methyl-5-iiracilyl)acryIate (6). This ester was prepared in 
quantitative yield from the corresponding acid (392 mg, 2 mmol) and pentafluorophenol (386 mg, 2.1 
mmol) in dry DMF at room temperature using DCC (433 mg, 2.1 mmol) as the coupling reagent. The 
yellowish solid was purified by washing with diisopropyl ether TLC Rf 0.62 (eluent МеОН/СНСЦ, 
1:4); 1П NMR (DMSO-d6) δ 2.37 (s, ЗН, С(б)-СНз), 7.26 and 7.72 (ABq, 1^=15.4 Hz, CH=CH), 7.96 (S, IH, ΜΗ), 11.5 (br s, IH, NH). FAB MS, miz 363 (47%, M+H, C^HgN^Fs), 179 (100%, 
C8H7N203). 
(ScRs) l-[(4-hydroxyphenyl)suIfinyl]-2-[(E)-ß-(6-methyl-5-uracilyl)acrylamido]-propane (7). 
This compound was prepared in 70% overall yield (250 mg) from 4b (390 mg, 0.94 mmol) in the 
following way. The N-Boc protecting group of 4b was removed by treatment with 10 mL of TFA for 30 
min at 0 0C. After evaporation of the excess TFA, stripping twice with EtOH and drying in vacuo, the 
amine was dissolved in 20 mL of dry DMF and the solution was neutralized with Et3N. Subsequently, 
Et3N (0.13 mL, 0.94 mmol) and the pentafluorophenyl ester 6 (410 mg, 1.13 mmol) were added and the 
Chapter 4.2 139 
reaction mixture was stirred in the dark for 18 h at room temperature. The hydroxy protecting group 
was removed by stirring the reaction mixture for another 5 min with (n-Bu^NF.12 After concentration 
in vacuo, gel filtration of the crude reaction product on Fractogel (eluent МеОНД^О, 1:1), 
lyophilization of the pooled fractions from HOAc and drying of the product in an exsiccator on KOH, 
the desired product was obtained: TLC Rf 0.36 (eluent MeOH/CHCl3, 1:4); 'H NMR (CD3OD) δ 1.38 (d, J=6.7 Hz, 3H, CHCHj), 2.41 (s, 3H, С(б)-СНз), 3.05 (d, J=1.5 Hz) and 3.12 (s, 2H, CHCH2), 
4.24-4.70 (m, IH, CH), 6.99 and 7.59 (ABq, JAB=8.6 Hz, 4H, Ph-H), 7.19 and 7.44 (ABq, ^ = 1 4 . 9 Hz, 
2H, CH=CH), FAB MS, m/z 378 (45%, M+H, C ^ H ^ O s S ) , 236 (56%, С ц Н ^ О з ) , 200 (66%, 
C9H14N02S), 179 (100%, C8H7N203), 141 (33%, C6H502S); [o]i0D +46.1° (c 0.115, DMF). 
(ScSs) l-[(4-hydroxyphenyl)suirinyl]-2-[(E)-ß-(6-methyl-5-uracilyI)acrylamido]-propane (8). 
This compound was prepared in 76% overall yield (250 mg) from 5b (365 mg, 0.88 mmol) according to 
the procedure used in the preparation of 7. TLC Rf 0.36 (eluent МеОН/СНСЦ, 1:4); Ή NMR (CD3OD) 
δ 1.33 (d, J=6.7 Hz, 3H, CHCH3), 2.39 (s, 3H, С(б)-СНз), 3.05 and 3.30 (AB part of ABX spectrum, 8 
lines, 1^=7.6 Hz, JBx=5.8 Hz, 1^=12.9 Hz, 2H, CHCH2), 4.02-4.45 (m, IH, CH), 6.99 and 7.62 (ABq, 1^=8.6 Hz, 4H, Ph-H), 7.18 and 7.42 (ABq, 1^=15.4 Hz, 2H, CH=CH), FAB MS, m/z 378 
(69%%, M+H, C17H20N3O5S), 236 (58%, С ц Н ^ О з ) , 200 (54%, α,Η1 4Ν028), 179 (100%, 
С8Н7М2Оз), 141 (31%, C6H502S); [a]20D +23.3° (с 0.12, DMF). 
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CHAPTER 4.3 
SYNTHESIS OF ARYL AZIDE ANALOGUES OF SPARSOMYCIN SUITABLE 
FOR RIBOSOME PHOTOAFFINITY LABELING STUDIES 
Analogues for photoaffinity labeling studies 
Me _ R 
1 0 H, 
O ^ N ^ O 
Η 
R=CH2OH 
R=Me 
Conclusions: 
-the photoprobes drawn above can be prepared 
-they do interact with the peptidyl transferase, 
but less effectively than sparsomycin itself 
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SUMMARY 
The synthesis is described of compounds 9-11, photoreactive aryl azide analogues of the antitumor 
antibiotic sparsomycín (1). The key step in the synthetic scheme followed is the reaction of the 
chloromethyl sulfoxides 2 and 3 with the properly protected cystamine 4 in liquid ammonia, to give the 
N-protected sparsomycín amines 5 and 6, respectively. Subsequently, the photoreactive groups, i.e. a 
4-azidosalicylyl and a 4-azido-2-nitrophenyl group, were coupled with these amines. Compounds 9-11 
are to be used as photoprobes in photoaffmity labeling studies on the interaction of 1 with the ribosomal 
peptidyl transferase center. The compounds were tested for their inhibition of peptide bond formation, 
cell growth inhibition and antitumor activity. They do interact with the ribosome, but less effectively 
than sparsomycin itself. 
INTRODUCTION 
Sparsomycin (I),1 a natural product isolated originally from the bacteria Streptomyces sparsogenes, 
shows a broad spectrum of biological activities. It is active against numerous prokaryotic and 
eukaryotic organisms and various types of tumors. The chemotherapeutic action of sparsomycin 
depends on the ability of the compound to bind to the ribosome and to inhitit protein synthesis. The 
reaction route allowing the first total synthesis in 1981 of this cytotoxic drug,2 opened the way to the 
synthesis of structural analogues of 1. Since then, structure-activity relationship studies led to the 
preparation of more potent and less toxic derivatives of sparsomycin.1·3 
OH 
Me
 n „ S О .. 
Г О H 
HN^Y^^^N-^-- 5 — ò - M e 
Ο ^ Ν Λ ) 
Η Sparsomycin, 1 
Our aim was to prepare photoreactive analogues of sparsomycin in order to study - by photoaffmity 
labeling4 - the interaction of 1 with its cellular target: i.e. the peptidyl transferase center located on the 
large ribosomal subunit. Photoaffmity labeling has proven to be a powerful technique for an 
unambiguous identification and characterization of the site of interaction between a specific drug and 
its receptor; it allows the study of reversible, noncovalent, as well as irreversible, covalent, interactions. 
The reactive nature of such photoreactive compounds allows for the generation of a highly reactive 
species that will covalently modify the site of interaction.4 
As the photoreactive group to be incorporated into 1 we chose the 4-azidosalicylyl as well as the 
4-azido-2-nitrophenyl group. Recently, the former group has been used successfully for the preparation 
of a photoaffinity analogue of ^-acetylgalactosamine5 and of clinically important chemotherapeutic 
drugs like methotrexate6 and vinblastine.7 The latter group has been used lately to synthesize 
photolabile derivatives of e.g. puromycin,8 insulin,9 acyl-CoA,10 and NAD+.11 
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Here, we report the synthesis of 9, 10 and 11, photoaffmity labeling derivatives of sparsomycin. 
These compounds - including their precursors - were tested for their biological activity. Their ability to 
inhibit protein synthesis was measured in the phenylalanine polymerization (polyPhe) assay and in the 
puromycin reaction. Growth inhibition of E. coli was evaluated in liquid medium. Their antitumor 
activity was tested by measuring the inhibition of colony formation of murine leukemia L1210 cells in 
soft agar. 
RESULTS AND DISCUSSION 
Chemistry. Our strategy towards the synthesis of the photoreactive derivatives of 1 is depicted in 
Scheme I. We decided to incorporate the azidophenyl groups in the sulfur-containing side chain of 1 as 
we had demonstrated earlier that modification of this region does not alter the drug's ability to inhibit 
protein synthesis significantly.3,12 We envisaged that the ethylamine moiety of cysteamine 
(2-ammoethanethiol) might serve as a link between sparsomycin and the photoactive aryl azide groups. 
Introduction of this link might be achieved starting with the a-chloro sulfoxides 2 or 3. This approach 
was found to be viable. 
The synthesis of 9-11 started from the chloromethyl sulfoxides 2 and 3, the synthesis of which we 
have reported earlier.3·12 These compounds were allowed to react with two equivalents of N-Boc 
protected sodium 2-aminoethanethiolate in liquid ammonia. The thiolate was prepared in situ by 
reduction of the N-protected cystamine 4 with two equivalents of sodium in liquid ammonia. Compound 
4 was prepared easily in 96% yield by reaction of cystamine dihydrochloride with di-rerf-butyl 
pyrocarbonate in 1,4-dioxane/water (1:1) using Et3N as a base. The monoxodithioacetals 5 and 6 were 
thus obtained in 66% and 81% overall yield, respectively. 
For the substitution reaction ammonia was used as the solvent, as we had observed previously13 
that it is the solvent of choice for this type of substitution reaction, in particular for substrates that are 
poorly soluble in less polar solvents. 
The N-Boc protecting group of 5 and 6 was removed by treatment with neat TFA for 20 min at 0 "C 
to yield the trifluoroacetates of 7 and 8, respectively. Coupling of these amines 7 and 8 with p-azido-
salicylic acid was effected by means of its У -hydroxysuccinimide ester (NHS-ASA). These reactions 
were carried out under exclusion of light to give 9 and 10 in 76% and 91% yield, respectively. 
Compound 11 was prepared analogously in 35% overall yield by reaction of the amine 8 with 
4-azido-2-nitrophenyl fluoride (ANPF). 
Biological Activity. The inhibitory activity of the photoprobes 9-11 and their synthetic precursors 
2, 3, 5 and б was evaluated in four in vitro assays. Peptidyl transferase activity was tested in the 
polyPhe synthesis assay,3 using ribosomes of E. coli от S. cerevisiae, and in the puromycin reaction,3 
using ribosomes of E. coli. The growth inhibition of intact E. coli cells was investigated in liquid 
medium3 and antitumor activity was assessed in the L1210 murine leukemia clonogenic assay.14 The 
biological activity data are presented in Table I. The following conclusions can be drawn. 
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NHS-ASA: N-Hydroxysuccinimidyl-p-azidosalicylic acid 
ANPF: 4-Azido-2-nitrophenyl fluoride 
The photoaffinity analogues show no activity against intact cells. However, in the protein synthesis 
inhibition assays inhibition of the peptidyl transferase reaction was observed, although up to a level 
tenfold less than the unmodified antibiotic. The lower affinity for the ribosome of these photoprobes in 
comparison with sparsomycin, does allow, however, to study the interaction of these photoaffinity 
analogues with the ribosome. The binding and photoaffinity labeling studies of the analogues 9-11 are 
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currently in progress and are the subject of a future report. 
Table I. Biological Activity Data" 
compd 
1 
2 
3 
5 
6 
9 
10 
11 
PolyPhe syn 
E. coli 
ΕΟ50,μΜ 
8.5 
450 
86 
80 
350 
82 
100 
18 
thesis 
5. cerev. 
5.2 
220 
1000 
51 
500(40%) 
8 
28 
18 
Puromycin 
reaction 
E. coli 
ΕΟ50,μΜ 
0.10 
0.65 
6.6 
0.81 
1.7 
0.70 
1.1 
5.8 
Growth 
inhibition 
E. coli 
ΕΟ50,μΜ 
11 
20 
7.5 
85 
100 
100(14%) 
100(18%) 
inactive 
Colony 
formation 
L1210 
ΙΟίο,μΜ 
0.47 
0.29 
0.15 
1.75(0.2) 
>2.2(0.8) 
> 1.9(0.9) 
>1.9(1.3) 
1.7(0.7) 
"The values in parentheses indicate the percentage of inhibition at the indicated 
highest concentration tested (growth inhibition assay) or the ID 1 0 values (L1210 
assay). Drugs that show no inhibition at the highest concentration tested, i.e. 100 
μΜ, are considered inactive. 
EXPERIMENTAL SECTION 
Synthesis. 'H NMR spectra were measured on a Bruker WH-90 or WM-200 spectrometer with 
Me4Si as an internal standard. Mass spectra (MS, m/z, relative intensity) were recorded on a double 
focussing VG 7070E mass spectrometer; for FAB MS, glycerol was used unless indicated. IR spectra 
were taken on a Perkin-Elmer 257 grating spectrometer. UV spectra were measured on a Perkin-Elmer 
555 spectrophotometer. Thin-layer chromatography (TLC) was carried out on Merck precoated F-254 
plates (thickness 0.25mm). Spots were visualized with a UV lamp, ninhydrin or CI2-TDM.15 For 
determination of the specific rotation ([a]20D) а Perkin Elmer 241 Polarimeter was used. Gel filtration 
was carried out on Fractogel TSK HW-40(F). NHS-ASA and ANPF were purchased from Pierce 
Chemical Co. (Rockford, IL, USA). 
(ScRs) l-[[(ß-^-/er/-Butyloxycarbonyl)aminoethyl]thiomethyl]suinnyl-2-[(E)-ß-(6-methyl-
5-urac¡lyl)acryIamido]-propanol (5). This compound was prepared in the dark in the following way. 
A/^ V-di-Boc-cystamine 4 (375 mg, 1.06 mmol) was reduced in 15 mL of liquid NH3 with 2 equiv. of 
sodium under an argon atmosphere analogously to the procedure described earlier.3 After evaporation 
of the ammonia, compound 2 (372 mg, 1.06 mmol) (TLC Rf 0.21; eluent МеОН/СНСІз, 1:4) was 
introduced into the reaction vessel, in which again ammonia (15 mL) was condensed. After stirring the 
reaction mixture for 45 min at -35 0C the ammonia was evaporated with a stream of argon. The crude 
reaction product was dissolved in water-methanol and the solution was neutralized with a IN HCl 
solution. Purification was done by gelfiltration on Fractogel (eluent MeOH/H20, 1:1) to give the pure 
product in 66% overall yield: TLC Rf 0.34 (eluent MeOH/CHCl·,, 1:4); Ή NMR (CD3OD) δ 1.51 (s, 
9H, f-Bu), 2.44 (s, ЗН, С(б)-СНз), 2.92 (t, J=6.6 Hz, 2H, SCH2CH2), 3.08-3.63 (m, 4H, CHCH2S(0), 
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SCH2CH2), 3.81 (d, J=5.3 Hz, 2H, CHjOH), 4.02 and 4.15 (ABq, JAB=13.9 Hz, 2H, S(0)CH2S), 
4.33-4.75 (m, IH, CH), 7.28 and 7.50 (ABq, 1^=15.1 Hz, 2H, CH=CH). FAB MS, m/z491 (2%, M+H, 
С
І 9 Нз^ 4 0 7 5 2 ) , 391 (14%, C14H23N405S2), 302 (8%, СцНі^зОзЗ), 179 (44%, C8H7N203), 90 (100%, CjHgNS); [a]20D +51.3° (c 0.16, MeOWH20, 1:1). 
(ScRs) l-[[(P-A'-iert-Butyloxycarbonyl)aminoethyl]thiomethyl]suirinyI-2-[(E).ß-(6-methyl-
5-uracilyl)acrylamido]-propane (6). This compound was synthesized in 81% overall yield 
analogously to the preparation of 5 starting from 4'° (352 mg, 1 mmol) and 3 (334 mg, 1 mmol) (TLC 
Rf 0.47; eluent MeOH/CHCL, 1:1): TLC Rf 0.58 (eluent MeOH/CHCl·,, 1:4); 'H NMR (CD3OD) δ 
1.42 (d, J=6.9 Hz, 3H, CHCHj), 1.46 (s, 9Н, í-Bu), 2.38 (s, ЗН, С(б)-СНз), 2.87 (t, J=6.6 Hz, 2H, 
SCH2CH2), 2.93-3.35 (m, 4H, CHCH2S(0), SCHjCH^, 3.89 and 4.09 (ABq, J A B=13.9 Hz, 2H, 
S(0)CH2S), 4.35-4.75 (m, IH, CH), 7.24 and 7.47 (ABq, 1^=15.3 Hz, 2H, CH=CH), FAB MS, miz 
475 (8%, M+H, Сі 9 Нз^ 4 0 6 5 2 ) , 375 (12%, C ^ H ^ N ^ S ^ , 286 (6%, С ц Н ^ О ^ ) , 179 (37%, 
C8H7N203), 90 (100%, CjHgNS); [a]20D +84.2° (c 0.165, MeOH/H20, 1:1). 
(ScÄs) l-[[ß-(p-azidosalicylamido)ethyl]thiomethyl]suirinyl-2-[(E)-ß-(6-methyl-5-uracilyl)-
acrylamidol-ргорапоі (9). This compound was prepared in the dark as follows. The Boc protecting 
group of 5 (200 mg, 0.41 mmol) was removed by reaction with TFA for 20 min at 0 0C. 2 The reaction 
mixture was concentrated to dryness, the residue was dissolved in 5 mL of DMF, and the solution was 
neutralized with Et3N. Subsequently, Et3N (6.25 μι, 0.45 mmol) and N-hydroxysuccinimidyl-p-azido-
salicylic acid (NHS-ASA, 122 mg. 0.45 mmol) were added at 0 0C. The reaction mixture was stirred 
overnight at room temperature. After concentrating the reaction mixture to dryness in vacuo, the residue 
was partitioned between n-BuOH/EtOAc (1:1) and H 20. The organic layer was separated and extracted 
twice with a saturated aqueous NaCl solution. After separation of the organic layer and removal of the 
organic solvents, the solid remainder was washed several times with n-hexane and MeCN yielding 172 
mg (76%) of a slightly brownish powder: TLC Rf 0.25 (eluent MeOH/CHCl·,, 1:4); Ή NMR (200 
MHz, DMSO-d6) δ 2.24 (s, ЗН, С(6)-СНз)> 2.87-3.00 (m, 4Н, CHCHjSíO), SCH2CH2), 3.46-3.52 (m, 
2H, SCH2CH2), 3.91 and 4.08 (ABq, 1^=13.86 Hz, 2H, S(0)CH2S), 4.15-4.30 (m, IH, CH), 6.51 (br s, 
IH, C(3,)-H), 6.56 (br s, IH, C(5')-H), 7.06 and 7.21 (ABq, 1^=15.26 Hz, 2H, CH=CH), 7.83 (d, 
j ^ ^ g ^ Hz, IH, (C(6')-H), 8.28 (d, J=7.63 Hz, IH, NH); [a]26D+40° (c 0.17, DMF/MeOH, 1:1). IR 
(KBr) 2120 (Nj), 1715, 1670 and 1645 (C=0), 1600 (Ph), 1025 (S=0) cm1. FAB MS, miz 552 (4%, 
M+H, C21H26N707S2), 179 (18%, C8H7N203), 162 (19%, С7Н4Ыз02), 147 (100%, C7H4N202), 136 (37%, C7H6N02). 
(ScÄs) l-[[ß-(p-azidosalicylamido)ethyl]thiomethyl]suinnyl-2-[(E)-ß-(6-methyl-5-uracilyl)-
acrylamidoj-propane (10). This compound was synthesized in 91% yield as a sligthly brownish 
powder analogously to the preparation of 9 starting from 6 (220 mg, 0.46 mmol) and NHS-ASA (139 
mg, 0.51 mmol): TLC Rf 0.50 (eluent MeOH/CHClj, 1:4); Ή NMR (200 MHz, DMSO-d6) δ 1.22 (d, 
J=6.68 Hz, 3H, CHCH3), 2.25 (s, ЗН, С(б)-СНз), 2.84 and 3.02 (AB part of ABX spectrum, 8 lines, 
1^=9.45 Hz, JBx=4.72 Hz, 1^=13.15 Hz, 2H, CHCH2S(0)), 2.92 (t, J=7.12 Hz, 2H, SCH2CH2), 
3.40-3.60 (m, 2H, SCH2CH2), 3.90 and 4.09 (ABq, 1^=13.82 Hz, 2H, S(0)CH2S), 4.17-4.40 (m, IH, 
CH), 6.59 (d, IH, J
meta=2.21 Hz, C(3')-H), 6.66 (dd, ima=2.2\ Hz, Jortho=8.53 Hz, IH, C(5,)-H), 7.06 
and 7.21 (ABq, JAB=15.32 Hz, 2H, CH=CH), 7.88 (d, Jgrtho=8.53 Hz, IH, C(6')-H), 8.25 (d, J=7.96 Hz, 
IH, NH), 9.03 (br t, IH, NH), 11.22 (br s, 2H, 2x NH); Ή NMR (200 MHz, DMF-d7) δ 1.30 (d, J=6.64 
Hz, 3H, CHCH3), 2.35 (s, 3H, C(6)-CH3), 2.89 and 3.24 (AB part of ABX spectrum, 8 lines, JAX=9.67 
Hz, JBx=4.17 Hz, JAB=12.98 Hz, 2H, CHCH2S(0)), 3.01 (t, J=6.60 Hz, 2H, SCH2CH2), 3.50-3.75 (8 
lines, J=7.0 Hz, 2H, SCH2CH2), 3.98 and 4.13 (ABq, 1^=13.80 Hz, 2H, S(0)CH2S), 4.42-4.56 (m, IH, 
CH), 6.45 (dd, J
ortho=8.44Hz, Jmeta=2.21 Hz, IH, C(5,)-H), 6.52 (d, J=2.21 Hz, IH, C(3')-H), 7.18 and 
7.40 (ABq, JAB=15.32 Hz, 2H, CH=CH), 7.96 (d, JOTlho=8.44 Hz, IH, C(6')-H), 8.54 (d, J=7.83 Hz, IH, 
NH); [a]2eD +54° (c 0.12, DMF/MeOH, 1:1). IR (KBr) 2120 (N3), 1710 and 1650 (C=0), 1600 (Ph), 
1025 (S=0) cm 1 . UV (DMF/MeOH, 1:1) X
max
 256 nm. FAB" MS, miz 534 (2%, M-H, C2,H2 4N706S2); 
FAB+ MS, miz 558 (M+Na), 179 (62%, C8H7N203), 162 (78%, С 7 Н 4 ^ 0 2 ) , 136 (78%, C7H6N02). 
(ScÄs) l-[[ß.(4'-azido-2'-nitrophenyIamino)ethyl]thiomethyl]sulfinyl-2-[(E)-ß-(6-methyI-
5-uracilyl)acrylamido]-propane (11). This compound was prepared in the dark in the following way. 
To a solution of the У -deprotected amine 8 (0.2 mmol) (see the preparation of 9) in 5 mL of DMF was 
added 4-fluoro-3-nitrophenyl azide (ANPF, 37 mg, 0.2 mmol) and 1 equiv. of Et3N. The reaction 
mixture was stirred for 48 h at 40 0C. After evaporation of the solvent in vacuo, the residue was 
partitioned between n-Bu0H/CH2Cl2 (1:1) and H20. The organic layer was separated, washed with a 
saturated NaCl solution and concentrated and the solid remainder was washed several times with 
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MeCN to give an orange coloured powder in 35% yield. TLC Rf 0.59 (eluent MeOH/CHCl·,, 1:4); λΗ 
NMR (DMSO-d6) δ 1.22 (d, J=6.63 Hz, ЗН, СНСН3), 2.23 (s, ЗН, С(б)-СНз), 2.83 (dd, J ^ or 
JBX=4.62 Hz, JAB=13.05 Hz, IH, CHCHHS(O)), 2.92-3.06 (m, ЗН, CHCHHS(O), SCH2CH2), 
3.53-3.72 (m, 2H, SCH2CH2), 3.93 and 4.11 (ABq, JAB=14.06 Hz, 2H, S(0)CH2S), 4.20-4.38 (m, IH, 
CH), 7.02 and 7.19 (ABq, JAB=15.26 Hz, 2H, CH=CH), 7.19 (d, Jortho=9.94 Hz, IH, C(6,)-H), 7.32 (dd, 
Jortho=9· 9 4 H z - Jmet
a
=2.61 Hz, I H , C(5 , )-H) 7.70 (d, J
m e l a = 2 . 6 1 Hz, I H , С О ^ - Н ) , 8.18 (d, J=8.03 Hz, 
IH, NH), 8.33 (t, J=5.82 Hz, IH, NH); [a]20D +36° (c 0.05, DMSO). IR (KBr) 2110 and 2130 (N3), 
1710 and 1665 (C=0), 1605 (Ph), 1520 and 1350 (N02), 1030 (S=0), 810 (Ph) cm"1. FAB MS (HOAc/DMSO), m/z 537 (M+H, C^H^NgOéS;,), 286 (С11Н16Кз045), 252 (C9H10N5O2S), 179 (С8Н7М20з). 
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CHAPTER 5 
CHIRAL ECONOMY IN THE SYNTHESIS OF SPARSOMYCIN 
Reduction-oxidation-separation sequence 
R1 
t 
H 
BocN 
H 
(/) 2-phenylene phosphochloridite, (ii) mCPBA 
\ R2 
Conclusions: 
-recycling of highly functionalized, optically active sulfoxides 
is effected via a sequence of reduction-oxidation-separation steps 
-the procedure increases the efficiency of the total synthesis 
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OTTENHEIJM1: "A convenient reduction-oxidation procedure for the partial epimerization of highly 
functionalized, optically active sulfoxides". Submitted to The Journal of Organic Chemistry 
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SUMMARY 
A convenient method is described for the selective epimerization at sulfur of highly functionalized, 
optically active sulfoxides. The approach followed involves a sulfoxide reduction (with 2-phenylene 
phosphochloridite) - oxidation (with m-chloroperoxybenzoic acid) - separation of diastereomers 
sequence of steps. It was applied for the conversion of 3a, 3b and 3c into 2a, 2b and 2c, respectively, 
key intermediates in the total synthesis of sparsomycin and derivatives. Overall yields range from 26% 
to 37%. 
INTRODUCTIO\ 
Sparsomycin (la),2 a bacterial metabolite, is a broad-spectrum antibiotic which shows auspicious 
antitumor activity. Structure-activity relationship studies2,3 furnished analogues showing higher 
cytostatic activity and lower toxicity than la. The analogues showing this improved therapeutic index 
belong either to the class of the 5-alkyl sparsomycins - derivatives of la in which the S-methyl group 
has been replaced by more lipophilic S-alkyl substituents - or to the class of the deshydroxy 
sparsomycins lb. Our studies demonstrated unequivocally the importance of the absolute configuration 
at the chiral carbon atom and sulfur atom for la and lb to show antitumor activity.3 The analogues are 
presently evaluated in preclinical studies as antineoplastic drugs. Consequently, practical amounts of 
these analogues are needed. 
R1 О 
I/ 
S s 
s / ^ М е 
H la, R^CHjOH: sparsomycin (Scfls) 
lb, R^Me: deshydroxy-sparsomycin (ScRs) 
The key intermediates in the synthesis of the analogues are the sulfoxides 2a and 2b, prepared from 
D-cysteine4 and L-alanine,5 respectively (see Scheme I). In the approaches employed these sulfoxides 
2a and 2b are formed together with their diastereomeric counterparts 3a and 3b, respectively, from 
which they are separated by short column chromatography or crystallization. Our need for larger 
quantities of the proper diastereomers called for a facile method enabling us to convert 3a and 3b into 
2a and 2b, respectively. 
This selective epimerization of the sulfoxide group was realized indeed on a large scale. The 
sulfoxide 3c was also incorporated in this study. For 3a and 3c it was achieved in a four-step sequence 
involving protection of the hydroxyl function, reduction of the sulfoxide function followed by 
re-oxidation and finally deprotection of the hydroxyl group to give a mixture of 2a/3a and 2c/3c, 
respectively. For 3b the sequence of reactions comprises only the reduction and re-oxidation steps. 
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Some reactions deserve further comment. 
The hydroxyl function of 3a and 3c was protected with the tetrahydropyranyl (THP) group6 to give 
the corresponding O-protected derivatives 3d and 3e in 75% and 51% yield, respectively. For the 
reduction of the sulfoxide group the reagent of choice proved to be 2-phenylene phosphochloridite.7·8 
When the sulfoxides 3b, 3d and 3e were treated with this reagent in CH2CI2 for 15 min at room 
temperature the corresponding sulfides 4b, 4d and 4e were formed in 71%, 81% and 50% yield, 
respectively. 
Scheme I 
4b,d,e 
(a) R^CHjOH, К^СНгСІ; (b) R^Me, R2=CH2C1; (c) R^CHjOH, R2=C6H13 
(d) R1=CH2OTHP, R2=CH2C1; (e) R^CfyOTHP, R2=C6H13 
(0 2-phenylene phosphochloridite, (ii) mCPBA 
Oxidation of the sulfides 4b, 4d and 4e with m-chloroperoxybenzoic acid (mCPBA)9 in CH2CI2 for 
15 min at О "С afforded a nearly 1:1 mixture of the corresponding sulfoxides 2b/3b (94% yield), 2d/3d 
and 2e/3e, respectively. Removal of the THP protecting group was achieved subsequently in situ by 
addition of MeOH to the reaction mixture and raising the reaction temperature to 40 0C for 10 min to 
yield a mixture of 2a/3a (80% overall yield) and 2b/3b (80% overalll yield). Finally the diastereomers 
were separated by crystallization. The overall yields of the conversions 3a-3d-4d-2d/3d-2a/3a-2a and 
3b-4b-2b/3b-2b amounted to 26% and 37%, respectively, where the maximum yield is 50%. 
The described procedure proves to be a convenient method for the selective epimerization at sulfur 
of highly functionalized optically active sulfoxides. This procedure was applied successfully in the 
synthesis on a large scale of the antitumor drug sparsomycin and structural analogues thereof. 
EXPERIMENTAL SECTION 
lH NMR spectra were measured on a Bmker WH-90 spectrometer with Me4Si as an internal 
standard. Mass spectra (MS, m/z, relative intensity) were recorded on a double-focusing VG 7070E 
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standard. Mass spectra (MS, /n/z, relative intensity) were recorded on a double-focusing VG 7070E 
mass spectrometer, for FAB MS, glycerol was used. Thin-layer chromatography (TLC) was carried out 
on Merck precoated F-254 plates (thickness 0 25 mm). Spots were visualized with a UV lamp or 
CI2-TDM.1' For column chromatography, Merck silica gel H (type 60) was used. 
(ScRs) S-Oxo-5-chloromethyI-Af-(/er/-butyloxycarbonyl)-cysteinol (2a) (Small Scale). To a 
solution of 4d (275 mg) in 4 mL of СН2СІ2 at 0 0C was added 1 equiv. of mCPBA (175 mg) dissolved 
in 2 mL of CH2CI2. After stirring the reaction mixture for 15 mm at О 0C, a white precipitate was 
formed. Methanol was added to this mixture and the solution was heated for 10 mm at 40 0C. Then, the 
solution was concentrated in vacuo to yield a white solid. This crude reaction product was dissolved in 
CH2CI2 and washed with a saturated aqueous НаНСОз solution The organic layer was separated, dried 
(№2504) and concentrated in vacuo to dryness to yield the diastereomenc sulfoxides 2a/3a as a white 
solid in 80% yield (175 mg): TLC Rf 0.33 (За) and 0.29 (2a) (eluent MeOH/CHClj, 7:93). The desired 
compound 2a was obtained by crystallization from EtOAc in 40% yield. All physical data for 2a 
matched with those of authentic material.4 An overall yield of 26% over four reaction steps was 
calculated. 
In a similar fashion, 4e was converted into 2c in comparable overall yield. The physical data for 2c 
matched with those of authentic material.5 
(ScÄs) l-[(Chloromethyl)sulfinyI]-2-[(ter/-butyloxycarbonyl)aniino]-propane (2b) (Large 
Scale). To a soluuon of 3b (24.75 g, 96.9 mmol) and 15 mL of dry pyridine (194 mmol) in 200 mL of 
CH2CI2 at 0 0C was added 2-phenylene phosphochlondite (18.6 g, 106.6 mmol). The reaction mixture 
was stured for 15 mm at 0 0C. Water was added to the reaction mixture and after shaking and 
separation of the organic layer, this layer was extracted once with an aqueous 2M KHSO4 solution and 
twice with an aqueous 5% МаНСОз solution. The organic layer was separated, dned (N32804) and 
concentrated in vacuo to give 23 g (99% yield) of 4b. TLC Rf 0.79 (eluent MeOH/diisopropyl ether, 
1:9). 
To a solution of 4b (16 g, 66 8 mmol) in 350 mL of CH2CI2 at 0 0 C was added a solution of 
mCPBA (16.3 g, 73.5 mmol) in 50 mL of CH2CI2.9 After stirring for 15 min at 0 0C, a white precipitate 
was formed. After filtration of the solid, the solution was extracted twice with a saturated aqueous 
NaHCOj solution. Drying of the organic layer (Na2S04) and concentration in vacuo afforded 16 g (94% 
yield) of a mixture of the the sulfoxides 2b and 3b: TLC Rf 0.26 (eluent MeOH/dnsopropyl ether, 1:9). 
From this mixture, 6.8 g (40% yield) (37% overall yield based on 3b) of 2b was obtained by 
crystallization from EtOAc. All physical data for 2b matched with those of authentic material.5 
(ScSs) N-(tert-Butyloxycarbonyl)-0-(tetrahydropyranyl)-S-oxo-S-chloroinethyl-cysteinol (3d). 
Freshly distilled dihydropyran (2.52 g, 30 mmol) was added dropwise to a stirred solution of 3a (5.43 g, 
20 mmol) and p-toluenesulfonic acid monohydrate (0.76 g, 4 mmol) in 50 mL of anhydrous THF.6 The 
reaction mixture was stirred ovemight at room temperature. After completion of the reaction as judged 
by TLC (eluent EtOAc/hexane, 2:1), the solution was concentrated in vacuo to afford a white solid. 
This crude product was dissolved in EtOAc and the solution was washed with a saturated aqueous 
NaHC03 solution. The organic layer was dried (N32804) and concentrated in vacuo to dryness to yield 
the desired compound as a white solid in 75% yield: TLC Rf 0.20 (eluent EtOAc/hexane, 2-1), 'H NMR 
(CDCI3) δ 1.43 (s, 9H, í-Bu), 1.43-2.07 (m, 6H, ОСН2(СН2)з), 2.92-3.78 (m, 2Н, CHCHjStO)), 
3.78-4.30 (m, 5H, ОСЩСЩ, CtìCH20), 4.48-4.76 (m, IH, OC(H)O), 4 67 (s, 2Н, StOìCHjCl), 
5.04-5.56 (m, IH, NH). CI MS, m/z 356.1304; exact mass caled for C14H27N05SC1, 356.1298 (M+H); 
m/z 356 (14%), 272 (61%, C9H19N04SC1), 216 (100%, СзНцМ^СІ), 172 (72%, ^ Н ц Ж ^ С І ) , 85 (54%, С5ЩО), 57 (31%, QH)). 
(ScSs) W-(tert-Butyloxycarbonyl)-0-(tetrahydropyranyl)-S-oxo-S-n-tiexyl-cysteinol (3e). This 
compound (a yellow oil) was prepared in 51% yield analogously to the synthesis of 3d starting from 3c 
(1.06 g, 3.45 mmol): TLC Rf 0.50 (eluent MeOH/CHClj, 7:93); Ή NMR (CDCI3) δ 0.89 (br t, J=6 Hz, 
3H, CH2CH3), 1.13-2.24 (m, 14H, ОСН2(СН2)з, (СН2)4СНз), 1.42 (s, 9H, í-Bu), 2.60-3.18 (m, 4H, 
CHCH2S(0)CH2), 3.31-4.40 (m, 5H, OCH2CH2, CHCH20), 4.60 (br s, IH, OC(H)O), 5.02-5.60 (m, 
IH, NH). CI MS, m/z 392 (39%, M+H), 308 (62%, С14Нз0Ж>48), 252 (57%, C1oH22N04S), 208 (41%, 
C9H22N02S), 85 (100%, С5ЩО), 57 (50%, С^Щ). 
(S) l-[(Chloromethyl)thio]-2-[(ter/-butyloxycarbonyl)amino]-propane (4b). This compound (a 
colourless oil) was prepared m 71% yield similarly to the preparation of 4d starting from 3b (510 mg, 
2.0 mmol): TLC Rf 0.81 (eluent EtOAc/hexane, 1:1); Ή NMR (CDCI3) δ 1.17 (d, J=6 Hz, 3H, 
154 Chapter 5 
CHCH3), 1.36 (s, 9H, f-Bu), 2.79 (d, J=6 Hz, 2H, CHCH2S), 3.58-4.04 (m, IH, CHCH2S), 4.67 (s, 2H, 
SCH2C1), 4.59-4.86 (m, IH, NH). CI MS, m/ζ 240 (3%, M+H), 204 (14%, Ο,Η18Ν025), 148 (100%, 
C5H10NO2S), 104 (68%, C4H10NS), 57 (94%, C4H9); FAB MS, m/г 239 (9%, M), 204 (6%), 148 (41%), 
104 (100%). 
(5) iV-(íerí-Butyloxycarbonyl)-0-(tetrahydropyranyl)-5-chloromethyl-cyste¡nol (4d). То a 
solution of 3d (178 mg, 0.5 mmol) and dry pyridine (44 mg, 0.55 mmol) in 5 mL of СН2СІ2 at 0 0C was 
added 2-phenylene phosphochloridite (96 mg, 0.55 mmol).7 The reaction mixture was stirred at room 
temperature for 15 min. The solution was concentrated and the crude reaction product was dissolved in 
CH2C12. The organic layer was extracted with an aqueous IN NaOH solution, followed by one water 
wash. After separating the organic layer and drying (N32804), the solution was concentrated in vacuo to 
yield a yellow oil. The crude reaction product was subjected to column chromatography on silica gel 
(eluent EtOA^exane, 2:1) to give 275 mg (81% yield) of a colourless oil: TLC Rf 0.74 (eluent 
EtOAc/hexane, 1:1); Ή NMR (CDCI3) δ 1.38 (s, 9H, r-Bu), 1.30-1.94 (m, 6H, O C ^ O ^ j ) , 2.91 (d, 
J=6 Hz, 2H, CHCH2S), 3.27-4.08 (m, 5H, CHCH20, OCH2CH2), 4.41-4.62 (m, IH, ÒC(H)O), 4.72 (s, 
2H, SCH2C1), 4.84-5.30 (m, IH, NH). CI MS, m/z 340.1342; exact mass caled for C14H27N04SC1, 
340.1349 (M+H); m/z 340 (21%), 256 (45%, CgH^NOjSCl), 200 (41%, CjHuNOjSCl), 156 (16%, 
С4Ні^08С1), 85 (100%, С5Н90), 57 (89%, C4H9). 
(S) N-(terf-Butyloxycarboiiyl)-0-(tetrahydropyranyl)-S-n-hexyl-cysteinol (4e). This compound 
(a yellow oil) was prepared in 50% yield after column chromatographic purification on silica gel (eluent 
EtOAc/hexane, 1:9), analogously to the synthesis of 4d starting from 3e (650 mg, 1.66 mmol): TLC Rf 
0.17 (eluent EtOAc/hexane, 1:9); 'H NMR (CDCI3) δ 0.90 (br t, J=5.7 Hz, 3H, СН2СНз), 1.09-1.91 (m, 
14H, OCH2(CH2)3, (СН^СНз), 1.47 (s, 9Н, r-Bu), 2.58 (t, J=6.9 Hz, 2H, SCH2CH2), 2.74 (d, J=6.0 
Hz, 2H, CHCH2S), 3.29-4.09 (m, 5H, CHCH2O, OCHjCH^, 4.47-4.71 (m, IH, OC(H)O), 4.82-5.24 (m, IH, NH). CI MS, m/z 376.250; exact mass caled for C19H38N04S (M+H), 376.252; m/z 376 (7%), 
292 (19%, C^HjoNOaS), 236 (57%, С 1 0Н 2 2Шз8), 192 (24%, C9H22NOS), 85 (100%, C5H90). 57 (47%, C4H9). 
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CHAPTER 6 
THE TOTAL SYNTHESIS OF γ-GLUTAMYLMARASMINE USING THE SYNTHETIC 
METHODOLOGY DEVELOPED FOR SPARSOMYCIN 
Synthesis of γ-glutamylmarasmine 
HaN/,,,,, 
ScRcSs 
Conclusions: 
-γ-glutamylmarasmine could be prepared following the 
methodology developed for sparsomycin 
-the biological activity of this fungal metabolite is distinct 
from that of sparsomycin 
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Total Synthesis and Absolute Configuration of the Natural Dipeptide 
•y-Glutamylmarasmine 
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Harry C. J . Ottenhei jm* 
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The natural dipeptide γ-glutamylmarasmine (1) and its sulfoxide epimer 22 have been eynthesbed in optically 
active form starting from L-glutamic acid and L-cystine In a convergent approach, the amine 14 and the anhydride 
15 were synthesized and subsequently coupled by amide formation After separation of the epimene sulfoxides 
16 and 17 and subsequent removal of the amino and carboxvl protecting groups (—* 20 and 21), the chlorine atom 
was substituted by SMe by reaction with NaSMe in liquid ammonia to yield 1 and 22, respectively. By comparison 
of V and [a] values it was concluded that 1 is identical with γ-glutamylmarasmine The absolute configuration 
of 1 was determined by CD spectroscopy; the sign of the Cotton effect was employed in the absignment of the 
configuration of the sulfoxide sulfur atom. 7-Glutamylmarasmine was thus assigned the 3^ί
ε
8
Λ
 configuration. 
Introduct ion 
During the last 25 years, a large number of -y-glutamyl 
derivatives of amino acids and amines have been isolated 
from plants including mushrooms (Basidiomycetes). 1 
Among these are eighteen 7-glutamyl derivatives of sulfur 
or selenium containing non-protein amino acids. ' One of 
these is 7-glutamylmarasmine (1) an Ν-γ-L-glutamyl S-
subst i tuted L-cysteine derivative. 
This dipeptide has been isolated 2 from the Basidiomy-
ceteous mushrooms Marasmius alliaceus, M. scorodonius, 
and M. prasiosmus which are known for their garlic like 
odor. 3 In aqueous solution it gradually decomposes with 
the formation of the typical odor of the p a r e n t mush-
(1) Каваі, Τ; Ілгяеп, Ρ О In Fortschritte der Chemie organischer 
Naturstoffe; Hera, W , Gnsebech, H., Kirby, G. W , Eds., Spnnger Verlag-
New York, 1980, ρ 173 
(2) Gmelin, R, Luxa, H -H , Roth, К ; Hölle, G.. Phytochemistry 1»76, 
15, 1717 
(3) Michael, E , Hennig, В., Kreisel, Η Handbuch für Pilzfreunde, 6 
Bd., VEB Gustav Fischer Verlag Jena, 1975. 
rooms.2 This odor has been ascribed to products derived 
from the sulfenic acid МеЗСНгЗОН formed from 1 by an 
acid-catalyzed ^-elimination 4 reaction with concomitant 
formation of 7-glutamyldehydroalanine. In the mushroom 
itself a similar degradation takes place catalyzed by the 
fungal C-S lyase.2,5 However, this ^-elimination reaction 
takes place a t higher p H (8.5) and only after cleavage of 
the amide bond of 1 by 7-glutamyl transpeptidase 6 ' 7 This 
(4) Ostermayer, F , Tarbell, D S J Am.Chem Soc 1960. «2,3752 
(5) А С S lyase from the endosperm of seeds of Albizzia lophantha 
(Mtmoeaceae) also catalyzes the enzymp-mediated d-ehmmation reaction 
of 7-glutamylmaraemine. Both this C-S lyase and the C-S lyase (EC 
4.4 1 1 n) extracted from the mycelium and carpophores of M alliaceus 
and M scorodonius show a broad activity spectrum against different 
substrates (L-cysteme, S-alkyl- or aralkyl- and aryl-L cysteines, L-djenkohc 
acid, and the corresponding sulfoxides) affording HjS, RSH, СН
г
(ЗН)
г
, 
or RSS(0)R, respectively, together with pyruvic acid and ammonia 
(6) Turner, W В , Aldridge, D С Fungal metabolites II, Academic. 
New York, 1983, pp 468, 487 
(7)Meiater,A D., Tate, S S; Griffith, О. W Methods ЕпгутоІ 1981, 
77, 237 
© 1987 American Chemical Society 
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Scheme I 
' ; Y C " C 
Scheme III 
H A II 
13 
-ν-" 
Scheme II 
fg-^N-*- 5 
C-S lyase-induced ^-elimination reaction is characteristic 
for many S-substituted 7-glutamylcysteine compounds 8 
The presently accepted structure 1 of the title compound 
was proposed by R G mei in et al 2 on the basis of spec­
troscopic methods as well as chemical and enzymatic 
degradation studies The chirality of the two carbon atoms 
was shown to correspond to that of the L-amino acids 
However, the chirality of the sulfur atom was not deter­
mined 
There is a wealth of information showing that the bio­
logical activity of naturally occurring sulfoxides is de­
pendent upon the chirality of the sulfoxide function " 
(Θ) Noteworthy examplee are (epi)lentinic acid (ref 9) m Lentinus 
edodes, flhutake, the popular Japaneae edible mushroom, and Ύ gluta 
myl 5 (prop-l-enyl)cyBteine aulfoxidea in onion ІАІІшт сера) (геГ 10) 
Via consecutive transpeptidation and C-S lyase-mediated β elimination, 
these compounds give пае to the formation of pyruvic acid ammonia and 
various volatile sulfur compounds including lenthionine the major Па 
voring substance obtained from Lentmus edodes—and thiopropanal 
5 oxide, which is the lachrymatonc substance of οηιοηβ and other Allium 
species 
(9) Yasumoto, К, Iwami К Mitsuda Η Agrie Biol C/iem 1971 35, 
2059 Lentinic acid and epilentmic acid are supposed to be epimers that 
differ in chirality of one of the sulfoxide sulfur atoms Gmelin, R, 
N Galamulume Treves M Hofle G Phyioc/iemistry 1980 19. 553 
(10) Kuttan, H , Nair, N G , Radhakrishnan, A N , Spande, Τ F , 
Yeh H J , Witkop, В Biochemistry 1974 13, 4394 and references cited 
therein 
(11) There is a large number of naturally occurring sulfoxides for 
which the absolute configurations have been determined Particularly 
intriguing among these are toxins obtained from poisonous mushrooms 
of the genus ^ mamta, whereas the compounds of one sulfoxide confìgu 
ration, ι e A, are very lethal, the compounds of the opposite configu 
ration are inactive up to rather high dose levels (ref 12) Another class 
of naturally occurring sulfoxides, y glutamylcysteine sulfoxides, gives rise 
to a number of curious sulfur compounds that underlie the odor of garlic 
and the crying brought on by slicing an onion Investigations on the 
chemistry of garlic and the onion revealed (ref 13) that enzymes (alii 
nases) occurring in these plants preferentially act on (4-) 5 (trans 2 
propenyl) L cysteine sulfoxide d e , allnn) and (+)-S (frans 1 
propenyl) L cysteine sulfoxide d e lacnraatory precursor of onions), 
leaving the isomers with opposite chirality at the sulfur atom unreacled 
Another interesting occurrence of diastereomenc sulfoxides was observed 
in the 7 L glutamyl S (irons 1 propenyl) L cysteine sulfoxides from both 
Sandal (Santalum album L ) and onion {Allium сера) (ref 10) The 
sulfoiide sulfur atoms in the Sandal and onion metabolites have the R 
and 5 chirality respectively It is of interest that in Sandal no lacrunation 
was observed 
Therefore we decided to establish the absolute configu­
ration of the sulfoxide sulfur atom of γ-glutamylmarasmine 
by total synthesis of both diastereomers 
Strategy 
-y-Glutamylmarasmine (1) may be considered as a di-
peptide derived from L-glutamic acid (4) and the amine 
3, ι e , marasmine (Scheme I) The latter can be viewed 
as a derivative of L-cysteme (5) having the sulfhydryl 
function alkylated and oxidized The method of choice 
for coupling these two amino acids seems to be reaction 
of marasmine (3) with the properly N protected L-glutamic 
anhydride 2, which is known to react predominantly at the 
7-carbonyl function ' u For JV-protection we selected the 
phthaloyl group which can be removed by hydrazinolysis 15 
More challenging was the synthesis of marasmine (3) 
Its monoxodithioacetal moiety is acid labile and is also 
capable of undergoing thermal- or base-induced ^-elimi­
nation reactions (vide supra) 1 б 
Recently, in the course of a total synthesis of sparso-
mycin we developed an approach to the monoxodithio­
acetal moiety employing the reaction of an a-chloro sulf­
oxide derivative of cysteine with sodium methyl mercap-
tide ^ Here we report that this approach can also be 
employed for the synthesis of 1 (Scheme II) The key 
intermediate is the Ν,Ο-protected cysteine derivative 6 
Of ultimate importance is the selection of the protecting 
groups which had to meet the following requirements 
(12) Wieland Th, Úmee, Μ Ρ J de Indest H Faulslich H Liebigs 
Ann Chem 1974 1570 Buku, A , Altmann R W,eland Th Liebigs 
Ann Chem 1974 ;5Я0 
(13) SpAre С G, Virtanen A I Acta Chem Scand 1963, 17 641 
Virtanen A I Quai Piani Mater Veg 1969 18 8 Block E Sa Am 
1985, 94 
(14) In a large-scale synthesis of V* (1 hydroxycyclopropyl) L glut 
amine (coprine, 250 g) howe\er, a leaser amount of isocoprme ill g) was 
isolated See Lindberg, Ρ , Bergman, R Wickberg, В J Chem Soc 
Perkin Trans 1977 684 
(15) Houben Weyl Methoden der organischen Chemie, 15/1, Georg 
Thieme Verlag Stuttgart, 1974 
(16) The monoxodithioacetal moiety is rarely encountered in nature 
but has drawn attention recently because of its synthetic utility (ref 17) 
The only other natural products featuring this moiety are the antibiotics 
sparsomycin (ref 18-21), SE-3 (ref 6 and 22) a precursor of lenthionine, 
and N acetyl and djenkohc acid monosulfoxide (ref 41) 
(17) The dithioacetal monoxide is a masked carbonyl compound whose 
carbamon can serve as an асу] anion equivalent See Ogura, Κ, 
Tsuchihashl, С Tetrahedron Lett 1971, 3151 In addition their aci-
dolytic cleavage can be used to prepare unsymmetric disulfides See 
Kishi, Y , Fukuyama Τ , Nakatsuka, S J Am Chem Soc 1973,95 6490 
Zwanenburg В , Kielbasinski Ρ Tetrahedron 1979, 35 169 
(18) Ottenheijm Η С J Liskamp, R M J van Nispen S Ρ J Μ , 
Boots H A Tijhuis, M W J Org Chem 1981, 46, 3273 
(19) Liskamp, R M J , Zeegers, H J M , Ottenheijm, H С J J Org 
Chem 1981. 46. 5408 
(20) Ottenheijm H С J , Liskamp, R M J Helquist, Ρ , Lauher, J 
W.Shekham, M S J Am Chem Soc 1981, 103 1720 
(21) Hwang, D R Helquist, Ρ , Shekhani, M S J Org Chem 1985, 
50 1264 
(22) Monta. К Kobayashi, Sh Jpn Kokai Tokkyo Toko 1970,18, 459; 
Chem Abstr 1970 73,95594 
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The> have to be stable to the reaction conditions employed 
for the construction of the monoxodithioacetal function 
Moreover, their removal has to avoid the use of base to 
prevent racemization and β elimination On basis of these 
considerations the Boc (ieri butyloxycarbonyl)·" group and 
the Tmse (2 (tnmethylsilvDethyl)242-'' group were selected 
for protection of the amine function and the ester function 
respectively Whereas both protecting groups can be re 
moved by treatment with tnfluoroacetic acid г ч ^ they can 
also be removed selectively, the Boc group by treatment 
with hydrochloric acid in tnfluoroethanol24 and the Tmse 
group by treatment with fluoride ions 2 4 2 5 
Tv/o routeb for the conversion of 6 into 1 were explored 
Initially we studied coupling of the completed monoxo­
dithioacetal 7 with 2 to yield 1 (Scheme 2 route A) As 
this approach failed (vide infra), the sequence of reactions 
was inverted, the a-chloro sulfoxide derivative 6 was cou­
pled first with 2 to yield 8 after which the monoxodi 
thioacetal moietv was formed to yield 1 (route B) 
Route A. Cystine derivative 10 (Scheme HI) was pre­
pared in 67% overall yield from L cystine (9) by subse 
quent introduction of the Boc group using di tert butyl 
pyrocarbonate23 and the Tmse group in a DCC coupling 
procedure employing 2-(trimethylsilyl)ethanoll* Treat 
ment of 10 with 3 equiv of chlorine in the presence of acetic 
anhydride, followed by reaction with dry dia^omethane 
afforded in 59% yield the a chlorosulfoxides 11 as a 
mixture of two diastereomers 1 8 These could not be sep 
arated at this stage of the reaction sequence Reaction of 
a mixture of the α-chlorosulfoxides 11 with sodium methyl 
mercaptide2827 in ethanol yielded the dehydroalamne de­
rivative 12 instead of the desired compound 7 The for­
mation of 12 can be rationalized by a ^-elimination18 and 
a transestenfication reaction Reaction of 11 with sodium 
methyl mercaptide in DMF instead of in ethanol also led 
to a ^-elimination product Another attempt to synthesize 
7 employed the sulfinate ester 13 This compound was 
prepared in 56% yield from 10 by using wet—instead of 
dry—chlorine However, reaction of 13 with methylthio 
methyl lithium19 resulted again in the formation of a β-
ehmination product This apparent inclination to β elim­
ination, which had not played a part during the synthesis 
of sparsomycin1819 must be ascribed to the presence of the 
ester function, the proton at the chiral carbon atom is 
acidic, which—in combination with the leaving group 
character of the SfOXUHjCl moiety—facilitates the ob­
served β elimination To circumvent this side reaction, we 
decided to deprotect the acid function prior to the reaction 
with sodium methyl mercaptide 
By treatment of 11 or 13 with an excess of tetra η bu 
tylammonium fluoride, the Tmse group was removed, 
these reactions proceeded sluggishly Unfortunately, 
during the workup procedure, the Boc group was largely 
removed So far we have no satisfactory explanation for 
this observation In view of the apparent lability of the 
Boc group in 11 and 13 during or after the procedure for 
removal of the Tmse group and the observed β elimination 
caused by sodium methyl mercaptide, it seemed sensible 
to reconsider the sequence of reactions 
(23) Moroder L Hallett A. Wflmch E Keller О, Weisin G Hoppe 
SeylersZ Physiol Chem 1976 357 1651 
(24) Sieber Ρ Heb Chim Acta 1977 60 2711 Cerlach H Heh 
Chim Acta 1977 60 3039 
(25) The Tmse group hae been used recently by Forsch R A Ro-
Bowsky, A J Org Chem 1984 49 1305 and by Still W С Ohmizu, Η 
J Org Chem 19S1 46 S242 
(26) The quality of MeSNa was found to be crucial see ref 16 
(27) The nucleophdic displacement of halogen by MeS is a known 
reaction for a chloro sulfoxides See Ogura, К Tsuchihaahi G J Chem. 
Soc Chem Commun 1970 1689 
S c h e m e IV 
Route B. Subsequently route В was explored (Scheme 
II) This route allows deprotection of the eysteme-
carboxyhc acid function subsequent to the removal of the 
Boc group and prior to the displacement of the a chloro 
atom by a methyl mercaptide function The N protecting 
group of 11-present as a diastereomeric mixture—was 
removed by treatment with hydrochloric acid in tri-
fluorocthanol24 to give 14 (Scheme IV) in 76% yield 
Coupling of the hydrochloride 14 with N phthaloyl I -
glutamic anhydride 15—prepared28 in two steps from L-
glutamic acid (4)—was achieved in tetrahydrofuran in the 
presence of tnethylamine, yielding (96%) the у isomers 
16 and 17 as a mixture of diastereomers None of the 
corresponding a isomers could be detected " The dia­
stereomeric a chloro sulfoxides 16 and 17 were separated 
by careful column chromatography on silica gel, and their 
ratio was determined by analytical HPLC Values for six 
reaction mixtures ranged between 65% and 77% de2 9 in 
favor of 17 
From this stage on the diastereomers were subjected 
separately to the following conversioni The carboxyhc 
acid protecting group of 16 and 17 was removed by 
7 Я Τ η e 
- < V C H 0 0-
"--WOU-
о 
21 
0 V 0 ' ^ о н 
о 
22 
treatment with tnfluoroacetic acid at 0 "C to yield (96%) 
compounds 18 and 19, respectively We had noticed that 
reaction of JV-phthaloyl L glutamic acid with sodium 
methyl mercaptide in ethanol resulted in a nucleophdic 
attack of the methyl mercaptide anion on the phthaloyl 
carbonyl group giving quantitatively a thioester There­
fore, we chose to remove the N protecting group before 
completing the monoxodithioacetal function Thus, the 
(28) King F E Kidd D A A J Chem Soc 1949 Э315 
(29) Unfortunately the minor isomer is the desired one We have 
observed previously (ref 18) a similar induction in reactions leadmg to 
Cbo-cystemol and Boc cysteinol α chloro sulfoxides although in these 
examples the diastereoselectivity was less ι e 22 and 28% respectively 
This increase m diastereoselectivity must be attributed to the presence 
of the bulky 2 (tnmethylsilyl) ethyl ester in 11 
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phthaloyl group of 18 and 19 was removed by hydrazino-
lysis with hydrazinehydroacetate in methanol1"' at elevated 
temperature (35-40 °C) to give 20 and 21, respectively in 
yields ranging from 67 to 84%.30 The diastereomers 20 
and 21 could not be distinguished on TLC. 
Finally, having accomplished the reaction sequence as 
depicted in Scheme IV so far, we now turned to the con­
version of 20 and 21 to 1 and 22, respectively. Following 
the procedure we described earlier l s for the synthesis of 
monoxodithioacetals we studied these conversions using 
sodium methyl mercaptide in ethanol. However, only-
starting material was isolated. We ascribe this failure to 
poor solubility of 20 and 21 in ethanol.32 When the re­
action was carried out at 50 °C employing ultrasonic vi­
bration for 1 week, only 30% of the n-chloro sulfoxides 
were converted into the desired monoxodithioacetals 1 and 
22, respectively as judged by the Ή NMR spectra of the 
reaction products Since the above mentioned procedure 
failed to give a clean conversion, we studied the use of 
liquid ammonia as solvent for the substitution reaction.33 
Following this procedure the a-chloro sulfoxides 20 and 
21 were successfully converted into the desired monoxo­
dithioacetals 1 and 22, respectively, in quantitative yield. 
These compounds were purified by gel filtration on 
Fractogcl HW-40(S) 
Structure Assignment. Compounds I and 22 could 
not be distinguished on TLC. Their structures were se­
cured by Ή NMR and CD spectroscopy as follows The 
gross structures of 1 and 22 were deduced from proton 
decoupling studies.3'' The -y-linkage in both compounds 
was also deduced from an analysis of the respective Ή 
NMR spectra. Both compounds show a triplet at 3 77 ppm 
for the α-proton of the glutamic acid moiety whereas in 
α-isomers of glutamic acid derivatives this proton is usually 
observed between 3.93 and 4.16 ppm.1 
To establish which of the two compounds is identical 
with 7-glutamylmarasmine the V and [a] values were 
compared.16 Salient features of the Ή NMR spectra of 
1 and 22 are depicted in Figure 1. These data show that 
compound 1 and the natural product are identical 
CD Spectroscopy. As to determine the absolute con­
figuration at the sulfoxide sulfur atom of compounds 1 and 
22, circular dichroism (CD) measurements were employed. 
(30) This mild dephlhaloylation procedure was uaed in order to avoid 
reaction of hydrazine with the σ-chloro sulfoxide moietv This side 
reaction had to be considered in view of the known reaction of alkyl-
halides with hydrazines (ref 31) 
(31) Gibson. M S , Bradshaw, R W Angew Chem 1968. SO, 98β 
(32) When the substitution reaction was carried out in water, the 
generation of two singlets at Ь 1 and 5 9 ppm in the 'H NMR spectrum 
of each product suggested the formation of ^-elimination products 
(33) Liquid ammonia has been employed as solvent previously for the 
preparation of S-alkylat«d cysteine derivatives (ref 1Θ and 34) 
(34) Brownlee. Ρ J E , Coi, M E . Handford, В О , Marsden, J С , 
Young, G T . J Chem Sor 1964,3822 
(35) Proton decoupling studies were carried out using a Bmker WH-90 
apparatus For both compounds irradiation at СНСНгЗЮ) gives a singlet 
for the CHCHjSlO) proton at 4 68 ppm Irradiation at CHCHjCHi turns 
the original triplet for the CHCH3CH2 proton—centered at 3.82 ppm — 
into a singlet The difference in the signal pattern for the CHC/f2S(0) 
protons of the two sulfoxide diastereomers (see Figure 1) becomes more 
pronounced after irradiation at CHCH^fO) For compound 22, the eight 
linea pattern ш transformed into an AB-quartet at 3 23 and 3 ftf ppm, ¿¿д 
= 13 5 Hz The five lines pattern of 1 turns into a singlet at 3 37 ppm 
after irradiation at CWCHjSIO) The "C NMR spectra of the diaste­
reomers I and 22 are both identical with the spectrum of γ-glutamyl-
marasmme 
(36) 500-MHz 'H NMR spectra showed the following coupling con­
sunte for the CHCH,S(0) protons (AB part of ABX spectrum) of 1 and 
22 Compound 1 Л,, = 10 4 Hz, JBX = 3 9 Hz, J A B - 13 6 Hz Com­
pound 22 JA% = 8 6 Hz, Jex - 5 3 Hz, J»B - 13 6 Hz T-Glutamyl-
marasmine (values from ref 2, 200-MHz spectrum). J A x = 11 Hz, Λ χ = 
3 5 Hz, t/ді, = 14 Hz The specific rotations are: compound 1, ( a l p 0" 
(c 0.2. H 2 0). compound 22 | о ] и в -23" (с 0.2, HjO), vglutamyl-
marasmine (ref 2), (n) M D -S 5» (c 0 1, H 20) 
Compound 17 
5 0 0 M H z Ή N M R 30 PPM 
F i g u r e I. AB part of ABX spectrum fur CHCH^SfO) of I and 
22 
16 2 
Η 
Δε 
-32 
-61 
-96 
230 210 250,- ' 260 270 
Xlnml 
,' 22,ScMs 
Figure 2. CD spectrum of I and 22. 
Previously, we showed for sparsomycin18 as well as for 
several other o-functionalized sulfoxides19·20 that CD 
spectrscopy can be employed in the assignment of the 
configuration of the sulfoxide sulfur atom.37 In the ab­
sence of strongly perturbing groups, a negative sign of the 
Cotton effect—centered at the S(O) absorption band in 
the 220-240 nm region—correlates with an R configuration 
whereas a positive sign correlates with an S configuration. 
The CD spectra of 1 and 22 as well as of their synthetic 
precursors 20 and 21, respectively, are shown in Figures 
2 and 3.38 Application of the above mentioned correlation 
(37) CD spectroscopy was also used in the determination of the con 
figuration of the sulfoxide sulfur atom of -y-glutamylcyeteine sulfoxides 
isolated from sandal and onion (ref 10) and of sulfoxides isolated from 
mushrooms of the genus Amanita (ref 12) 
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Figure 3. CD spectrum of 20 and 21 
learns that 1 and 20—showing a positive sign—possess the 
S configuration, while 21 and 22—showing a negative 
sign—possess the R configuration From this it can be 
concluded that •y-glutamylmarasmine (1) possesses the 
ScR(:Si configuration. 
Conclusion. We have developed an efficient route to 
the natural dipeptide Y-glutamylmarasmine (1) and its 
iS-epimer 22. Our approach proceeds via coupling of the 
L-cysteine derivative 14 with the L-glutamic acid derivative 
15 and subsequent separation of the resulting epimeric 
sulfoxides 16 and 17 by column chromatography Sub-
stitution of the chlorine atom in 20 and 21 by SMe was 
accomplished in liquid ammonia. Unlike in our studies 
towards the total synthesis of sparsomycin18 /?-elimination 
involving the cysteine α-proton was observed in some re­
actions. By comparison of V and [a] values it was shown 
t h a t 1 is identical with 7-glutamylmarasmine. T h e abso­
lute configuration of γ-glutamylmarasmine was determined 
by CD spectroscopy. 
Exper imenta l Sect ion 
Melting points were determined on a Reichert hot stage and 
are uncorrected 'H NMR spectra were recorded on a Bruker 
WH-90 or on a Bruker WM-500 spectrometer with Me4Si or 
Me3SiCD2CD2C02Na as an internal standard. " C NMR spectra 
were measured on a Bruker WP-60 spectrometer IR spectra were 
taken on a Perkm-Elmer 257 grating spectrometer Maas spectra 
were recorded on a double-focusing VG 7070E mass spectrometer 
UV spectra were measured on a Perkm-Elmer Model 555 spec­
trophotometer. Circular dichroism spectra were recorded with 
(38) In the region of 220-240 nm each spectrum consists of a com-
posite chromophore, which includes an inherent!) symmetric—but chi-
rallv perturbed amide band as well as an inherently chiral sulfoxide band. 
In studying Вос-сувіеіпоі monoxodithioacetals (ref 1ft) it was shown, that 
the contribution due to the chiral carbon atom is small, so that the CD 
curves of the diaetereomenC sulfoxides were nearly mirror images In our 
work on sultmes (ref 19), however, it was shown that the contribution of 
the chiral center can be significant resulting in a striking difference in 
the magnitude of rotational strength Now we also found a difference in 
the magnitude of rotational strength for -y-glutamylmarasmine (1) and 
ite precursor 20 on the one hand and their S-epimere 21 and 22 on the 
other 
a autodichrograph Mark V apparatus (Jobin Yvon) For deter­
mination of specific rotations, a Perkm-Elmer 241 Polarimeter 
wa-s used. Thin-laver chromatography (TLC) was carried out by 
using Merck precoated silica gel F-254 plates (thickness 0 25 mm). 
Spots were visualized with a UV lamp, ninhvdnn, and 012-TDM ^ 
For column chromatography, Merck silica gel H (type 60) was 
used For gel filtration Pharmacia Sephadex LH-2() and Merck 
Fractogel TSK HW-40 (S) were used The HPLC analyses were 
performed using a "SP-STOO solvent deliver> system" instrument 
equipped with a **SP-84()0 variable wavelength" detector using 
a Chrompack LiChrosorb S16O-IO column (25 cm) 
N-(tert -Butyloxycarbonyl)-! -cystine 2-(TriinethyI-
silyl)ethyl Ester (10). N-Uevi-butyloxvcarbonyD-L-cystme was 
prepared in 787o yield from L-cystine, 9 (9 6 g, 40 mmol), according 
to a procedure that has been described earlier18 b> treatment with 
di-íerí-butylpyrocarbonate. The Tmse ((trimeth>lsilyl)ethyl) 
protecting group was introduced analogous to the procedure 
described by Sieber 2* To a solution of iV-Boc-cystine (8 8 g, 20 
mmol) in 40 mL of acetomtnle and 15 mL of DMF was added 
6 4 mL (79 1 mmol) of pyridine followed by the addition of 6 8 
mL (47.5 mmol) of 2-(trimethylbilyl)ethanoI Subsequently, the 
reaction mixture was cooled (0 0C), and after IO min, DCC (9 0 
g, 43 6 mmol) was added The reaction and workup procedure 
were carried out as described 24 The crude product was purified 
by flash column chromatograph> on silica gel (eluent ethyl ace-
tate/hexane, 1/8) to give 10 in 86% yield ns a colorless semisolid 
oil mp 45-46 0C; TLC R, 0 55 (eluent ethyl acetate/hexane, 1/4); 
IR (KBr) 1720, 1680 (urethane, ester), 1510 (amide), 1250, 860, 
840 cm l (SiMe,), lH NMR (CDClg) Ó 0 02 (s, 9 H, SiMe-,), 
О 78 1 35 (m, 2 H, CH2Si), 1 42 (s, 9 H, i-Bu), 3 15 (d, J = 5 Hz, 
2 H, CH2S), 3 Э7-4 39 (m, 2 H, OCH2>, 4 39-4 72 (m, 1 H, CH), 
5 17-5 52 (br d, 1 H, NH), CI MS, m/e 641.275 (M+ + 1), caled 
for C^H^N^SaSiz, 641 278, M " D -64° (с 0 22, EtOH). 
(R
e
S
я
)/(RCK,)-N-{tert -Buty\oxyc&Tbony\)'S oxo-S-
(chloromethyl)-L-cysteine 2-(TrimethylsilyI)cthyI Ester (11). 
These compounds were prepared from 10 (9 8 g, 15 3 mmol) 
following the procedure described earlier"* for the preparation 
of Λ'-,Ο-protected cysteine nr-chloro sulfoxides The crude reaction 
product was purified by flash column chromatography (silica gel 
60H, eluent ethyl acetate/hexane, 1/2), yielding a mixture of 
diastereomers in 59% yield as a yellow oil TLC Rf 0 46 and 0.41 
(eluent ethyl acetate/hexane, 2/3), lH NMR (CDCI3) δ 0 05 (s, 
9 H, SiMeg), 0 95-1 33 (m, 2 H, CH^Si), 1 45 (s, 9 H, ¿-Bu), 3 30 
and 3 58 (AB part of ABX spectrum, 8 lines, JAx = 53 Hz, JBx 
= 6 3 Hz, JAB = 12 6 H?, 2 H, CHCff¿S(0», i 00-4 79 (m, 5 H, 
OCH2, CHCH2S(0). S(0)CH2C1), 4 56 (part of AB spectrum of 
S(0)CH2CI), 5 57 (br d, 1 H, NH), EI MS, m/e 386 121 (M+ + 
1), caled for CuH^NOsSSiCl, 386 122 
Ethyl /V (ieri Butyloxycarbonyl) 2 aminoacrylate (12). 
Treatment of compound 11 (386 mg, 1 mmol) with sodium methyl 
mercaptide, analogous to the procedure described earlier18 for 
substitution of cysteinol n-halosulfoxides, afforded 12 in quan-
titative yield. TLC Rf 0.92 (eluent ethyl acetate/hexane, 1/1), 
lH NMR (CDCI3) Ò 1.3 (t, 3 H, СНзСНч), 1 45 (s, 9 H, t-Bu), 4.25 
(q, 2 H, СЯзСНэ), 5.65 (s, 1 H. C=CH), 6 05 (s, 1 H, С—CH), 
7.0 (brs, 1 H, NH) 
{RcSJ/iRcRJ-N-itert-ButyioxycarbonyiyS-OTto-S-
methoxy-L cysteine 2-(Trimethylsilyl)ethyl Ester (13). The 
procedure used for the preparation of 111H was adapted in order 
to prepare the sulfinate ester 13 Wet-instead of dry-chlorine 
was used. The sulfinate ester-a mixture of diastereomers-was 
obtained after column chromatography (silica gel, eluent ethyl 
acetate/hexane, 1/3) in 56% yield: TLC ft, 0.77 (eluent ethyl 
acetate/hexane, 1/1), l H NMR (CDCl,) δ 0 05 (s, 9 H, SiMe3), 
0.70-0.80 (m, 2 H, CH2S1), 1 40 (s, 9 H, i-Bu), 2 95-3.35 (m, 2 H, 
СНСЯгЗЮ)), 3.75 (s, 3 H, ЗЮЮСН-,), 4 00-4.40 (m, 2 H, OCH2), 
4 40-4.85 (m, 1 H, CHCHfiiO)), 5.40 (br d, 1 H, NH). 
(ÄcS1)/(Ä (J*1)-S-Oxo-S-(chloromethyl)-L-cy9tcine 2-
(Trimethylsilyl)ethyl Ester Hydrochloride (14). TheN-Boc 
protecting group was removed from 11 (3.4 g, 8.8 mmol) by 
treatment with HCl in 2,2,2-trifluoroethanol analogous to the 
procedure desenbed by Sieber u The crude reaction product thus 
obtained was purified by crystallization from methanol/hex-
(39) Агж, E von, Faupel, M. J. Chromatogr 1976, 120, 224 
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ane/ethy) acetate to give 14 as a mixture of diastereomerb in 76% 
yield, mp 120-123 °C TLC Rf 064 (eluent aceU>nilrile/H¿0,8/1), 
IR (KBP) 1740 (ester), 1265, 1250, 860, 840 (SiMe,), 1060, 1020 
(S=0) , 745 cm-' (CI). Ή NMR (CDCVCDjOD) 6 0 04 (s. 9 H, 
SiMej), 0 87-1 34 (m, 2 H, CH,Si), 3 46-4 07 (m, 2 H. CHCH.S 
(O)), 4 07 4 54 (m, 2 H, ОСН.,), 4 Vt-I 17 (m, 3 H, CHCH,S(0), 
S(0)CH2CI). CI MS. m/e 286 068 (M* HCl), cakd for (λ,Η,, 
NOjSSiCI, 286 070 Anal Caled for QH^NOnSSiCU С, 33 54. 
Η, 6 56, Ν, 4 35 Found С, 33 22, Η, 6 19, Ν, 4 30 
7V-Phthaloyl ι glutamic Anhydride (15). This compound 
was prepared in 51% overall yield in two steps from ι glutamic 
acid following procedures described in the literature 2 і и п 
(SCRCS,)- and {8,НсН,)-\-{У-РЫЬл\оуІ-у-1-
g lu tamyl) S-oxo S (chloromethyl) [ c y s t e i n e 2 (Tri 
mcthylsilyDethyl Ester (16 and 17). To a cooled suspension 
(0 °C) of 14 (518 mg, 2 mmol) und 15 (644 mg, 2 mmol) in I 5 
mL of THF was slowly added tncthylamine (202 mg, 2 mmol) 
After stirring overnight, the reaction mixture was concentrated 
by evaporation of the solvent Flash column chromatography 
(silica gel, eluent toluene/ethsl formate/formic acid, 14/3/3) gave 
16 and 17 as a mixture of diaslereomers in 96% yield as a colorless 
oil The diaslereomers could be separated by repetition of the 
chromatographic pnxedure Both compounds were homogeneous 
on TLC (17, R/ 0 47, 16, Я, 0 43 toluene/ethyl formate/formic 
acid, 10/7/3) and were crystallized from dichloromethane/hexanc 
For 16 mp 72-75 "C, Ή NMR (Cl^COCDj) δ 0 04 (s, 9 H, 
SiMe,), 0 77-1 26 (m 2 H, CH^Si), 2 15-2 6 i (m, 4 H, CH¿CH¿), 
3 23 (br d, 2 H, CHCHjS(O)). 4 00-4 29 (m, 2 H, OCH2), 4 55-5 02 
(m, 2 H, CHCH^SIO), CWCH/ГН
г
), 4 60 and 4 77 (ABq, ,/
д в
 = 
11 3 Hz, 2 H, S(0)CH;CI), 7 70 (br d, 1 H, NH), 7 84 (s, 4 H, Ar), 
FAB MS, m/e 545 (M* + 1), |«) 2 5 D 64° (с 0 31, CHjCOCH·,) 
Anal Caled for C ^ H ^ N ^ S S i C I C, 48 48, H, 5 36, N, 5 14 
Found C,4841,H,547,N,505 IR (KBr) 1770, 1715 (s) (ester, 
carboxylic acid, amide, imide), 1250, 860,840 (SiMe,), 1045 (S—O), 
725 cm ' (Cl) 
For 17 mp 143 145 "C, 'H NMR (CD^OCD·,) S 0 05 (s. 9 H, 
SiMej), 0 78-1 20 (m, 2 H, CH2Si), 2 23 2 83 (m, 4 H, СН2СН г). 
3 45 and 3 25 (AB part of ABX spectrum, 8 lines, </
Α
χ = 5 9 Hz, 
J B X = 6 1 Hz, J A B = 13 2 Hz, 2 H, CHC«2S(0)>, 4 05-4 36 (m, 
2 H, OCH2), 4 59 5 08 (m, 2 H, CWCH2S(0), CHCH2CH2), 4 80 
(ABq, J A B = 113 Hz, 2 H, S(0)CH2C1), 7 75 (d, 1 H, NH), 7 90 
(s, 4 H, Ar), FAB MS, m/e 545 (M* + 1), [c t] 2 s D -23° (с 0 14, 
CHjCOCH,), IR (KBr) 1770, 1715 (s) (ester, carboxylic acid, 
anude, imide), 1250, 860, 840 (SiMe5), 1045 (S=0), 725 cm"1 (CD 
Determination of de by HPLC, Si-60, 300 nm, 1 0 mL/min, 
toluene/ethyl formate/formic acid (14/3/3) Anal Caled for 
C ^ H M N A S S I C I С, 48 48, H, 5 36, Ν, 5 14 Found С, 48 63, 
Η, 5 33, Ν, 5 15 
(SCR,S,)- and (.ScÄ,.Ä,>-;V-<;V'-PhtIieloyl-r-[-
glutamyl) S охо Я (chloromethyl)-I -cysteine (18 and 19). 
A solution of the diastereomenc mixture of 16 and 17 (5 9 g, 10 9 
mmol) in 100 mL of trifluoroacetic acid was stirred for 2 h at 0 
°C Subsequently, excess trifluoroacetic acid was removed in 
vacuo Flash column chromatography (silica gel, eluent tolu­
ene/ethyl formate/formic acid, 10/7/3) of the residue gave a 
diastereomenc mixture of 1Θ and 19 in 96% yield as a colorless 
oil By the same procedure, but starting now from pure 16 or 17, 
the homochiral compounds 18 or 19, respectively, were prepared 
Both compounds were homogeneous on TLC (19, Д/ 0 16, 18, R/ 
0 13, toluene/ethyl formate/formic acid, 10/7/3) and could be 
crystallized from methanol 
For 18 mp 115-120 °C, Ή NMR (CDjOD) Í 2 41-2 94 (m, 
4 H, CH2CH2), 3 23-3 81 (AB part of ABX spectrum, 2 H, 
CHCH2S(0)), 4 74-5 30 (m, 4 H, CHCHjSfO), CHCH2CH2. S-
(0)CH2C1), 4 93 and 5 03 (part of AB spectrum of S(0)CH2C1), 
8 04 (s, 4 H, Ar) FAB MS, m/e 445 (M* + I), IR (KBr) 1770, 
1710 (s) (carboxylic acid, amide, imide), 1020 (S=0) , 725 cm"1 
(CI) Anal Caled for ΰ „ Η „ Ν 2 0 β 3 Ο · Η 2 0 С, 44 11, Η, 4 14, Ν, 
6 05 Found С, 43 95, Η, 3 96, Ν, 5 95 
(40) Nefbns, G Η L , Teaser, G I Nivard, R J F Reel Trau Chim 
Pays Bos 1960, 79, 688 See also McArthur, С R , Woreter, Ρ Μ , Окоп, 
A V.Synth Commun 1983, 13, 311, and compare with 1983, 11 393 
Woreter Ρ M.Leznoff, С С . McArthur, С R.J Org Пет 1980, 45, 
174 
(41) Seneviralne, A S. Fowden, L Phytochemistry 1968, 7, 1039 
For 19 mp 128-1,10 °C Ή NMR (СІ)П„ CD.COCI),) о 
2 28-2 75 (m, 4 H, CH/ 'H 2 ) , ) )7 and .1 58 (AB part of ЛВ.Ч 
spectrum. 8 lines J A 4 = 57 Hz, Jm = 6 1 Hz, -Ли = 11 0 H/ 2 
H, CHCH_,S(0)) 4 60-5 08 (m 4 H CHCH S(O) (7/<'H( 'H„ 
S(0)CH,CÎ). 1 76 and 4 78 (part ofAB spectrum of SlOK'H,CD. 
7 49(d ΓΗ, NH) 7 64-7 9 Km, 4 H Ar) FAB VIS m
 (M4">(M* 
+ 1) IR (KBr) 1770 1710(b) 1630 (iarhox\lic acid, amide imidel, 
1025 (S -О), 725 cm MCI) Anal Calid for C, H, \ 0„S(4 H ,0 
C, 44 11. H, 4 14, N. 6 05 Found С, I M I . H, 4 Π Ν Ί bh 
(Я.Я.Я,) and (S,Я,Я,) N (у 1 Clulamyl) S охо S 
(chloromethyl)-! -cysteine (20 and 21) A diaslereomeric 
mixture of 18 and 19 (2 4 g, 5 4 mmol) was treated wilh 21 (5 ml. 
of a 2 M solution of Ν 2Η 4 ·Η 20 and AcOH in methanol ( 11 2 
mmol) The solution was stirred OMTmght at Γι 40 °C The 
reaction mixture, a white suspension, was concentrated to a small 
volume and filtered and the filtrate was purified bv gel filtration 
on bephadex LH 20 (eluent wdlcr/mpthanol, 15/85) to give a 
diastereomenc mixture of 20.uid 21 in h7 817c yield Bv the same 
procedure, the homochiral compounds 20 or 21 were obtained 
starting from 18 or 19, respeclivelv These diaslereomers could 
not be disCinguished on TLC R/ 0 56 (eluent 2 propnnol 'water, 
7/3), Rf 0 15 (eluent n-butanol/acelic acid, water/2-propanol, 
8/2/ 5/ 3) Both compounds were handled and stored after 
freeze drying 
For 20 mp 187-189'C, Ή NMR (Π,Ο) 0 2 06-2 16 (m, 1 H, 
CHC//2CH,), 2 44-2 7Km, 2 H. CHCH VU ) 1 2" and JbKAB 
part of ABX spedrum, 8 lines, .7A 4 = 5 5 H/ /| t\ = ) 5 H/ 7 A H 
= 13 5 Hz, 2 H, CHCH2S(0)), 3 90 (t 7 = 60 Hz, I H, 
C//CH2CH,), 161-5 01 (m, 1 H,CHCHS(0)> 4 87 and 5 15 (ABq. 
7A,i = 21 0 Hz, 2 H, S(0)CH2CI) FAB MS, m/e (Γ> (M* + 1) 
IR (KBr) 3300, 1675, 16)5, 15)0, 1055. 1015 im ', [,»]-">„ 51° (с 
0 2. Н 2 0). CI) spectrum, at 231 5 nm a single positive maximum 
was observed for an aqueous solution (Л« +19 8, Figure 1) Anal 
Caled for CaH^N A S C I C, 34 )5, H, 4 80, N, 8 90 Found C, 
34 47, H. 4 90. N. 8 82 
For 21 mp >200 0 C, Ή NMR (I)20) Λ 2 02-2 36 (m, 2 H, 
СНСЯ2СН2), 2 41 2 69 (m, 2 H, CHCH2CH,). 3 38 and 3 62 (AB 
part of ABX spectrum, 8 lines, ι/
Α
χ = 5 t Hz, J B X = 8 5 Hz, JAtí 
= 13 6 Hz, 2 H. CHCH2S(0)), 3 87 (t, J = 5 9 Hz, 1 H, 
CHCH^H,). 4 60-4 90 (m, 1 H, CHCH^SfO)), 4 80 and 4 96 (ABq, 
</
А
в = 1 2 6 Hz, 2 H, S(0)CH2C1) FAB MS, m/e 315 (M* + 1), 
IR (KBr) 1630, 1530, lOÌOcm ', [«)"„ +16° (с 0 2, Н 2 0) CD 
spectrum at 232 5 nm a single negative maximum was observed 
for an aqueous solution (A< 10 3, Figure )) Anal Caled for 
C 9H 1 5N 20 bSCl C, 34 35, H, 4 80, N, 8 90 Found C, 34 79, H, 
5 04, N,8 92 
(SCRCS,) and (Scfl ffl .)-/V-(7-l-Glutamyl)-íí-oxo-S-
((methylthio)niethyl)-i -cysteine (1 and 22). In a reaction vessel 
containing 628 mg (2 mmol) of 20 or 21 and 420 mg (6 mmol) of 
sodium methyl mercaptide26 was condensed 20 mL of liquid 
ammonia at -78 eC The ammonia had been distilled from sodium 
in a connected vessel Special care was taken to exclude moisture 
by bringing the reaction system under an argon atmosphere and 
by attaching tubes containing potassium hydroxide The reaction 
mixture was allowed to react at -78 °C for 1 h Subsequently, 
the ammonia was allowed to evaporate rapidly and completely 
by an argon stream The solid remainder was dissolved in 1 mL 
of water after which the solution was neutralized immediately 
by the addition of 1 N hydrochloric acid Nitrogen was passed 
through the solution to remove excess of methyl mercaptan The 
reaction mixture was subjected to gel filtration on Fractogel TSK 
HW 40 (s) (eluent, water) to give 1 or 22 m quantitative yield 
The diaslereomers could not be distinguished on TLC fi, 0 54 
(eluent 2-propanol/water, 7/3), R/ 0 12 (eluent l-butanol/acetic 
acid/water/2 propano!, 8/2/5/3) Both compounds were handled 
and stored after freeze-drying 
For 1 mp 162-165 °C, Ή NMR (500 MHz, D 2 0, Figure 1)Μ 
4 2 10-2 20 (m, 2 H, CHCH2CH2), 2 27 (s, 3 H, SCHj), 2 50 
(distorted t, J = 7 4 Hz, 2 H, СНСН
г
СН^, 3 30 and 3 37 (AB part 
of ABX spectrum, 8 linea, */
Α
χ = 10 4 Hz, Jgx = 3 9 Hz, JAB = 
13 6 Hz, 2 H, CHCHjSfO)), 3 77 (t, J = 6 2 Hz, 1 H, СНСН2СН2), 
3 93 and 4 09 (ABq, J ^ = 1,3 9 Hz, 2 H, StOtCHjS), 4 60 (X part 
of ABX spectrum, 4 lines, J « + JBx = 14 3 Hz, 1 H, CHCHjSfO)), 
FAB MS, m/e 327 (M+ + 1), [a] 2 5 D ±0° (с 0 2, Н 2 0), IR (KBr) 
1620, 1535, 1010 cm ', 13C NMR (D20) β 15 6 (SCHj), 25 5 (CH-
CH2CH2), 31 0 (СНСН2('Н2), 49 8 (CHCH2S(0)), 52 8 (СНС-
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HsSIO)), 53.6 (CHCH2CH2), 54.2 (StOlCHjS), 173.5 (Glu-COOH 
and Cys-COOH), 174 4 (C(O)NH); CD spectrum, at 237 5 nm a 
single positive maximum was observed for an aqueous solution 
(A<+17 5, Figure 2) Anal Caled for С ю Н ^ С НгО С, 34 87, 
H, 5 85, Ν. 8 13 Found С, 34 24, Η, 6 29, Ν, 8 06 
For 22: mp 169 172 "С: Ή NMR (500 MHz. D 20, Figure l ) 3 5 
δ 2 07-2 20 (m, 2 H, CHCH,CH,>, 2 27 (s, Я H, SCH}), 2 47 
(distorted t. J = 7 7 Hz. 2 H. CHCH ,СН
г
), 3 18 and 3 55 (AB part 
of ABX spectrum, 8 lines. Λ χ = 8 6 Hz, J B X = 5.3 Hz, J^ = 13 6 
Hz, 2 H, CHCHjStO)), 3 76 (t, J = 6.1 Hz, 1 H, CHCH2CH,), 3.91 
and 4.11 (ABq, J A B = 13 8 Hz, 2 H, ЗІОСНгЗ), 4 60 (X part of 
ABX spectrum, 4 lines, J « + JBX = 14.0 Hz, 1 H, CHCH2S(0)). 
FAB MS, m/e 327 (M+ + 1), («]"[, -23° (с 0.2, Н 2 0), IR (KBr) 
1615,1525, 1020 cm '; 13C NMR (D20) J 15 6 (SOH·,), 2 57 (CH-
CHjCHj), 31 2 (CHCH2CH2), 49.5 (('НСН25(0)), 53.0 (CHC-
HjStO)), 53.8 (CHCH2CH2). 54 2 (SiOCH^S), 173 5 (Glu-COOH), 
173.9 (Cys-COOH), 174.9 (C(O)NH); CD spectrum at 237 5 nm 
a single negative maximum was observed for an aqueous solution 
(Ae -9 8, Figure 2). 
Acknowledgment. We express our gratitude to the late 
Professor Rolf Gmelin (Inst i tut fur Pharmakognosie und 
Phytochemie der Freien Universität Berlin) for his kind 
suggestions at the beginning of this project. We thank 
Professor G Hofle (Gesellschaft fur Biotechnologische 
Forschung, Braunschweig, W Germany) for sending a copy 
of the Ή N M R spectrum of 7-glutamylmarasmine and Dr. 
W. ten Hoeve (University of Groningen, T h e Netherlands) 
for help in recording the CD spectra. This research was 
supported by the Nether lands Foundat ion for Chemical 
Research (SON) with financial aid from the Nether lands 
Organization for the Advancement of Pure Research 
(ZWO). N M R spectra were recorded at the Dutch Na­
tional 500/200 MHz-hf-NMR facility a t Nijmegen. 
Registry No. 1. 106565-95-1, 9, 56-89 3, 10, 106501-49-9; 
(A
c
S g)-ll, 106501-50-2; (Ä(-Rb)-Il, 106301-56-8; 12,96846-37-6; 
(ЯсА'ьМЗ, 106501-31-3, (Д
С
Я8)-13, 106501-57-9. (RcSs)-H, 
106501-52-4, (fi
r
fi
s
)-14, 106501-58-0, 15, 25830-77-7, 16, 106501-
53-5; 17, 106565-96-2; 18, 106501-54-6, 19, 106565-97-3, 20, 
106501-55-7; 21, 106565-98-4, 22, 106565-99-5, Boc-cystme, 
10389-65-8; di-fert-butyl pyrocarbonate, 24424-99-5; 2-(tri-
methylsilyDethanol, 2916-68-9 

165 
SAME1WATTI\G 
Synthese van aan sparsomycine verwante structuren: de ontwikkeling van een antitumor antibioticum. 
Sparsomycine (1) werd in 1962 als een metaboliet van Streptomyces sparsogenes geïsoleerd 
(Schema I). Vanwege zijn structuur en biologische activiteit heeft het in ruime mate de belangstelling 
van scheikundigen en biochemici getrokken. Het molecuul is opgebouwd uit een 6-methyluracil 
fragment (2) en een D-cysteine fragment (3), welke door middel van een amide band met elkaar zijn 
verbonden. Het zwavelatoom van het aminozuur vormt onderdeel van een monoxodithioacetaal 
RS(0)CH2SMe functie, een functie die slechts sporadisch in natuurproducten wordt aangetroffen. 
Schema I. Retrosynthese van sparsomycine 
Me
 n S0"°.. 
^
8
" М е 
7 0 H f ··• 
H N
 I ^ A N 
O N O Sparsomycine, 1 
1 
Me o / O H o , · · 
Η
Ν
Λ Ν / ^ Α Ο Η H > L / S ' S^  
? Τ + HaN ^ ^ ^ ^ M e 
O ^ N ^ O 2 3 
H
 \ \ 
Me 
C02H 
SH 
H 2 N " 
H
 6-methyluracU D-cysteine 
Sparsomycine is een sterke remmer van de eiwitbiosynthese. Het interfereert met de vorming van 
de peptide band, de centrale stap in de eiwitsynthese, welke plaats vindt in het peptidyl transferase 
centrum van het ribosoom. Uit onderzoeken met sparsomycine werd belangrijke informatie omtrent de 
structuur van dit peptidyl transferase centrum en van de ribosomen als geheel verkregen. Als remmer 
van de eiwitsynthese is sparsomycine intrinsiek toxisch voor cellen waarin de stof kan doordringen. Op 
grond van deze eigenschap is een breed spectrum van biologische activiteit, waaronder antiparasitaire, 
antivirale, antibacteriële, antischimmel en antikanker activiteit, waargenomen. 
In dit proefschrift wordt de scheikundige synthese alsmede de in vitro en in vivo biologische 
activiteit van structuuranaloga van sparsomycine (1) beschreven. Alle nieuwe verbindingen werden in 
eerste instantie op hun remmend effect op de peptidyl transferase activiteit en op de groei van bacteriën 
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en tumorcellen getest. Stoffen die in deze in vitro testsystemen een hoge activiteit lieten zien, werden 
daama op hun antikanker activiteit tegen L1210 leukemie bij muizen onderzocht. De meest belovende 
stoffen werden vervolgens uitgebreid in meerdere experimentele tumoren getest. Tevens werd de 
farmacokinetiek en toxicologie in muizen en beagle honden onderzocht. De in vivo studies werden 
verricht door Z. Zylicz van de afdeling Medische Oncologie van het Academisch Ziekenhuis Nijmegen. 
In hoofdstuk 2 is het belang van de verschillende functionele groepen van het molecuul voor de 
biologische activiteit onderzocht. Er werd aangetoond dat een toename van de lipofiliteit van het 
molecuul, door vervanging van de SMe groep door een langere alkylthio of aralkylthio groep, een 
toename van de activiteit van de stof tot gevolg heeft. De ScRs stereochemie, de frawi-dubbele band en 
een onveranderd S(0)CH2S fragment (zie Schema II) bleken van cruciaal belang te zijn voor de 
activiteit van de verbinding. 
Schema II. Sparsomycine analoga 
4, R^CfyOH, R2=(CH2)4Me: pentyl-sparsomycine 
5, R^Me, R2=Me: deshydroxy-sparsomycine 
6, R^Me, R2=Et: ethyl-deshydroxy-sparsomycine 
Om de invloed van de lipofiliteit op de activiteit en toxiciteit van de stof systematisch te kunnen 
bestuderen, werden drie homologe reeksen van sparsomycine analoga gesynthetiseerd (zie Schema III) 
(hoofdstuk 2.2). De CfyOH groep werd vervangen door een Me groep en/of de SMe groep werd 
vervangen door een S(CH2)
n
Me (л=1-7) of een (CI^^Me (m=l-8) groep (zie b.v. de structuren 4, S en 
6 in Schema II). In elke serie werd een optimum in de relatie tussen lipofiliteit en biologische activiteit 
gevonden. Er werd geconcludeerd dat de "oost" kant van het molecuul een interactie aangaat met een 
hydrofoob gebied in het peptidyl transferase. Dit gebied functioneert waarschijnlijk als de 
herkenningsplaats voor de zijketens van hydrofobe aminozuren tijdens de eiwitsynthese. De toxiciteit 
nam af wanneer de lipofiliteit van de stof toenam. 
Naast de lipofiliteit bleek ook de vorm en afmeting van de 5-alkyl substituent van belang; zie de 
structuur van sparsomycine analoga in Schema П. Zo is de л-butylthio verbinding veel actiever, terwijl 
de fm-butylthio verbinding veel minder actief is dan sparsomycine. En zo bleek de cyclohexylthio 
verbinding iets minder actief te zijn, terwijl de pentylthio en octylthio verbindingen veel actiever zijn 
dan sparsomycine. 
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Schema III. Lipofiele derivaten van sparsomycine 
Me 
О 
CANAD 
Η 
De deshydroxy analoga, waaronder S en 6, werden uitgaande van het goedkope aminozuur 
L-alanine volgens een nieuwe syntheseroute gemaakt. In de synthese van sparsomycine wordt van het 
vrij kostbare aminozuur D-cysteine uitgegaan (zie Schema I). Het gebruik van L-aminozuren is o.a. om 
deze reden interessant. In hoofdstuk 2.3 wordt de synthese van L-aminozuur derivaten van 1, afgeleid 
van valine, isoleucine, phenylalanine, proline en glycine, beschreven. Hierdoor ontstaan analoga die op 
de CH2OH positie van het molecuul zijn gemodificeerd (Schema Г ). Het overeenkomstige glycine 
derivaat werd niet uit glycine, maar via een andere syntheseroute uit cysteamine (2-aminoethaanthiol) 
bereid. 
Schema IV. L-aminozuur derivaten van sparsomycine 
Met uitzondering van de proline en glycine derivaten, wier conformatie mogelijk sterk afwijkt van 
die van sparsomycine, bleek geen van de aangebrachte veranderingen de activiteit sterk te beïnvloeden. 
De CH2OH functie van sparsomycine is niet essentieel voor de biologische activiteit. De "noord" kant 
van het molecuul gaat blijkbaar geen interactie aan met een hydrofoob gebied in het peptidyl transferase 
centrum. 
In hoofdstuk 2.4 werd het effect van veranderingen in het uracil fragment van sparsomycine (1) 
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onderzocht (zie Schema V). Alle derivaten met een gemodificeerde "west" kant bleken inactief te zijn. 
De 6-methyluracil ring speelt blijkbaar een belangrijke rol in de interactie van sparsomycine met het 
peptidyl transferase. Zijn aanwezigheid is van cruciaal belang voor de biologische activiteit. 
Schema V. Modificaties van het uracil fragment 
Vervolgens werden enkele geselecteerde analoga in vitro onderzocht op hun antiparasitaire 
(hoofdstuk 3.1) en antivirale (hoofdstuk 3.2) activiteit en op hun antitumor (hoofdstuk 3.3) activiteit 
tegen verschillende humane tumor cellijnen. 
De hydroxymethyl-bevattende verbindingen vertoonden in tegenstelling tot de deshydroxy 
verbindingen een hoge activiteit tegen Leishmania d. donovani promastigoten. Sommige van de analoga 
bleken activiteit te bezitten tegen een aantal virussen. De stoffen bleken toxisch te zijn tegen sommige 
gastheercellen, o.a. MT-4 cellen, die als gastheercellen voor het humane immunodeficiëntie virus (HIV) 
dienst doen, in een concentratie die niet veel hoger lag dan die waarbij antivirale activiteit werd 
waargenomen. Alle geteste derivaten waren sterk cytotoxisch voor de onderzochte humane tumor 
cellijnen. De activiteit tegen de tumorcellen nam toe met toenemende lipofiliteit van de stof. 
Verschillende lipofiele analoga van sparsomycine (zie Schema ΠΙ) werden op hun antitumor 
activiteit in muizen met L1210 leukemie en op hun acute toxiciteit in muizen onderzocht (hoofdstuk 
3.3). Daarnaast werden een aantal fysicochemische parameters, te weten lipofiliteit en water­
oplosbaarheid, bepaald, om hun correlatie met de biologische activiteit vast te stellen. Evenals in de in 
vitro systemen, werd ook hier een optimum in de relatie tussen lipofiliteit en in vivo antitumor activiteit 
waargenomen. De verbinding waarin de SMe groep door een SiCH^Me (4) groep en de verbinding 
waarin de CHjOH groep door een Me (5) groep is vervangen, vertoonden de hoogste antikanker 
activiteit. Met toename van de lipofiliteit van de stof nam de acute toxiciteit met een faktor 5-100 af. De 
deshydroxy-sparsomycine analoga, waaronder 5 en 6, waren ondanks hun verhoogde lipofiliteit beter 
wateroplosbaar dan de overeenkomstige hydroxy-bevattende verbindingen. 
In hoofdstuk 4.1 wordt de synthese van tritium-gemerkt sparsomycine (7) beschreven (Schema VI). 
Het verkregen product, met een specifieke activiteit van 31.4 Ci/mmol, bleek volgens het 3H NMR 
spectrum een 2:1 mengsel te zijn van mono- en digetritieerd sparsomycine. Recent zijn experimenten 
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gestart waarin de interactie met het ribosoom en het farmacokinetisch gedrag van getritieerd 
sparsomycine in muizen wordt bestudeerd. 
Alhoewel werd vastgesteld dat sparsomycine interfereert met de vorming van de peptideband, 
wordt het exacte werkingsmechanisme nog onvoldoende begrepen. Mogelijk wordt het molecuul d.m.v. 
een Pummerer omlegging, waarbij de sulfoxide groep van 1 een rol speelt, covalent aan de groeiende 
peptideketen gebonden. 
Schema VI. [3H]Sparsomycine 
Me 0 T f 0 H ? , · ' 
Μ Π ,ft ç с 
H N ^ Y ^ ^ V ^ ^ N ^ 4 ^ / V/ \ме 
cANA) 7 
Schema VII. Fenol-sparsomycine 
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Schema Ш. Fotoreactieve sparsomycine analoga 
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Om te onderzoeken of sparsomycine covalent aan de groeiende eiwitketen of aan het ribosoom 
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wordt gebonden, was het noodzakelijk om een syntheseroute naar hoog radioactief gemerkt 
sparsomycine te ontwikkelen. Hiervoor werd een fenol derivaat (8) van sparsomycine, welke middels 
radiojodering in een hoog radioactive verbinding (9) kan worden omgezet, gesynthetiseerd (Schema 
VII). Uit de eerste resultaten met de radioactief gemerkte fenol verbinding kan worden geconcludeerd, 
dat sparsomycine zich niet irreversibel aan het ribosoom en aan de groeiende eiwitketen bindt. 
Om nu de exacte interactieplaats van sparsomycine met het peptidyl transferase te kunnen 
onderzoeken, werden drie fotoreactieve arylazide derivaten van sparsomycine, namelijk 10, 11 en 12, 
gemaakt (Schema VIII) (hoofdstuk 4.3). Door bestraling met ultraviolet licht kunnen deze derivaten 
covalent aan het ribosoom worden gebonden. Deze experimenten zijn recent gestart. 
Na selectie van verschillende sparsomycine analoga voor een uitgebreid preklinisch onderzoek, 
was een evaluatie van de efficiëntie van de gebruikte syntheseroutes noodzakelijk geworden. In 
hoofdstuk 5 wordt een cyclus van reductie, oxidatie en scheiding beschreven, welke geschikt is voor de 
recycling van gefunctionaliseerde, optisch actieve sulfoxides (14, Schema IX). Deze sulfoxides (13) 
vormen belangrijke intermediairen in de synthese van sparsomycine en afgeleiden. 
Schema IX. Reductie-oxidatie-scheiding cyclus 
R1 
H 
\ P 2 + Boe N 
s x R 2 
! -
H 14 
H 
Boe Ν 
Η 
\ R 2 
15 
(i) 2-phenylene phosphochloridite, (/i) wCPBA 
Met de ontwikkelde methodologieën voor de synthese van sparsomycine konden een groot aantal 
structuuranaloga worden bereid. In hoofdstuk 6 wordt aangetoond dat het d.m.v. de ontwikkelde 
syntheseroutes mogelijk is gebleken om γ-glutamylmarasmine (16, Schema X)), een dipeptide 
geïsoleerd uit de schimmel Marasmius alliaceus, welke eveneens de ongewone cysteinyl monoxodithio-
acetaal eenheid bevat, te synthetiseren. 
Concluderend kan worden gezegd dat efficiënte syntheseroutes voor de bereiding van een 
verscheidenheid aan sparsomycine analoga werden gevonden. Een nauw verwante verbinding, 
γ-glutamylmarasmine, kon eveneens worden gesynthetiseerd. Het overgrote deel van de derivaten werd 
171 
Schema Χ. γ-Glutamylmarasmine 
ScRcSs 
bereid met als doel om een antikankermiddel te ontwikkelen. Daarnaast bleek het mogelijk stoffen te 
synthetiseren die op dit ogenblik voor onderzoek naar de farmacokinetiek van sparsomycine en naar de 
interactie van sparsomycine met het ribosoom worden gebruikt. Verschillende derivaten werden 
gesynthetiseerd die een veel sterkere antitumor activiteit bezitten en die bovendien veel minder toxisch 
zijn dan sparsomycine (1) zelf. Er werd een sterk potentiërend effect van sparsomycine op de 
cytotoxiciteit van verschillende bekende cytostatica waargenomen. Een drietal analoga, te weten 4, 5 en 
6, zijn als veelbelovende cytostatica uit het onderzoek naar voren gekomen. 
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